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A brief history of sepsis
Since ancient times, humanity has been plagued by pathogenic microorganisms. 
Infectious disease has been a leading cause of death that contributed 
significantly to a shorter average lifespan due to high infant mortality and 
many population-decimating plagues (e.g. the bubonic plague ‘Black Death’ 
in the 14th century, estimated to kill 30-60% of Europe’s total population). 
The term ‘sepsis’ originates from the Greek word ‘ıȘȥȚȢ’ (rotting, putrefying 
or decaying)1, and was first encountered in Homer’s Iliad (c. 750 BC)2. It was 
also found in the medical writings of the Greek physician Hippocrates (c. 
460-377 BC).
The oldest known report on sepsis dates back to an Egyptian papyrus 
manuscript written around 1600 BC (and appears to be a copy of a manuscript 
from 3000 BC)3. It summarizes 48 cases of traumatic lesions and wounds, 
explaining their signs and symptoms, treatment and follow-up (Figure 1). In a 
few of these cases, fever and pus are clearly described as secondary phenomena 
and associated with an unfavourable prognosis.
One of the earliest thoughts of disease - the concept of dysregulated bodily 
humors as a cause of disease - was put forth by Hippocrates4. In addition, 
the early Greeks and Romans believed that bad or corrupt air (later termed 
‘miasma’) could cause pestilence, and physician Galenus traced individual 
susceptibility to miasma to the balance of humors in the body. These early 
concepts remained largely unchallenged for over two millennia.
General introduction and outline of this thesis
Figure 1. Hieroglyphs (lines 10-11, case 47) from the Edwin Smith surgical papyrus (bought 
by Edwin Smith in 1862 in Luxor, Egypt). Described is the disease-course of a patient with 
a shoulder wound. On the third examination of the patient, the physician observed an 
inflamed wound and fever (which a modern physician would likely diagnose as an infection). 
Next, he declared the patient’s condition critical. Translation of depicted hieroglyphs: ‘Thou 
shouldst say concerning him: One having a gaping wound in his shoulder, it being inflamed, and 
he continues to have fever from it. An ailment with which I will contend.’ Adapted from: J.H. 
Breasted. The Edwin Smith Surgical Papyrus. 1980. Chicago University, Chicago Press.
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The existence of microorganisms as a cause of disease was hypothesized by 
scholars such as Marcus Terentius Varro4 (c. 100 BC), long before their actual 
discovery. It was not until the 17th century that scientists such as Antonie 
van Leeuwenhoek and Robert Hooke were the first to actually observe 
microbial life through their microscopes, paving the way for major scientific 
discoveries such as the germ-theory of disease (Louis Pasteur and Robert 
Koch), desinfection5,6, vaccination7, anti-septic surgical procedures8 and 
antimicrobial therapies9-11.
In the 20th century, researchers began unravelling the pathogenesis of sepsis. 
Several remarkable discoveries have increased our understanding of the 
pathophysiology of sepsis, such as the existence of (endo)toxins12, cytokines13 
and pattern recognition receptors14, the importance of the coagulation 
system15 and endothelium16, the role of substances such as nitric oxide17 and 
catecholamines18, as well as technical advances, for example in hemodynamic 
monitoring19-21.
In order to promote early sepsis detection in patients, the  SIRS (Systemic 
Inflammatory Response Syndrome) criteria were adopted by the medical 
community in 199222. SIRS was defined as a pro-inflammatory state that 
affected the whole body and could be evoked by an infectious or non-
infectious insult. Sepsis was present when two or more SIRS criteria were 
observed together with a suspected or documented infection. However, later 
studies showed that the SIRS criteria have important limitations, including 
poor specificity (i.e. many patients were falsely diagnosed with sepsis) and 
sensitivity (i.e. sepsis can be present in the absence of SIRS criteria)23. Given 
the emphasis on ‘pro-inflammation’ at that time, the general accepted idea 
was that patients died as ‘collateral damage’ of their own overzealous immune 
response. Many studies aimed to improve sepsis outcomes by inhibiting pro-
inflammation through pharmacological interventions (e.g. TNF-Į and LPS 
antibodies, IL-1 inhibitors, etc.), often targeting only a single molecule or 
pathway. Overall, in non-selected sepsis patients, none of these interventions 
were proven to be effective, indicating that the disease is more complex than 
is often assumed, with a large patient heterogeneity and many pathways and 
mediators leading to injury. Recently, new sepsis definitions were put forth that 
recognize the limitations of SIRS and shift the focus from pro-inflammation 
to organ dysfunction in patients with a dysregulated immune response24. 
In addition, sepsis-induced immunoparalysis - a hypoinflammatory state 
General introduction and outline of this thesis
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characterized by profound immunosuppression - is increasingly recognized 
to play a role in the later phase of sepsis, making patients more vulnerable to 
opportunistic secondary infections25,26.
Sepsis as we know it today
In present times, sepsis remains a major worldwide health issue with an 
estimated 30 million episodes and 6 million deaths per year, although this 
number is probably a significant underestimation27,28. The World Health 
Organization recently made sepsis a global health priority by adopting a 
resolution to improve, prevent, diagnose and manage sepsis. In the latest 
definitions, sepsis is characterized as a systemic, dysregulated host response 
to infection that leads to life-threatening organ dysfunction24. Septic shock 
is considered a subset of sepsis in which extensive circulatory, cellular, and 
metabolic abnormalities are associated with an even greater mortality risk. 
In the clinical setting, septic shock is characterized by elevated plasma lactate 
concentrations and the need for vasopressors to maintain sufficient blood 
pressure, despite adequate fluid resuscitation.
Due to the nature and inherent risks of sepsis and septic shock, the syndrome 
should be considered a medical emergency and treatment should be started 
as soon as possible29. Cornerstones of sepsis treatment are source control, 
antibiotic therapy, hemodynamic stabilisation through fluid resuscitation and 
vasopressor therapy, as well as organ support (e.g. mechanical ventilation and 
renal replacement therapy).
Despite advances in the knowledge of sepsis pathophysiology and refinement 
of existing therapies, the mortality of sepsis remains very high as one out of 
every three to four patients die30. As mentioned before, no new sepsis-specific 
adjuvant therapies were proven to be effective. Therefore, exploration of other 
treatment targets for sepsis is highly warranted.
The vascular endothelium might be an attractive target for pharmacological 
interventions31. The vascular endothelium consists of a single layer of cells 
that lines the interior of the blood vessel. Its main function is to control 
diffusion of molecules and cells between the intravascular and interstitial 
space. Endothelial dysfunction is one of the primordial hallmarks of sepsis16. 
During sepsis, the endothelium may become compromised due to the 
profound inflammatory response, resulting in endothelial cell death and loss 
General introduction and outline of this thesis
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of barrier integrity32,33. This can result in extravascular accumulation of fluids 
and molecules, causing edema, hemodynamic instability and subsequent 
organ failure.
Adrenomedullin, a key vasoactive hormone in sepsis
Adrenomedullin was discovered by Japanese researchers (Kitamura and 
colleagues) in 1993 who were searching for vasoactive peptides in tissue extracts 
originating from human pheochromocytoma34. The researchers identified 
a novel 52-amino acid peptide that induced a profound cyclic adenosine 
monophosphate (cAMP) response in platelets and subsequently named 
this peptide hormone ‘adrenomedullin’, because the pheochromocytoma 
originated from the adrenal medulla. Interestingly, adrenomedullin is 
ubiquitously expressed in animals belonging to the biological kingdom 
‘animalia’. So far, over 193 species belonging to the subphylum ‘vertebrata’ 
were found to have orthologs to adrenomedullin (i.e. genes in different species 
that evolved from a common ancestral gene by speciation, generally retaining 
the same function in the course of evolution), including amphibians, birds, 
cetacea and mammals. Moreover, highly comparable amino acid sequences of 
adrenomedullin are found across different species (Figure 2). The fact that the 
gene and amino acid sequence have been retained throughout evolution in 
highly different species suggests that adrenomedullin is an important, perhaps 
essential peptide.
Preclinical studies have confirmed the importance of adrenomedullin, as 
deletion of crucial parts of the adrenomedullin signalling pathway in knockout 
models were shown to result in lethal hydrops fetalis, indicating inadequate 
development of the vascular endothelial barrier39,40. Adrenomedullin levels 
are increased in sepsis patients and correlate with disease severity and 
mortality41,42. However, it is of importance to emphasize that correlation does 
not imply causation, and therefore these observational studies do not reveal 
whether the increased concentrations of adrenomedullin may be beneficial or 
detrimental in sepsis patients. Mechanistic in vitro and in vivo studies have 
Figure 2. Adrenomedullin amino acid sequence in humans35, Cynomolgus monkeys36, 
dogs37, mice38 and chickens38. Underscored letters indicate a different amino acid sequence 
compared to humans.
General introduction and outline of this thesis
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shown that adrenomedullin exerts many different effects in different organ 
systems and cells, including vasorelaxation of vascular smooth muscle cells 
and stabilization of the endothelial barrier. Preclinical work in animal models 
of systemic inflammation and septic shock showed that administration of 
adrenomedullin is able to beneficially influence outcome. However, given its 
strong vasodilatory effects (thereby potentially augmenting shock) and short 
half-life, adrenomedullin infusion may not be ideal for use in patients.
Adrenomedullin as a treatment target
Previously, various high-affinity monoclonal antibodies were developed, 
each targeting different epitopes of the adrenomedullin peptide, resulting in 
complete or partial inhibition of adrenomedullin signaling43. The efficacy of 
these antibodies was investigated in a lethal model of murine septic shock43. 
Interestingly, a non-neutralizing antibody directed against the N-terminal 
epitope of adrenomedullin resulted in a survival benefit, whereas antibodies 
targeting the C-terminal epitope that completely inhibited adrenomedullin's 
function did not. Subsequent studies with this non-neutralizing antibody 
in a resuscitated model of murine septic shock showed that pretreatment 
with the antibody improved various outcome parameters, including reduced 
catecholamine demand and renal dysfunction44. 
Subsequently, a humanized variant of this murine antibody has been developed, 
and was named Adrecizumab. The name Adrecizumab can be broken down into 
Adre-ci-zu-mab, marking it as a humanized (‘zu’) monoclonal antibody (‘mab’) 
acting on the cardiovascular system (‘ci’), targeting adrenomedullin ('Adre'). 
The preclinical and first-in-human safety, efficacy and pharmacokinetics/-
dynamics of this novel, humanized, adrenomedullin-binding antibody are 
presented in this thesis.
General introduction and outline of this thesis
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Aims of this thesis
• To provide an overview of adrenomedullin’s effects in the context of sepsis 
and heart failure
• To unravel the mechanism of action of Adrecizumab
• To provide a detailed overview of experimental human endotoxemia
• To assess the association of adrenomedullin levels and outcome in critically 
ill and sepsis patients
• To evaluate the safety and efficacy of Adrecizumab in both animals and 
humans
General introduction and outline of this thesis
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Outline of this thesis
Part I provides in-depth background information on adrenomedullin and 
the adrenomedullin-binding antibody Adrecizumab in the context of sepsis 
and heart failure, as well as background information on the experimental 
human endotoxemia model. Chapter 2 provides information on endothelial 
dysfunction and the role of adrenomedullin during sepsis. Furthermore, the 
use of adrenomedullin as a therapy or treatment target is discussed. In chapter 
3 and chapter 4 a hypothesis on the mechanism of action of Adrecizumab is 
presented, which may have therapeutic potential in sepsis patients. Chapter 
5 describes the potential role of adrenomedullin in heart failure, together 
with a hypothesis on the potential therapeutic use of Adrecizumab in heart 
failure patients. Part I ends with chapter 6, in which an extensive description 
of experimental human endotoxemia is provided, a model of systemic 
inflammation in humans that is also used in part IV of this thesis.
Recently, a novel assay has been developed to measure circulating levels of 
biologically active adrenomedullin (bio-ADM)45. Two initial studies revealed 
increased bio-ADM concentrations in sepsis, which correlated with disease 
severity and mortality41,42. Part II contains two chapters on the use of bio-
ADM as a biomarker in a general critically ill population (chapter 7) and in 
patients with severe sepsis and septic shock (chapter 8).
Part III focuses on preclinical evaluation of Adrecizumab. In chapter 9, the 
effects of Adrecizumab on vascular barrier function and survival in rodent 
models of systemic inflammation and sepsis are described. In chapter 10, 
the effects of Adrecizumab on hemodynamics and the myocardium are 
investigated in septic rats. Chapter 11 contains a preclinical safety evaluation 
of Adrecizumab in rodents, beagle dogs and non-human primates.
Part IV describes the first-in-human clinical evaluation of Adrecizumab. Two 
phase I studies in healthy human volunteers are described in chapter 12. 
First, the safety, tolerability and pharmacokinetics/-dynamics of Adrecizumab 
were investigated during non-inflammatory conditions. Subsequently, a study 
with Adrecizumab was performed during systemic inflammation induced by 
experimental human endotoxemia. Chapter 13 comprises the study protocol 
of the currently ongoing phase II, randomized, double-blind, placebo-
controlled study with Adrecizumab in patients with early septic shock 
(AdrenOSS-2).
General introduction and outline of this thesis
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Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis
Abstract
Sepsis remains a major medical challenge, for which, apart from improvements 
in supportive care, treatment has not relevantly changed over the last 
few decades. Vasodilation and vascular leakage play a pivotal role in the 
development of septic shock, with vascular leakage being caused by disrupted 
endothelial integrity. Adrenomedullin (ADM), a free circulating peptide 
involved in regulation of endothelial barrier function and vascular tone, is 
implicated in the pathophysiology of sepsis. ADM levels are increased during 
sepsis, and correlate with extent of vasodilation, as well as with disease severity 
and mortality. In vitro and preclinical in vivo data show that administration 
of ADM exerts anti-inflammatory, antimicrobial, and protective effects on 
endothelial barrier function during sepsis, but other work suggests that it may 
also decrease blood pressure, which could be detrimental for patients with 
septic shock. Work has been carried out to negate ADM's putative negative 
effects, while preserving or even potentiating its beneficial actions. Preclinical 
studies have demonstrated that the use of antibodies that bind to the 
N-terminus of ADM results in an overall increase of circulating ADM levels 
and improves sepsis outcome. Similar beneficial effects were obtained using 
coadministration of ADM and ADM-binding protein-1. It is hypothesized 
that the mechanism behind the beneficial effects of ADM binding involves 
prolongation of its half-life and a shift of ADM from the interstitium to 
the circulation. This in turn results in increased ADM activity in the blood 
compartment, where it exerts beneficial endothelial barrier-stabilizing effects, 
whereas its detrimental vasodilatory effects in the interstitium are reduced. 
Up till now, in vivo data on ADM-targeted treatments in humans are lacking; 
however, the first study in septic patients with an N-terminus antibody 
(Adrecizumab) is currently being conducted.
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Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis
Introduction
Sepsis remains a major health problem in the 21st century, with an increasing 
incidence and high mortality in intensive care units worldwide1,2. Sepsis is an 
inflammatory syndrome in which a dysregulated host response to infection 
results in life-threatening organ dysfunction3. Its most severe form, septic 
shock, is defined by increased lactate levels and vasopressor requirement to 
maintain sufficient blood pressure and organ perfusion, despite adequate 
fluid resuscitation3. The sepsis syndrome is characterized by a very complex, 
multilayered pathogenesis, that involves many harmful and protective 
pathways4,5. The vascular endothelium is a protective barrier involved in the 
maintenance of vessel integrity that controls diffusion of molecules between 
the intravascular and interstitial space. Endothelial dysfunction is one of the 
major hallmarks of sepsis6. The profound inflammatory response observed 
in sepsis plays a pivotal role in this phenomenon, which is accompanied by 
endothelial cell death and loss of barrier integrity5-8. Underlying processes 
of loss of barrier integrity include increased actomyosin contraction (also 
known as ‘stress fiber formation’) in response to phosphorylation of myosin 
light chains by myosin light chain kinase (MLCK)9. Loss of barrier integrity 
leads to extravascular accumulation of fluids and molecules, causing edema, 
a decreased blood pressure and subsequent organ failure. A considerable 
percentage of mortality occurs in the early phase of sepsis, when multi-
organ failure develops despite supportive therapies. Although the general 
knowledge of the pathophysiology of sepsis has improved, this has not 
translated to a single effective adjuvant therapy. The lack of clinical trials 
that show a therapeutic benefit may partially be explained by large patient 
heterogeneity, but also because of the complexity of the pathophysiology8,10. 
Thus, there is still an urgent and unmet need for new therapeutic options, and 
interventions that may improve the endothelial barrier function and vascular 
tone are an attractive category11. A key hormone involved in regulation of 
the endothelium barrier and vascular tone is adrenomedullin (ADM). In 
the current review, we describe the general vascular properties of ADM and 
provide an overview of the current understanding of the role of ADM in 
sepsis and septic shock. Furthermore, we discuss the potential of ADM and 
ADM-targeted treatments for sepsis patients.
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Adrenomedullin
ADM was first discovered in human pheochromocytoma tissue in 199312. 
Although ADM's initially discovered effects were vasodilation and blood 
pressure lowering effects12-14, later work demonstrated that ADM exerts a 
multitude of biological actions, in both health and disease15,16. ADM is a 52 
amino acid peptide belonging to the calcitonin gene-related peptide family17. 
In humans, the gene encoding ADM is located on chromosome 11 and consists 
of 4 exons and 3 introns18. The gene is transcribed into a pre-messenger RNA 
(mRNA) molecule, containing 4 exons and 3 introns. The removal of all 
introns results in the formation of a mature mRNA molecule (form A) which 
is eventually translated and processed into ADM as detailed below. However, 
if the third intron of this pre-mRNA molecule is not removed, this results in 
the formation of a longer mRNA molecule (form B). Due to the presence 
of a stop codon in this intron, a smaller prohormone is produced that does 
not result in the production of ADM19. It remains unknown which factors 
regulate the splicing of this third intron and whether this is altered during 
sepsis. Translation of the form A mRNA molecule leads to a 185 amino acid 
long preprohormone (prepro-ADM) that undergoes a multistep cleavage 
process. First, a 21-residue N-terminal signalling peptide is cleaved of prepro-
ADM, generating a 164 amino acid pro-ADM peptide. Next, pro-ADM is 
cleaved into pro-ADM N-terminal 20 peptide (PAMP)20-22, midregional pro-
ADM (MR-proADM)23, adrenotensin24 and a glycine-extended 53-amino 
acid peptide, the latter of which is subsequently converted to the 52-amino 
acid mature ADM by enzymatic amidation to an extent, which may vary 
depending on the pathology and other factors25. Besides ADM, several of the 
other cleavage products are also vasoactive (e.g. PAMP exerts vasodilatory 
effects, whereas adrenotensin is vasoconstrictive). ADM is widely expressed 
in virtually all human tissues. The highest concentrations of the peptide 
were found in the adrenal medullae, cardiac atria and lungs26,27, whereas the 
highest concentrations of ADM mRNA were measured in the lungs, cardiac 
atria, aorta and mesenteric arteries28. Many cells are capable of producing 
ADM, including endothelial cells, vascular smooth muscle cells (VSMCs), 
monocytes, renal parenchymal cells and macrophages29-35. ADM exerts its 
effects by ligation of receptor complexes consisting of the calcitonin receptor-
like receptor (CRLR) combined with a specific receptor activity-modifying 
protein (RAMP)36,37. The ADM1 and ADM2 receptors consist of the CRLR 
combined with RAMP2 and RAMP3, respectively, whereas the combination 
of CRLR and RAMP1 forms the CGRP (calcitonin gene-related protein) 
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receptor. Most functional studies do not specify which receptor is specifically 
activated, and are therefore referred to as ‘ADM receptors’. Analogous to 
the ubiquitous expression of the ADM peptide, ADM receptors have also 
been detected in various tissues and organs, including blood vessels, skeletal 
muscles, heart, lungs and nerve tissue38-41. On a cellular level, ADM receptors 
are expressed on many different cell types, including endothelial cells, vascular 
smooth muscle cells, cardiomyocytes, macrophages and dendritic cells33,42-44. 
Interaction of ADM with its receptor occurs through its C-terminal moiety45, 
and the N-terminal part of ADM is thought to be only of minor importance 
for its agonist function46. Circulating ADM has a half-life of approximately 
22 minutes47, and is rapidly degraded from its N-terminus by proteases48-50. 
Moreover, it has been reported that the three CRLR/RAMP receptors are 
internalized upon stimulation together with ADM, and thus function as 
clearance receptors51,52. On a more organ specific level, the lungs appear to be 
involved as a site of clearance53,54.
The role of adrenomedullin in the regulation of blood pressure
As mentioned before, the first discovered physiological effect of ADM was 
vasodilation, leading to hypotension and reduced peripheral resistance12-14. 
Over the following years, many studies have confirmed these results. In 
vitro studies demonstrated potent vasodilatory effects of ADM on isolated 
blood vessels42,55 and in isolated organs56, and in vivo studies showed that 
direct infusion of ADM resulted in decreased blood pressure and induced 
a compensatory increase of heart rate, endogenous noradrenaline and 
renin concentrations in various mammalian species (including humans), 
which coincided with increased cardiac output14,57-62. These vasodilatory 
effects of ADM are mediated through binding with its receptors present 
on vascular endothelial cells and VSMCs42. It is unknown, though, how 
both types of interaction contribute quantitatively under physiological and 
pathophysiological conditions to vasodilation. Several signaling pathways have 
been described through which ADM causes vasodilation, both endothelium-
dependent and endothelium-independent55, which are depicted in Figure 1. 
In an endothelium-independent way, binding of ADM with its receptors on 
VSMCs increases intracellular cyclic adenosine monophosphate (cAMP)63,64, 
which subsequently activates protein kinase A (PKA, also known as cAMP-
dependent kinase)42. PKA inhibits smooth muscle cell contraction in several 
ways. For example, it induces the opening of vascular potassium channels, 
causing potassium efflux, leading to subsequent membrane potential 
Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis
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hyperpolarisation and closing of voltage gated calcium channels, ultimately 
reducing intracellular calcium content42,65-67. Of note, potassium channel 
activation is known to play an important role in the blunted norepinephrine-
responsiveness observed in sepsis68, and potassium channel blockers have 
been shown to restore norepinephrine sensitivity in a human in vivo model 
of systemic inflammation69. Other effects of PKA include inhibition of 
sarcoplasmatic calcium channels and MLCK. The endothelium-dependent 
mechanisms through which ADM induces vasodilation are the inositol-1,4,5-
triphosphate (IP3) system and the phosphatidylinositol-4,5-bisphosphate 
3-kinase-protein kinase B (PI3K/Akt) pathways. Both of these pathways 
stimulate endothelial nitric oxide (NO) synthase (eNOS), leading to NO 
release. In turn, NO activates cyclic guanoside monophosphate (cGMP) in 
VSMCs, resulting in activation of protein kinase G (PKG), ultimately leading 
in inhibition of sarcoplasmatic calcium channels and activation of myosin 
light chain phosphatase69,70 and vasodilation. Prostaglandins have also been 
linked to ADM-induced vasodilation, through the endothelium-dependent 
cyclooxygenase-1 (COX-1) pathway42,71, although results are inconsistent66, 
which may be due to differences between animals and the origin of the 
vessels studied. Finally, it has been suggested that ADM is involved in the 
central regulation of blood pressure, although these data are equivocal. The 
presence of ADM has been demonstrated in the hypothalamus72, and some 
studies have reported that micro-injections of ADM into the hypothalamic 
paraventricular nucleus elicited a rapid, short decrease in blood pressure73,74. 
Conversely, both infusion of ADM into the intracerebral fluid and micro-
injections of ADM in the rostral ventrolateral medulla have been shown to 
increase blood pressure in animal studies75,76.
Adrenomedullin regulates endothelial barrier function
The vascular endothelium comprises the inner layer of all blood vessels. This 
single-cell vascular barrier separates the intravascular from the interstitial space 
and regulates diffusion of molecules and other substrates through paracellular 
and transcellular transport77,78. Additional roles of the endothelium include 
regulation of vessel tone, vascular wall permeability, inflammation, hemostasis 
and angiogenesis6,78,79. Inflammation leads to barrier compromise at the level of 
the endothelial cell-cell junction, causing the boundary between intravascular 
and interstitial spaces to become more porous, subsequently allowing for 
leakage of inflammatory mediators (e.g. cytokines and prostaglandins) to the 
interstitium and leukocyte infiltration into the tissues6. This “leaky barrier” 
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Figure 1. ADM causes vasodilation through endothelium-dependent and endothelium-
independent pathways. In an endothelium-independent way, binding of ADM with its 
receptors on VSMCs increases intracellular cAMP. This leads to subsequent activation 
PKA which inhibits smooth muscle cell contraction in several ways. First, PKA opens 
VSMC potassium channels, causing potassium efflux, leading to membrane potential 
hyperpolarisation and closing of voltage gated calcium channels, reducing intracellular 
calcium content. Other effects of PKA include inhibition of sarcoplasmatic calcium channel 
and MLCK. The latter of which is essential for actomyosin contraction. Several endothelium-
dependent pathways have been identified. This includes a COX/PGI2 pathway which activates 
the cAMP pathway in VSMCs. Other involved endothelium-dependent pathways are PI3k/
Akt and PLC/IP3, which both activate eNOS which leads to subsequently activation of 
a cGMP/cGMP-dependent kinase pathway in VSMCs. This pathway leads to activation 
of MLCP which ‘inactivates’ the myosin light chain, and again lowers levels of calcium 
by inhibiting sarcoplasmatic calcium channels. Abbreviations: AC, Adenylyl cyclase; ADM, 
adrenomedullin; AKT, protein kinase B; ATP, adenosine triphosphate; Ca2+, calcium; cAMP, cyclic 
adenosine monophosphate; cGMP, cyclic guanosine monophosphate; COX-1, cyclooxygenase-1; 
eNOS; endothelial nitric oxide synthase; GTP, guanosine triphosphate; IP3, inositol triphosphate; 
MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase; NO, nitric oxide; 
PGI2, prostacyclin; PI3K phosphoinositide 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; 
PKA, protein kinase A; PLC, phospholipase C; SR, sarcoplasmatic reticulum; VSMC, vascular 
smooth muscle cell.
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is part of the physiological response to infection, as it is required to combat 
pathogens in tissues. However, the excessive endothelial barrier disruption 
observed in sepsis also results in large amounts of fluid leaking from the 
blood into the tissues, where it accumulates and forms interstitial edema5,80. 
This is a major contributor to the development of shock. Underlying 
mechanisms of endothelial barrier compromise include rearrangement of the 
actin cytoskeleton, with cortical actin bundles promoting adherens junction 
formation and endothelial cell junction tightening, whereas the formation of 
stress-fibers and phosphorylation of the myosin light chain promotes junction 
dissociation81. 
ADM is essential for endothelial barrier development and barrier stability. In 
knock-out models where crucial parts of the ADM-ADM receptor signaling 
pathway were deleted, development of lethal hydrops fetalis was noted, 
indicating inadequate development of the endothelial barrier82,83. Moreover, 
in conditional knock-out models, in which either ADM production by 
endothelial cells (ECs), or formation of the RAMP2 part of the ADM1 receptor 
was abolished, increased vascular permeability and systemic edema formation 
was observed84,85. This coincided with altered expression of the small GTPases 
Rac1 (Ras-related C3 botulinum toxin substrate 1) and RhoA (Ras homolog 
gene family, member A), which are involved in the formation of cortical actin 
and stress fibers; concentration of the protective GTPase Rac1 were reduced 
whereas levels of the detrimental RhoA GTPase were increased85.
Additional preclinical work has elucidated underlying intracellular signaling 
pathways involved in the endothelial barrier-stabilising effects of ADM. In 
cultured human umbilical vein endothelial cell (HUVEC) cultures and porcine 
pulmonary artery endothelial cell (PAEC) monolayers, pretreatment with 
ADM reduced endothelial hyperpermeability elicited by hydrogen peroxide, 
thrombin or hemolysin A by attenuating myosin light chain phosphorylation, 
stress-fiber formation and subsequent gap formation through a cAMP-
dependent mechanism86. Moreover, ADM pretreatment diminished hydrogen 
peroxide-induced edema formation in isolated perfused rabbit lungs, 
which was accompanied by increased cAMP levels in the lung perfusate86. 
Other preclinical work demonstrated similar effects; both treatment with 
ADM prior to and following an inflammatory insult reduced endothelial 
hyperpermeability in S. aureus Į-toxin-exposed isolated rat ileum, again by 
reducing endothelial myosin light chain phosphorylation and endothelial 
Adrenomedullin and adrenomedullin-targeted therapy as treatment strategies relevant for sepsis
2
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 33
33
cell contraction87. In cortactin-deficient HMEC-1 (human microvascular 
endothelial cell) monolayers, which show increased permeability, ADM 
administration reversed myosin light chain phosphorylation and stress-fiber 
formation through ADM-induced Rap1 activation and Rock1 inhibition89. 
In line, ADM rescued the increase in endothelial permeability in cortactin 
knockout mice88. Similar effects were observed in lymphatic endothelial cells, 
in which ADM stimulation caused a reorganization of the tight junction 
protein ZO-1 (zonula occludens-1) and VE-cadherin in the plasma membrane, 
thereby tightening the membrane89. Other experiments demonstrated barrier 
disrupting effects of ADM blockade through functional inhibition of the VE-
cadherin/ȕ-catenin complex90. Underlying mechanisms included induction 
of Src-dependent VE-cadherin phosphorylation, which prevented binding 
of ȕ-catenin to the cytoplasmic tail of VE-cadherin, inhibiting cell barrier 
function. Furthermore, ȕ-catenin phosphorylation was induced, which targets 
ȕ-catenin for ubiquitination and proteasomal degradation. Finally, possible 
involvement of the PI3K/Akt pathway was suggested90. These data emphasise 
that the ADM system is essential for endothelial barrier stabilization.
Figure 2 summarizes the mechanisms through which ADM may stabilize the 
endothelial barrier. Note that the cAMP/PKA pathway once again plays an 
important role. Ligation of ADM with its receptors elicits a strong increase in 
intracellular cAMP in endothelial cells, which is thought to be one of the most 
important signaling molecules involved in stabilization of the endothelial 
barrier69,91. This results in subsequent activation of PKA and inhibition of 
Rho GTPase (i.e. RhoA; Ras homolog gene family, member A). Independent 
of PKA, cAMP leads to activation of Rap1 by the Rap1 guanine-exchange 
factor EPAC81,92. Rap1 is thought to enhance endothelial cell barrier function 
in multiple ways, including inhibition of RhoA which reduces actomyosin-
induced tension on adherens junctions81. Moreover, Rap1 promotes junctional 
adhesiveness via Afadin, a promoter of junctional tightening by mediating 
attachment of adherens junctions and the actin cytoskeleton81. Finally, both 
PKA and Rap1 activate Rac1, which results in enforcement of adherens 
junctions and strengthening of the cortical actin cytoskeleton93 and inhibition 
of RhoA93. Another relevant mechanism through which ADM exerts barrier-
enhancing effects is by stabilizing the VE-cadherin/ ȕ-catenin complex at the 
cell-cell junctions, possibly mediated through the PI3K/Akt pathway. 
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Figure 2. Several pathways have been identified through which ADM exerts endothelial barrier 
stabilizing effects. Ligation of ADM with its receptors elicits a strong increase in intracellular 
cAMP in endothelial cells, which subsequently activates PKA and, through activation of 
EPAC, Rap1. PKA and Rap1 inhibit RhoA/ROCK which results in reduced myosin light 
chain phosphorylation, decreasing actomyosin contraction (i.e. the ‘pulling forces’ exerted 
on the endothelial cell junctions). Rap1 also promotes junctional adhesiveness via Afadin, 
strengthening junctional tightening by mediating attachment of adherens junctions and the 
actin cytoskeleton. PKA also increases cortical actin formation through Rac1, which promotes 
cell-cell stability and cell-matrix adhesion by its connection to tight and adherens junctions. 
Moreover, Rac1 is also able to inhibit RhoA, decreasing myosin light chain phosphorylation 
and actomyosin contraction, similar to PKA and Rap1. Ligation of ADM with its receptor 
is also thought to prevent phosphorylation of VE-cadherin and ȕ-catenin complexes (which 
would be detrimental for barrier function because phosphorylation of VE-cadherin prevents 
binding of ȕ-catenin to the cytoplasmic tail of VE-cadherin, and because phosphorylation 
of ȕ-catenin targets ȕ-catenin for ubiquination and proteasomal degradation), through the 
PI3K/Akt pathway. Abbreviations: AC, Adenylyl cyclase; ADM, adrenomedullin; AJ, adherens 
junction; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; cGMP, cyclic 
guanosine monophosphate; EPAC, exchange factor directly activated by cAMP; MLCK, myosin 
light chain kinase; MLCP, myosin light chain phosphatase; PI3K/Akt, phosphatidylinositol-4,5-
bisphosphate 3-kinase-protein kinase B; PKA, protein kinase A; Rac, Ras-related C3 botulinum 
toxin substrate 1; Rap1, Ras-related protein 1; ROCK, rho-associated protein kinase; TJ, tight 
junction; VE-cadherin, vascular endothelial-cadherin; ZO, zonula occludens.
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Miscellaneous effects of adrenomedullin relevant for sepsis
The above described data suggest potential utilization of the ADM system 
for the treatment of diseases with marked endothelial barrier dysfunction, of 
which septic shock is a prime example, although these beneficial properties 
might be offset by vasodilatory effects, an issue we will discuss later on in 
this review. Furthermore, next to effects on vascular tone and the endothelial 
barrier, ADM also has other properties relevant in the context of sepsis, 
including immunoregulatory, anti-microbial and cardioprotective effects.
Immunoregulatory effects
The immune system plays a pivotal role in the pathogenesis of sepsis4,8. 
Therefore, it is relevant to discuss the potential immunoregulatory effects 
of ADM. Several in vitro studies have demonstrated that ADM exerts anti-
inflammatory effects and we have summarized the involved pathways in Figure 
3. One of the first studies conducted on this matter, investigated the effects 
of ADM in lipopolysaccharide (LPS)-stimulated rat alveolar macrophages. 
Interestingly, ADM significantly inhibited cytokine-induced neutrophil 
chemoattractant (CINC/CXCL-1) release, possibly through a cAMP-
dependent mechanism94. Other experiments in Swiss 3T3 murine fibroblasts 
demonstrated that ADM inhibits interleukin-1 beta (IL-1ȕ)-induced tumor 
necrosis factor alpha (TNFĮ) secretion and confirmed the major role of 
the cAMP-PKA pathway: A cAMP-dependent protein kinase inhibitor was 
able to negate ADM's inhibitory effects95. Similar effects of ADM were 
observed in microglia upon stimulation with LPS, inhibiting both TNFĮ 
and IL-696, as well as in LPS-stimulated murine RAW264.7 macrophages 
and rat Kupffer cells97. In vivo experiments have confirmed these in vitro 
studies. Coadministration of ADM and AMBP-1 (adrenomedullin binding 
protein-1, a protective peptide with putative ADM-enhancing effects) in a 
rat endotoxemia model attenuated the TNFĮ response through a mechanism 
that involves PPARG (peroxisome proliferator-activated receptor-gamma)98. 
Interestingly, ADM has also been a subject of interest for the treatment of 
inflammatory bowel disease. Intracolonic administration of ADM resulted in 
a dose-dependent and significant reduction of the size of the ulcerative lesions 
in a model of acetic acid-induced colitis, and reduced tissue IL-6 levels99. 
Subsequent studies have confirmed these results. For instance, lower levels 
of IFN-Ȗ (interferon-gamma) and TNFĮ were observed in rodent models of 
dextran sulphate sodium-induced colitis100,101. A case series on 7 ulcerative 
colitis patients that received intravenous infusion of ADM for 8 hours daily 
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over a period of 2 weeks reported improved disease activity index scores, 
and substantial improvement of ulcers upon endoscopic examination102. 
No serious adverse effects were observed, apart from minor effects on blood 
pressure and heart rate.
Figure 3. Intracellular mechanisms behind ADM-induced anti-inflammatory effects. 
Stimulation of the ADM-receptors results in increased intracellular cAMP concentrations, 
which subsequently activate PKA. PKA prevents NF-țB from entering the nucleus, resulting 
in reduced transcription of pro-inflammatory genes. PKA-induced activation of CREB 
results in augmented anti-inflammatory transcription of anti-inflammatory cytokines. 
Abbreviations: AC, Adenylyl cyclase; ADM, adrenomedullin; ATP, adenosine triphosphate; cAMP, 
cyclic adenosine monophosphate; CREB, cAMP response element-binding protein; NF-țB, nuclear 
factor kappa-light-chain-enhancer of activated B cells; PKA, protein kinase A. 
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Anti-microbial properties
The epithelium represents the first protective barrier against pathogens. Many 
types of epithelial cells secrete ADM, and it can thus be found in many 
bodily fluids at much higher concentrations than in plasma103,104. ADM has 
chemical and structural similarities with other antimicrobial peptides (i.e. 
ȕ-defensin-2), including peptide length, a net positive charge, a disulphide 
bond between residues 16 and 21 and an amidated tyrosine at the carboxyl 
terminus105. This forms an amphipathic structure which permits bacterial 
membrane intercalation106. In vitro studies have demonstrated that both the 
ADM peptide and also smaller ADM fragments are able to inhibit bacterial 
growth107.
Cardiac protection
ADM may also confer cardioprotective effects. Increased cardiac hypertrophy 
and fibrosis were observed after subjecting heterozygous ADM knock-out 
mice to stress-induced cardiac hypertrophy compared with their wild-type 
counterparts108,109. Other work demonstrated ADM-induced reduction of 
doxorubicin-induced cardiac myocyte apoptosis via a cAMP-dependent 
mechanism110, which was later confirmed in vivo in a mice model111. The 
first steps concerning ADM treatment in heart failure patients have been 
undertaken. In patients with stable congestive heart failure, a short-course 
ADM infusion resulted in a significant decrease of pulmonary capillary wedge 
pressure and pulmonary arterial pressure, as well as an increase of cardiac 
index58. Moreover, ADM increased urinary volume and sodium excretion, 
while decreasing plasma aldosterone levels. In a pilot study in patients 
with acute decompensated heart failure, combined therapy of ADM and 
human atrial natriuretic peptide also resulted in beneficial hemodynamic 
and hormonal changes, including decreased pulmonary arterial pressure, 
increased urine production and reduced aldosterone and brain natriuretic 
peptide plasma concentrations112. Until now, no further studies have been 
conducted in patients with heart failure.
In contrast to the data presented above, ADM has also been named a ‘cardiac 
depressant factor’, because administration of an ADM-receptor antagonist 
resulted in increased myocyte contractility in isolated ventricular cardiac 
myocytes during the early phase rat endotoxemia, although no measurements 
of cardiac output were performed113,114.
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Adrenomedullin in sepsis
Several processes that take place during sepsis stimulate ADM secretion, 
including hypoxia, increased circulating levels of LPS, and production of 
cytokines such as TNF, interleukin-1 (IL-1), and interferon-Ȗ (IFN-Ȗ)33,115-118. 
Circulating ADM levels have been measured in various pathophysiological 
conditions, and interestingly, the highest concentrations were found in 
patients with septic shock119-122. In sepsis patients, circulating ADM levels 
correlated with relaxation of vascular tone123 as well as with disease severity 
and mortality119-121,124. These associations suggest that ADM may play a 
detrimental role in sepsis, and that ADM-targeted therapies could be of benefit. 
However, no causal relationships can be deducted from these observational 
studies and it may also be possible that increases in ADM represent a (failing) 
compensatory response. In other words, in light of ADM's aforementioned 
beneficial effects on various pathophysiological processes that take place 
during sepsis, increased ADM levels might also represent a strategy employed 
by the body to curtail organ damage during sepsis.
Adrenomedullin and adrenomedullin-targeted therapy as treatment 
strategies relevant for sepsis
Over the last decades, many have sought to investigate whether administration 
of ADM, modulation of its function, or antagonizing ADM may influence 
outcome in various preclinical models of sepsis as well as in models of systemic 
inflammation and organ injury. Below, we provide an overview of the available 
data on each of these treatment strategies. Please note that models of systemic 
inflammation and organ injury do not comprehensively mimic sepsis, but do 
capture distinct pathophysiological hallmarks of the disease and are therefore 
of relevance for this overview. 
Adrenomedullin administration
An overview of preclinical studies that have investigated the effects of ADM 
administration is presented in Table 1. It needs to be emphasized that except 
for one, these studies were not performed using infection models, but in 
clinically less relevant models of systemic inflammation or organ injury.
ADM administration resulted in improved hemodynamics, reduced vascular 
leakage and organ damage, and improved outcome in different models of 
endotoxemia125-129. Furthermore, beneficial effects of ADM were reported 
on various outcome measurements in models of lung injury, including 
attenuated endothelial hyperpermeability, liver injury, less histopathological 
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changes and reduced pro-inflammatory cytokine levels130-132. Moreover, ADM 
showed protective effects on organ injury in several models of acute kidney 
injury133,134. Although the potential beneficial effects of ADM infusion have 
been extensively investigated in the abovementioned models of endotoxemia, 
lung- and renal injury, data obtained in models that are more relevant to 
sepsis (for example, in resuscitated cecal ligation and puncture models in 
larger animals) are lacking. 
There may be some drawbacks to ADM administration. Because of the short 
half-life of ADM (22 minutes)47, infusion would have to be continuous over 
longer periods of time, as was done previously in ulcerative colitis patients102. 
Moreover, as alluded to before, ADM has potent vasodilatory effects, which 
may raise concerns for ADM-induced hypotension. Finally, ADM may be 
difficult to handle in clinical practice, because of its adhesiveness, arguably 
sticking to artificial surfaces135. 
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Intervention Model Results (compared to placebo) Reference
Bolus of ADM 
(pretreatment)
H2O2-induced vascular 
leakage in isolated, 
mechanically ventilated 
rabbit lungs
ĻVascular leakage Hippenstiel et al.86
Continuous infusion of 
incremental dosages of 
ADM (posttreatment)
Ovine endotoxemia (24 
hours of Salmonella typhosa 
LPS administration)
ĻPulmonary vascular resistance 
ĹCardiac index and heart rate
Westphal et 
al.128
Continuous infusion 
of ADM (pre- and 
posttreatment groups)
Isolated rat ileum with S. 
aureus Į-toxin administration
Ĺ Endothelial barrier function 
in both pre- and posttreatment 
groups.
Brell et al.87
Continuous infusion 
of ADM (pre- and 
posttreatment groups)
Ovine endotoxemia (4 hours 
of Salmonella typhosa LPS 
administration)
Ĺ Cardiac index 
Ļ Pulmonary arterial pressure
Ĺ Lactate clearance
(for both pre- and posttreatment 
groups)
Ertmer et 
al.125
Continuous infusion of 
ADM (pretreatment)
Intratracheal LPS-induced 
lung injury in rats
Ļ Vascular leakage 
Ļ Histopathological abnormalities
Ļ Protein, albumin and 
inflammatory markers in BAL 
fluid
Itoh et al.126
Continuous infusion of 
ADM (posttreatment)
S. aureus Į-toxin model in 
resuscitated rats.
Ļ Vascular leakage
Ĺ 6-hour blood pressure 
Ĺ Cardiac index and 6-hour 
survival
Temmesfeld-
Wollbrück et 
al.127
Continuous infusion of 
ADM (posttreatment)
S. aureus Į-toxin model in 
rats
Ļ Gut epithelial 
hyperpermeability
Temmesfeld-
Wollbrück et 
al.129
Continuous infusion of 
ADM 
(started pretreatment 
in 2 hour experiments, 
and after 2 hours of 
ventilation in the 6 
hour experiments)
Ventilator induced lung 
injury model in mice, 
experiments with 2 and 6 
hours of ventilation
For both experiments
Ļ Lung hypermeability, leukocyte 
accumulation and MLCP 
expression 
Ĺ Oxygenation, lactate and 
creatinine clearance
Müller et 
al.130
Bolus of intrapleural 
ADM (posttreatment)
Carrageenan-induced 
pleurisy model in mice
Ļ Pro-inflammatory cytokines 
Ļ Oxidative and nitroxidative 
lung tissue injury
Talero et al.132
Continuous infusion of 
ADM (pretreatment)
Aortic ischemia-reperfusion 
in rats 
Ļ Kidney injury (various 
morphological and biochemical 
parameters)
Oyar et al.134
Bolus of ADM 
(pretreatment)
Contrast-induced 
nephropathy in rats
Ļ Kidney injury and 
inflammation Inal et al.
133
Continuous infusion of 
ADM (pretreatment)
Pneumococcal pneumonia in 
mechanically ventilated mice
Ļ Lung injury
Ļ Lung hyperpermeability
Ļ Indirect liver and gut injury
Müller-
Redetzky et 
al.131
Table 1. Overview of preclinical studies investigating ADM administration in different 
models related to sepsis.
Only studies using models of sepsis or models that capture some of the prominent hallmarks 
of sepsis have been included. Abbreviations: ADM, adrenomedullin; BAL, bronchoalveolar 
lavage; E. coli, Escherichia coli; H2O2, hydrogen peroxide; LPS, lipopolysaccharide; MLCP, myosin 
light chain phosphorylase; S. aureus; Staphylococcus aureus.
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Coadministration of adrenomedullin and complement factor H
Complement factor H is thought to be capable of binding to ADM (and 
therefore also known as ‘ADM binding protein-1’ [AMBP-1] in this context), 
and chaperone ADM in the circulation136. However, note that this has 
been subject to some debate in literature. The observed in vitro binding 
could theoretically be due to unspecific (ionic) interaction. Interference of 
complement factor H with ADM could not be demonstrated in other recent 
work, in which up to almost 400.000 fold molar excess of complement factor 
H did not influence ADM recovery137. Furthermore, in vivo plasma levels of 
complement factor H are approximately 109 fold higher than ADM levels. 
Therefore, it could be hypothesised that exogenous administered complement 
factor H would not add significantly to endogenous levels.
The ADM binding site of AMBP-1 has not yet been discovered, although it 
is thought that AMBP-1 may modulate ADM activity and degradation. A 
functional assay revealed a 2-fold increased cAMP response after coincubation 
of cells with ADM and AMBP-1 compared to incubation with ADM alone138. 
Other work has demonstrated that AMBP-1 protects ADM from proteolytic 
degradation49, thereby presumably increasing its half-life. Because of these 
possible potentiating effects, several studies have investigated the therapeutic 
potential of coadministration of ADM and AMBP-1 in various preclinical 
animal models. Initially, the effects of coadministration of ADM and AMBP-
1 were assessed in a model of CLP-induced sepsis in rats, where pretreatment 
with the combination of ADM and AMBP-1, but not of each compound 
individually, resulted in positive effects on hemodynamic parameters, 
augmenting oxygen delivery, cardiac output and lactate clearance139. 
Furthermore, improved 10-day survival was observed in animals undergoing 
CLP surgery. Note that in these survival experiments, treatment was started 
5 hours after CLP surgery. Other studies have also demonstrated beneficial 
effects coadministration of ADM and AMBP-1 in models of hemorrhagic 
shock140-142, ischemia/reperfusion143,144, endotoxemia98 and septic shock145,146. 
To what extent complement factor H influences the described ADM-mediated 
effects remains unclear as the majority of preclinical studies on ADM with 
AMBP-1 coadministration did not compare ADM/AMBP-1 with ADM 
alone. Please refer to Table 2 for an overview of this work. 
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Table 2. Overview of preclinical studies investigating ADM with co-administration of 
AMBP-1 in different models related to sepsis.
Intervention Model Results (compared to placebo) Reference
ADM and AMBP-1 
(posttreatment)
Cecal ligation and puncture 
(CLP) induced sepsis in 
rats
Ĺ CO, DO2 and lactate clearanceĹ Hepatic blood flow Ļ Plasma ALT, 
AST
Ļ Hemodilution Ĺ 10-day survival
Yang et al.139
ADM and AMBP-1 
for 45 min 
(posttreatment)
Hemorrhagic shock rats 
(MAP 40 mmHg for 90 
min), then resuscitated
Ļ Plasma AST, ALT, TNF and 
HMGB-1
Ĺ IL-10 
Ĺ Lactate and creatinine clearance 
Ĺ 12-day survival
Cui et al.140
ADM and AMBP-1 
(posttreatment)
Hemorrhagic shock rats 
(MAP 40 mmHg for 90 
min), then resuscitated
Ĺ CO and organ blood flow (liver, 
kidney and small intestine)
Ļ Cardiac TNF-Į
Wu et al.142
ADM and AMBP-1 
at start of reperfusion
Intestinal ischemia-
reperfusion in rats 
Ļ Plasma TNF-Į, IL-1ȕ, IL-6 and 
IL-10
Ļ Plasma AST and ALAT
Ļ Histopathological changes small 
intestine
Ĺ Lactate and creatinine clearance
Ĺ 10-day survival
Carrizo et 
al.144
ADM and AMBP-1 
(pretreatment) Endotoxemic rats
Ļ TNF-Į Ĺ IL-10
Ĺ Lactate clearance 
Miksa et 
al.98
ADM and AMBP-1 
(pretreatment) CLP-induced sepsis in rats
Ĺ eNOS signaling
Ļ Endothelial dysfunction
Zhou et 
al.156
ADM and AMBP-1 
at start of reperfusion
Intestinal ischemia-
reperfusion induced lung 
injury in rats
Ļ Lung edema
Ļ Lung TNF-Į and IL-6 
Ļ Histopathological changes
Dwivedi et 
al.143 
ADM and AMBP-1 
(posttreatment)
Hemorrhagic rats (MAP 40 
mmHg for 90 min), then 
resuscitated
Ļ Plasma AST and ALT
Ĺ Lactate and creatinine clearance
Ļ Plasma TNF-Į and IL-6
Ĺ 12-day survival
Wu et al.141
ADM and AMBP-1 
at start of reperfusion
Renal ischemia-reperfusion 
in rats
Ļ Renal edema
Ļ Tissue injury
Ļ Plasma and tissue pro-inflammatory 
cytokines
Shah et al.157
ADM and AMBP-1 
(posttreatment)
Bile duct ligation / CLP 
model of induced sepsis 
in rats
Ļ Systemic markers of tissue injury
Ļ Inflammatory response
Ĺ 7-day survival
Yang et al.146
Only studies using models of sepsis or models that capture some of the prominent 
hallmarks of sepsis have been included. Abbreviations: Adrenomedullin, ADM; ALT, alanine 
aminotransferase; AMBP-1, adrenomedullin binding protein-1; AST, aspartate aminotransferase; 
BAL, bronchoalveolar lavage; CLP, cecal ligation and puncture; CO, cardiac output; DO2, delivery 
of oxygen rate; E. coli, Escherichia coli; H2O2, hydrogen peroxide; HMGB-1, high mobility group 
box protein 1; IL, interleukin; LPS, lipopolysaccharide; MLCP, myosin light chain phosphorylase; 
S. aureus; Staphylococcus aureus; TNF, tumor necrosis factor.
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Antibodies against and/or receptor antagonists of adrenomedullin
To date, three studies have investigated the effects of ADM antagonists on 
hemodynamic parameters in preclinical models of endotoxemia and sepsis, 
using either a neutralizing anti-ADM antibody147 or the ADM receptor 
antagonist ADM(22-52)113,148. Both these treatments prevented the occurrence 
of a ‘hyperdynamic’ hemodynamic response (characterized by decreased blood 
pressure and peripheral vascular resistance, and an increased cardiac output) 
during the first hours after induction of sepsis or systemic inflammation147,148. 
This is in line with previous data demonstrating vasodilatory effects of ADM, 
accompanied by a reduction of peripheral vascular resistance and increase of 
cardiac output. Furthermore, ADM(22-52) administration after initiation of 
endotoxemia resulted in improved myocyte contractility, but did not improve 
7-day survival113.
Further efforts have been put into the development of various high-affinity 
monoclonal anti-ADM antibodies, each targeting different regions of the 
ADM peptide, resulting in full or partial inhibition of ADM signalling. 
The efficacy of these antibodies was investigated in a survival study in CLP-
induced sepsis in mice149. A non-neutralizing antibody targeted against 
the N-terminus of ADM, which only partially inhibits ADM-signalling, 
conferred survival benefit, whereas a completely inhibiting antibody targeted 
against the C-terminal, did not. Subsequent experiments were conducted in a 
model of resuscitated CLP-induced murine sepsis, in which pretreatment with 
the non-neutralizing antibody resulted in decreased catecholamine infusion 
rates, kidney dysfunction, iNOS, but not eNOS expression, and ultimately 
improved survival150. Due to these positive results, a humanized version of 
the antibody, named Adrecizumab, has been developed for further clinical 
development. Beneficial effects of Adrecizumab on vascular barrier function 
and survival were recently demonstrated in preclinical models of systemic 
inflammation and sepsis151. In this study, pretreatment with Adrecizumab 
attenuated renal vascular leakage in endotoxemic rats as well as in mice with 
CLP-induced sepsis, which coincided with increased renal expression of the 
protective peptide Ang-1 and reduced expression of the detrimental peptide 
VEGF151. Also, pretreatment with Adrecizumab improved 7-day survival in 
CLP-induced sepsis in mice from 10% to 50% for single and 0% to 40% for 
repeated dose administration151. Moreover, in a phase I study excellent safety 
and tolerability was demonstrated: no serious adverse events were observed, 
no signal of adverse events occurring more frequently in Adrecizumab-treated 
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subjects was detected, and no relevant changes in other safety parameters 
were found152. Of particular interest is the proposed mechanism of action of 
Adrecizumab. Both animal and human data reveal a potent, dose-dependent 
increase of circulating ADM following administration of this antibody. Based 
on pharmacokinetic data and the lack of an increase in MR-proADM (an 
inactive peptide fragment derived from the same prohormone as ADM), 
the higher circulating ADM levels cannot be explained by an increased 
production152. A mechanistic explanation for this increase could be that the 
excess of antibody in the circulation may drain ADM from the interstitium 
to the circulation, since ADM is small enough to cross the endothelial barrier, 
whereas the antibody is not. Additionally, binding of the antibody to ADM 
leads to a prolongation of ADM’s half-life153. Even though Adrecizumab 
partially inhibits ADM signaling, a large increase of circulating ADM results 
in an overall ‘net’ increase of ADM activity in the blood compartment, 
where it exerts beneficial effects on endothelial cells (predominantly barrier 
stabilization), whereas ADM's detrimental effects on VSMCs (vasodilation) 
in the interstitium are reduced153. This hypothesis is in line with previous 
studies demonstrating overall beneficial effects of agonists of the ADM system, 
whereas complete inhibition of ADM was shown not to improve outcome. A 
detailed description of the proposed mechanisms of action of Adrecizumab 
is provided elsewhere153. Please refer to Table 3 for an overview of studies 
that investigated ADM-antagonists and/or modulating antibodies. Currently, 
a phase II study with Adrecizumab is ongoing in septic patients (clinicaltrials.
gov identifier: NCT03085758).
PEGylation of adrenomedullin
PEGylation is the process by which polyethylene glycol (PEG) chains are 
attached to protein and peptide drugs154. PEGylation of polypeptide drugs 
often results in improved pharmacokinetic and pharmacodynamic properties, 
as it offers protection from proteolytic enzymes, increases water solubility, 
reduces renal clearance, and limits toxicity154. Human ADM was previously 
molecularly modified by conjugating ADM's N-terminal with PEG, in an 
attempt to reduce potentially unfavourable effects of ADM (hypotension, 
activated sympathetic nerve activity, and increased renin secretion)156. 
Compared to native ADM, PEGylated ADM had a slightly lower half maximal 
effective concentration (EC50) in a functional assay, while the maximum 
possible effect (Emax) values remained similar. Moreover, in rats, PEGylated 
ADM resulted in a longer half-life and a significantly less blood lowering 
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Table 3. Overview of preclinical studies with adrenomedullin antibodies and/or antagonists 
in different models related to sepsis.
Only studies using models of sepsis or models that capture some of the prominent hallmarks 
of sepsis have been included. Abbreviations: ADM, adrenomedullin; CLP, cecal ligation and 
puncture; E. coli, Escherichia coli; iNOS, inducable nitric oxide synthase; LPS, lipopolysaccharide; 
VEGF, vascular endothelial growth factor.
Intervention Model Results Reference
Anti-ADM antibody (post-
treatment)
CLP-induced sepsis 
in rats
Anti-ADM antibodies prevented 
occurrence of hyperdynamic response 
during first 5 hrs after CLP
Wang et 
al.147
ADM receptor antagonist 
ADM(22-52) (pretreat-
ment)
E. coli LPS in rats Ĺ Blood pressure (during first 6 hours) Mazzocchi et al.148
ADM antagonist ADM(22-
52) (posttreatment) E. coli LPS in rats
Ĺ Survival myocyte contractility
No effect on 7-day survival
Hyvelin et 
al.113
N-terminus murine anti-
body against N-terminus of 
ADM (pretreatment)
CLP induced sepsis 
in mice Ĺ Survival
Struck et 
al.149
N-terminus murine anti-
body against N-terminus of 
ADM (pretreatment)
Resuscitated 
CLP-induced sepsis 
in mice
Ļ Noradrenaline infusion rates
Ĺ Urine production, 
Ĺ Creatinine clearance & ĻNGAL
ĻiNOS and peroxynitrate formation 
Ļ Systemic inflammation
Ļ Tissue apoptosis
Wagner et 
al.150
N-terminus humanized an-
tibody against N-terminus 
of ADM
(pretreatment)
E. coli LPS in rats
CLP induced sepsis 
in mice
Ļ Vascular leakage in LPS rats
Ļ Renal vascular leakage, Ļ VEGF and 
Ĺ angiopoietin-1 levels in CLP mice
Ĺ Survival in CLP mice
Geven et 
al.151
effect compared with native ADM155. A subsequent study in a mouse DSS-
induced colitis model revealed an attenuation of the total inflammation score. 
Unfortunately, no studies have been performed in animal sepsis models.
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Conclusion
Adrenomedullin is an important peptide hormone involved in sepsis. 
Its effects include vasodilation, stabilization of the endothelial barrier 
and immunoregulation. Administration of ADM in animal models of 
inflammation, organ injury and infection resulted in improved outcome. 
Attempts have been made to negate the potential hypotensive effects of ADM 
to further enhance its beneficial effects. Coadministration of ADM with 
ADM binding peptide-1, administration of ADM bound to polyethylene 
glycol and administration of partially inhibiting ADM antibodies (which in 
fact increase the net circulating ADM levels without causing hypotension) 
showed promising results. However, it is difficult to translate these results to 
septic patients, because these preclinical studies have often been performed in 
small animals using clinically less relevant models of systemic inflammation 
or induced organ injury. Moreover, in a significant proportion of studies no 
resuscitation or antibiotics were applied, and the intervention was initiated 
prior to the induction of disease. Finally, many treatments have not been 
compared head-to-head. Given the current lack of adjuvant therapies in sepsis, 
future research on this promising peptide in more relevant animal models of 
sepsis and ultimately humans is highly warranted.
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Abstract
Sepsis remains a major scientific and medical challenge, for which, apart from 
significant refinements in supportive therapy, treatment has barely changed 
over the last few decades. During sepsis, both vascular tone and vascular 
integrity are compromised, and contribute to the development of shock. The 
free circulating peptide adrenomedullin (ADM) is involved in the regulation 
of the endothelial barrier function and tone of blood vessels. Several animal 
studies have shown that ADM administration improves outcome of sepsis. 
However, in higher dosages, ADM administration may cause hypotension, 
limiting its clinical applicability. Moreover, ADM has a very short half-life 
and easily adheres to surfaces, further hampering its clinical use. The non-
neutralizing anti-ADM antibody Adrecizumab (HAM8101) which causes a 
long lasting increase of plasma ADM has shown promising results in animal 
models of systemic inflammation and sepsis; it reduced inflammation, 
attenuated vascular leakage, and improved hemodynamics, kidney function, 
and survival. Combined with an excellent safety profile derived from animal 
and phase I human studies, Adrecizumab represents a promising candidate 
drug for the adjunctive treatment of sepsis. In this review, we first provide a 
brief overview of the currently available data on the role of adrenomedullin in 
sepsis and describe its effects on endothelial barrier function and vasodilation. 
Furthermore, we provide a novel hypothesis concerning the mechanisms of 
action through which Adrecizumab may exert its beneficial effects in sepsis.
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Introduction
Sepsis is an inflammatory disorder, in which a dysregulated host response 
to an infection results in life-threatening organ dysfunction1. Sepsis is a 
prevalent syndrome; approximately one third of all patients in Intensive Care 
Units (ICU) present with sepsis on admission or develop sepsis during their 
ICU stay2. Despite many advances in medical care, the incidence of sepsis 
is increasing and its mortality remains high3. Sepsis is characterized by a 
complex and multi-layered pathogenesis. In short, a host response is mounted 
by ligation of pathogen associated molecular patterns (PAMPs) to pattern 
recognition receptors (PRRs) present on immune cells, in turn activating 
inflammatory and coagulation pathways, characterized by leukocyte and 
complement activation as well as release of cytokines, reactive oxygen species, 
and damage-associated molecular patterns (DAMPs). These events result 
in perpetuation of the inflammatory response and ultimately cause organ 
failure, which is a key determinant of survival4. The vascular endothelium is a 
protective barrier involved in the maintenance of vessel integrity that controls 
diffusion of molecules and fluids between the intravascular and interstitial 
space. Endothelial function is often compromised during sepsis, leading to 
increased leukocyte adhesion, vascular wall permeability, and vasodilation4-7. 
These changes result in, amongst others, extravascular fluid accumulation, 
causing tissue edema, a decrease in circulating volume, hypotension, and 
subsequent organ failure.
A considerable proportion of deaths are attributed to the early phase of 
sepsis, as a result of multi-organ failure despite supportive therapy. For 
decades, treatment of sepsis consists of antimicrobial therapy, source control 
and supportive treatments such as fluid resuscitation, vasopressor use and 
mechanical ventilation6. Many trials have investigated possible adjuvant 
treatments, primarily focussing on anti-inflammatory therapies. Unfortunately, 
not a single intervention is currently in use because of lack of efficacy. This can 
partially be explained by methodological issues, such as heterogeneity of the 
study population and timing of the intervention, but also by the complexity 
of the immune response with multiple pathways contributing to injury6,8. 
Thus, there is still a great unmet need for novel adjuvant therapies for sepsis. 
Interestingly, interventions aimed at improving endothelial barrier function 
have only sparsely been investigated, while this represents a highly relevant 
target9.
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Adrenomedullin
Adrenomedullin (ADM) is a free circulating 52 amino-acid peptide belonging 
to the calcitonin gene-related peptide family that was first discovered in 
human pheochromocytoma tissue more than two decades ago10,11. Although 
ADM was initially thought to primarily possess vasodilatory properties12, it 
was subsequently discovered that it exerts a multitude of biological effects, 
both in health and disease, including anti-inflammatory effects, stabilization 
of endothelial barrier function, and regulation of vascular tone13. These effects 
are attained through binding of ADM to heterodimeric receptor complexes 
consisting of the calcitonin receptor-like receptor (CRLR) and a specific 
receptor activity-modifying protein (RAMP), RAMP2 and RAMP314. ADM 
is produced by many cells, including endothelial cells, vascular smooth muscle 
cells (VSMCs), monocytes, renal parenchymal cells and macrophages15-20. 
A wide variety of mediators involved in the pathophysiology of sepsis have 
been reported to enhance ADM production. For instance, in rat VSMCs, 
interleukin-1 (IL-1) alpha and beta, tumor necrosis factor (TNF) alpha & 
beta, epinephrine, substance P, endothelin-1, angiotensin II, fetal calf serum 
(FCS), and lipopolysaccharide (LPS) all increased ADM gene expression 
and synthesis21,22. Conversely, other substances known to play a role in 
sepsis, such as thrombin, vasoactive intestinal polypeptide and interferon-
gamma (IFN-ࢢ), were shown to decrease ADM production in VSMCs22. 
Studies in rat endothelial cells revealed that ADM is not stored, but rather 
constitutively produced, and that endothelial cells secrete ADM at a higher 
rate than VSMCs23. Similar to rat VSMCs, TNF, IL-1, LPS and thyroid 
hormone increase ADM secretion by endothelial cells, whereas transforming 
growth factor ȕ1, IFN-ࢢ and FCS suppress ADM secretion. Other studies 
have demonstrated increased ADM production by renal parenchymal cells 
and endothelial cells under hypoxic conditions19,24. The effects of endotoxin 
and hypoxia on ADM production were also confirmed in vivo in a rat 
model of LPS-induced inflammation, as well in models of induced hypoxia 
with inhalation of carbon monoxide and air with reduced concentrations 
of oxygen25,26. ADM has a short circulating half-life (22 minutes)27, and is 
removed from the circulation in two ways. First, the ADM receptors function 
as clearance receptors: upon ligation of ADM with its receptors, the ADM-
receptor complex is internalized and subsequently degraded28. The lung has 
been reported as a significant site of clearance via this mechanism29,30. The 
second clearance mechanism is represented by proteolytic degradation of 
ADM31-33.
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Adrenomedullin in sepsis
Increased levels of circulating ADM are found during sepsis which correlate 
with relaxation of vascular tone34 as well as with disease severity and mortality 
in septic patients35-38. Although these associations may suggest that ADM 
plays a detrimental role in sepsis, they should be interpreted with caution, as 
no causal relationships – detrimental or beneficial – can be directly deducted 
from these observational studies. In fact, many experimental studies, both 
in vitro39 and in vivo40-42, have demonstrated that ADM administration is 
beneficial during systemic inflammation and sepsis through favorable effects 
on endothelial barrier function. Another relevant peptide in this context is 
adrenomedullin-binding protein 1 (AMBP-1), also known as complement 
factor H43. AMBP-1 binds to ADM, albeit with a lower overall affinity 
than ADM binding to its receptors44. AMBP-1 is reported to protect ADM 
from proteolytic degradation32, and modulates ADM activity: coincubation 
of fibroblasts with ADM and AMBP-1 resulted in a 2-fold increase of 
cyclic adenosine monophosphate (cAMP), compared to treatment with 
ADM alone45. Furthermore, several studies have demonstrated that co-
administration of ADM and AMBP-1 improves outcome in preclinical 
animal studies employing various models of systemic inflammation, organ 
injury, and septic shock46-49. 
Adrenomedullin stabilizes the endothelial barrier
Studies in genetically modified mice deficient for crucial parts of the 
ADM receptor signalling pathway reported development of lethal hydrops 
fetalis, indicating impaired development of the endothelial barrier50-52. In 
conditional murine knock-out models, in which either ADM or the RAMP2 
part of the AM1 receptor was abolished in endothelial cells, increased vascular 
permeability and edema formation was observed53,54. Furthermore, in vitro 
studies demonstrated that ADM stabilizes the endothelial barrier through 
regulation of the actin myosin cytoskeleton55. ADM is thought to prevent 
formation of stress fibers that pull on cell-cell junctions56, which is primarily 
mediated through the cAMP-PKA pathway involving Rap1 activation and 
RhoA/ROCK inhibition57. This is accompanied by attenuated endothelial 
myosin light chain phosphorylation, actomyosin contractility, and ultimately 
attenuation of endothelial cell gap formation39,56. In addition, ADM activates 
Rac1, which stimulates cortical actin formation58. Moreover, completely 
blocking ADM has been shown to increase endothelial layer permeability 
by inhibiting cell-cell contacts predominantly through disruption of VE-
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cadherin/ȕ-catenin & Akt signalling pathways59. Figure 1 presents a 
schematic overview of the pathways through which ADM exerts endothelial 
stabilizing and vasodilatory effects. Beneficial effects of ADM administration 
on endothelial barrier function have been demonstrated in animals in vivo, 
using models of systemic inflammation and sepsis. For example, ADM 
administration in a murine model of lung injury resulted in attenuation of 
pulmonary hyperpermeability, lung injury, and systemic hyperinflammation42. 
In rats, administration of ADM significantly reduced extravasation of albumin 
and plasma fluid, and ultimately improved survival in septic shock induced 
by Staphylococcus aureus alpha-toxin40. 
Figure 1. Schematic overview of intracellular pathways through which ADM exerts vasodil-
atory and endothelial stabilizing effects.
Adrenomedullin exerts vasodilatory effects, has a short half-life, and is 
difficult to handle
As mentioned earlier, one of the initially discovered properties of ADM is 
that it lowers blood pressure. Several studies have demonstrated that ADM 
promotes vasodilation in isolated blood vessels60,61. Furthermore, infusion of 
high dosages of ADM was shown to decrease blood pressure and peripheral 
vascular resistance in rats, cats, sheep and humans, thereby inducing a 
compensatory increased heart rate and cardiac output27,41,62-65. The vasodilatory 
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effects of ADM are mediated through binding to the ADM receptors present 
on vascular endothelial cells and VSMCs. Several signalling pathways, both 
endothelium-dependent and -independent, appear to account for ADM-
mediated vasodilation66. Binding of ADM to its receptors on VSMCs leads 
to increased cAMP67,68 in an endothelium-independent fashion, which 
subsequently activates protein kinase A (PKA). PKA phosphorylates a large 
number of proteins which ultimately results in relaxation of smooth muscle 
cells. Endothelium-dependent pathways have in common that they act through 
stimulation of endothelial NO synthase (eNOS), which in turn stimulates 
the cyclic guanosyl monophosphate (cGMP) system in VSMCs, leading 
to activation of PKA and protein kinase G (PKG). PKG acts downstream 
to reduce intracellular calcium levels and alters sensitivity of contractile 
proteins for calcium, thereby also inducing smooth muscle relaxation. 
These pathways include the inositol-1,4,5-triphosphate (IP3) system and the 
phosphatidylinositol-4,5-bisphosphate 3-kinase-protein kinase B (IP3K/Akt) 
pathway69,70. It remains unknown as to what extent endothelium-dependent 
or -independent pathways account for ADMs vasodilatory effects.
So, despite ADMs potent endothelial barrier-stabilizing effects, systemic 
administration in higher dosages exerts hemodynamic effects, mainly 
vasodilatory, that may be detrimental for sepsis patients and even more so 
for septic shock patients71. Moreover, it has a very short half-life (several 
minutes)27,29 and is cumbersome to handle being very adhesive72 and thus 
arguably sticking to artificial surfaces used in the clinic. Taken together, these 
unfavourable pharmacological properties might seriously hamper its clinical 
applicability in sepsis, and modulating the endogenous ADM response 
may represent a more viable strategy. Although at first glance it may appear 
counterintuitive, a specific type of antibody targeting ADM may represent 
such a strategy.
The anti-adrenomedullin antibody Adrecizumab improves outcome in 
experimental sepsis
ADM interacts with its receptor via the C-terminal moiety73, and the N-terminal 
part of ADM is not required for its agonist function74. Previously, several high-
affinity mouse monoclonal anti-ADM antibodies were investigated, targeting 
different epitopes of ADM75. Complete functional inhibition of ADM (by 
blocking the C-terminus) did not improve survival in cecal ligation and 
puncture (CLP) induced murine sepsis. However, pretreatment with high-
affinity antibodies targeting the N-terminus of ADM (HAM1101), which 
Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in sepsis
3
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 64
64
only partially inhibits ADM signaling, even when applied in large molar 
excess over ADM, showed profound beneficial effects on mortality75. A later 
study, investigating the effects of this antibody in a resuscitated CLP-induced 
murine sepsis, reported decreased catecholamine infusion rates, prevention 
of kidney dysfunction, reduction of iNOS but not eNOS expression, and 
ultimately improved survival76. Following these initial preclinical experiments 
HAM1101 was humanized to HAM8101 for further preclinical and clinical 
studies and named Adrecizumab. Adrecizumab was shown to reduce renal 
interstitial edema in endotoxemic rats and decreased renal VEGF expression 
(a potent inducer of vascular permeability) in CLP-induced murine sepsis, 
whereas expression of the protective peptide angiopoietin-1 was augmented77,78. 
Furthermore, it reduced mortality in CLP-induced murine sepsis to a similar 
extent as the parent antibody HAM1101. An overview of these preclinical 
antibody studies is provided in Table 1. 
Table 1. Overview of studies that have investigated Adrecizumab or its murine predecessor.
Authors (year) Intervention Model Effects
Struck (2013)
Pretreatment with murine 
antibody against N-terminus 
ADM (HAM1101, 2 mg/kg)
Cecal ligation and 
puncture (CLP) 
induced murine 
sepsis
Ĺ Survival
Wagner (2013)
N-terminus murine antibody 
against N-terminus ADM 
(HAM1101, 2 mg/kg), 
administered immediately 
after CLP surgery
Resuscitated CLP-
induced murine 
sepsis
Ļ Norepinephrine infusion
Ĺ Urine production & 
creatinine clearance
Ļ Neutrophil gelatinase-
associated lipocalin (NGAL)
Ļ iNOS expression & 
peroxynitrite formation in 
kidney & aorta
Ļ Systemic inflammation
Ļ Tissue apoptosis in kidney
Geven (2018)
Pretreatment with humanized 
antibody against N-terminus 
ADM (Adrecizumab, 0.02, 
0.1, 0.5 or 2.5 mg/kg)
Lipopolysaccharide 
(LPS) induced 
systemic 
inflammation in rats
Ļ Renal albumin extravasation
Geven (2018) Pretreatment Adrecizumab (0.1, 2.0 or 20 mg/kg)
CLP-induced 
murine sepsis
Ļ Renal albumin extravasation
Ļ Renal vascular endothelial 
growth factor (VEGF)
Ĺ Renal angiopoietin-1
Geven (2018)
Pretreatment single dose 
Adrecizumab (2 mg/kg) and 
repeated dose Adrecizumab 
(pretreatment with 4 mg/kg 
followed by 2 mg/kg after 24 
and 48 hours).
CLP-induced 
murine sepsis Ĺ Survival
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Proposed mechanism of action of Adrecizumab
The mechanisms by which Adrecizumab exerts its beneficial effects remain to 
be fully elucidated. However, there are indications that it involves modulation 
of the ADM equilibrium between the blood compartment and interstitium. 
The endothelium is a single cell monolayer, separating the blood compartment 
from the interstitial space. As ADM is a small peptide (6 kDa), it freely diffuses 
between the blood vessels and the interstitial space. In this homeostatic ‘normal’ 
situation, ADM regulates the endothelial barrier function through ligation of 
receptors on endothelial cells, and regulates vascular tone through binding 
to receptors on endothelial cells (indirect effect) and VSMCs (direct effect 
[Figure 2A]). During septic shock, circulating ADM levels are profoundly 
increased35,38,79. Although there is no data on ADM concentrations in the 
interstitial compartment, it is plausible to assume that ADM concentrations 
are in equilibrium with the circulation, because ADM is able to diffuse freely 
between the two compartments29. The previously described preclinical studies 
suggest that ADM present in the circulation counteracts – albeit insufficiently 
– sepsis-induced vascular leakage through its effects on endothelial cells, while 
excess circulating and interstitial ADM may lead to vasodilation and septic 
shock through indirect effects on endothelial and direct effects on VSMCs 
(Figure 2B). Interestingly, in both preclinical studies in healthy animals and 
animals with LPS-induced inflammation and CLP-induced sepsis, and the 
recently performed phase I study in humans (unpublished, discussed in the 
next section), an immediate (<5 minutes) dose-dependent increase of plasma 
ADM concentrations was observed after Adrecizumab administration80. This 
effect has been observed across all species investigated (mice, rats, beagle 
dogs, cynomolgus monkeys and humans). The measured elevated plasma 
ADM concentrations in fact mainly represent complexes of ADM bound to 
Adrecizumab, as Adrecizumab is administered in several orders of magnitude 
molar excess over endogenous ADM, and the assay used to measure plasma 
ADM (sphingotest® bio-ADM, Sphingotec GmbH, Hennigsdorf, Germany) 
detects both free ADM and ADM complexed with Adrecizumab81. Given 
the small volume of distribution of Adrecizumab (100 mL/kg; unpublished 
data from phase I study in human volunteers), it can be concluded that 
Adrecizumab does not freely diffuse from the circulation into the interstitial 
space, which is not surprising it being a large IgG antibody of 160 kDa. 
Because plasma concentrations of MR-proADM, a non-functional peptide 
stemming from the same precursor peptide as ADM do not increase upon 
administration of Adrecizumab80, it can be concluded that the antibody 
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does not induce increased expression of ADM. Therefore, we hypothesize 
that Adrecizumab induces a shift of ADM from another compartment (most 
likely the interstitium) into the circulation (Figure 2C).Whether bio-ADM 
concentrations after Adrecizumab administration also increase in patients 
with septic shock remains to be investigated, although based upon preclinical 
available data, this is to be expected. 
Another effect of Adrecizumab is the prolongation of the half-life of endogenous 
ADM: Spiking of Adrecizumab to ADM-containing serum samples in vitro 
strongly increased the half-life of ADM in a dose-dependent manner (Figure 
3, based on unpublished data). A plausible mechanistic explanation for this 
observation is that binding of Adrecizumab to the N-terminus of ADM 
reduces accessibility for proteolytic decay, which is known to occur at the 
N-terminus of ADM31. 
Because Adrecizumab is only a weak inhibitor of ADM signaling, the net 
effect of Adrecizumab administration is that ADM activity on endothelial 
cells is not reduced, but rather increased. This allows for ADM levels in the 
circulation to exert the aforementioned beneficial effects on the endothelium 
(reduction of capillary leakage), whereas ADMs detrimental effects in the 
interstitium (vasodilation of VSMCs) may concurrently be reduced. Overall, 
we hypothesize that as a result of the weak inhibitory effects of the antibody, 
the net effects of ADM on endothelial cells are augmented by Adrecizumab, 
resulting in stabilization of vascular integrity (Figure 2C). This proposed 
mechanism of action also explains why the antibody directed against the 
C-terminus, that resulted in complete inhibition of ADM activity, did not 
improve sepsis outcome in preclinical studies75.
Adrecizumab may have additional benefits over ADM for the treatment of 
sepsis. As alluded to before, ADM has a short half-life, therefore it needs 
to be infused continuously. Adrecizumab has a half-life of approximately 15 
days, allowing administration of a single dose. Moreover, Adrecizumab does 
not have the adhesive properties that ADM has. Naturally, as our proposed 
mechanism of action is hypothetical, future experimental studies should focus 
on downstream signaling targets of ADM-pathways and measuring tissue 
and/or interstitial ADM concentrations.
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Figure 2. +\SRWKHVL]HGPHFKDQLVPRIDFWLRQRI$GUHFL]XPDE (A) ,Q WKHKRPHRVWDWLF µQRUPDO¶
VLWXDWLRQ$GUHQRPHGXOOLQ$'0LVDEOHWRGLIIXVHIUHHO\RYHUWKHYDVFXODUEDUULHUDQGH[HUWHIIHFWV
RQHQGRWKHOLDOFHOOVDQGYDVFXODUVPRRWKPXVFOHFHOOV960&(B)6HSVLVLQGXFHGYDVRGLODWLRQ
DQGLPSDLUHGYDVFXODUEDUULHUIXQFWLRQFRQWULEXWHWRWKHGHYHORSPHQWRIVKRFN&LUFXODWLQJ$'0
OHYHOVDUH LQFUHDVHGEXWQRW WRDQH[WHQW WKDW VXI¿FLHQWO\FRXQWHUDFWV LPSDLUHGEDUULHU IXQFWLRQ
0RUHRYHU LQFUHDVHG$'0 OHYHOV OHDG WR H[FHVVLYH YDVRGLODWLRQ (C) )ROORZLQJ DGPLQLVWUDWLRQ
RI$GUHFL]XPDE \HOORZ$'0 FRQFHQWUDWLRQV LQ WKH FLUFXODWLRQ LQFUHDVH UDSLGO\ EHFDXVH RI
UHGXFHGSURWHRO\WLFGHJUDGDWLRQDQG WKH LQDELOLW\RI$GUHFL]XPDE$'0FRPSOH[HV WRFURVV WKH
HQGRWKHOLDOEDUULHU$VWKHUHLVQRLQFUHDVHG$'0V\QWKHVLVZHK\SRWKHVL]HWKDW$'0WUDQVORFDWHV
IURPWKHLQWHUVWLWLXPWRWKHFLUFXODWLRQ$V$'0WKDWLVERXQGWR$GUHFL]XPDEUHPDLQVIXQFWLRQDO
WKHUHLVDQHWHQKDQFHGEHQH¿FLDOHIIHFWRI$'0RQHQGRWKHOLDOFHOOVVWDELOL]DWLRQRIWKHEDUULHU
IXQFWLRQZKHUHDV$'0VGHWULPHQWDOHIIHFWVRQ960&VYDVRGLODWLRQDUHUHGXFHGGXHWRDORZHU
FRQFHQWUDWLRQVLQWKHLQWHUVWLWLDOFRPSDUWPHQW
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Safety of Adrecizumab
The safety and tolerability of Adrecizumab were extensively investigated in 
preclinical animal studies. Toxicology and safety was studied in three different 
animal species. In short, Adrecizumab was well tolerated and safe up to the 
highest dosages tested (400 mg/kg), which are about hundredfold over the 
preclinically efficacious and intended clinical therapeutic dose (unpublished 
data). Moreover, application of up to 50 mg/kg Adrecizumab did not influence 
the blood pressure in telemetered beagle dogs (unpublished data). Recently a 
human phase I study was successfully completed (ClinicalTrials.gov identifier 
NCT02991508), and excellent safety results were observed80.
Possible limitations
In the preclinical studies discussed before, Adrecizumab was administered 
prior to, or immediately after endotoxin administration or the cecal ligation 
Figure 3. Serum samples (three pools from healthy donors) were spiked with a high 
concentration of synthetic ADM (640 pg/mL) in the absence or presence of Adrecizumab 
(0, 30, 300 µg/mL). The ADM concentration used was similar as in very severe septic shock, 
and the 30 µg/mL Adrecizumab concentrations was in the range measured in plasma shortly 
after in vivo administration of 2 mg/kg Adrecizumab, a dose used in preclinical experiments77. 
After incubation at 22°C for increasing time intervals, aliquots of the samples were measured 
in the sphingotest® bio-ADM assay. In the absence of Adrecizumab, bio-ADM concentrations 
decreased by approximately 80% after 45 minutes of incubation, whereas they decreased 
by approximately 50% and 25% in the presence of Adrecizumab at 30 and 300 µg/mL, 
respectively (both p<0.001).
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and puncture procedure. This approach is common for proof of principle 
studies, but represents a relevant limitation, as pretreatment of septic patients 
is unattainable in clinical practice. Moreover, previous work has convincingly 
shown that Adrecizumab administration results in a rapid and potent increase 
of circulating ADM, both in healthy animals and humans as well as in inflamed 
and/or septic animals77,78,80. Because ADMs vasodilatory effects are mediated 
not only through direct effects on VSMCs (which are presumably reduced by 
Adrecizumab [Figure 2C]), but also through indirect effects on endothelial 
cells, the increase in ADM levels could theoretically also cause unwanted 
vasodilation and subsequent aggravation of hypotension in septic shock 
patients. However, the relative importance of the indirect endothelial cell 
pathway compared to the direct effects on VSMCs in the vasodilatory effects 
of ADM remains to be determined. Nevertheless, no hypotensive effects were 
observed after Adrecizumab administration in telemetered healthy beagle 
dogs (unpublished data) and healthy human volunteers80. Furthermore, in 
the aforementioned preclinical study in CLP-induced sepsis in mice76, lower 
norepinephrine infusion rates were observed in the treatment group, which 
strongly suggests that Adrecizumab did not exert vasodilatory effects. Finally, it 
is unclear whether the long half-life of Adrecizumab is a benefit or a limitation 
of the compound. While it enables single dosing treatment, increasing the 
feasibility of the therapy, this also may represent a limitation if unwanted 
effects of the drug may occur. Taken together, although there are currently 
no indications of hypotensive effects of Adrecizumab, the compound has not 
been investigated in septic patients yet, so no definitive conclusions can be 
drawn on the safety profile in patients. Moreover, it is imperative that future 
research also encompasses administration of ADM after the inflammatory 
and/or infectious insult to increase clinical relevance.
Other endothelial barrier stabilizing agents
Current guidelines do not recommend any adjunctive treatment for sepsis, 
except for hydrocortisone in patients with septic shock who respond poorly 
to fluid resuscitation and vasopressor therapy82. Although several adjunctive 
interventions (mainly anti-inflammatory agents) have been investigated in 
septic patients, up to now no clinical trials have been performed that have 
investigated endothelial barrier-stabilizing agents. This is slowly changing: 
Currently, the short-acting selective vasopressor 1a receptor agonist selepressin 
is under investigation in a study aiming to include 1800 patients with septic 
shock (ClinicalTrials.gov NCT02508649). Preclinical data suggest that 
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this selective V1-agonist83 can improve vascular leakage by ligation of V1a 
receptors. In two studies employing ovine models of septic shock induced 
by burn injury combined with Pseudomonas aeruginosa pneumonia or CLP, 
selepressin decreased fluid accumulation compared with vasopressin and 
norepinephrine, indicating decreased vascular leakage84,85. Also, in a recent 
phase IIa study, selepressin was an effective substitute for norepinephrine, 
and in one dosage group an improved fluid balance was observed86. Another 
important regulator and potential target for endothelial barrier-stabilizing 
therapy is the angiopoietin-Tie-2 receptor pathway87,88. Several studies 
have demonstrated that Tie-2 agonists such as angiopoietin-1 (ang1) and 
modifications/alterations of ang1 which increase the half-life and binding 
efficacy, can prevent capillary leakage in animal models of septic shock89-91, 
whereas targeted angiopoietin-2 inhibition also appears to hold potential92. 
Another potential treatment target with respect to endothelial barrier 
function is vascular endothelial growth factor (VEGF)93, a potent inducer of 
endothelial barrier hyperpermeability94, although the body of evidence is small 
and negative studies have also been reported95. It remains to be determined 
whether these strategies are truly effective in septic patients and whether one 
agent holds advantage over another. 
Conclusion
ADM freely diffuses over the endothelial cell layer. In the blood compartment 
ADM improves endothelial barrier function, while in the interstitium it causes 
vascular smooth muscle relaxation. During sepsis, higher ADM concentrations 
are found which may aggravate vasodilation. As the non-neutralizing anti-
adrenomedullin antibody Adrecizumab does not cross the endothelium, we 
hypothesize that ADM distribution is shifted towards the circulation where 
it is still functional after binding to Adrecizumab. Adrecizumab was shown 
to enhance endothelial barrier function in experimental models of systemic 
inflammation and sepsis, in the absence of untoward (vasodilatory) effects. 
Furthermore, administration of the antibody improved clinical outcomes, 
while safety and tolerability studies so far showed no side effects. These results 
pave the way for further clinical studies with Adrecizumab, which will have to 
reveal whether these effects are also present in patients with sepsis.
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Letter to editor
With interest we read the review by Levy et al.1 that provides a thorough 
overview of current and future therapies aiming to treat vasoplegia, an 
ubiquitous phenomenon in shock. In their work, the authors dedicated a 
section to the novel adrenomedullin (ADM)-binding antibody adrecizumab, 
which is mentioned as an ADM-blocking compound in the section title. 
Recently published studies demonstrate that blocking of ADM does not 
accurately describe Adrecizumab’s mechanism of action, though. In contrast 
to what is often intuitively assumed, not all antibodies completely inhibit the 
activity of their targets. The extent of signaling inhibition can vary greatly, 
depending on the epitope to which the antibodies bind and other factors, 
such as antibody concentrations.
In contrast to C-terminus binding anti-ADM antibodies which completely 
inhibit ADM signaling, antibodies against the N-terminus of ADM, including 
the humanized monoclonal antibody adrecizumab, only marginally inhibit 
ADM activity, despite their high affinity and even when applied in vast molar 
excess over ADM2.
Interestingly, animal and human data reveal a strong, dose-dependent increase 
of plasma ADM concentrations upon adrecizumab infusion3,4, which cannot 
be explained by increased production of ADM. A mechanistic explanation for 
this occurrence was recently proposed5. Excess antibody that remains in the 
circulation is thought to drain ADM from the interstitium into the circulation, 
since ADM is small enough to cross the endothelial barrier, whereas the 
antibody is not. While adrecizumab only partially inhibits ADM signaling, 
the strong concentration increase of ADM (complexed with adrecizumab) in 
the circulation is thought to result in an overall 'net' increase of ADM activity 
on endothelial cells, augmenting endothelial barrier stabilizing effects, while 
decreased concentrations of ADM in the interstitium reduce vasodilatory 
effects on vascular smooth muscle cells. The combination of attenuation of 
both endothelial leakage and vasodilation likely represents the therapeutic 
potential of adrecizumab. This hypothesis fits well with previous studies that 
showed beneficial effects of ADM agonists in animal models of shock, while 
complete inhibition of ADM did not improve outcome.
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As is mentioned by the authors, a proof-of-concept and dose-finding phase II 
study with adrecizumab is currently ongoing in patients with septic shock and 
elevated levels of ADM (ClinicalTrials.gov identifier NCT03085758). This 
trial incorporates a number of innovative features such as a novel composite 
efficacy endpoint and biomarker-guided patient selection (enrolment based 
on bio-ADM level), making it one of the first personalized treatment trials in 
sepsis.
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Abstract
Adrenomedullin (ADM) is a peptide hormone first discovered in 1993 in 
pheochromocytoma. It is synthesized by endothelial and vascular smooth 
muscle cells and diffuses freely between blood and interstitium. Excretion 
of ADM is stimulated by volume overload to maintain endothelial barrier 
function. Disruption of the ADM system therefore results in vascular 
leakage and systemic and pulmonary oedema. In addition, ADM inhibits 
the renin–angiotensin–aldosterone system. ADM is strongly elevated in 
patients with sepsis and in patients with acute heart failure. Since hallmarks 
of both conditions are vascular leakage and tissue oedema, we hypothesize 
that ADM plays a compensatory role and may exert protective properties 
against fluid overload and tissue congestion. Recently, a new immunoassay 
that specifically measures the biologically active ADM (bio‐ADM) has 
been developed, and might become a biomarker for tissue congestion. As a 
consequence, measurement of bio‐ADM could potentially be used to guide 
diuretic therapy in patients with heart failure. In addition, ADM might be 
used to guide treatment of (pulmonary) oedema or even become a target for 
therapy. Adrecizumab is a humanized, monoclonal, non‐neutralizing ADM‐
binding antibody with a half‐life of 15 days. Adrecizumab binds at the N‐
terminal epitope of ADM, leaving the C‐terminal side intact to bind to its 
receptor. Due to its high molecular weight, the antibody adrecizumab cannot 
cross the endothelial barrier and consequently remains in the circulation. 
The observation that adrecizumab increases plasma concentrations of ADM 
indicates that ADM‐binding by adrecizumab is able to drain ADM from the 
interstitium into the circulation. We therefore hypothesize that administration 
of adrecizumab improves vascular integrity, leading to improvement of tissue 
congestion and thereby may improve clinical outcomes in patients with acute 
decompensated heart failure. A phase II study with adrecizumab in patients 
with sepsis is ongoing and a phase II study on the effects of adrecizumab 
in patients with acute decompensated heart failure with elevated ADM is 
currently in preparation.
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Introduction
Hospitalizations for heart failure are a major burden for patients, relatives, 
health care providers and society. Despite improvements in therapy for 
patients with heart failure with a reduced ejection fraction, we have not been 
able to reduce the risk of heart failure readmissions after a hospitalization for 
worsening heart failure. Approximately 35–50% of heart failure patients are 
rehospitalized within 6 months of discharge, making heart failure the most 
frequent diagnosis for 30‐day readmissions and incurring billions in costs1-3.
Therefore, preventing hospital (re‐)admissions is recognized as a major unmet 
need in the treatment of heart failure.
Risk prediction models have become reasonably accurate for predicting 
(cardiovascular) mortality, but models to predict hospital (re‐)admissions 
perform much worse4. Given its poor predictive value, identifying patients 
for clinical trials who are at high risk of hospital (re‐)admission is difficult. 
Therefore, there is a need for markers to better identify patients who are at 
high risk for heart failure (re‐)hospitalization. Preferably, these markers should 
reflect a process that can be pathophysiologically linked to worsening heart 
failure.
Several studies have consistently shown that the main reason for (re‐)
hospitalization for worsening heart failure is related to dyspnoea or 
breathlessness, mainly caused by pulmonary congestion5-9. The great majority 
of patients are treated with loop diuretics to relieve congestion, but a large 
number of patients are discharged without losing body weight and with 
persistent signs of congestion7, 9-11. This is particularly true when patients are 
discharged early and in patients without weight loss despite loop diuretic 
therapy. Consequently, studies have shown higher risks of hospital readmission 
in patients with a shorter duration of hospitalization, with a poor diuretic 
response, and with residual signs of congestion at discharge. Therefore, 
markers that reflect residual congestion might be useful to identify patients 
that are both epidemiologically and pathophysiologically at higher risk of 
hospital (re‐)admission. Currently, clinical signs at physical examination 
such as oedema, rales and jugular venous pressure are the mainstay for 
assessment of congestion. However, this examination is often not performed 
in clinical practice, is very dependent on the clinician's skills12, has a low 
interrater reliability and specificity13-15 and is subjective due to the lack of 
standardized metrics or (de)congestion scores16. In view of the high incidence 
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of rehospitalization, clinical assessment of congestion is clearly insufficient. 
What clinicians therefore need is an easy‐to‐use surrogate for the assessment of 
a patient's (de)congestion status that may facilitate clinical decision making. 
The use of biomarkers for this purpose is attractive, since they are objective, 
easily available and have a known sensitivity and specificity. While by many 
heart failure clinicians natriuretic peptides are regarded as the main biomarker 
for congestion, recent studies show that there are several limitations in the use 
of natriuretic peptides as markers of congestion17. Since natriuretic peptides 
reflect stretch and pressure of the heart, they mainly reflect intravascular 
volume overload, but do not reflect tissue and interstitial fluid. Therefore, 
better and more specific markers for tissue congestions are needed.
Adrenomedullin: an introduction
Adrenomedullin (ADM) is a peptide hormone discovered in 1993 by Kitamura 
et al.18. ADM is a 52 amino acid peptide, containing a ring structure and a 
C‐terminal amide, both of which are essential for binding to ADM receptors. 
The ADM gene is located on chromosome 11 and consists of four exons19. 
One of the key determinants for biological activity of ADM is the group of 
receptor activity‐modifying proteins (RAMPs). The combination of RAMP 2 
or 3 with the calcitonin receptor‐like receptor (CRLR) confers specificity of 
the receptor for ADM, and thus both RAMPs and CRLR are key in ADM 
expression20-25. While ADM was first discovered in pheochromocytoma 
originating from the adrenal medulla (hence the name ‘adrenomedullin’), 
further investigation showed that it was synthesized by many other tissues/
cells, especially endothelial and vascular smooth muscle cells, and due to 
its small size (6 kDa) diffuses freely between blood and interstitium26,27. 
By proteolytic fragmentation of the pro‐hormone (pro‐ADM), a glycine‐
extended, inactive ADM is formed, which subsequently is enzymatically 
converted from ADM‐glycine to the biologically active ADM‐amide. ADM 
receptors and binding sites are widespread in the body, but cardiovascular 
and lung tissues have highest density of these binding sites28. The in vivo 
half‐life of ADM is approximately 22 min29. ADM is thought to mainly 
be metabolized by neutral endopeptidase, also known as neprilysin30 – a 
molecule that clinicians might recognize from the recent beneficial findings 
with sacubitril/valsartan as a novel treatment for patients with heart failure31. 
Sacubitril is a neprilysin inhibitor, and thus is supposed to inhibit breakdown 
of ADM and several other peptide hormones. An additional mechanism by 
which ADM is cleared is through binding with its receptors and subsequent 
internalization and degradation32,33.
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Vascular effects of adrenomedullin
The most recognized function of ADM is vasodilatation in both vascular 
resistance and capacitance vessels. ADM lowers blood pressure, yet increases 
blood flow18,34. Even low doses induce vasodilatation, indicating that the 
plasma levels of ADM under conditions such as heart failure are in the range 
that directly affect vascular tone34.
Beside vasodilation, ADM seems to play an important role in preservation of 
endothelial integrity. ADM expression can be induced by various stimuli, one 
of them being volume overload, and increased plasma ADM reflects excessive 
fluid volume35. This is most likely the consequence of a counteracting 
response, as the ADM‐induced stabilization of endothelial barrier function is 
thought to limit tissue fluid overload. Indeed, disruption of the ADM system 
results in vascular leakage and systemic and pulmonary oedema36-38. Also 
the role of the ADM–RAMP 2 system has been investigated. Mice lacking 
the gene encoding for RAMP 2 showed enhanced vascular permeability and 
systemic oedema36. Similarly, mice with a conditional knock‐out of ADM in 
endothelial cells revealed increased vascular permeability in comparison with 
wild‐type littermates39.
Further support for the effects of ADM in maintaining vascular integrity 
comes from experimental studies showing that experimental overexpression 
of ADM inhibits systemic and pulmonary vascular leakage in animals40-42. 
For example, in a rat model of Staphylococcus aureus‐toxin induced systemic 
inflammation, accompanied by extensive vascular leakage, ADM infusion 
protected endothelial barrier function via cyclic adenosine monophosphate 
(cAMP) elevation40. Also, ADM dose‐dependently reduced experimentally 
induced endothelial hyperpermeability of cultured human umbilical vein 
endothelial cell and porcine pulmonary artery endothelial cell monolayers41. 
Suppression of ADM contributes to vascular leakage and altered epithelial 
repair during asthma42. In two animal models, intranasal ADM completely 
attenuated the acute‐induced airway hyper‐responsiveness and mucosal 
plasma leakage42,43. ADM acts on several pathways in order to stabilize the 
endothelial barrier, including the cAMP/protein kinase A (PKA) pathway 
that inhibits RhoA/ROCK and reduces subsequent myosin light chain kinase‐
induced actomyosin contraction (the ‘pulling forces’ exerted on endothelial 
cell junctions), as well as the cAMP/PKA and possibly the PI3K/Akt pathway 
to promote production of (protective) cortical actin and stabilization of the 
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VE‐cadherin/ȕ‐catenin complex (part of adherens junctions)44. Finally, ADM 
inhibits the renin–angiotensin–aldosterone system45. Although ADM increases 
plasma renin activity, it induces reductions in the aldosterone/plasma renin 
activity ratio and attenuates angiotensin II‐induced aldosterone secretion. 
In addition, ADM is upregulated by angiotensin II, and protects against 
cardiac hypertrophy and renal damage induced by angiotensin II. Altogether, 
it is suggested that ADM acts as a functional antagonist to angiotensin II, 
hereby inhibiting aldosterone secretion and thus compensating for renin–
angiotensin–aldosterone system escalation.
In summary, vasodilatation and maintaining vascular integrity are the two 
most important functions of ADM. Importantly, the effects of ADM depend 
on its location. ADM is present both intravascular and in the interstitium. 
Its mode of action intravascular as opposed to the interstitium is depicted 
in Figure 1. Intravascular ADM is thought to improve vascular integrity 
and decrease vascular permeability through its effects on endothelial cells. 
Interstitial ADM however is thought to cause vasodilatation by acting on 
vascular smooth muscle cells, in an endothelium‐independent mechanism. 
Note that endothelial‐dependent pathways have also been described, 
although it remains unknown to what extent each pathway is involved in vivo 
in humans46-48.
Adrenomedullin is elevated in heart failure and related to congestion and 
clinical outcome in heart failure
In healthy humans, ADM circulates in the plasma in low concentrations. In 
1995, it was first reported that ADM levels were elevated in heart failure49. 
Plasma ADM concentration was 13 pg/mL in healthy subjects and 3 to 4 
times higher in patients with chronic heart failure49. The observation that 
ADM levels decreased after treatment with diuretics and digitalis led to the 
assumption that ‘volume expansion and an activated sympathetic nervous 
system may be associated with this increase and that plasma ADM levels 
change in response to the pathophysiologic changes of heart failure50. After 
this, many studies have shown elevated levels of ADM in patients with heart 
failure. In addition, several studies found a strong association between higher 
levels of ADM and adverse clinical outcome51,52. The majority of these studies 
used a stable part of the ADM precursor peptide, mid‐regional pro‐ADM 
(MR‐proADM)53. The drawback to this assay, however, is that it measures a 
stable fragment of a non‐functional ADM pro‐peptide, and therefore does 
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Figure 1. Simplistic representation of the mode of action of intravascular vs. interstitial 
adrenomedullin. 1. Adrenomedullin present within the blood vessels improved vascular 
integrity, thereby putatively reducing vascular permeability. 2. Adrenomedullin present in 
the interstitium acts on the vascular smooth muscle cells and causes dilatation of the vascular 
resistance and capacitance vessels.
not distinguish between the biologically active amidated ADM and the non‐
functional ADM variant containing a glycine‐extended C‐terminal residue. 
Recently, a new immunoassay that specifically measures biologically active 
ADM (bio‐ADM) has been developed53. Plasma bio‐ADM was measured 
in 246 patients admitted at the emergency department with suspicion of 
acute heart failure54. Plasma bio‐ADM concentrations were higher among 
patients who experienced a cardiovascular event (median 80.5 pg/mL; 
interquartile range [IQR] 53.7–151.5 pg/mL) compared with those who did 
not (median 54.4 pg/mL; IQR 43.4–78.4 pg/mL) (P < 0.01). After adjusting 
for the other biomarkers, plasma bio‐ADM remained a strong predictor of a 
cardiovascular event54. Another study showed that bio‐ADM was a marker 
of impaired haemodynamics, organ dysfunction, and poor prognosis in 
patients with cardiogenic shock55. We recently studied the clinical correlation 
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and prognostic value of serial measurements of plasma bio‐ADM levels in 
1562 patients admitted for acute decompensated heart failure56. We showed 
that plasma bio‐ADM had the strongest association with clinically assessed 
congestion during hospital admission for acute decompensated heart failure. 
Moreover, bio‐ADM was a better predictor of residual congestion than any 
other individual baseline variable. In patients with clinical signs of residual 
congestion 7 days after hospital admission, bio‐ADM levels were high at 
baseline and remained high throughout the first week of hospitalization. This 
in contrast to brain natriuretic peptide (BNP) levels, which decreased in all 
patients irrespective of the presence and degree of residual congestion. Finally, 
plasma bio‐ADM concentrations, both at baseline and at day 7, provided 
significant added predictive value for 60‐day heart failure rehospitalization, 
even after adjustment for a pre‐defined 11‐item rehospitalization risk model, 
residual congestion by day 7 and BNP at day 7.
Rationale for bio-adrenomedullin as a biomarker for tissue congestion
Adrenomedullin is a vasoactive peptide that is increased in patients that 
are volume overloaded. Main functions of ADM are vasodilatation and to 
maintain vascular integrity and decrease vascular leakage. Elevated levels are 
found in heart failure, but ADM is particularly elevated in patients with 
septic shock. A common factor between both diseases is vascular leakage and 
organ hypoperfusion. In heart failure, higher levels of ADM are associated 
with more severe heart failure, and are the strongest predictor of (residual) 
congestion in patients with acute decompensated heart failure. Increased 
ADM concentrations have been associated with impaired clinical outcome 
in several studies of patients with heart failure. In a recent study, higher levels 
of bio‐ADM were independently associated with a higher risk of hospital 
readmissions56. We therefore propose the following concept, as depicted 
in Figure 2. We propose that higher bio‐ADM levels reflect residual tissue 
congestion, and residual tissue congestion is related to worse outcome after 
discharge, and a higher likelihood for frequent hospital readmissions in 
particular. Therefore, such a measurement might guide physicians to treat 
certain patients more intensively, and this might also facilitate discharge 
decisions.
Adrenomedullin in heart failure: pathophysiology and therapeutic application
5
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 91
91
Figure 2. Bio-adrenomedullin (ADM) as a marker and inhibitor of tissue congestion. Brain 
natriuretic peptide (BNP) as a marker and inhibitor of intravascular congestion.
Adrenomedullin as a target for therapy
Several preclinical (Table 1)57-66 and small clinical (Table 2)67-70 studies have 
established the effects of exogenous administration of ADM in heart failure. 
Briefly, these effects included a reduction in myocardial infarct size, cardiac 
myocyte apoptosis, left ventricular remodelling (in animals) and aldosterone 
levels (animals and humans), while haemodynamics (in both humans and 
animals) and survival (in animals) were improved. In a rat coronary ligation 
model, ADM administration during the early period of a myocardial 
infarction improved survival and ameliorated progression of left ventricular 
remodelling and heart failure62. Similar results were found in another study 
where chronic administration of ADM attenuated transition from left 
ventricular hypertrophy to heart failure in rats60. In a case series of seven acute 
heart failure patients with dyspnoea and pulmonary congestion, the effects 
of long‐term intravenous administration of ADM in acute decompensated 
heart failure were studied. ADM infusion significantly reduced mean arterial 
pressure, pulmonary arterial pressure and systemic and pulmonary vascular 
resistance without changing heart rate, and increased cardiac output for 
most time‐points compared with those at baseline69. In another small study 
of seven chronic heart failure patients and seven healthy subjects, ADM 
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significantly decreased mean arterial pressure and increased heart rate in the 
healthy volunteers68. In patients with heart failure, ADM also decreased mean 
arterial pressure and increased heart rate, but to a much lesser degree. ADM 
markedly increased cardiac index while decreasing pulmonary capillary wedge 
pressure68.
Author 
(year) Intervention Animal model Effects
Nakamura 
(2002)57
ADM infusion for 
4 weeks via osmotic 
pump versus saline
Left coronary ligation-
induced myocardial 
infarction in rats
Ļ Heart weight/body weight 
Ļ Myocyte size 
Ļ Collagen volume fraction of non-
infarct LV area, without affecting infarct 
size
Ļ LV end-diastolic pressure
Okumura 
(2003)58
ADM infusion for 60 
minutes after coronary 
ligation
Ischemia-reperfusion 
(30 min of left 
coronary artery 
ischemia) in rats
After 24 hours:
Ļ LV end-diastolic pressure and Ļ cardiac 
myocyte apoptosis
After 4 weeks:
Ļ Myocardial fibrosis
Ļ Myocardial infarct size
Niu 
(2003)59
Heterozygous 
ADM(+/-) knock-out 
mice compared to 
wild-type
Stress-induced cardiac 
hypertrophy by 
angiotensin II infusion
Knock-out resulted in:
Ĺ Cardiac hypertrophy (heart weight/
body weight and LV thickness) 
Ĺ Renal dysfunction
Nishikimi 
(2003)60
ADM infusion over 
7 weeks using a 
micro-osmotic pump, 
compared with placebo 
and diuretic treatment 
groups
Heart failure model of 
Dahl salt-sensitive rats
ADM infusion:
ĻLV end-diastolic pressure, Ļ RV 
systolic pressure, Ļ RA pressure
Ļ LV weight/body weight
Ļ Renin-aldosterone & ANP
Ĺ Cardiac output & systemic vascular 
resistance
Ĺ LV end-systolic elastance
Ĺ Survival compared to diuretic and 
placebo
Okumura 
(2004)61
ADM infusion, or 
ADM + wortmannin, 
or placebo, for 60 
minutes after coronary 
ligation
Ischemia-reperfusion 
(30 min of left 
coronary artery 
ischemia) in rats
Ļ Infarct size 
Ļ LV end-diastolic pressure 
Ļ Myocardial apoptotic death
Pretreatment with wortmannin 
abolished beneficial effects of ADM, 
indicating involvement of the PI3K/Akt 
dependent pathway
Table 1. Overview of preclinical studies investigating ADM in different models related to 
heart failure
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Author 
(year) Intervention Animal model Effects
Nakamura 
(2004)62
I.p. ADM or 
placebo over 7 days, 
immediately after 
induction of myocardial 
infarction
Left coronary ligation-
induced myocardial 
infarction in rats. 
Observed over 9 weeks
At 9-weeks:
Ĺ Survival, Ļ heart/lung weight
Ļ Oxidative stress and ACE transcription
ĻLV end-diastolic pressure 
Ļ Collagen volume fraction of the non-
infarcted LV.
No effect on infarct size
During 7-days of infusion:
No effects on urinary output or 
hemodynamic parameters
Niu 
(2004)63
Heterozygous 
ADM(+/-) knock-out 
mice compared to 
wild-type
Stress-induced cardiac 
hypertrophy by 
aortic constriction or 
angiotensin II infusion
More pronounced in ADM knock-out 
mice:
ĹHeart weight/bodyweight ratio, 
Ĺ LV wall thickness, Ĺ perivascular 
fibrosis, 
Ĺ Expression of ACE, angiotensinogen, 
collagen type 1, BNP and c-fos
Ĺ Renal damage with glomerular 
sclerosis
Involvement of a PKA/PKC pathway 
Looi 
(2006)64 ADM bolus 
Left coronary ligation 
induced myocardial 
infarction in 
anesthetized rats
ĻVentricular arrhythmias
Involvement of NO mechanism
Yoshizawa 
(2016)65
Subcutaneous infusion 
of ADM using an 
osmotic minipump for 
3 or 7 days
Doxorubicin-induced 
cardiac damage in mice
Ĺ 14 day survival
Ļ LDH levels
Ļ DOX-induced cardiac tissue damage, 
mitochondrial abnormalities and cell 
death
Li (2018)66
Myocardial 
transplantation of 
mesenchymal stem 
cells overexpressing 
ADM (ADM-MSC) 
compared to GFP-
MSCs
Isoproterenol-induced 
global heart failure
Ĺ Cardiac function
Ļ Cardiac fibrosis
Abbreviations: ACE, angiontensin-converting enzyme; ADM, adrenomedulline; ANP, atrial natriuretic 
peptide; BNP, brain natriuretic peptide; GFP, green fluorescent protein; i.p., intraperitoneal; LV, left ventricular; 
MSC, mesenchymal stem cell, MSC; PKA, protein kinase A; PKC, protein kinase C; RA, right atrial; RV, right 
ventricular. 
Taken together, these data consistently show that ADM induces beneficial 
haemodynamic, hormonal and myocardial changes in both experimental 
models and patients with heart failure. These effects are likely related to the 
vasodilatory properties of intravascular ADM, although other pathways may 
also be involved. Many vasodilators have been studied in acute and chronic 
heart failure with mixed results. Therefore, it would be more interesting to 
be able to stimulate the effects of ADM on endothelial permeability, and to 
prevent decreases in blood pressure, since this might be deleterious in patients 
with worsening heart failure.
Table 1. Continued
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Author 
(year) Intervention Condition Effects
Nakamura 
(1997)67
FBF and SBF test with 
intra-arterial ADM
Healthy  subjects 
(n=10)
Patients with CHF 
(n=10)
Ĺ FBF and ĹSBF
Effects partially NO-mediated
Impaired FBF and SBF responses in 
CHF group
Nagaya 
(2000)68
I.v. infusion of ADM 
(n=7) or placebo (n=6), 
90 min total
Patients with 
precapillary pulmonary 
hypertension (n=13 
total)
Ĺ Cardiac index (44%)
Ļ Pulmonary arterial pressure (32%)
Ļ MAP (9 mmHg), Ĺ HR
Ļ Plasma aldosterone (but not renin)
No effect ANP/BNP
Nishikimi 
(2009)69
I.v. infusion of ADM 
+ hANP for 12 h, 
followed by 12 h of 
hANP
Acute heart failure 
patients with dyspnoe 
and pulmonary 
congestion (n=7)
ADM + hANP:
Ļ MAP, PAP, systemic and pulmonary 
vascular resistance
Ĺ Cardiac output, urine volume and 
urine sodium excretion
Ļ Aldosterone, BNP, free-radical 
metabolites
Kataoka 
(2010)70
I.v. infusion of ADM 
for 12 h
No placebo arm
Patients with acute 
myocardial infarction 
before undergoing PCI 
(n=10)
During infusion, two patients showed 
unstable hemodynamics
MRI 3 vs. 1 month after PCI: 
Ĺ:DOOPRWLRQLQGH[Ļ infarct size
Table 2. Overview of studies investigating ADM in human patients with forms of heart 
failure
Abbreviations: ADM, adrenomedullin; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; 
CHF, chronic heart failure; FBF, forearm blood flow; hANP, human atrial natriuretic peptide; HR, heart 
rate; MAP, mean arterial pressure; MRI, magnetic resonance imaging; NO, nitric oxide; PAP, pulmonary 
artery pressure; PCI, percutaneous coronary intervention; SBF, skin blood flow.
Adrecizumab for the treatment of heart failure and sepsis
Adrecizumab is a humanized, monoclonal, non‐neutralizing antibody against 
the N‐terminus of ADM. It has a half‐life of 15 days when administered by a 
single intravenous infusion. The mode of action of adrecizumab is presented in 
Figure 3. Administration of adrecizumab leads to a dose‐dependent increase 
in plasma ADM bound to the administered antibody. The increase occurs 
within a few minutes and is not caused by induction of de‐novo synthesis, 
because concentrations of MR‐proADM are not increased (an inactive peptide 
fragment originating from the same precursor as ADM, which is synthesized 
in a 1:1 ratio). It is hypothesized that translocation of pre‐existing ADM 
accounts for the observed increase in circulating ADM71. Briefly, circulating 
adrecizumab cannot leave the blood compartment due to its high molecular 
weight (160 kDa), whereas ADM (with a much lower molecular weight of 
6 kDa) can freely cross the endothelial barrier between the interstitium and 
the circulation55. Binding of ADM by adrecizumab (present in the circulation 
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in a large excess over ADM) prevents ADM from leaving the blood vessel, 
effectively ‘trapping’ ADM in the circulation. In addition, adrecizumab 
may translocate ADM from the interstitium into the circulation. Because 
adrecizumab is a non‐neutralizing antibody, the net effect is a significant 
increase of functional plasma ADM which leads to – as we hypothesize – 
the restoration of vascular integrity (endothelial effect) and less vasodilatation 
(vascular smooth muscle cell effect due to decreased concentrations of ADM 
in the interstitium). Further, it is thought that adrecizumab prevents ADM 
from being degraded by proteases and prolongs half‐life of ADM71.
Figure 3. Mode of action of Adrecizumab. Administration of adrecizumab leads to a dose‐
dependent increase of plasma adrenomedullin (ADM) bound to the administered antibody. 
Circulating adrecizumab cannot leave the blood compartment due to its high molecular 
weight (160 kDa), whereas ADM (with a much lower molecular weight of 6 kDa) can freely 
cross the endothelial barrier between the interstitium and the circulation. Binding of ADM 
by adrecizumab (present in the circulation in a large excess over ADM) prevents ADM from 
leaving the blood vessel, effectively ‘trapping’ ADM in the circulation.
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In animal models of systemic inflammation and septic shock, adrecizumab 
improved haemodynamics, renal function, systemic inflammation and 
reduced inducible nitric oxide synthase expression71. Currently, adrecizumab 
is being evaluated in a phase II trial in human septic shock (http://clinicaltrials.
gov identifier: NCT03085758). There were no safety concerns observed in 
pre‐clinical studies, as well as in two phase I studies in which 0.5, 2 and 
8 mg/kg were administered to healthy volunteers71. Importantly, even though 
adrecizumab induced great increases in circulating levels of ADM, this did 
not cause hypotension. In a phase Ib study, where healthy subjects received 
an infusion of bacterial lipopolysaccharide to induce a systemic inflammatory 
response, administration of adrecizumab significantly reduced the perception 
of illness/sickness, as assessed by clinical scores72.
A phase II proof of concept study in patients with worsening heart failure 
and elevated bio‐ADM levels after initial stabilization is currently being 
considered. Patients with elevated bio‐ADM have (residual) congestion 
and are at high risk for clinical events, and a heart failure readmission in 
particular. Adrecizumab is expected to increase intravascular ADM and 
decrease interstitial ADM, since adrecizumab may translocate ADM from 
the interstitium into the circulation. The hypothesis of this study is that by 
improving vascular integrity, it is expected that adrecizumab will decrease 
tissue congestion and thereby improve dyspnoea, potentially reducing heart 
failure readmissions. However, it should be noted that long‐term effects of 
ADM on development and/or progression of heart failure have never been 
clinically investigated. In addition, adrecizumab itself has not been investigated 
in pre‐clinical models of heart failure, but only in septic shock and systemic 
inflammation. Tissue congestion was never an outcome parameter in pre‐
clinical studies with ADM.
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Conclusions
Adrenomedullin is an endogenous hormone that is released as a counteracting 
response to volume overload. Levels of ADM are clearly increased in patients 
with heart failure, and higher levels are related to more advanced heart failure 
and worse outcomes. Since elevation of ADM is a feedback response to 
volume overload to maintain vascular integrity and decrease vascular leakage 
of fluid from the the vasculature to the tissues, measurement of ADM might 
reflect tissue and pulmonary oedema. Such a measurement might guide 
physicians to more intensively treat patients with heart failure hospitalization 
and facilitate discharge decisions. In addition, ADM might become a target 
of therapy in heart failure. The mode of action of adrecizumab, a humanized 
monoclonal antibody that binds but does not significantly inhibit ADM, 
might be of particular interest, since it is assumed to translocate ADM 
from the interstitium into the vasculature to improve vascular integrity and 
prevent vascular leakage. A clinical study with adrecizumab is currently being 
conducted in patients with sepsis and a study in hospitalized heart failure 
patients is currently being prepared.
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Abstract
Systemic inflammation plays a pivotal role in a multitude of conditions, 
including sepsis, trauma, major surgery and burns. However, comprehensive 
analysis of the pathophysiology underlying this systemic inflammatory 
response is greatly complicated by variations in the immune response observed 
in critically ill patients, which is a result of inter-individual differences in 
comorbidity, comedication, source of infection, causative pathogen, and onset 
of the inflammatory response. During experimental human endotoxemia, 
human subjects are challenged with purified endotoxin (lipopolysaccharide) 
intravenously which induces a short-lived, well-tolerated and controlled 
systemic inflammatory response, similar to that observed during sepsis. 
The human endotoxemia model can be conducted in a highly standardized 
and reproducible manner, using a carefully selected homogenous study 
population. As such, the experimental human endotoxemia model does not 
share the aforementioned clinical limitations and enables us to investigate 
both the mechanisms of systemic inflammation, as well as to evaluate novel 
(pharmacological) interventions in humans in vivo. The present review 
provides a detailed overview of the various designs, organ-specific changes, 
and strengths and limitations of the experimental human endotoxemia model, 
with the main focus on its use as a translational model for sepsis research.
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Introduction
Systemic inflammation plays a pivotal role in a multitude of conditions, 
including sepsis, trauma, major surgery, and burns1. For many years, efforts 
have been undertaken to unravel the complex etiology of the systemic 
inflammatory response. Unfortunately, comprehensive analysis of the 
pathophysiology underlying this response is greatly complicated by variation 
in the immune responses observed in critically ill patients, which are a result of 
inter-individual differences in comorbidity, comedication, source of infection, 
causative pathogen, and onset of the inflammatory response. The heterogeneity 
between patients impedes evaluation of pathophysiological mechanisms 
and hampers accurate comparison of (pharmacological) interventions. As 
a consequence, large numbers of patients need to be included in clinical 
trials to demonstrate intervention efficacy. And strikingly, even when these 
numbers were met, many of the positive results found in preclinical (animal) 
studies of systemic inflammation could not be reproduced in expensive (phase 
III) clinical trials2,3. Therefore, an intermediate step is highly warranted to 
improve translation of preclinical animal data to sepsis patients, which will 
likely prevent more disappointing results, and may allocate resources more 
efficiently.
The experimental human endotoxemia model can be used to overcome the 
aforementioned constraints of translating preclinical results into clinical 
practice. During experimental human endotoxemia, volunteers are challenged 
with purified endotoxin (lipopolysaccharide [LPS]) derived from the Gram-
negative bacterium Escherichia coli. An intravenous challenge with LPS induces 
a short-lived, well-tolerated, and controlled systemic inflammatory response, 
mimicking the initial inflammatory response observed in septic patients4. 
Importantly, these challenges can be conducted in a highly standardized 
and reproducible manner in a carefully selected (h omogeneous) study 
population. To this end, experimental human endotoxemia does not share 
the aforementioned limitations of clinical trials4,5 and therefore is an example 
of translational research that facilitates us to investigate the mechanisms of 
systemic inflammation and to evaluate novel (pharmacological) interventions 
in humans in vivo5.
The aim of the present review is to provide a detailed overview of the 
various designs, organ-specific changes, and strengths and limitations of the 
experimental human endotoxemia model, with the main focus on its use as a 
translational model for sepsis research.
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 106
106
The human endotoxemia model
For over a century, the experimental human endotoxemia model has been 
successfully applied using LPS in different types, dosages, and forms of 
administration1,4,5. The models used are safe, well-tolerated, and bear no 
known long-term health risks to the participants. The most frequently 
described method is by intravenous administration of LPS, although other 
forms have also been described, e.g., intrabronchial administration6. The 
cornerstone of the endotoxemia model is the interaction of LPS with the Toll 
Like receptor (TLR)-4, an interaction which also constitutes the first step in 
the inflammatory cascade in for example Gram-negative sepsis4,7. Intravenous 
LPS administration elicits a transient and controlled systemic inflammatory 
response, clinically characterized by an increase in core temperature of 
approximately 1.5–2 °C, flu-like symptoms (such as headache, chills, fatigue, 
myalgia, backache, and nausea) during 2–4 h, as well as hemodynamic 
alterations (tachycardia, tachypnea, and decrease in blood pressure).
Experimental setup
After approval of the local ethics committee and written informed consent, 
all subjects are thoroughly screened prior to inclusion (using medical history, 
physical examination, laboratory tests, and a 12-leads electrocardiogram). 
The procedure and general requirements for conducting a LPS challenge are 
displayed in Figure 1.
Dose regimens
Currently, the only commercially available LPS for use in humans is the 
GMP-grade E. Coli Type O113 (Lot no. 94332) produced by List Biological 
Laboratories in Campbell, USA. The use of different doses have been 
well described in literature, varying from extremely low dosages of 0.1–
0.3 ng/kg (only causing minor cytokine peaks with the absence of clinical 
symptoms), to a maximum used dose of 4 ng/kg (resulting in a profound 
systemic inflammatory response accompanied by the aforementioned clinical 
symptoms)4,8,9. The magnitude of the inflammatory response after LPS is 
highly dose-dependent and therefore, higher dosage regimens are mainly used 
as an in vivo translational model for sepsis, while the lower dosage ranges are 
increasingly applied to model a state of low grade inflammation, which is 
observed in e.g. diabetes and metabolic syndrome9,10. While most studies use 
the traditional single bolus administration of LPS, a recent study proposed 
a novel method consisting of a bolus administration of 1 ng/kg followed by 
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Figure 1. Overview of the experimental setup used to conduct experimental human endo-
toxemia. On the experiment day, subjects are hospitalized and receive one or two (18 gauge) 
venous catheters to accommodate infusion of LPS, fluids, and study medication. Subsequent-
ly, an arterial catheter is placed, preferably in the radial artery of the nondominant arm, 
for frequent blood withdrawals and blood pressure monitoring. Vital signs are continuously 
monitored during the experiment using 3-lead electrocardiography, peripheral pulse-oxime-
try, and the intra-arterial blood pressure signal. Body temperature (determined using an ear 
thermometer) and severity of symptoms are determined every half hour. Approximately 1 h 
prior to LPS administration, subjects are prehydrated with 1.5 L NaCl 0.45%/Glucose 2.5% 
solution, as this is known to reduce the risk of a vasovagal reaction following endotoxemia54. 
Hereafter, fluid administration is continued at a rate of 150 mL/h until the end of the exper-
iment. Arterial blood is drawn at baseline and serially during the endotoxemia to determine 
leukocyte differentiation and cytokine concentration over time. Furthermore, depending on 
the research questions proposed, the evaluation of numerous parameters and/or (pharmaco-
logical) interventions can be added to the protocol. Abbreviations: LPS, lipopolysaccharide; BP, 
blood pressure; ECG, electrocardiography; NaCl, sodium chloride.
a continuous administration of 1 ng/kg/h for 3 h1. This continuous model 
resulted in a more prolonged inflammatory response compared to bolus 
LPS administration, exemplified by higher plasma cytokine concentrations 
and circulating leukocytes, and an increased duration of fever and clinical 
symptoms, while no safety issues were reported. Therefore, the continuous 
model may better resemble the ongoing inflammation seen during sepsis, 
and may also provide a larger (and clinically more relevant) time window to 
examine the effects of immunomodulatory interventions.
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Repeated experimental human endotoxemia
The immune response in septic patients is highly variable and can comprise 
both a hyperinflammatory as well as an immune-suppressed phenotype. The 
latter state, also known as sepsis-induced immunoparalysis, is increasingly 
recognized as the overriding immune dysfunction in sepsis, rendering patients 
vulnerable to secondary infections and impairing sepsis outcome. However, 
the identification of immunoparalyzed patients remains difficult, this is 
why few clinical studies have investigated immunostimulatory therapies. 
Interestingly, LPS administration results in a phenomenon called ‘endotoxin 
tolerance’, which is characterized by severely attenuated cytokine responses 
and less pronounced changes in clinical symptoms upon a second challenge, 
compared to the first LPS challenge11,12. Endotoxin tolerance bears many 
hallmarks of (sepsis-induced) immunoparalysis, such as a decreased ex vivo 
cytokine production of LPS-stimulated monocytes and a decreased HLA-DR 
expression on monocytes11. To this end, the repeated human endotoxemia 
model can be used to model sepsis-induced immunoparalysis, allowing us 
to investigate immunostimulatory therapies in humans in vivo, without the 
aforementioned clinical constraints11. Please note that the similarities between 
endotoxin tolerance and immunoparalysis are mainly observed in the innate 
immune response, as LPS administration does not strongly affect the adaptive 
immune response.
Experimental human endotoxemia-induced organ-specific effects
The intravenous administration of LPS, especially within the high dose ranges 
(2–4 ng/kg), exerts many organ-specific effects. Since the model is conducted 
in a highly standardized and reproducible manner, it offers an unique 
opportunity to investigate the pathophysiology underlying these changes and 
to evaluate new (organ-specific) interventions9. In the following section, we 
complement previous reviews on experimental endotoxemia4,5,8 and focus on 
the effects of experimental human endotoxemia on important organ systems, 
and recite the most important interventions concerning each organ system. 
An overview of the LPS-induced organ-specific effects is displayed in Figure 
2.
The immune system
Upon administration, LPS monomers bind to TLR-4-MD2 receptor-
domains expressed on antigen presenting cells, which leads to an activated 
TLR-4 dimeric receptor complex. Mediated by adaptor protein MYD88, 
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Figure 2. Summary of experimental human endotoxemia-induced organ-specific effects. 
Overview of the organ-specific effects resulting from intravenous administration of LPS with-
in the high dose ranges (2-4 ng/kg). Abbreviations: FEV1, forced expiratory volume in 1 s; FVC, 
forced vital capacity.
several intracellular protein-complex-pathways are subsequently activated, 
resulting in the activation of the transcription factor NF-kB. Binding of 
NF-kB to its target genes triggers the synthesis of RNA-sequences which are 
translated to various pro- and anti-inflammatory cytokines. Plasma cytokine 
levels upon LPS administration have a distinct, dose-dependent and highly 
reproducible time course1,7,8. Tumor necrosis factor (TNF)-Į is the first to 
peak (90–120 min) and is believed to be the primary mediator leading to the 
LPS-induced systemic inflammatory cascade. TNF-Į is closely followed by 
peak concentrations of IL-1ȕ, IL-6, but also of the anti-inflammatory cytokine 
IL-10, all of which have maximum plasma concentrations at approximately 
3 h following LPS administration. Within 6–8 h after the LPS challenge, all 
plasma cytokines levels return to baseline values1.
The inflammatory cytokine responses observed during experimental human 
endotoxemia, as well as a multitude of interventions targeted against it have 
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been extensively studied. A study investigating gender-based differences 
during experimental endotoxemia, found significantly higher peak TNF-Į 
concentrations in females, while no difference in the anti-inflammatory IL-
10 cytokine response was observed13. Arguably, this more pronounced pro-
inflammatory response in females could partially explain both the lower 
incidence, and the better outcome of sepsis in female patients. Prednisolone, 
a well established anti-inflammatory therapeutic, was found to reduce the 
release of pro-inflammatory cytokines TNF-Į and IL-6 during endotoxemia 
in a dose dependent manner, while it enhanced the release of the anti-
inflammatory cytokine IL-1014. These findings might explain the high 
susceptibility to infection in patients often observed after prolonged use of 
corticosteroids.
Using repeated human endotoxemia as a model for sepsis-induced 
immunoparalysis, several immunostimulatory agents have been investigated 
for their effect on preventing or restoring the suppressed immune function. 
Of interest, while ex vivo endotoxin tolerance (ex vivo re-stimulation of 
leukocytes with LPS) resolves quickly, in vivo endotoxin tolerance (in vivo 
re-challenge with LPS) persists for at least 2 weeks15. Based on the poor 
correlation between ex vivo and in vivo responses, clearly ex vivo endotoxin 
tolerance kinetics do not accurately reflect the in vivo innate immune response, 
further emphasizing the need for an in vivo translational model of endotoxin 
tolerance. Indeed, in a recent double-blind randomized controlled trial it was 
shown that treatment with IFN-Ȗ during repeated experimental endotoxemia 
could partially reverse endotoxin tolerance11. These in vivo results further 
support the hypothesis that immunostimulatory agents could be a promising 
treatment option to reverse sepsis-induced immunoparalysis.
Hematology
Sequestration of immune cells results in neutrophilia, and a mono- and 
lymphocytopenia, with lowest counts at 2 and 4 h following intravenous 
administration of LPS, respectively1. Interestingly, a recent study using 
deuterium labeling to monitor immune cells, reported that the repopulation 
of monocytes is achieved by the early release of classical monocytes from 
the bone marrow, and not by return of monocytes from the marginating 
pool (monocytes that do not circulate as they adhere to the endothelium)16. 
Another study investigating the function of different neutrophil subsets during 
experimental endotoxemia found a down-regulation of neutrophil receptors 
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necessary for chemotaxis, microbial recognition and killing17. Moreover, a 
moderately decreased interaction with opsonised Staphylococcus epidermidis 
bacteria was found17. Intriguingly, these suppressed neutrophil phenotypes 
were also associated with a marked upregulation of the capacity to produce 
reactive oxygen species (ROS), which are essential for neutrophil bactericidal 
activity. These apparently contradictory findings may be explained by priming 
and activation of already circulating neutrophils by LPS leading to the 
enhanced ROS production on one hand, while LPS also induces the release 
of refractory, immature neutrophils with lower antimicrobial functionality 
from the bone marrow.
The cardiovascular system
Endotoxin-induced systemic inflammation has profound effects on the heart 
and vascular system. In the first hours following endotoxin administration, 
a hyperdynamic cardiovascular state is present, characterized by decreased 
systemic vascular resistance, lower arterial blood pressure and blunted 
responsiveness to sympathetic vasoconstrictors, as well as increased cardiac 
output and heart rate1,18-20. Myocardial contractility parameters (including 
left ventricular ejection fraction) typically show a biphasic response, with 
an initial increase, but later decrease (even though the hyperdynamic state 
persists for 6–12 h)18,19,21. Experimental human endotoxemia therefore 
represents (at least to a certain extent) cardiovascular manifestations of sepsis, 
and can be used to study the cardiovascular effects of interventions. For 
example, an antagonist against the toxic lipid A component of LPS (E5531) 
inhibited the early hyperdynamic cardiovascular response, as well as the late 
myocardial depression21 and recombinant human activated protein C (APC) 
prevented the decrease in mean arterial blood pressure (MAP) during human 
endotoxemia22.
The microcirculation and vascular endothelial permeability
Extensive microcirculatory alterations are present during sepsis, resulting in a 
mismatch of oxygen supply and demand due to shunting23. In addition, tissue 
edema develops due to vascular hyperpermeability combined with the need 
for fluid resuscitation. This contributes to development of for instance acute 
respiratory distress syndrome (ARDS) and acute kidney injury (AKI)24. It is 
well known that LPS administration can cause profound vascular leakage in 
animals25, and indeed, plasma obtained during human endotoxemia causes 
vascular leakage in vitro26. In contrast, an increased capillary leakage could 
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not be detected in humans in vivo, indicating that the experimental human 
endotoxemia model is not suitable to study microvascular permeability27. 
Prolonged duration and increased severity of the inflammatory response 
observed in animal models of endotoxemia, as a consequence of higher 
dose administration of LPS (approx. 1000 times higher) likely explain 
this discrepancy. Note that there is one report that describes the case of a 
laboratory worker self-administering an extremely high dose of Salmonella 
endotoxin. This resulted in severe shock with non-cardiogenic pulmonary 
edema and multi-organ failure, indeed similar to septic shock28. Even though 
hyperpermeability is not present in the experimental human endotoxemia 
model, several other manifestations of endothelial and vascular dysfunction 
can be observed. These include reduced tissue oxygenation (using near-
infrared spectroscopy in combination with upper-arm ischemia), reduced 
blood flow in medium and large microvessels (using sidestream dark-field 
imaging) and an attenuation of acetylcholine-induced vasodilation through 
forearm blood flow measurements29. In addition, plasma levels of different 
endothelial dysfunction/adhesion markers are increased, such as endocan, 
E-selectin, P-selectin, VCAM-1 and ICAM-1, although in contrast to sepsis, 
angiopoeitin-1, Tie2, thrombomodulin and VE-cadherin are not increased30-35.
The kidneys
The development of AKI is common in sepsis and associated with increased 
mortality36. AKI is thought to arise through a complex mechanism of immune-
mediated microvascular and tubular dysfunction37. Similar to sepsis, several 
urinary tubular damage markers are also increased following experimental 
human endotoxemia. For example, glutathione-S-transferase-A1 (GSTA1-1), 
a marker of proximal tubule damage, was increased in urine and correlated 
with increased nitric-oxide (NO) metabolite excretion38. Interestingly, co-
administration of the inducible nitric oxide synthase (iNOS) inhibitor 
aminoguanidine during human endotoxemia reduced upregulation of iNOS 
mRNA, urinary NO metabolites and urinary GSTA1-1, suggesting a role of 
iNOS and NO in renal proximal tubule damage38. More recently, significant 
increases of urinary B2MG and KIM-1, markers indicating (subtle) proximal 
tubular damage were reported. In contrast, many other markers, among 
which serum creatinine, were not affected35. Also note that these increases 
of urinary B2MG and KIM-1 were 3–4 fold less pronounced as compared 
to septic AKI. Therefore, one may conclude that there is only subtle kidney 
injury during human endotoxemia, making its clinical relevance as a model 
for septic AKI questionable.
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Pulmonary system
In addition to intravenous administration, LPS has also been administered 
intrapulmonary to induce a local inflammatory response in the bronchoalveolar 
space6, which bears features of acute lung injury and/or pneumonia6. In this 
pulmonary LPS model, intravenous co-administration of activated protein C 
(APC) resulted in both anti-coagulatory and anti-inflammatory effects in the 
bronchoalveolar space6,39, whereas intrapulmonary APC administration led to 
a pro-coagulatory and pro-inflammatory phenotype40. Moreover, changes in 
respiratory capacity and pulmonary gas exchange were recently investigated 
following both systemic and pulmonary endotoxin administration41. Both 
models decreased forced expiratory volume (FEV1) and forced vital capacity 
(FVC), although this effect was more pronounced after intravenous LPS 
administration. Furthermore, the alveolar-arterial oxygen gradient increased 
after intravenous, but not after intrapulmonary LPS administration41.
Respiratory muscles
Systemic inflammation is thought to contribute to respiratory muscle weakness 
in mechanically ventilated patients, which may lead to weaning problems42. 
A recent study investigated whether LPS affects diaphragm function, and if 
it could act as a model of respiratory muscle weakness. In contrast to animal 
studies and findings in critically ill patients, in vivo diaphragm contractility 
was not impaired, but rather augmented during experimental human 
endotoxemia, possibly related to the release of stress hormones43.
Coagulation
Experimental human endotoxemia induces platelet activation and 
consumption, prolonged APTT and an increased INR44,45. In addition, 
increased fibrinolysis and fibrinogen consumption is reported, which is 
followed by downregulation of fibrinolysis. Primary hemostasis is reduced, 
whereas secondary hemostasis is enhanced45. Different interventions that 
act on coagulation and/or fibrinolysis have been examined using the human 
endotoxemia model. Colistin, which electrostatically interacts with LPS46, 
blunted endothelial activation and the fibrinolytic response, while activation 
of the coagulation system was not severely affected. This suggests that colistin 
may exert other effects besides its antimicrobial activity in patients with 
Gram-negative sepsis46. In a study with APC (also mentioned earlier), no 
effects were observed on fibrinolysis, coagulation or inflammation during 
human endotoxemia22. Interestingly, the human endotoxemia model is not 
necessarily limited to application in healthy subjects. Factor V Leiden (FVL) 
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mutations (causing hypercoagulability) were initially thought to worsen 
clinical outcome in patients with disseminated intravascular coagulation in 
sepsis, although clinical trials and animal data later indicated the opposite. 
Therefore, a study was conducted to explore the mechanism of action of 
the FVL mutation during human endotoxemia47. Interestingly, males with 
a heterozygous FVL mutation showed an enhanced fibrinolytic response to 
endotoxin, possibly due to higher levels of soluble fibrin acting as cofactor 
in tissue plasminogen-induced plasminogen activation. This may therefore 
result in better clearance of fibrin deposits, a reduction of fibrinogen levels 
and generation of ‘anticoagulant’ fibrinogen degradation products.
The gastrointestinal tract
During sepsis, the permeability of the intestinal barrier increases, allowing 
translocation of bacteria and luminal contents (e.g. pancreatic enzymes)36. 
Thirty years ago, the increased intestinal permeability following endotoxin 
administration was first reported, when a study found urinary secretion of 
the (normally) non-metabolizible sugars lactulose and mannitol after oral 
ingestion48. Results were confirmed in another study using polyethylene 
glycol, indicating that inflammation-induced paracellular permeability and 
not ischemia-mediated enterocyte damage was responsible for the increased 
intestinal permeability49. Interestingly, increased permeability seems to be 
limited to the small intestine50.
The gut microbiota is known to have an important interaction with gut-
barrier function and modulation of the immune system during sepsis51. In 
addition, sepsis and/or antibiotics influence gut-microbiota composition. 
Nevertheless, antibiotic-induced alterations in microbiota composition 
did not influence inflammation during experimental human endotoxemia, 
even though gut microbiota diversity was decreased by broad-spectrum 
antibiotics52. Moreover, no endotoxemia-induced increase in liver damage 
marker GSTA1 was observed, indicating that the human endotoxemia model 
is probably too mild to cause inflammation-induced liver injury53.
Limitations of the human endotoxemia model
To date, the experimental human endotoxemia is the only in vivo model 
of systemic inflammation. However, several important factors may limit its 
clinical relevance and extrapolation to clinical research in sepsis. A summary of 
the main differences between experimental human endotoxemia and sepsis is 
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displayed in Table 1, a summary of the main similarities is displayed in Table 
2. The differences listed in Table 1, as well as those mentioned earlier for the 
different organ systems, underline that while some aspects of experimental 
endotoxemia are highly comparable to sepsis, others are markedly different 
(e.g. capillary leakage, liver injury, and an adaptive immune response). 
Considering the complex pathophysiology of systemic inflammation, 
experimental endotoxemia should therefore never be envisioned as an 
alternative or direct comparison to sepsis, but rather function as an important 
bridge between preclinical (laboratory and animal) studies on one side, and 
the indispensable clinical research in patients on the other side.
Experimental human endotoxemia Sepsis
Subject 
characteristics
- Homogeneous population
- (Mostly) young adults
- (Mostly) healthy
- (Mostly) males
- Heterogeneous population
- Average age >50 years
- Comorbidities
- Comedication
Inflammatory 
cascade
- Highly standardized (known time of 
onset)
- LPS-induced
- TLR-4 mediated
- Predominantly innate immune 
response
- Unknown time of onset
- Live pathogens
- Multi-causative
- Innate and adaptive immune 
response
Cytokines - Short elevation of plasma cytokines (hours)
- Prolonged cytokine response 
(days-weeks)
Cardiovascular and 
clinical features
- Short 'hyperdynamic response' with 
limited decrease in blood pressure
- No capillary leak/shock symptoms
- Sustained and profound 
hemodynamic compromise often 
leading to multi-organ failure
- Capillary leak leading to 
substantial edema formation
Risks/outcome
- Transient flu-like symptoms
- Well-tolerated
- Safe
- No long-term effects
- Up to 40% mortality
- Significant (long-term) 
morbidity in survivors, often need 
for medical rehabilitation
Table 1. Differences between experimental human endotoxemia and sepsis.
Abbreviations: LPS, lipopolysaccharide; TLR, Toll-like receptor.
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Similarities
General symptoms - Fever response with characteristic 'chills and shivering'- Headache, myalgia, nausea and vomiting
Inflammatory 
cascade - Innate immunity mediated cytokine release
Cerebral - Decreased pain threshold
Cellular response
- Marked leukocytosis
- Induction of immune suppression upon secondary challenge
- Induction of nitric oxide release
- Induction of hepcidin-mediated anemia
Cardiovascular
- Reduced left ventricular contractility
- Hyperdynamic circulation with elevated cardiac index
- Induction of endothelial dysfunction
Pulmonary - Tachypnea- Reduced alveolar gas exchange
Renal - Increased urinary excretion of tubular injury markers
Coagulation - Reduced platelet count and function- Increased secondary hemostasis
Metabolic
- Catecholamine and cortisolic stress response
- Reduced insulin sensitivity
- Catabolic protein response
Gastrointestinal - Increased gut permeability
Table 2. Similarities between experimental human endotoxemia and sepsis
Future improvements on the model
Research performed during the past decade has also focused on ways to further 
improve the comparability between experimental human endotoxemia and 
sepsis. As mentioned earlier, in a recently introduced continuous model 
of (high dose) LPS administration, bolus administration was followed by 
continuous LPS infusion during three hours1. This leads to more sustained 
and higher plasma cytokine concentrations, more circulating leukocytes, and 
an increased duration of fever and clinical symptoms compared to LPS bolus 
injection models. The continuous LPS infusion model may therefore better 
resemble the state of ongoing inflammation as observed during sepsis. Future 
research should concentrate on further optimizing LPS dosage regimens, 
possibly through even longer durations of continuous LPS administration.
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Conclusion
Experimental human endotoxemia is a translational model of systemic 
inflammation in humans in vivo and has been successfully performed in 
thousands of healthy volunteers. It has proven to be safe, well-tolerated and 
without any known long-term health risks for the participating subjects. 
Unlike the heterogeneous inflammatory response observed in sepsis patients, 
the inflammatory responses observed during experimental endotoxemia are 
mono-causative (TLR-4 driven), highly standardized, and reproducible, 
greatly facilitating the possibilities for between-subject and intervention-based 
comparisons. The overlap in inflammatory response, clinical parameters, and 
organ-specific changes emphasize that experimental human endotoxemia 
may serve as a model for sepsis. However, the model also has limitations, 
implying that direct comparisons between experimental endotoxemia and 
clinical causes of systemic inflammation should always be made with caution. 
Nevertheless, the multitude of studies performed on the observed cytokine 
responses, the different inflammation-induced organ dysfunctions, as well as 
therapeutic interventions directed against these have been indispensable in 
advancing our understanding of the complex pathophysiology of systemic 
inflammation and sepsis. Therefore, the experimental human endotoxemia 
model should be used to facilitate the translation of preclinical work to the 
sepsis population.
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Abstract
Objectives: Adrenomedullin (ADM) is a vascoactive peptide and elevated 
ADM levels have been detected in sepsis. We assessed the relationship between 
circulating ADM, the need for organ support and mortality in a general 
intensive care unit (ICU) population, using a novel assay that measures 
biologically active ADM (bio-ADM).
Design: Prospective multicenter observational cohort study.
Setting: Data from the FROG-ICU study (French and European Outcome 
reGistry in Intensive Care Units).
Patients: Consecutive patients admitted to intensive care with a requirement 
for invasive mechanical ventilation and/or vasoactive drug support for more 
than 24 h following ICU admission were included.
Interventions: Clinical and biological parameters were collected at baseline, 
including bio-ADM. Status of ICU survivors was assessed up until 1 year 
after discharge. The main outcome was the need for organ support, including 
renal replacement therapy (RRT) and/or for inotrope(s) and/or vasopressor(s). 
Secondary endpoints included the ICU length of stay (LOS) and the 28-day 
all-cause mortality.
Measurements and main results: Median plasma bio-ADM (n=2003) was 
66.6 [34.6-136.4] pg/ml and the median SAPS-II score 49 [36-63]. RRT 
was needed in 23% and inotropes(s) and/or vasopressor(s) in 77% of studied 
patients. ICU LOS was 13 [7-21] days and mortality at 28 days was 22%. 
Elevated bio-ADM independently predicted 1) the need for organ support 
(OR [95% CI] 4.02 [3.08-5.25]) in ICU patients whether admitted for septic 
or non-septic causes and 2) the need for RRT (OR 4.89 [3.83- 6.28]), and for 
inotrope(s) and/or vasopressor(s) (OR 3.64 [2.84-4.69]), even in patients who 
were not on those supports at baseline. Elevated bio-ADM was also associated 
with a prolonged LOS (OR 1.85 [1.49-2.29]) and, after adjustment for SAPS-
II, with mortality (OR 2.31 [1.83-2.92]).
Conclusions: Early measurement of bio-ADM is a strong predictor of the need 
of organ support and of short-term mortality in critically ill patients.
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Introduction
Adrenomedullin (ADM) is a 52 amino-acid peptide hormone belonging to 
the calcitonin gene-related peptide family. ADM has strong vascular actions1,2 
and has previously been described as a ‘double-edged sword’3: preclinical 
studies have shown that ADM administration causes vasodilation4–6 and may 
lead to hypotension7,8, whereas other studies have demonstrated beneficial 
effects on endothelial cells in the prevention of vascular leakage9–11 and 
improved outcome in preclinical animal models of systemic inflammation 
and septic shock12,13.
Previous studies have assessed ADM activity in sepsis patients by measuring 
levels of its inactive precursor MR-proADM14, or by using assay of uncertain 
validity or with technical difficulties15. However, the measurement of the 
bioactive form of ADM (bio-ADM) may better reflect the biological relevance. 
Using this novel sandwich immunoassay, two studies in sepsis and septic 
shock patients demonstrated that bio-ADM correlated with disease severity, 
the need for organ support and mortality15,16. Additional measurements 
over the first week after sepsis onset allowed for a better prediction of long-
term mortality15. Whether baseline bio-ADM is associated with short-term 
outcome, especially the need of organ-support, and long-term outcome, in all 
Intensive Care Unit (ICU) patients and in patients admitted for causes other 
than sepsis, remains unclear.
The present study is an ancillary study from the FROG-ICU (the French and 
European Outcome Registry in Intensive Care Units) study17. The FROG-
ICU study was a prospective, observational, multicenter cohort study that 
included septic and non-septic ICU patients, as well as a novel assay specific 
for bio-ADM. The main objective of the FROG-ICU study was to identify 
clinical and biological determinants of death in the year following ICU 
discharge. Multivariable analysis identified age, comorbidity, red blood cell 
transfusion, ICU length of stay and abnormalities in common clinical factors 
at the time of ICU discharge as independent factors associated with 1-year 
mortality. Bio-ADM was independently associated with 1-year death and 
when mixed in a panel of elevated biomarkers of cardiac and vascular failure 
improved the risk of death. The original FROG-ICU study focused on the 
risk of 1-year mortality according to the number of cardiovascular biomarkers 
elevated at discharge from the ICU. This study focuses on the relationship 
between baseline circulating bio-ADM, organ support therapies and short-
term mortality in the critical ill. This is the first and largest prospective cohort 
study so far to investigate prognostic value of bio-ADM in the general ICU 
population.
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Materials and methods
Study design and patients
Our study uses the data of the FROG-ICU study (ClinicalTrials.gov 
NCT01367093)17. The FROG-ICU study was a prospective, observational, 
multicenter cohort study, designed to assess the incidence and to identify the 
risk factors of mortality during the year following discharge from the ICU. The 
study protocol was previously published18. The study was conducted in France 
and in Belgium in accordance with Good Clinical Practice, the Declaration 
of Helsinki (2013, Fortalenza), and approved by the ethical committee. The 
study involved medical, surgical or mixed ICUs in 14 hospitals. The study 
cohort included 2087 consecutive patients who were admitted to the ICU 
in any of the participating centers during the recruitment period when the 
following inclusion criteria were met: invasive mechanical ventilation support 
for at least 24 h and/or treatment with a positive inotropic agent for more 
than 24 h. Exclusion criteria were the following: less than 18 years old, severe 
head injury (initial Glasgow Coma Scale < 8) or brain death or a persistent 
vegetative state, pregnancy or breastfeeding, transplantation in the past 12 
months, not expected to survive or to leave the hospital and/or no social 
security coverage17.
Data collection and biological samples
In the FROG-ICU study, for each patient included, an electronic case report 
form was completed that documented relevant information about the ICU 
stay. At the time of inclusion, the following patient data was collected: 
demographics, data on past medical history, ICU admission diagnosis, 
hemodynamic and respiratory parameters, and severity of disease classification 
scores. Blood samples were collected in ethylenediaminetetraacetic acid 
(EDTA)-coated vials at patient inclusion. Bio-ADM was measured batch-
wise in blinded fashion in aliquots of plasma stored at −40 °C, using a recently 
developed immunoassay16,19. In short, the assay is a one-step sandwichcoated 
tube chemiluminescence immunoassay, based on Acridinium NHS-ester 
labeling for the detection of human ADM in unprocessed, neat plasma. 
Further details on the immunoassay can be found in the Supplemental 
Material. Among the 2087 patients included in the FROG-ICU cohort, bio-
ADM concentration at baseline was available for 2003 patients; this is our 
studied population.
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Outcome
The main outcome was the need for organ-support therapies during the ICU 
stay (i.e. renal replacement therapy and/or inotrope(s) and/or vasopressor(s)) 
and secondary endpoints were ICU length of stay (ICU LOS) and 28-day 
all-cause mortality.
Statistical methods
Results are presented as count and percentage for categorical variable or median 
and first to third quartile range for continuous variables. Comparison between 
groups was performed using chi-square tests or Wilcoxon tests as appropriate. 
We tested the normality of the biomarker bio-ADM with the Shapiro test 
(p-value < 0.001), and we dichotomized the variable according to previously 
defined cut-off value of 70 pg/mL16. First, we studied the requirement of 
organ support therapies by recording the need of renal replacement therapy 
(RRT) and/or inotrope(s) and/or vasopressor(s) treatment during ICU 
stay. As inotrope(s) and/or vasopressor(s) treatment is an inclusion criteria, 
we focused on the need of inotrope(s) and/or vasopressor(s) treatment in 
patients without inotrope(s) and/or vasopressor(s) treatment at admission. 
Association between baseline bio-ADM and secondary endpoints (length of 
stay in ICU and 28-day mortality) was also considered. Marginal associations 
of bio-ADM and SAPS-II with the outcome was studied by a Wilcoxon test 
and logistic regression. We estimated the association between bio-ADM 
and the outcome with adjustment for SAPS-II using logistic regression. 
The results of logistic regression analysis are presented as odds ratios (ORs) 
and 95% confidence interval (CI). The area under the receiver operating 
characteristic curve (AUC ROC) to predict the all cause 28-day mortality was 
determined. We used SAPS-II as a clinical score to predict 28-day mortality, 
as previously described20. We added the biomarker bio-ADM to this score 
and the change in AUC with and without the biomarker was compared using 
the DeLong test. We assessed the primary endpoint in several predefined 
subgroups. First we considered subgroups based on the four most prevalent 
causes of admission in ICU: patients with septic shock, neurologic disorder, 
out of hospital cardiac arrest and acute respiratory failure (ARF). Then, we 
considered subgroups based on severity (SAPS-II score) and comorbidities 
(Charlson score). Additionally, Kaplan-Meier survival plots were used to 
examine the relationship between baseline bio-ADM and 28 days ICU’s 
survival time. In order to determine the relationship between levels of bio-
ADM and outcome, we performed restricted cubic splines which explore 
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the linearity of the association between bio-ADM and outcome and ROC 
curves to determine the cut-off point; sensitivity analysis was performed 
with the latter cut-off point, SOFA (Sequential Organ Failure Assessment) 
score at admission and Charlson score. Incremental predictive value of bio-
ADM was determined by elevated net reclassification improvement (NRI) 
and integrated discrimination improvement (IDI)21. A two-sided p-value of 
0.05 was considered significant. All analyses were performed using R 3.2.3 
statistical software (the R Foundation for Statistical Computing, Vienna, 
Austria). ROC curve analyses were performed using the package “pROC” 
and graphics were plotted using the package “ggplot2”.
Results
Patient characteristics
Patients had a median age of 63 [51-74] years and were predominantly male 
(n = 1297, 65%). Other characteristics are presented in Suppl. Table 1. 
Main reasons for ICU admission were septic shock, ARF, acute neurological 
disorder, out-of-hospital cardiac arrest and cardiogenic shock. At admission, 
patients admitted in our ICUs were in severe conditions with median SAPS-
II score at 49 [36-63] and median Charlson’s score at 3 [1-5]. Mortality at 28 
days was 22%.
Circulating levels of bio-ADM
The median level of plasma bio-ADM was 66.6 pg/ml [34.6-136.4] in our 
studied patients (n = 2003). Levels of circulating bio-ADM organized by 
causes of admission, Charlson and SAPS-II scores are presented in Table 1. 
Highest levels of circulating bio-ADM were observed in septic shock patients 
(99.7 pg/ml [62-194.4]) compared to the lowest, found in patients with 
neurological disorders (27.9 [18.4-48.2]) that had normal bio-ADM values 
(99th percentile reported at 43 pg/mL16) (Figure 1). Furthermore, patients 
with the highest SAPS-II score (greater than the median of 49, n = 977) 
at admission had greater circulating baseline bio-ADM levels: 88.9 pg/ml 
[46.9-173.6] compared to the patients with SAPS-II score < 49 at admission 
(n = 1026, 49.6 pg/ml [28.2-101.8], p < 0.001). Plasma bio-ADM leves were 
increased in patients with chronic kidney disease and low eGFR at admission 
(Suppl. Table 2).
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All Alive Dead p-value
All patients (n=2003) 67 [35-136] 56 [30-115] 105 [62-219] <0.001
Septic shock (n=465) 100 [62-194] 86 [54-165] 147 [87-284] 0.002
Neuro disorder (n=273) 28 [18-48] 26 [18-44] 47 [29-64] <0.001
Out of hospital cardiac 
arrest (n=176) 52 [31-99] 43 [29-80] 75 [45-137] <0.001
Cardiogenic shock 
(n=137) 72 [37-136] 64 [34-112] 104 [65-222] <0.001
Acute respiratory failure 
(n=381) 53 [30-96] 47 [28-88] 78 [50-139] <0.001
Charlson I (n=816) 46 [26-94] 42 [25-89] 86 [49-164] <0.001
Charlson II (n=648) 72 [40-142] 64 [37-123] 105 [58-246] <0.001
Charlson III (n=539) 98 [53-173] 87 [46-155] 121 [75-226] <0.001
SAPS-II < 49 (n=1026) 59 [28-102] 46 [27-92] 94 [47-159] <0.001
SAPS-II ≥ 49 (n=977) 89 [47-174] 76 [39-146] 114 [67-244] <0.001
Table 1. Levels of baseline bio-ADM according to 28-day mortality in ICU.
Abbreviations: SAPS-II score, Simplified Acute Physiology II Score
Figure 1. Bio-ADM levels according to the five most frequent causes of admission. Grey 
shadow area indicates normal range (< 43 pg/mL). The cut-off value of 70 pg/ml, used to 
define high versus low level of ADM, is highlighted by a dotted line. The dark band in each 
box represent the median value of the subgroup. The upper limit of the box represents the 
third quartile, and the lowest limit the first quartile. The dotted vertical line represents the 
95% confident interval. Abbreviations; ARF, acute respiratory failure; OHCA, out of hospital 
cardiac arrest.
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Association between baseline levels of bio-ADM and the need for organ-support 
therapies during ICU stay
Characteristics of studied patients (n = 2003) are presented in Suppl. Table 
1. Among studied patients, 23% needed RRT and 77% inotrope(s) and/or 
vasopressor(s) during the ICU stay. Suppl. Table 1 further describes patients 
characteristics based on baseline bio-ADM level. At admission, 564 (20%) 
patients were not treated with vasopressors and/or inotropes and none were 
on RRT.
Figure 2A shows that high levels of bio-ADM at baseline were significantly 
associated with the need for organ-support therapies (OR [95% CI] 4.02 
[3.08-5.25]) in all ICU patients and in patients admitted for septic (OR [95% 
CI] 3.21 [1.22-8.43]) or non-septic cases (OR [95% CI] 3.57 [2.69-4.74]). 
High levels of bio-ADM were associated with the need of RRT during ICU 
stay in all studied ICU patients (adjusted OR [95% CI] 4.89 [3.83-6.28]) 
and also in patients with a good renal function at admission (OR [95% CI] 
3.98 [2.21-7.18]). High levels of bio-ADM were also associated with the need 
for inotrope(s) and/or vasopressor(s) during ICU stay in all studied patients 
(OR [95% CI] 3.64 [2.84-4.69]), and in ICU patients without inotrope(s) 
and/or vasopressor(s) treatment at admission (OR [95% CI] 3.7 [2.36-5.83]) 
(Figure 2A and Suppl. Table 3). The latter subgroup had a bio-ADM level 
greater than bio-ADM of patients who never received inotrope(s) and/or 
vasopressor(s) during their ICU stay (Suppl. Figure 1). 
Likewise, the association between plasma bio-ADM, renal dysfunction, 
need of vasopressors or 28-day mortality remain high even after adjustment 
for SOFA score alone or for SOFA and Charlson scores (Suppl. Table 4). 
Furthermore, incremental predictive value of bio-ADM was confirmed by 
elevated net reclassification improvement (NRI) and integrated discrimination 
improvement (IDI) NRI: 37.1% (95% CI: 27.1 – 47.1] and IDI: 0.021 (95% 
CI: 0.013 – 0.029] compared to SOFA for mortality and compared to SOFA 
for risk of RRT. Thus, with the bio-ADM value, 37% of patients are better 
classified.
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Figure 2. Relation between high baseline bio-ADM level (≥ 70 pg/mL) and the need for life-
support therapies (A) and with all-cause 28-day mortality (B). High level of ADM is defined 
as ≥ 70 pg/mL. Prediction of organ support by bio-ADM was performed among patients 
without this organ dysfunction at admission. Need of organ support refers to any need at 
admission and/or during the ICU stay. Need of RRT was only seen during ICU stay. Need of 
vasopressor refers to any need at admission and/or during the ICU stay for all patients (non-
septic and septic), and exclusively after admission for patients who were not treated with 
vasopressors at admission. Abbreviations; ARF, acute respiratory failure; bio-ADM, bioactive 
adrenomedullin; SAPS-2, Simplified Acute Physiology Score II. 
A
B
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Association between baseline levels of bio-ADM, lenght of stay in ICU and 28-day 
mortality
The median ICU length of stay was 13 [7-21] days. High baseline bio-ADM 
levels were associated with prolonged ICU stay in survivors (OR [95%] 1.85 
[1.49-2.29]). Concerning survival during the first 28 days, 441 patients 
(22.0%) died and 1562 (78.0%) survived; characteristics are described in 
Suppl. Table 5. Non-survivors had greater circulating levels of bio-ADM at 
baseline (105 pg/ml [62-219]) compared to survivors (56 pg/ml [30-114], p 
< 0.001). Table 1 shows that baseline circulating bio-ADM was consistently 
higher in non-survivors versus survivors for each of the five main causes of 
ICU admission (p < 0.001 for all, except p = 0.002 in neurologic disorder). 
Suppl. Figure 2 shows that the relationship between bio-ADM and mortality 
is non-linear and that the threshold at 70 pg/ml distinguishes between low 
and high risk of death; AUC is at 0.69 [0.66-0.72] and the threshold is at 
75 pg/ml. Sensitivity analyses using a threshold at 75 pg/ml, or adjusting by 
SOFA or by SOFA and Charlson score showed similar associations between 
bio-ADM levels, organ dysfunction or death (Suppl. Table 4). Suppl. Table 
6 shows similar performance whether the threshold is at 70 or 75 pg/mL. 
Figure 2B further shows that baseline levels of bio-ADM were associated 
with an increased risk of 28-day mortality: unadjusted OR [95% CI]) at 
3.03 [2.43-3.81] and adjusted OR for SAPS-II: 2.31 [1.82 – 2.92]) in our 
study cohort. Figure 2B further shows that high concentrations of bio-ADM 
were associated with an increased risk of 28-day mortality in all Charlson’s 
score levels, as well as in septic shock, acute respiratory failure, out of hospital 
cardiac arrest and cardiogenic shock, but not with neurological disorders.
The Kaplan Meier curves of 28-day mortality further showed added prognostic 
value of the baseline bio-ADM on top of the SAPS-II score at admission. 
Indeed, low (< 49) SAPS-II score and low concentrations of baseline bio-
ADM (< 70 pg/ml) showed low 28-day mortality (8.2%), whereas low SAPS-
II and high bio-ADM were associated with a higher mortality (21.5%, Figure 
3). High SAPS-II score and high bio-ADM were associated with the highest
mortality (38.2%). OR of low SAPS-II and low bio-ADM versus low SAPS-II 
and high bio-ADM, high SAPS-II and low bio-ADM and high SAPS-II and 
high bio-ADM were (OR [95%]): 3.06 [2.11-4.45], 3.02 [2.09-4.37] and 
6.91 [4.98-9.59] respectively (all p-values < 0.0001, Figure 3). Association 
between baseline bio-ADM and SAPS-II score is shown in Suppl. Figure 3.
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Figure 3. Kaplan-Meier survival curve according to SAPS-II and baseline bio-ADM. High 
level of ADM defined as ≥ 70 pg/mL, high levels of SAPS-II as ≥ 49. Abbreviations: SAPS-II 
score, Simplified Acute Physiology Score II score.
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Discussion
In this analysis of the FROG-ICU study, a prospective multicenter study in 
the general ICU population, we show that elevated baseline levels of bio-
ADM can be found in various critical illnesses associated with impaired 
vascular integrity or endothelial dysfunction. Our study further demonstrates 
that bio-ADM predicts the need for intensive therapies during ICU stay and 
had added prognostic value to SAPS-II to predict short-term outcome, in 
septic and in non-septic patients. 
Our study shows that concentrations of bio-ADM at baseline were greatly 
increased in the general ICU population. Highest concentrations of bio-ADM 
were found in patients with septic and cardiogenic shock, which is in line 
with results from three previous studies15,16,22. In addition, our study shows 
elevated levels among cardiac arrest and acute respiratory failure patients but 
not in ICU patients admitted for neurological disorders. Overall, these levels 
of bio-ADM reflect the activation of systemic inflammatory pathways and the 
involvement of the endothelium, which has been shown to be a predominant 
source of ADM production previously2,23. 
Our study reveals a strong association with baseline bio-ADM concentrations 
and the need for inotrope(s) and/or vasopressor(s) treatment, renal 
replacement therapies and length of ICU stay in our general ICU population. 
Inclusion criteria included the presence of at least one dysfunctioning organ, 
which resulted in a homogeneous cohort of severely ill ICU patients. Thus, to 
predict a specific organ dysfunction, only patients without this specific organ 
dysfunction at admission were studied. Hence we confirmed associations 
between high bio-ADM level and organ dysfunction in septic patients, in line 
with previous findings16 and more importantly we extend those associations 
to ICU patients admitted for non-septic causes. Effects of high levels of 
bio-ADM remain elusive. Some studies describe detrimental effects of high 
circulating bio-ADM that contribute to organ dysfunction including renal 
dysfunction, while other data suggest that high bio-ADM levels might protect 
the kidneys17,22. A trial was recently started to assess whether the modulation of 
the bio-ADM pathway by a specific non-neutralizing monoclonal anti-ADM 
antibody might improve organ support (AdrenOSS-2, NCT03085758). Of 
particular interest, our study also showed that baseline bio-ADM was able to 
predict the need for organ support in patients who did not need organ support 
at admission, but developed it later. Further studies are needed to elucidate 
the exact role of high bio-ADM as an early marker of organ dysfunction.
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Our study also confirmed the association between circulating baseline bio-
ADM and short-term outcome in sepsis and extended the knowledge in 
various non-septic causes of ICU admission. Our study further showed that 
the prognostic value of baseline bio-ADM exerts additive value to the SAPS-
II severity score. Hence, our data suggest that vascular dysfunction may be 
very frequent in the general ICU population, even outside sepsis patients and 
could affect the outcome in a very large spectrum of critically ill patients.
Our study does have some limitations. First, only a single measurement of 
baseline bio-ADM was taken after inclusion, while previous studies have 
demonstrated added value of repeated bio-ADM measurements15,16. For 
future studies, an additional measurement a few days after admission might 
be of a great interest. Second, the association between bio-ADM level and 
outcome could be different according to the diagnosis on admission. This is 
why we repeated the analyses in the subgroups of sepsis patients compared 
to the non-septic ones. We did not further divide the non-septic patients 
into subgroups in order to avoid power issues. Also, note that we did not 
add cardiac biomarker (such as NT-proBNP and ST-2) to these data as they 
were described in FROG-ICU study17 and were not the aim of this study. 
Furthermore, initiation of any organ support was determined by the treating 
physicians and not standardized among the 21 ICUs of FROG-ICU study. 
Another limitation was that doses of vasoactives drugs were not recorded. 
Finally, concerning the association between bio-ADM and organ function, 
only analyzed vascular and renal function were investigated in our study. Data 
on other organs (e.g. lungs, brain, etc.) were not assessed in the present study.
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Conclusion
This analysis of the FROG-ICU study, a multicenter, prospective study in 
general ICU patients, showed that baseline levels of bio-ADM were increased 
in patients with sepsis, acute respiratory failure and out of hopsital cardiac 
arrest, but not with neurological disorders. Furthermore, high bio-ADM 
levels were strongly associated with the need for organ support, even in 
patients that did not have organ support at admission, and with 28-day 
mortality. Those data were included in the design of the ongoing biomarker-
guided trial, AdrenOSS-2, that aims at improving/preventing organ function 
by modulation of the bio-ADM pathway in septic shock patients with high 
bio-ADM levels.
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Suppl. Figure 1. Association between baseline bio-ADM and the need for inotrope(s) and/
or vasopressor(s) during ICU stay.
Suppl. Figure 2. ROC curve of bio-ADM to predict 28-day mortality (left panel) and 
linearity of the association between bio-ADM level at admission and 28-day mortality (right 
panel). The vertical dotted line represents a bio-ADM level of 70 pg/mL.
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Suppl. Figure 3. Correlation between baseline bio-ADM and SAPS-II score.
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All patients (n=2003) Bio-ADM < 70 pg/mL (n=1044)
Bio-ADM ≥ 70 pg/mL 
(n=959) p-value
Age [year] 63 [51;74] 60 [47;71] 67 [56;77] <0.0001
Male gender 1297 (65) 669 (64) 628 (66) 0.51
BMI [kg/m2] 26 [23;31] 25 [22;29] 28 [25;32] <0.0001
SAPS-II score 49 [36;63] 43 [32;57] 55 [41;68] <0.0001
SOFA score 7 [4;10] 6 [3;8] 9 [6;11] <0.0001
Charlson score 3 [1;5] 2 [1;4] 4 [2;5] <0.0001
Main cardiovascular comorbidities 
Chronic heart failure 147 (7) 46 (4) 101 (11) <0.0001
Hypertension 866 (43) 381 (37) 485 (51) <0.0001
Diabetes mellitus 366 (18) 146 (14) 220 (23) <0.0001
Dyslipidemia 393 (20) 183 (18) 210 (22) 0.013
Peripheral artery 
disease 198 (10) 77 (7) 121 (13) <0.0001
Atrial fibrillation 215 (11) 81 (8) 134 (14) <0.0001
Main non-cardiovascular comorbidities
COPD 257 (13) 101 (10) 156 (16) <0.0001
Chronic liver disease 156 (8) 59 (6) 97 (10) 0.00019
Active recent mali-
gnant tumors 274 (14) 120 (12) 154 (16) 0.0029
Depression 245 (12) 147 (14) 98 (10) 0.0086
Alcohol 346 (17) 180 (17) 166 (17) 0.96
Smoking 539 (27) 288 (28) 251 (26) 0.49
Main cause of admission
Out of Hospital 
Cardiac Arrest 176 (9) 109 (10) 67 (7)
Cardiogenic shock 137 (7) 64 (6) 73 (8)
Septic shock 465 (23) 151 (15) 314 (33)
Acute respiratory 
failure 381 (19) 236 (23) 145 (15)
Acute neurological 
disorder 273 (14) 240 (23) 33 (3)
Suppl. Table 1. Baseline clinical characteristics according to low or high bio-ADM at 
ICU-admission.
Bioactive adrenomedullin, organ support therapies and survival in the critically ill: Results from the 
FROG-ICU study
7
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 145
145
Data are presented as median [IQR] or mean (SD). High level of ADM is defined as ≥ 
70 pg/mL. Abbreviations: BMI: Body Mass Index, SAPS-II score: Simplified Acute Physiology 
Score II score, SOFA score:  Sequential Organ Failure Assessment score, COPD: Chronic 
Obstruction Pulmonary Disease, ACR: Arrest Cardiac Respiratory, GCS: Glasgow Coma Scale, 
Hb: Hemoglobin, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, HR: Heart rate, 
ICU LOS: Intensive Care Units Length of Stay, RRT: Renal Replacement Therapy, RBC: Red 
Blood Cell, FFP: Frozen Plasma. 
All patients (n=2003) Bio-ADM < 70 pg/mL (n=1044)
Bio-ADM ≥ 70 pg/mL 
(n=959) p-value
Status at admission
Glasgow score 12 [3;15] 12 [3;15] 11 [3;15] 0.63
Hemoglobin [g/dL] 9.9 [8.9;11.4] 10.3 [9.2;11.8] 9.6 [8.7;10.8] <0.0001
SBP [mmHg] 122 [108;139] 125 [110;143] 119 [106;135] <0.0001
DBP [mmHg] 61 [53;70] 64 [55;74] 58 [51;67] <0.0001
HR [bpm] 91 [78;106] 88 [75;104] 94 [81;109] <0.0001
Temperature (°C) 37.2 (36.7 to 37.8) 37.3 (36.8 to 37.8) 37.2 (36.6 to 37.8) <0.0001
Bicarbonates 
[mmol/L] 24 [21;26] 24 [22;27] 23 [20;26] <0.0001
Lactate [mmol/L] 1.4 [1;1.9] 1.2 [0.9;1.6] 1.6 [1.1;2.4] <0.0001
Platelets count [/
mm3] 164000 [99000;243500]
186000 
[126000;263000]
131000 
[79000;222000] <0.0001
Prothrombin time 
[%] 69 [54;80] 74 [62;85] 63 [46;75] <0.0001
White Blood Cells (/
mm3) 10900 [7500;16200] 10200 [7472.5;14900] 11770 [7800;17918] <0.0001
CRP 124 [56;221] 101 [49;163] 164 [69;263] <0.0001
Creatinine (µmol/L) 83 [59;150] 66 [52;87] 134 [83;212] <0.0001
Urea (mmol/L) 8.5 [5.3;14.1] 6.6 [4.4;10] 11.7 [7.5;17.9] <0.0001
NGAL 211 [97;509] 112.5 [68;188] 483 [253;873] <0.0001
PCT 1.1 [0.3;5.6] 0.5 [0.2;1.6] 3.5 [0.9;13.1] <0.0001
AST 53 [31;119] 45 [28;89] 64 [37;152] <0.0001
ALT 40 [22;92] 38 [21;79] 42 [22;109] 0.0082
Bilirubine (mmol/L) 13 [8;28] 11 [7;19] 17 [9;38] <0.0001
Bio-ADM 66.6 [34.6;136.3] 35.5 [23.9;50] 141.6 [96.5;223.9] <0.0001
In-ICU management
In-ICU LOS (days) 13 [7;21] 11 [7;19] 14 [8;24] <0.0001
RRT 467 (23) 103 (10) 364 (38) <0.0001
Inotrope(s) and/or 
vasopressor(s) 1545 (77) 686 (66) 859 (90) <0.0001
28-day mortality 441 (22) 138 (13) 303 (32) <0.0001
Suppl. Table 1. continued.
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Bio-ADM at admission p-value
Chronic kidney disease <0.0001
No 60.9 (31.8 to 121)
Yes 130 (78.1 to 225.1)
eGFR at admission <0.0001
<60 125.6 (75.1 to 222.7)
60-90 57.9 (36.7 to 105.8)
>90 36.1 (22.3 to 63.9)
Suppl. Table 2. Bio-ADM value with regard to renal function at admission.
Abbreviations: eGFR, estimated glomerular filtration rate.
Suppl. Table 3.  Primary and secondary endpoints in septic shock and non-septic shock 
subgroups
All included
patients
Septic shock
patients
Non-septic shock 
patients
OR of high ADM
[95% CI]
OR of high ADM
[95% CI]
OR of high ADM
[95% CI]
Need for RRT
All patients 4.89 [3.82 - 6.26] 2.83 [1.77 - 4.53] 5.45 [4.06 - 7.31]
eGFR at adm > 60 
mL/min 3.14 [2.10 - 4.71] 1.93 [0.93 - 3.98] 3.2 [1.95 - 5.25]
eGFR at adm > 90 
mL/min 3.98 [2.21 - 7.18] 8.46 [1.78 - 40.34] 3.06 [1.52 - 6.14]
Need for vasopressor
All patients 3.64 [2.83 - 4.67] 2.75 [1.12 - 6.72] 3.25 [2.49 - 4.24]
No vasopressor at 
admission 3.70 [2.36 - 5.81] 4.96 [0.96 - 25.74] 3.21 [1.98 - 5.22]
Prolonged ICU LOS
All patients 1.85 [1.49 - 2.29] 1.58 [0.99 - 2.5] 2.00 [1.56 - 2.56]
28-day mortality 2.31 [1.82 - 2.92] 3.19 [1.81 - 5.61] 2.16 [1.65 - 2.82]
High level of ADM is defined as ≥ 70 pg/mL. Abbreviations: eGFR, estimated glomerular 
filtration rate; ICU LOS, intensive care unit length of stay; RRT, renal replacement therapy.
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Using a cut-off value 
of 75 pg/mL bio-
ADM
With adjustment on 
SOFA score at ad-
mission
With adjustment 
on SOFA at admis-
sion and Charlson’s 
score
28-day mortality 2.27 [1.8 - 2.87] 2.52 [1.93 - 3.29] 2.03 [1.54 - 2.68]
RRT
All patients 4.96 [3.89 - 6.32] 4.92 [3.67 - 6.59] 4.72 [3.5 - 6.36]
eGFR at adm > 90 mL/min 3.39 [2.26 - 5.08] 3.14 [1.9 - 5.18] 2.95 [1.77 - 4.91]
eGFR at adm > 60 mL/min 4.14 [2.29 - 7.48] 3.92 [1.88 - 8.16] 3.62 [1.73 - 7.58]
Vasopressor and/or inotropes
All patients 3.53 [2.74 - 4.56] 4.38 [3.17 - 6.06] 3.9 [2.8 - 5.44]
No vaso at admission 3.72 [2.36 - 5.87] 4.28 [2.43 - 7.54] 3.97 [2.21 - 7.12]
Suppl. Table 4.  Sensitivity analyses of the association between bio-ADM at ICU admission 
and outcome.
Abbreviations: adm, admission; eGFR, estimated glomerular filtration rate; RRT, renal replacement 
therapy; vaso, vasopressor(s) and/or inotrope(s).
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All patients 
(n = 2003)
Alive patients 
(n = 1562)
Dead patients 
(n = 841) p-value
Age [year] 63 [51;74] 61 [49;72] 71 [61;79] <0.0001
Male gender 1297 (65) 993 (64) 304 (69) 0.037
BMI [kg/m2] 26 [23;31] 26 [23;31] 27 [24;31] 0.24
SAPS-II score 49 [36;63] 46 [34;59] 60 [46;74] <0.0001
SOFA score 7 [4;10] 6 [4;9] 9 [7;12] <0.0001
Charlson score 3 [1;5] 3 [1;4] 4 [3;6] <0.0001
Main cardiovascular comorbidities
Chronic heart failure 147 (7) 99 (6) 48 (11) 0.0012
Hypertension 866 (43) 623 (40) 243 (55) <0.0001
Diabetes mellitus 366 (18) 266 (17) 100 (23) 0.0065
Dyslipidemia 393 (20) 305 (20) 88 (20) 0.83
Peripheral artery disease 198 (10) 143 (9) 55 (13) 0.039
Atrial fibrillation 215 (11) 152 (10) 63 (14) 0.0062
Main non-cardiovascular comorbidities
COPD 257 (13) 186 (12) 71 (16) 0.02
Chronic liver disease 156 (8) 97 (6) 59 (13) <0.0001
Active recent malignant 
tumors 274 (14) 190 (12) 84 (19) 0.0002
Depression 245 (12) 201 (13) 44 (10) 0.1
Alcohol 346 (17) 265 (17) 81 (18) 0.49
Smoking 539 (27) 445 (29) 94 (21) 0.0028
Main cause of admission
Out of Hospital Cardiac Arrest 176 (9) 116 (7) 60 (14)
Cardiogenic shock 137 (7) 103 (7) 34 (8)
Septic shock 465 (23) 337 (22) 128 (29)
Acute respiratory failure 381 (19) 298 (19) 83 (19)
Acute neurological disorder 273 (14) 242 (16) 31 (7)
Status at admission
GCS 11.5 [3;15] 13 [3;15] 6 [3;14] <0.0001
Hemoglobin [g/dL] 9.9 [8.9;11.4] 10 [9;11.4] 9.8 [8.8;11.2] 0.018
SBP [mmHg] 122 [108;139] 123 [110;140] 117 [104;133] <0.0001
DBP [mmHg] 61 [53;70] 62 [55;71] 56 [50;65] <0.0001
HR [bpm] 91 [78;106] 90 [77;105] 95 [82;111] <0.0001
Temperature (°C) 37.2 (36.7 to 37.8) 37.3 (36.8 to 37.8) 37 (36.4 to 37.7) <0.0001
Bicarbonates [mmol/L] 24 [21;26] 24 [21;27] 23 [20;25] <0.0001
Lactate [mmol/L] 1.4 [1;1.9] 1.3 [0.9;1.8] 1.7 [1.1;2.6] <0.0001
Suppl. Table 5.  Baseline clinical characteristics according to 28-day ICU mortality.
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All patients 
(n = 2003)
Alive patients 
(n = 1562)
Dead patients 
(n = 841) p-value
Platelets count [/mm3] 164000 [99000;243500]
169000 
[106000;252000]
136000 
[80000;218000] <0.0001
Prothrombin time [%] 69 [54;80] 71 [57;81] 59 [44;74] <0.0001
White Blood Cells (/mm3) 10900 [7500;16200] 10500 [7400;15498]
12560 
[8100;18543] <0.0001
CRP 124 [56;221] 124 [58;217] 121 [52;232] 0.91
Creatinine (µmol/L) 83 [59;150] 78 [57;134] 120 [75;193] <0.0001
Urea (mmol/L) 8.5 [5.3;14.1] 8 [5.1;13.1] 11.1 [7.1;17.4] <0.0001
NGAL 211 [97;509] 175 [86;418] 415 [182;877] <0.0001
PCT 1.1 [0.3;5.6] 0.9 [0.3;4.3] 2.7 [0.7;10.2] <0.0001
AST 53 [31;119] 49 [29;103] 76 [40;210] <0.0001
ALT 40 [22;92] 39 [21;86] 48.5 [26;148] <0.0001
Bilirubine (mmol/L) 13 [8;28] 12 [8;24] 16 [10;42] <0.0001
Bio-ADM 66.6 [34.6;136.3] 56.4 [30;114.7]
105.3 
[61.9;218.9] <0.0001
In-ICU management
In-ICU LOS (days) 13 (7;21) 13 (7;24) 11 (7;16) <0.0001
RRT 467 (23) 311 (20) 156 (35) <0.0001
Inotrope / vasopressor 1545 (77) 1154 (74) 391 (89) <0.0001
28-day mortality 441 (22) 0 (0) 441 (100) 0
Abbreviations: adm, admission; BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary 
Disease; DBP, Diastolic Blood Pressure; GCS, Glasgow Coma Scale; HR, Heart Rate; eGFR, 
estimated Glomerular Filtration Rate; RRT, Renal Replacement Therapy; SBP, Systolic Blood 
Pressure; SOFA, Sequential Organ Failure Assessment.
Value of the cut-
off Sensitivity Specificity NPV PPV
Predetermined cut-off 70 pg/mL 69% 68% 87% 32%
ROC curve derived 
cut-off (closest top-
left approach)
75 pg/mL 67% 60% 86% 32%
Suppl. Table 6.  Performance of the cut-off values considered in the study
Abbreviations: NPV, negative predictive value; PPV, positive predictive value; ROC, receiver 
operating characteristic.
Suppl. Table 5.  continued.
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The AdrenOSS-1 study
Abstract
Background
Adrenomedullin (ADM) regulates vascular tone and endothelial permeability 
during sepsis. Levels of circulating biologically active ADM (bio-ADM) 
show an inverse relationship with blood pressure and a direct relationship 
with vasopressor requirement. In the present prospective observational 
multinational Adrenomedullin and Outcome in Sepsis and Septic Shock 1 
(AdrenOSS-1) study, we assessed relationships between circulating bio-ADM 
during the initial intensive care unit (ICU) stay and short-term outcome in 
order to eventually design a biomarker-guided randomized controlled trial.
Methods
AdrenOSS-1 was a prospective observational multinational study. The 
primary outcome was 28-day mortality. Secondary outcomes included organ 
failure as defined by Sequential Organ Failure Assessment (SOFA) score, 
organ support with focus on vasopressor/inotropic use, and need for renal 
replacement therapy. AdrenOSS-1 included 583 patients admitted to the 
ICU with sepsis or septic shock.
Results
Circulating bio-ADM levels were measured upon admission and at day 2. 
Median bio-ADM concentration upon admission was 80.5 pg/ml [IQR 
41.5–148.1 pg/ml]. Initial SOFA score was 7 [IQR 5–10], and 28-day 
mortality was 22%. We found marked associations between bio-ADM 
upon admission and 28-day mortality (unadjusted standardized HR 2.3 [CI 
1.9–2.9]; adjusted HR 1.6 [CI 1.1–2.5]) and between bio-ADM levels and 
SOFA score (p<0.0001). Need of vasopressor/inotrope, renal replacement 
therapy, and positive fluid balance were more prevalent in patients with a bio-
ADM>70 pg/ml upon admission than in those with bio-ADM≤70 pg/ml. 
In patients with bio-ADM>0 pg/ml upon admission, decrease in bio-ADM 
below 70 pg/ml at day 2 was associated with recovery of organ function at 
day 7 and better 28-day outcome (9.5% mortality). By contrast, persistently 
elevated bio-ADM at day 2 was associated with prolonged organ dysfunction 
and high 28-day mortality (38.1% mortality, HR 4.9, 95% CI 2.5–9.8).
Conclusions
AdrenOSS-1 shows that early levels and rapid changes in bio-ADM estimate 
short-term outcome in sepsis and septic shock. These data are the backbone 
of the design of the biomarker-guided AdrenOSS-2 trial.
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Introduction
Adrenomedullin (ADM) is a free circulating peptide with potent vascular 
properties, including beneficial effects on endothelial barriers at physiological 
levels. ADM has previously been described as a “double-edged sword” in sepsis1 
because high levels of ADM induce vasodilation and hypotension2-4 on one 
hand while reinforcing the endothelial barrier and improving outcome on the 
other5-10. The potential of ADM as a prognostic biomarker has previously been 
studied in critically ill patients, often by measuring the inactive midregional 
pro-ADM11,12, or recently by direct measurement of the bioactive form of 
ADM (bio-ADM)13,14. It has been shown repeatedly that bio-ADM greater 
than 70 pg/ml is associated with worse outcome13,14.
On the basis of previous results, we tested the hypothesis that modulating 
the ADM pathway in patients with high levels of circulating bio-ADM may 
improve short-term outcome in sepsis. Adrecizumab, a monoclonal anti-
ADM antibody, has been shown to improve organ function in preclinical 
settings15. In order to design a human trial in whivach we would administer 
adrecizumab based on levels of bio-ADM, we needed to assess the relationship 
between initial levels of bio-ADM and short-term outcome in sepsis and in 
septic shock patients.
In the Adrenomedullin and Outcome in Sepsis and Septic Shock 1 
(AdrenOSS-1) study, we investigated whether the initial plasma concentration 
of bio-ADM (on intensive care unit [ICU] admission and after 48 h) may 
provide insight into 28-day survival and the recovery of organ function.
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Methods
Study design
AdrenOSS-1 was a European prospective observational study. Twenty-four 
centers in five countries (France, Belgium, The Netherlands, Italy, and 
Germany) contributed to the trial achievement of 583 enrolled patients. 
Patients were recruited from June 2015 to May 2016. The study protocol was 
approved by the local ethics committees and was conducted in accordance 
with Directive 2001/20/EC, as well as good clinical practice (International 
Conference on Harmonization Harmonized Tripartite Guideline version 4 of 
May 1, 1996, and decision of November 24, 2006) and the Declaration of 
Helsinki.
The study enrolled patients aged 18 years and older who were (1) admitted 
to the ICU for sepsis or septic shock or (2) transferred from another ICU 
in the state of sepsis and septic shock within less than 24 h after admission. 
Included patients were stratified by severe sepsis and septic shock based on 
definitions for sepsis and organ failure from 200116. In the present article, the 
term “sepsis” refers to the updated definition of Sepsis-317. Concerning septic 
shock, most data presented in this article are based on the former definition16, 
except for the confirmatory analyses presented in the last paragraph of the 
“Results” section, for which the new Sepsis-3 definition of septic shock was 
used17.
Exclusion criteria were pregnancy, vegetative coma, and participation in an 
interventional trial in the preceding month. Informed consent was obtained 
from all patients or their lawful representatives prior to enrollment in the 
study. Patients were treated according to local practice, and treatments as well 
as procedures were registered.
The primary endpoint was 28-day mortality. Secondary endpoints concerned 
organ failure (as defined by the Sequential Organ Failure Assessment [SOFA] 
score) and organ support, vasopressor/inotrope use, fluid balance, and use 
of renal replacement therapy (RRT), as well as validation of the previously 
identified cutoff value of 70 pg/ml14. The latter was identified as the optimal 
screening cutoff for AdrenOSS-2, an ongoing proof-of-concept and dose-
finding phase II trial assessing adrecizumab (an antibody modulating 
circulating bio-ADM) in patients with early septic shock (NCT03085758). 
The relationship between cardiovascular SOFA subscore and bio-ADM, being 
a biomarker of vascular dysfunction, was evaluated.
The AdrenOSS-1 study
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Collection of patient data
Upon admission, demographics (age, sex), body mass index, presence of 
septic shock, type of ICU admission, organ dysfunction scores (SOFA, Acute 
Physiologic Assessment and Chronic Health Evaluation II [APACHE II]), 
origin of sepsis, preexisting comorbidities (i.e., treated within the last year), 
past medical history, laboratory values, and organ support were recorded, and 
blood was drawn for measurement of bio-ADM and other markers.
After patient enrollment, the following data were collected daily during the 
first week: SOFA score, antimicrobial therapies, fluid balance, ventilation 
status, Glasgow Coma Scale score, central venous pressure, need for RRT, 
invasive procedures for sepsis control, and vasopressor/inotrope treatment. 
Moreover, discharge status and mortality were recorded on day 28 after ICU 
admission.
Sample collection
Blood for the central laboratory was sampled within 24 h after ICU admission 
and on day 2 (mean 47 h, SD 9 h) after the first sample. Samples were 
subsequently processed and stored at − 80 °C before transfer to the central 
laboratory for blinded bio-ADM analysis organized by the study sponsor 
(sphingotec GmbH, Hennigsdorf, Germany). Routine analyses (e.g., partial 
pressure of arterial oxygen, lactate) were performed by the local laboratories.
Bio-ADM measurement
Bio-ADM was measured using a recently developed immunoassay provided 
by sphingotec GmbH. For details and design principles on the assay, see 
publications by Marino et al.14 and Weber et al.18. The analytical assay 
sensitivity was 2 pg/ml.
Statistical analyses
Results are presented as number and percentage, mean and SD, or median and 
IQR, depending on their distribution. Group comparisons for continuous 
variables were performed using the Kruskal-Wallis test, and appropriate post 
hoc tests were applied if necessary. Categorical data were compared using the 
chi-square test with simulated p-values using 2000 replicates. Biomarker data 
were log-transformed if necessary. Cox proportional hazards regression was 
used to analyze the effect of risk factors on survival in uni- and multivariable 
analyses. The assumptions of proportional hazards were tested for all 
 The AdrenOSS-1 study
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variables. For continuous variables, HRs were standardized to describe the 
HR for a biomarker change of one IQR. CIs (95% CI) for risk factors and 
significance levels for chi-square (Wald) test are given. The predictive value of 
each model was assessed by the model likelihood ratio chi-square statistic. The 
concordance index (C index) is given as an effect measure. It is equivalent to 
the concept of AUC adopted for binary outcome. For multivariable models, 
a bootstrap-corrected version of the C index is given. To test for added 
predictive value, we used the likelihood ratio chi-square test for nested models 
to assess whether bio-ADM adds predictive value to a clinical model or a risk 
score. Survival curves plotted by the Kaplan-Meier method using quartiles 
or predefined cut points (70 pg/ml) of bio-ADM were used for illustrative 
purposes. ROC curve analysis was applied for 28-day mortality to determine 
the optimal Youden cutoff in this cohort.
A two-sided p-value of 0.05 was considered statistically significant. All 
analyses were performed using R version 2.5.1 (http://www.r-project.org, 
library Design, Hmisc, ROCR) and IBM SPSS Statistics version 22.0 software 
(IBM, Armonk, NY, USA).
Results
A total of 583 patients were included in the AdrenOSS-1 study. Patient 
characteristics, organ dysfunction scores, physiological and laboratory values, 
organ support upon admission, and outcome parameters are presented in 
Table 1. The median bio-ADM level at admission was 80.5 pg/ml [IQR 41.6–
148.1] in our studied patients; 55.9% had bio-ADM level greater than 70 pg/
ml at admission, and 44.1% had a bio-ADM less than 70 pg/ml. Of note, 
patients with septic shock had a significantly higher bio-ADM concentration 
at admission than patients with sepsis (114.4 [62.6–214.5] versus 57.5 pg/ml 
[31.2–101.5], p < 0.0001).
Bio-ADM levels and mortality
Over the 28-day follow-up period, 127 patients (22%) died: 33 with sepsis 
and 94 with septic shock.
In a Cox proportional hazards model adjusted for age, gender, comorbidities 
(cardiac and noncardiac), lactate, and diagnosis (sepsis, septic shock), bio-
ADM concentration at admission was independently associated with 28-
day mortality in the studied population (added chi-square 12.2, p = 0.0005; 
adjusted standardized HR 1.6 [95% CI 1.1–2.5], p = 0.0004) (Table 2). 
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Noticeably, the C index for prediction of 28-day mortality for bio-ADM at 
admission was 0.688 (95% CI 0.642–0.733, chi-square 54.8, p < 0.0001) in 
the univariate Cox regression. C indexes for lactate, SOFA, and APACHE II 
were 0.720 (95% CI 0.672–0.768), 0.728 (95% CI 0.680–0.777), and 0.701 
(95% CI 0.657–0.746), respectively (all p < 0.0001). A multivariate model 
further demonstrated that bio-ADM had added value on top of APACHE 
II or SOFA score (added chi-square 24.4 [p < 0.0001] and 10.2 [p = 0.0014], 
respectively) (Table 2) when used as a continuous variable.
With the predefined cutoff value of 70 pg/ml, Kaplan-Meier analysis 
confirmed predictive value of bio-ADM for 28-day mortality in all studied 
patients (Figure S1) and in subgroups of sepsis and septic shock (Figure 
1a and b). Patient characteristics for high and low bio-ADM levels are 
illustrated in Table 1, and characteristics for survivors versus nonsurvivors are 
provided in Table S1. The optimal Youden cutoff in all patients was 101.9 
pg/ml (sensitivity 67.7%, specificity 67.3%). In septic shock, the optimal 
Youden cutoff was 99.1 pg/ml (sensitivity 71.3%, specificity 52.3%), and in 
severe sepsis it was 101.9 pg/ml (sensitivity 57.6%, specificity 78.6%). This 
compares with a sensitivity of 77.2% and specificity of 48.9% in all patients 
for the predefined bio-ADM cutoff of 70 pg/ml.
Additionally, we assessed outcome in relation to bio-ADM changes in the 
initial 48 h using time-dependent Cox regression. Bio-ADM trajectory over 
the initial 48 h after study inclusion improved prediction of 28-day survival 
in the overall population (added chi-square 25.8, p < 0.0001) (Table 2; Fig. 
2, Figure S2) and was independent of time-dependent lactate or SOFA score 
evaluation (Table 2). Patients were divided into four groups based on baseline 
and day 2 bio-ADM concentrations and under implementation of the cutoff 
value of 70 pg/ml: remaining low (low-low, LL), high-to-low (HL), low-to-
high (LH), and remaining high (high-high, HH). Patient characteristics of 
these subgroups are presented in Table S2.
In patients admitted with high bio-ADM upon admission, those with 
decreased bio-ADM towards normal values within the first 48 h (HL group) 
had a similar 28-day mortality to the LL group (HL 9.5%, LL 10.5%) and a 
more favorable outcome than patients whose bio-ADM remained high (HH 
group) or became high (LH group) (28-day mortality of 38.1% and 38.2%) 
(Table S2).
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Table 1.  Patient characteristics.
Patient characteristics All Bio-ADM < 70 pg/ml at admission
Bio-ADM > 70 pg/ml 
at admission p-value* n
Epidemiological data n=538 n=257 n=326
Bio-ADM at admission (pg/ml) 80.5 [41.5-148.0] 36.9 [27.1-51.0] 136.7 [97.6-241.0] <0.0001
Age (year) 66 [55-76] 64 [53-75] 67 [58-76] 0.0052
Males (No. %) 364 (62.4) 171 (66.5) 193 (59.2) 0.0837
Body Mass Index (kg/m2) 25.7 [22.9-30.1] 25.0 [22.3-28.4] 26.7 [23.2-31.6] 0.0013
Septic shock at admission (yes) 293 (50.3) 84 (32.7) 209 (64.1) <0.0001
Type of ICU admission <0.0001
Medical 473 (81.1) 230 (89.5) 243 (74.5)
Surgical – emergency procedure 93 (16) 21 (8.2) 72 (22.1)
Surgical – elective procedure 17 (2.9) 6 (2.3) 11 (3.4)
Origin of sepsis <0.0001
Lung 218 (37.4) 129 (50.2) 89 (27.3)
Blood stream 90 (15.4) 31 (12.1) 59 (18.1)
Urinary tract 62 (10.6) 10 (3.9) 52 (16)
Catheter 29 (5) 9 (3.5) 20 (6.1)
Peritonitis 31 (5.3) 12 (4.7) 19 (5.8)
Endocarditis 31 (5.3) 12 (4.7) 19 (5.8)
Bile duct infection 8 (1.4) 2 (0.8) 6 (1.8)
CNS 4 (0.7) 4 (1.6) 0 (0)
Skin and soft tissue 10 (1.7) 9 (3.5) 1 (0.3)
Gynaecologic 2 (0.3) 1 (0.4) 1 (0.3)
Other 98 (16.8) 38 (14.8) 60 (18.4)
Medical history**
Any cardiac comorbidity (yes) 400 (68.6) 147 (57.2) 253 (77.6) <0.0001
   Chronic heart failure (yes) 60 (10.3) 19 (7.4) 41 (12.6) 0.0544
   Hypertension (yes) 293 (50.3) 105 (40.9) 188 (57.7) <0.0001
   Diabetes Mellitus (yes) 160 (27.4) 57 (22.2) 103 (31.6) 0.0150
Any non-cardiac comorbidity (yes) 414 (71) 167 (65) 247 (75.8) 0.0058
   Chronic renal disease (yes) 76 (13.0) 19 (7.4) 57 (17.5) 0.0004
   Active/recent malignant tumors 
(yes) 124 (21.3) 34 (13.2) 90 (27.6) <0.0001
   Smoking (active, yes) 117 (20.1) 63 (24.5) 54 (16.6) 0.0302
   COPD (yes) 89 (15.3) 37 (14.4) 52 (16.0) 0.6421
Any chronic medications (yes) 371 (63.6) 138 (53.7) 233 (71.5) <0.0001
   Immunosuppressive therapy 
(yes) 46 (7.9) 11 (4.3) 35 (10.7) 0.0066
Physiological values at admission
Temperature (°C) 37.2 [36.4-38.2] 37.4 [36.6-38.2] 37.1 [36.2-38.1] 0.0034
Mean blood pressure (mmHg) 75 [64-90] 81 [69-95] 72 [60-85] <0.0001
Heart rate (bpm) 104 [90-119] 100 [86-116] 105 [94-121] 0.0013
Central venous pressure (mmHg) 8 [5-13] 8 [5-13] 10 [6-14] 0.2419
The AdrenOSS-1 study
8
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 159
159
Patient characteristics All Bio-ADM < 70 pg/ml at admission
Bio-ADM > 70 pg/ml 
at admission p-value* n
Glasgow score 15 [14-15] 15 [14-15] 15 [14-15] 0.8161
Fluid balance (ml) 1928 [592-3552] 1425 [500-2699] 2311 [764-4202] <0.0001
Urine output for 24 hours (ml) 1000 [450-1900] 1276 [650-2050] 800 [300-1650] <0.0001
PaO2/FiO2 228 [137-340] 233.5 [140-360] 223 [137-337] 0.4995
Laboratory values at admission
Lactate (mmol/l) 1.4 [1.0-2.2] 1.1 [0.8-1.6] 1.8 [1.2-2.7] <0.0001 n=562
Arterial pH 7.38 [7.3-7.44] 7.42 [7.36-7.46] 7.36 [7.27-7.42] <0.0001
Bilirubin (umol/l) 11 [6-19] 10 [6.5-17] 12 [6-21] 0.1360
Platelets (109/l) 190 [121-275] 196 [136-279] 181 [104-271] 0.0583
Creatinine (mg/dl) 1.4 [0.9-2.2] 1 [0.7-1.4] 1.8 [1.2-2.9] <0.0001
BUN or Urea (mg/dl) 61 [37-107] 44 [28-69] 80 [50-127] <0.0001
Hematocrit (%) 34 [29-38] 35 [30-38] 34 [29-38] 0.1010
White blood count (per mm3) 12525 [7200-18585] 13000 [8475-18075] 12025 [5942-19025] 0.0547
Troponin T, maximum on day 1 42 [18-158] 29 [14-124] 55 [25-176] 0.0230 n=153
Troponin I, maximum on day 1 69 [20-246] 40 [11-228] 99 [40-289] 0.0049 n=186
PCT, maximum on day 1 (ng/ml) 11.4 [1.9-49.8] 3.9 [0.9-19.5] 24 [6-84] <0.0001 n=330
PCT, central lab (ng/ml) 10.2 [2.3-34.3] 3.7 [0.8-13.0] 18.2 [6.0-52.7] <0.0001 n=583
BNP, maximum on day 1 257 [102-723] 187 [61-388] 473 [147-1154] 0.0004 n=131
NT-proBNP, maximum on day 4382 [1525-11565] 2170 [497-6633] 6116 [2816-15431] 0.0001 n=117
Organ support at admission
Mechanical ventilation 0.0739
   Invasive 219 (37.6) 85 (33.1) 134 (41.1)
   Non-invasive 131 (22.5) 67 (26.1) 64 (19.6)
   None 233 (40.0) 105 (40.9) 128 (39.3)
Renal replacement therapy (yes) 49 (8.4) 8 (3.1) 41 (12.6) 0.0001
Vasopressors/inotropes at admis-
sion (yes) 349 (59.9) 109 (42.4) 240 (73.6) <0.0001
Organ dysfunction scores
SOFA (points) 7 [5-10] 5 [3-8] 8 [6-11] <0.0001 n=509
APACHE 2 (points) 15 [11-20] 14 [9-17] 18 [13-22] <0.0001
Length of stay (days)
ICU 5 [2-10] 4 [2-8] 5 [2-10] 0.0554
Mortality (%)
28-day, deaths 127 (21.8) 30 (11.7) 97 (29.8) <0.0001
90-day, deaths 166 (28.5) 41 (16) 125 (38.3) <0.0001
* p-value from non-parametric Kruskal-Wallis or Chi2 test. 
** most common comorbidities reported individually.
Abbreviations: APACHE, acute physiology and chronic health evaluation; Bio-ADM, bioactive 
adrenomedullin; BNP, brain-derived natriuretic peptide; BUN, blood urea nitrogen; CNS, central nervous 
system; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; PCT, procalcitonin; SOFA, 
sequential organ failure assessment; NT-proBNP, N-terminal brain natriuretic peptide. 
Table 1. continued.
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Table 2.  Association between bio-ADM and 28-day mortality.
Variables Chi2 Added chi2 P-value (add-ed value) Std. HR bio-ADM p-value
Bio-ADM (univariate) 54.8 2.3 [1.9-2.9] <0.0001
... adj. for SOFA at 
admission 85.1 10.2 0.0014 1.6 [1.2-2.1] 0.0014
... adj. for APACHE 2 at 
admission 88.9 24.4 <0.0001 1.9 [1.5-2.4] <0.0001
... adj. for covariates 132.1 12.2 0.0005 1.6 [1.1-2.5] 0.0004
Bio-ADM (time-depen-
dent Cox) 80.6 25.8 <0.0001 2.5 [2.1-3.1] <0.0001
... adj. for SOFA at 
admission 89.3 11.5 0.0007 1.8 [1.4-2.2] <0.0001
... adj. for APACHE 2 at 
admission 108.4 19.5 <0.0001 2.1 [1.7-2.6] <0.0001
... adj. for SOFA (t-d*) 101.0 7.9 0.0049 1.5 [1.1-2.0] 0.0048
... adj. for lactate (t-d*) 138.0 35.7 <0.0001 1.9 [1.5-2.3] <0.0001
Results are from uni- (chi-square), multi- (added chi-square), and *time-dependent Cox re-
gression analysis. *Time-dependent analysis includes measurements observed at baseline and 
day 2. n = 562 for covariates (i.e., age, gender, comorbidities [cardiac and noncardiac], diag-
nosis [sepsis, septic shock], lactate) model due to missing data for time-dependent lactate, 
and n = 509 for models including *time-dependent SOFA score. Abbreviations: APACHE, 
Acute Physiology and Chronic Health Evaluation II; bio-ADM, Bioactive adrenomedullin; 
SOFA, Sequential Organ Failure Assessment.
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Figure 1. Twenty-eight-day Kaplan-Meier survival curves of low versus high biologically 
active adrenomedullin at admission, based on a cutoff value of 70 pg/ml, in (A) sepsis, and 
(B) septic shock patients.
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Figure 2. Association between the changes of biologically active adrenomedullin (bio-ADM) 
levels over 48 h and mortality. HR between high-high (HH) (levels of bio-ADM remained 
high) and high-low (HL) (levels of bio-ADM declining over 48 h) 4.9 (95% CI 2.5–9.8; 
HR of LL 1.1 [0.52–2.4]). Only a small number (n = 16, 2.7%; 28-day survival rate 68.8%) 
of patients who presented with a low bio-ADM concentration upon admission had higher 
bio-ADM level on day 2 (low-high (LH) group), which is why this group is not represented 
in the figure.
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Bio-ADM levels and organ dysfunction
Bio-ADM levels upon admission correlated with the initial SOFA score in all studied 
patients (n = 509, r = 0.49, p < 0.0001) (Figure S3). SOFA score was higher in patients 
in septic shock than in those in sepsis, and for each group in patients with high initial 
bio-ADM (Figure S4). Figure 3A indicates that the initial level of circulating bio-
ADM relates to the need for and duration of organ support in survivors (p < 0.0001). 
Concerning circulating bio-ADM levels and cardiovascular function, we found an 
almost linear relationship of bio-ADM and both cardiovascular SOFA subscore 
(p < 0.001) (Figure S5) and duration of cardiovascular drug support (Figure 3B) 
(p < 0.0001). Understandably, patients with high bio-ADM needed norepinephrine 
at admission more frequently (73% versus 42%, p < 0.0001) and at greater dose (0.4 
[0.3–0.8] versus 0.2 [0.1–0.4] ȝg/kg/min, p = 0.0022) than patients with low bio-
ADM (Table S3). Our analysis further revealed that patients with high bio-ADM 
at admission needed more vasopressors/inotropes over the following 7 days even if 
they did not have those treatments at admission (Figure 3C). Regarding other organ 
support, patients who needed volume resuscitation of more than 5 L over the first 
2 days (Figure 3D) (p < 0.0001) or RRT (Figure S6) or had long ICU stay (Figure 
S7) had much higher circulating bio-ADM levels upon ICU admission than those 
patients who did not.
In agreement with the fact that serial measurements of bio-ADM indicated survival 
benefit in patients who dropped bio-ADM levels at day 2, we could demonstrate that 
drop of bio-ADM over the first 2 days also preceded the decrease of total SOFA score 
(p-value for differences between HH vs. HL: p < 0.0001 for all days) (Figure 4).
Finally, using the Sepsis-3 definition of septic shock (i.e., vasopressor use and lactate 
≥ 2mmol/L [or 18 mg/dl] despite adequate volume resuscitation17), our analysis 
confirmed that bio-ADM upholds a strong prognostication for organ recovery and 
survival in AdrenOSS-1 (both p < 0.0001) (Figure S8A and B).
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Figure 3. Association between biologically active adrenomedullin levels upon admission and 
(A) length of total organ support over the first 7 days (p < 0.0001), (B) length of vasopressor/
inotropic support over the first 7 days (p < 0.0001), (C) overall need for vasopressor support 
(p < 0.0001), and (D) total fluid balance over the initial 48 h (p = 0.0001).
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Figure 4. The absolute Sequential Organ Failure Assessment (SOFA) scores at (A) admission, 
(B) day 2, and (C) day 7 for groups high-high (HH; i.e., above 70 pg/ml at baseline and day 
2), high-low (HL), and low-low (LL), excluding patients who died within 7 days. P-value for 
differences between HH vs. LL: p < 0.0001 for all days; p-value for HH vs. HL: p < 0.0001 
for all days; p-values for HL vs. LL: p < 0.0001, 0.6016, and 0.9969 for days 1, 3, and 7, 
respectively. Of note, the number of patients is less at day 2 than at day 7 because there were 
more values missing at day 2 owing to the fact that discharged patients (mostly at day 7) were 
given a SOFA score of 0. Furthermore, only a small number (n = 16, 2.7%) of patients who 
presented with a low bio-ADM concentration upon admission had a higher bio-ADM level 
on day 2 (low-high [LH] group), which is why this group is not represented in the figure. 
Median [IQR] SOFA scores for the LH group were 7.5 [6.0–9.8], 9.0 [4.0–11.2], and 4.0 
[0.0–6.5] for admission, day 2, and day 7, respectively.
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Discussion
The AdrenOSS-1 study was a prospective multinational observational cohort 
study assessing the relationship between rapid changes in circulating bio-
ADM levels in the first 2 days and clinical outcome in ICU patients with 
sepsis and septic shock. We confirmed elevated levels of bio-ADM in septic 
patients and the striking relationship between circulating bio-ADM at ICU 
admission, organ dysfunction, and death. We also demonstrated that early 
recovery of circulating bio-ADM levels towards normal values (i.e. < 70 pg/
ml) was associated with normalization of vascular function and better 28-day 
survival.
Our study found moderately elevated circulating levels of bio-ADM at 
admission in sepsis and strongly elevated bio-ADM levels in patients with 
septic shock, in accordance with earlier reports13,14. Our study also confirmed 
the marked association between bio-ADM level at admission and short-
term mortality as well as the prognostic cutoff value of 70 pg/ml, previously 
described by Marino et al.14 and Caironi et al.13 in both sepsis and septic 
shock (including the most recent definition17). Our study showed moderate 
prognostic value of bio-ADM at admission using AUC but marked prognostic 
value using Cox proportional hazards model adjusted for various parameters. 
Moreover, our study showed that prognostic value of bio-ADM at ICU 
admission exerts additive value (positive changes in chi-square) to various 
ICU severity scores. We described also the association between a bio-ADM 
≤ 70 pg/ml on day 2 and very low 28-day mortality, even in patients with 
initial high bio-ADM levels. The association of low bio-ADM by day 2 with 
full restoration of organ function at day 7 has been shown as well.
Concerning organ dysfunction, we found a relationship between circulating 
bio-ADM at ICU admission and the subsequent need for cardiovascular and/
or renal support. In our studied patients, high circulating bio-ADM—known 
to have vasodilatory actions—might account for the deterioration of vascular 
tone and blood pressure, as previously described13,14. In the present study, 
patients with high bio-ADM levels on ICU admission were more likely to 
need vasopressors and/or inotropes either at admission or in the following 
days. Moreover, they had a higher total fluid balance and higher incidence 
of RRT during their ICU stay. The ADM-induced vascular dysfunction may 
have contributed to this condition, although some data suggest that high 
bio-AM levels might also be protective to the kidney19,20. Further studies are 
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needed to elucidate the exact role of bio-ADM in renal function. Of interest, 
the relationship between circulating bio-ADM levels and extent of organ 
dysfunction, present during ICU admission, was also true during the recovery 
phase. Indeed, bio-ADM levels decreased before the improvement of total 
SOFA score in our investigation. Patients with high bio-ADM levels at ICU 
admission who showed a decline towards normal bio-ADM values at day 2 
were more likely to recover vascular function and vasopressor need by day 7. By 
contrast, the drop in bio-ADM from ICU admission to day 2 was associated 
with only limited improvement in renal function or no improvement in lung 
function at day 7. These observations also warrant further exploration.
Circulating bio-ADM levels were lower in AdrenOSS-1 than in the previously 
described ALBIOS cohort13. Indeed, in ALBIOS, septic patients were more 
severe, as suggested by greater prevalence of mechanical ventilation, length 
of stay, and short-term mortality. Likewise, the prevalence of septic shock 
was greater in ALBIOS than in AdrenOSS-1 (Table S4). Of note, different 
definitions of septic shock in the two studies may have influenced study 
assessments.
Limitations included that in the present population only patients with sepsis 
and septic shock were studied, and results cannot be directly translated to 
a general ICU population. Future studies should focus on extrapolation 
of our results to patients with hemodynamic instability related to other 
disease, because as study has already been performed for cardiogenic shock21. 
Furthermore, our data suggest that ADM may be associated with myocardial 
function (e.g. patients with high ADM also had significantly higher circulating 
natriuretic peptide levels). However, data on cardiac function (e.g. cardiac 
output or left ventricular ejection fraction) were available in only few studied 
patients. Finally, we used the cut point of 70 pg/ml of circulating bio-ADM 
for validation of the previously published cut point, even though the optimal 
Youden cut points in AdrenOSS-1 showed that 70 pg/ml with respect to a 
technical optimality criterion is not optimal.
Strong points of the study are the fact that it was a prospective international 
multicenter study with a large number of patients, with a focus on mortality 
and organ dysfunction. However, as is true of any observational study, only 
associations can be described, and cause-and-effect relationships cannot be 
deducted.
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Conclusion
In this large prospective international cohort of critically ill patients admitted 
to the ICU with sepsis or septic shock, we confirmed the strict relationship 
between high levels of bio-ADM at ICU admission and organ dysfunction 
and mortality. We demonstrated that early decrease towards the normal values 
of circulating bio-ADM in the first days after ICU admission was associated 
with improvement of cardiovascular and renal function and was associated 
with very low 28-day mortality.
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Figure S1. Twenty-eight-day Kaplan-Meier survival curves of low versus high bio-ADM at 
admission (bioADM.d0) in all patients, based on a cutoff value of 70 pg/ml. 
Figure S2. Bio-ADM levels at baseline and on day 2 in 28-day survivors and nonsurvivors. 
If data were missing at day 2 (e.g., owing to death or discharge; 12.7%), the last available 
measurement was carried forward. Horizontal lines at 70 and 130 pg/ml for better orientation; 
y-axis is truncated at 300 pg/ml.
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Figure S3. Association between the initial bio-ADM concentration and initial SOFA score 
(r = 0.49, n = 509, p < 0.0001; missing values due to missing SOFA score components).
Figure S4. Association of initial SOFA score by sepsis and septic shock and initial bio-
ADM concentration below or above 70 pg/ml (p < 0.0001 for both bio-ADM and diagnosis; 
p = 0.2015 for interaction; two-way analysis of variance). All data are from admission.
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Figure S5. Relationship between bio-ADM and cardiovascular SOFA subscore (p < 0.001).
Figure S6. Association between bio-ADM concentration on admission and need for renal 
replacement therapy on admission, later during ICU stay, or never (70.4 [36.3–128.8] vs. 
149.0 [87.1–320.5] and 162.6 [99.8–367.3] pg/ml, for patients without need for RRT, on 
admission, or later during ICU stay, respectively, p < 0.0001).
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Figure S7. Bio-ADM levels upon admission in 28-day survivors and time to ICU discharge 
(p < 0.0001): Patients with early discharge (< 2 days) are significantly different from all other 
groups (all p < 0.016), and late discharge (> 21 days) is significantly different from early 
discharge (< 2 days and 2–7 days, both p < 0.013).
Figure S8. (A)Twenty-eight-day Kaplan-Meier survival curves of low versus high bio-ADM 
at admission, based on a cutoff value of 70 pg/ml, in patients with lactate > 2 mmol/L 
(p < 0.0001) and (B) SOFA score for low versus high bio-ADM at admission (p < 0.0001).
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Patient characteristics all 28-day survivors 28-day non-survivor p-value* n
Epidemiological data n=583 n=456 n=127
Bio-ADM at admission (pg/ml) 80.5 [41.5-148.0] 70.2 [35.8-127.4] 131.0 [74.0-278.5] <0.0001
Age (year) 66 [55-76] 65 [54-74] 70 [62-78] 0.0001
Males  (n, %) 364 (62.4) 278 (61) 86 (67.7) 0.1985
Body Mass Index (kg/m²) 25.7 [22.9-30.1] 25.75 [22.5-30.3] 25.52 [23.7-29.8] 0.5693
Septic shock at admission 293 (50.3) 199 (43.6) 94 (74) <0.0001
Type of ICU admission (%): 0.5724
Medical 473 (81.1) 374 (82) 99 (78)
Surgical - emergency procedure 93 (16) 69 (15.1) 24 (18.9)
Surgical - elective procedure 17 (2.9) 13 (2.9) 4 (3.1)
Origin of sepsis (%): 0.0408
Lung 218 (37.4) 176 (38.6) 42 (33.1)
Blood stream 90 (15.4) 81 (17.8) 9 (7.1)
Urinary tract 62 (10.6) 43 (9.4) 19 (15)
Catheter 29 (5) 23 (5) 6 (4.7)
Peritonitis 31 (5.3) 24 (5.3) 7 (5.5)
Endocarditis 31 (5.3) 21 (4.6) 10 (7.9)
Bile duct infection 8 (1.4) 6 (1.3) 2 (1.6)
CNS 4 (0.7) 3 (0.7) 1 (0.8)
Skin and soft tissue 10 (1.7) 9 (2) 1 (0.8)
Gynaecologic 2 (0.3) 2 (0.4) 0 (0)
Other 98 (16.8) 68 (14.9) 30 (23.6)
Medical history** (%)
Any cardiac comorbidity 400 (68.6) 298 (65.4) 102 (80.3) 0.0019
   Chronic Heart Failure 60 (10.3) 43 (9.4) 17 (13.4) 0.2530
   Hypertension 293 (50.3) 214 (46.9) 79 (62.2) 0.0019
   Diabetes mellitus 160 (27.4) 120 (26.3) 40 (31.5) 0.2793
Any non-cardiac comorbidity 414 (71) 309 (67.8) 105 (82.7) 0.0015
    Chronic renal disease 76 (13.0) 57 (12.5) 19 (15.0) 0.5586
    Active/recent malignant tumors 124 (21.3) 88 (19.3) 36 (28.3) 0.0272
    Smoking (active) 117 (20.1) 90 (19.7) 27 (21.3) 0.8099
    COPD 89 (15.3) 67 (14.7) 22 (17.3) 0.4932
Any chronic medication 371 (63.6) 278 (61) 93 (73.2) 0.0148
    Immunosuppressive therapy 46 (7.9) 37 (8.1) 9 (7.1) 0.8464
Physiological values at admission
Temperature (°C) 37.2 [36.4-38.2] 37.3 [36.6-38.2] 36.8 [36-37.8] 0.0010
Mean blood pressure (mmHg) 75 [64-90] 76 [65-91] 73 [60-90] 0.1322
Heart rate (bpm) 104 [90-119] 103 [88-117] 110 [94-130] 0.0077
Central Venous pressure (mmHg) 8 [5-13] 8 [5-13] 10 [6-13] 0.4690
Glasgow score 15 [14-15] 15 [14-15] 15 [12-15] <0.0001
Fluid Balance (ml) 1928 [592-3552] 1745 [500-3131] 2853.5 [1145-5036] <0.0001
Urine output for 24 hours (ml) 1000 [450-1900] 1158 [583-1996] 550 [223-1440] <0.0001
PaO2/FiO2 228 [137-340] 234 [146-354] 190 [114-298] 0.0059
Table S1. Patient characteristics of survivors and non-survivors.
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Patient characteristics all 28-day survivors 28-day non-survivor p-value* n
Laboratory values at admission
Lactate (mmol/l) 1.4 [1.0-2.2] 1.2 [0.9-1.9] 2.2 [1.4-4.0] <0.0001 n=562
Arterial pH 7.38 [7.3-7.44] 7.4 [7.32-7.45] 7.33 [7.27-7.4] <0.0001
Bilirubin (umol/L) 11 [6-19] 10 [6-18] 13 [7-24] 0.0961
Platelets (109/L) 190 [121-275] 193 [124-281] 166 [96-261] 0.0301
Creatinine (mg/dL) 1.4 [0.9-2.2] 1.3 [0.8-2.1] 1.6 [1.1-2.6] 0.0023
BUN or Urea (mg/dL) 61 [37-107] 57 [34-101] 75 [49-120] 0.0002
Hematocrit (%) 34 [29-38] 34 [30-38] 33 [28-39] 0.4325
White blood count (per mm3)
12525 [7200-
18585] 13345 [8000-18975] 10365 [4150-16770] 0.0008
Troponin T, maximum on day 1 42 [18-158] 33 [18-131] 61 [34-241] 0.0989 n=153
Troponin I, maximum on day 1 69 [20-246] 60 [17-228] 150 [39-1001] 0.0468 n=186
PCT, maximum on day 1 (ng/mL) 11.4 [1.9-49.8] 10.7 [1.9-49.4] 11.8 [2.2-52.5] 0.6690 n=330
PCT, central lab (ng/mL) 10.2 [2.3-34.3] 9.7 [2.2-31.5] 14.8 [3.9-42.8] 0.0442 n=583
BNP, maximum on day 1 257 [102-723] 239 [87.7-650] 514 [139-1242] 0.1183 n=131
NT-proBNP, maximum on day 1
4382 [1525-
11565] 3400.5 [1026.88-9052] 7249 [4564-25007] 0.0007 n=117
Organ support at admission (%)
Mechanical ventilation: <0.0001
Invasive 219 (37.6) 141 (30.9) 78 (61.4)
Non-invasive 131 (22.5) 107 (23.5) 24 (18.9)
None 233 (40.0) 208 (45.6) 25 (19.7)
Renal replacement therapy 49 (8.4) 27 (5.9) 22 (17.3) 0.0002
 Vasopressors/inotropes at 
admission 346 (59.9) 246 (53.9) 103 (81.1) <0.0001
Organ dysfunction scores
SOFA (points) 7 [5-10] 6 [4-9] 10 [7.5-12] <0.0001 n=509
APACHE II (points) 15 [11-20] 15 [10-19] 19 [16-23.5] <0.0001
Length of stay (days)
ICU 5 [2-10] 5 [2-10] 4 [2-8] 0.0147
Mortality
28-day, deaths (%) 127 (21.8) 0 (0) 127 (100) <0.0001
90-day, deaths (%) 166 (28.5) 39 (8.6) 127 (100) <0.0001
* p-value from non-parametric Kruskal-Wallis or Chi2 test, respectively.
** most common comorbidities reported individually.
Abbreviations: APACHE, acute physiology and chronic health evaluation; Bio-ADM, bioactive 
adrenomedullin; BNP, brain-derived natriuretic peptide; BUN, blood urea nitrogen; CNS, 
central nervous system; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; 
PCT, procalcitonin; SOFA, sequential organ failure assessment; NT-proBNP, N-terminal brain 
natriuretic peptide.
Table S1. continued.
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Table S2. Patient characteristics of the four different groups with respect to adrenomedullin 
trajectory over the first 48 h after study inclusion.
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All Bio-ADM <70 pg/mL
Bio-ADM 
>70 pg/mL p-value
Dobutamine (%) 23 (4) 9 (4) 14 (4) 0.7842
Dobutamine (%) 23 (4) 9 (4) 14 (4) 0.7842
Epinephrine (%) 16 (3) 3 (1) 13 (4) 0.0696
Norephinephrine (%) 346 (59) 107 (42) 239 (73) <0.0001
Dose of   norepinephrine   
(mg/kg/min; median 
[IQR])
0.3 [0.2-0.7] 0.2 [0.1-0.4] 0.4 [0.3-0.8] 0.0022
Table S3. Association between ADM and need of vasopressors/inotropes at admission.
Data are expressed as median [IQR, interquartile range] or as number of patients (percent-
age). Abbreviations: Bio-ADM, bioactive adrenomedullin.
AdrenOSS-1
n = 583
ALBIOS
n = 956
Definition of septic shock Sepsis-2 SOFA score 3-4
Septic shock patients (%) 50.3 56.4
Baseline Bio-ADM value (median, pg/mL) 80.5 110
Bio-ADM value in severe sepsis (median, pg/mL) 58 86
Bio-ADM value in septic shock (median, pg/mL) 114 122
Mechanical ventilation upon study inclusion (%) 60 82.5
Length of ICU stay (median, IQR) 5 [2-10] 10 [5-20]
90-day mortality (%) 29 39
Table S4. Comparison of AdrenOSS-1 and ALBIOS.
Data are expressed as time range, median [IQR, interquartile range] or as number of pa-
tients (percentage). Abbreviations: Bio-ADM, bioactive adrenomedullin.
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Effects of the humanized anti-adrenomedullin 
antibody Adrecizumab (HAM8101) 
on vascular barrier function and survival 
in rodent models of systemic inflammation 
and sepsis
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Effects of the humanized anti-adrenomedullin antibody Adrecizumab (HAM8101) on vascular barrier 
function and survival in rodent models of systemic inflammation and sepsis.
9
Abstract
Purpose
Adrenomedullin (ADM) is an important regulator of endothelial barrier 
function during sepsis. Administration of a murine antibody targeted against 
the N-terminus of ADM (HAM1101) resulted in improved outcome in 
models of murine sepsis. We studied the effects of a humanized form of 
this antibody (HAM8101, also known as Adrecizumab) on vascular barrier 
dysfunction and survival in rodent models of systemic inflammation and 
sepsis.
Methods
Rats (n=48) received different dosages of HAM8101 or placebo (n = 8 per 
group), directly followed by administration of lipopolysaccharide (5 mg/kg). 
Twenty-four hours later, Evans Blue dye was administered to assess vascular 
leakage in kidney and liver tissue. Furthermore, mice (n = 24) were administered 
different dosages of HAM8101 or placebo (n = 6 per group), immediately 
followed by cecal ligation and puncture (CLP). Eighteen hours later, albumin, 
vascular endothelial growth factor (VEGF), and angiopoietin-1 were analyzed 
in the kidney. Finally, effects of single and repeated dose administration 
of HAM1101, HAM8101 and placebo on survival were assessed in CLP-
induced murine sepsis (n = 60, n = 10 per group).
Results
Dosages of 0.1 and 2.5 mg/kg HAM8101 attenuated renal albumin leakage 
in endotoxemic rats. Dosages of 0.1, 2.0, and 20 mg/kg HAM8101 reduced 
renal concentrations of albumin and the detrimental protein VEGF in septic 
mice, whereas concentrations of the protective protein angiopoietin-1 were 
augmented. Both single and repeated administration of both HAM1101 and 
HAM8101 resulted in improved survival during murine sepsis.
Conclusions
Pretreatment with the humanized anti-ADM antibody HAM8101 improved 
vascular barrier function and survival in rodent models of systemic 
inflammation and sepsis.
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Background
Sepsis is an inflammatory syndrome, in which a dysregulated host response 
to an infection results in life-threatening organ dysfunction1. It is a frequent 
reason for admission to the intensive care unit2, and despite many advances 
in medical care, its incidence is increasing3 and mortality remains high4. The 
current treatment of sepsis consists of source control, antimicrobial therapy, 
and supportive treatment such as fluid resuscitation, vasopressor use, and 
mechanical ventilation5. Currently, no adjunctive pharmacological therapies 
are used in clinical practice6. Hemodynamic instability plays an important 
role in the development of septic shock, and arises due to a combination 
of sepsis-induced vasodilation and vascular leakage, the latter of which is 
caused by disrupted endothelial integrity. Extensive changes occur in the 
endothelium as a result of circulating damage-associated molecular patterns 
and pathogen-associated molecular patterns that activate inflammatory and 
coagulation pathways during sepsis. In turn, this can result in increased 
leukocyte adhesion, a procoagulant state, vasodilation and endothelial cell 
permeability, and ultimately widespread edema, shock and lethal organ 
dysfunction5,7,8.
Adrenomedullin (ADM) appears to play an important role in the regulation 
of the endothelial barrier function and modulation of vascular tone. ADM 
is a free circulating peptide synthesized by several cell-types, including 
vascular endothelial and vascular smooth muscle cells9,10. ADM signals 
through binding to the AM1- and AM2-receptors, which are composed of 
a calcitonin-receptor-like receptor (CLR), and receptor activity modifying 
proteins (RAMP2 or RAMP3 for AM1 and AM2, respectively)11. Results on 
the role of ADM in sepsis are ambiguous. During sepsis, ADM levels are 
correlated with relaxation of vascular tone12 as well as with disease severity 
and mortality in septic patients13–15. In vitro and in vivo data demonstrate 
that ADM exerts beneficial effects on the endothelial barrier, as it prevents 
endothelial hyperpermeability and subsequent edema formation by 
inhibition of actin-myosin-based endothelial cell contraction and junctional 
disruption16–19. Furthermore, ADM administration was shown to improve 
gut microcirculation in models of inflammation17,20. However, other work 
revealed that ADM promotes vasodilation, and infusion of high doses of 
ADM decreases blood pressure and induces a compensatory increased heart 
rate in rats, cats, sheep, and humans21–25. These data suggest that the ADM 
response needs to be tightly regulated, maintaining adequate, but avoiding 
excessive signaling.
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Recently, a high-affinity antibody targeting the N-terminus of ADM 
(HAM1101), which only partially inhibits ADM signaling, showed beneficial 
effects on outcome in two cecal ligation and puncture (CLP) studies26,27. 
The observation that the antibody that only partially inhibits ADM exerts 
more benefit than the antibody that completely blocks ADM26, supports 
the paradigm that a moderate ADM response is needed. Subsequently, a 
humanized version of this antibody (HAM8101, also known as Adrecizumab) 
has been developed for clinical use. In the present study, we investigated the 
effects of HAM8101 on vascular barrier dysfunction in a rat model of systemic 
inflammation induced by endotoxin administration as well as in the more 
clinically relevant model of sepsis induced by cecal ligation and puncture 
in mice (CLP)28. Furthermore, we compared the effects of HAM8101 and 
HAM1101 on survival in the murine CLP model.
Methods
Animals
Animal experiments were performed according to the guidelines of the 
Federation of Laboratory Animal Science Associations (FELASA) and 
the society of Laboratory Animal Science (GV-SOLAS). All animals were 
obtained from Charles River Laboratories, Sulzfeld, Germany. Male Wistar 
rats were used for the lipopolysaccharide (LPS) vascular permeability study 
(n = 48, aged 2–4 months) performed by Preclinics (Potsdam, Germany). 
The CLP kidney barrier dysfunction study was performed by Phenos GmbH 
(Hannover, Germany), and male mus musculus C57BL/6 mice (n = 24, 12–15 
weeks old) were used. For the CLP survival experiments (also performed by 
Phenos GmbH), 12 to 15-week-old male mus musculus C57BL/6 mice were 
used (n = 30 for single and n = 30 for repeated dose experiments respectively. 
These were separate experiments, using different batches per survival 
experiment). To determine the robustness of HAM8101 during sepsis/
inflammation, its efficacy was investigated in different animal species, using 
different sepsis models and end-points. Animals were housed under routine 
laboratory conditions, kept under 12 h/12 h light–dark cycle conditions and 
fed ad libitum with standard chow (Ssniff R/M-H diet) with unlimited access 
to water. Substance administration, surgery, and blood withdrawal were 
performed under isoflurane anesthesia to avoid stress and pain in animals. This 
study is reported according to the ARRIVE (Animals in Research: Reporting 
In Vivo Experiments) guidelines.
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Antibodies
Generation of the murine monoclonal anti-Adrenomedullin antibody 
HAM1101 has been described previously26,27. From this murine monoclonal 
antibody a humanized recombinant monoclonal antibody (HAM8101;IgG1) 
was generated by CDR grafting, and it was produced in Chinese hamster 
ovary cells. HAM8101 was produced by Glycotope Biotechnology GmbH 
(Heidelberg, Germany) under Good Manufacturing Practice (GMP) 
conditions, and this antibody is also known as Adrecizumab; HAM1101 
was produced by InVivo GmbH (Hennigsdorf, Germany). The antibodies 
are directed against the N-terminus of ADM. The antibodies were kindly 
provided by Adrenomed AG (Hennigsdorf, Germany) in stock solutions 
in PBS and were stored at 2°C to 8°C under temperature controlled and 
restricted access conditions.
LPS-induced vascular permeability study procedures
Rats (n = 48 total) were randomly divided into six groups (n = 8 each), of which 
one group received placebo twice (saline and PBS [control]), whereas the 
other five groups received 5 mg/kg bodyweight LPS (E coli 055:B5; Sigma-
Aldrich, Taufkirchen, Germany) in combination with different dosages of 
HAM8101 (Adrecizumab, 0.02 mg/kg, 0.1 mg/kg, 0.5 mg/kg, or 2.5 mg/
kg) or PBS. HAM8101/PBS was administered 5 min before LPS/saline. 
All substances were administered as a bolus intravenously through a 24G 
indwelling catheter placed in the tail vein. 300 ȝL blood from each animal 
was collected in Multivette K-EDTA-tubes (Sarstedt, Nümbrecht, Germany) 
through the tail vein at baseline as well as 3, 6, and 24 h after injection of 
LPS/saline. Tubes were stored on ice until centrifugation (3,220 × g at 6°C 
for 10 min). Plasma was then transferred to a micro tube and stored at −80°C 
until analysis of plasma ADM concentrations. Twenty-four hours after LPS/
saline administration, deep isoflurane anesthesia was induced and Evans Blue 
(40 mg/kg, dissolved in saline, [Sigma-Aldrich, Taufkirchen, Germany]) was 
administered. Approximately 15 min after Evans Blue administration, the 
aorta was cannulated and whole body perfusion was started (15 min, saline + 
50 IU/mL heparin [Heparin-Sodium 25000 I.E./5 mL; B. Braun Melsungen 
AG, Melsungen, Germany]). Following perfusion, kidney and liver was 
harvested and directly processed for Evans Blue absorption (see further below).
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CLP-induced kidney barrier dysfunction study procedures
Mice were randomly divided into four groups (n = 6 each, n = 24 total) and 
received a single i.v. injection of saline (control group) or HAM8101 (0.1 mg/
kg, 2 mg/kg, or 20 mg/kg, respectively), 5 min prior to CLP surgery by tail 
vein injection. Peritonitis was surgically induced under isoflurane anesthesia. 
Incisions were made into the left upper quadrant of the peritoneal cavity 
(normal location of the cecum). The cecum was exposed and a tight ligature was 
placed around the cecum (at 70–75% cecum length). One puncture wound 
was made with a 24 G needle into the cecum and small amounts of cecal 
contents were pressed through the wound. The cecum was returned into the 
peritoneal cavity and the laparotomy site was closed. Animals were returned 
to their cages with free access to food and water. To prevent dehydration, 
500 ȝL saline was administered subcutaneously. For analgesic treatment, 
carprofen (Rimadyl, Zoetis, Berlin, Germany) 5 mg/kg was administered 
subcutaneously directly after surgery. Eighteen hours following surgery, mice 
were sacrificed by retrobulbar exsanguination, whereafter the left kidney 
was removed immediately and cut in two parts, which were processed for 
immunohistochemistry (see further below).
CLP survival study procedures
In the single-dose administration study, mice (n = 30 total) were randomly 
divided into three groups (n = 10 each) to receive either a single dose of PBS, 
2 mg/kg HAM1101, or 2 mg/kg HAM8101, administered by intravenous 
tail vein injection, 5 min prior to CLP surgery (performed as described 
in the previous section “CLP-induced kidney barrier dysfunction study 
procedures”). For analgetic treatment, 5 mg/kg carprofen (Rimadyl, Zoetis, 
Berlin, Germany) was injected subcutaneously after surgery, and metamizole 
(Novalgin, Sanofi-Aventis, Frankfurt, Germany) was added to the drinking 
water for 3 days after CLP surgery (0.8 mL / 500 mL water). To prevent 
dehydration, 500 ȝL saline was administered subcutaneously. Mice were 
followed up for 7 days and physical condition was monitored twice daily. 
If still alive on day 7, animals were sacrificed by retrobulbar exsanguination. 
In the repeated dose administration study, mice (n = 30 total) were randomly 
divided into three groups (n = 10 each) to receive doses of either PBS, 4 mg/kg 
HAM1101 or 4 mg/kg HAM8101 5 min prior to CLP surgery (performed as 
described in the previous section “CLP-induced kidney barrier dysfunction 
study procedures”). To prevent dehydration, 500 ȝL saline was administered 
subcutaneously. Additional dosages of PBS, 2 mg/kg HAM1101, or 2 mg/kg 
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HAM8101 were administered 24 and 48 h after CLP surgery by retrobulbar 
injection. Mice were followed up for 14 days, in which physical conditions 
were monitored twice daily, and if still alive on day 14, they were sacrificed by 
retrobulbar exsanguination.
Evans Blue analysis
Organs were homogenized and incubated in 1 mL formamide per gram organ 
sample (Sigma-Aldrich, Taufkirchen, Germany) at 55°C for 3 h to extract 
Evans Blue. Subsequently, the solution was transferred to fresh centrifugation 
tubes, of which 500ȝL was transferred onto a centrifugal filter (3K, VWR, 
Radnor, Pa) unit and centrifuged at 25,000 × g at room temperature for 
30 min. The filtrate was transferred to a 96-well-plate (non-treated; Costar) 
and absorption of samples and reference standards was measured at 620 nm 
using a plate reader (Mithras LB940; Berthold Technologies, Wildbad, 
Germany).
Immunohistochemistry
The left kidney tissues were formalin-fixed, dehydrated, and embedded in 
paraffin. Study procedures were done as described previously29. In short, 5-ȝm-
thick kidney sections were cut and deparaffinized with xylene, graded ethanol, 
and deionized water, followed by heat-induced antigen retrieval performed by 
microwaving with citrate buffer. Depending on the source of the secondary 
antibody, blocking was performed with normal (goat or donkey) serum. 
Next, primary antibodies were used for immunohistochemical localization 
of VEGF (rabbit polyclonal, Abcam, Cambridge, UK), angiopoietin-1 
(goat polyclonal, R&D Systems, Minneapolis, Minn), and extravasation of 
albumin (goat polyclonal M-13, Santa Cruz Biotech, Santa Cruz, Calif ). 
The primary antibodies were detected with secondary antibodies (goat anti-
rabbit or donkey anti-goat IgG alkaline phosphatase), followed by Dako 
REAL Detection System Chromogen Red, and counterstained with Mayer's 
hematoxylin. Slides were analyzed using the Axio Vision software (release 
4.8), multiple 800,000 ȝm2 fields were evaluated, and data are represented as 
mean densitometric sums red.
Adrenomedullin assay
The ADM assay was performed as described previously13. Briefly, plasma 
ADM (both free and antibody-bound) concentrations were measured using 
a sandwich-coated luminescence immunoassay, based on acridinium NHS-
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ester labeling and anti-ADM antibodies (a solid phase antibody targeted 
against the mid region of ADM and a labeled antibody against the amidated 
C-terminal moiety of ADM). Dilutions of rat ADM and labeled tracer were 
subsequently added to antibody-coated wells. After washing of unbound 
tracer, chemiluminescence was measured and evaluated against a standard 
curve from rat ADM standards.
Statistical analysis
Data were non-normally distributed, and therefore expressed as median and 
interquartile range. Differences across three or more groups were analyzed using 
Kruskal–Wallis tests. In case the two-sided P-value of the Kruskal–Wallis test 
was  < 0.05, pairwise comparisons were made using Mann–Whitney U tests. 
P-values of the Mann–Whitney U tests were not adjusted for multiple testing 
in view of the exploratory nature of the experiments. For survival analysis, 
Kaplan–Meier curves were generated and log-rank tests were performed to 
test statistical significance of observed differences. A two-sided P-value < 0.05 
was considered statistically significant. Calculations and statistical analyses 
were performed using GraphPad Prism version 6 for Windows (Graphpad 
Software Inc, La Jolla, California, USA).
Results
HAM8101 prevents LPS-induced vascular hyperpermeability in the kidney
The effect of HAM8101 on LPS-induced vascular hyperpermeability was 
studied in kidney and liver tissue using Evans Blue dye to detect albumin 
leakage. LPS administration resulted in a 3.5-fold increase in renal albumin 
leakage compared with saline-treated controls, which was significantly 
attenuated by HAM8101 at dosages of 0.1 mg/kg and 2.5 mg/kg (71% 
and 40% attenuation, respectively), whereas statistical significance was not 
reached for the 0.5 mg/kg dose (33% attenuation, P = 0.083, Figure 1A). LPS 
administration also resulted in a 2.3-fold increase in hepatic albumin leakage 
(Figure 1B). Only the highest dose of HAM8101 tended to attenuate albumin 
leakage in the liver, approaching but not reaching statistical significance (36% 
attenuation, P = 0.065, Figure 1B). LPS administration resulted in increased 
ADM plasma levels (Figure 2). HAM8101 administration in dosages of 
0.5 mg/kg or higher caused a dose-dependent increase in plasma ADM 
concentrations (Figure 2).
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Figure 1. Extravascular albumin accumulation indicated by Evans Blue dye in the kidney 
(A) and liver (B) of rats 24  h after lipopolysaccharide (LPS) or saline administration in 
combination with different dosages of HAM8101 (n = 8 per group). Data are expressed as 
median and interquartile range. Bold P-values were calculated using Kruskal–Wallis. Pairwise 
comparisons were made using Mann–Whitney U tests.
Figure 2. Plasma total ADM concentrations in rats treated with LPS (5 mg/kg) or saline in 
combination with different dosages of HAM8101 (n = 8 per group). Groups were evaluated 
using two-way ANOVAs (interaction term of group and time) on group pairs using log-
transformed data.
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HAM8101 improves kidney barrier function during murine sepsis
The effects of HAM8101 on albumin accumulation, VEGF, and 
angiopoietin-1 expression were investigated in murine CLP-induced sepsis. 
Representative images of immunohistological stainings are provided in Figure 
3A. Densitometric evaluation of immunohistological stained slides of renal 
tissue revealed significantly lower extravascular albumin accumulation with 
all three dosages of HAM8101 compared with saline-treated CLP animals 
(78%, 77%, and 77% attenuation for 0.1, 2.0, and 20 mg/kg Adrecizumab, 
respectively), without HAM8101 dose dependency (Figure 3B). Likewise, 
significantly lower VEGF expression was observed in all HAM8101-treated 
CLP mice (55%, 45%, 59% attenuation, respectively, Figure 3C). Expression 
of the protective protein angiopoietin-1 was significantly augmented in CLP 
mice treated with dosages of 0.1 and 2.0 mg/kg HAM8101 (387% and 474% 
augmentation, respectively, Figure 3D), whereas this effect did not reach 
statistical significance in the 20 mg/kg group (379% augmentation, P = 0.065).
Both single- and repeated-dose administration of HAM8101 improve survival 
during murine sepsis
Finally, the effects of single- and repeated-dose administration of HAM8101 
on survival in CLP-induced sepsis were studied in mice, and compared to 
the effects of the murine analogue HAM1101, which was previously shown 
to increase survival in the same model26. In single-dose administration 
experiments, CLP caused 90% 7-day mortality, which was significantly 
improved by both HAM8101 and HAM1101 (50% and 30% mortality, 
respectively, difference between both antibodies was not statistically 
significant, Figure 4A). In the repeated-dose administration experiments, 
CLP caused 100% 14-day mortality, which wa s also significantly improved 
by the administration of both HAM8101 and HAM1101 (60% and 80% 
mortality, respectively, no significant difference between both antibodies, 
Figure 4B).
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Figure 3. Representative images of immunohistological stainings are provided in the top of 
the figure (A).Extravascular albumin (B), vascular endothelial growth factor (VEGF) (C), 
and angiopoietin-1 (D) expression in the kidney determined using immunohistochemical 
analysis 18 h after cecal ligation and puncture, with or without HAM8101 treatment (n = 6 per 
group). Data are expressed as median and interquartile range. Bold P-values were calculated 
using Kruskal–Wallis tests. Pairwise comparisons were made using Mann–Whitney U tests.
Figure 4. Survival after cecal ligation and puncture (CLP) with our without treatment with 
single (A) and repeated (B) doses of placebo, HAM1101, or HAM8101 (n = 10 per group).
Kaplan–Meier curves are depicted and P-values were calculated using log-rank tests.
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Discussion
In the present study, we investigated the effects of the humanized recombinant 
monoclonal anti-Adrenomedullin antibody HAM8101 (Adrecizumab) 
on vascular barrier dysfunction and survival in rodent models of systemic 
inflammation and sepsis. We demonstrate that treatment with HAM8101 
prevents LPS-induced vascular hyperpermeability in the kidney. Second, 
we reveal that HAM8101 improves kidney barrier function during murine 
sepsis, exemplified by significantly reduced extravascular albumin and VEGF 
expression, as well as increased expression of the protective protein Ang-
1. Finally, the humanized recombinant monoclonal antibody HAM8101 
enhanced survival during murine sepsis to a similar extent as the murine anti-
ADM antibody HAM1101, which was previously shown to be efficacious26,27.
Our findings with HAM8101 support previous studies in which beneficial 
effects of ADM-binding with HAM1101 were demonstrated during murine 
sepsis, including reduced catecholamine infusion rates, attenuated kidney 
dysfunction, and improved survival26,27. Our finding of reduced renal 
interstitial edema formation in endotoxemic rats underscores findings from 
a previous study in which indirect evidence also pointed toward reduced 
vascular leakage: urine output was shown to be significantly higher in the 
HAM1101-treated mice, while fluid administration rates were similar27. 
This was accompanied by improved creatinine clearance, urea levels, and less 
urinary excretion of tubular damage marker neutrophil gelatinase-associated 
lipocalin (NGAL), which were not measured in the present study27.
HAM8101 pretreatment attenuated sepsis-induced VEGF expression in the 
kidney. VEGF is a potent inducer of vascular permeability30, cell adhesion 
molecule expression31, as well as cyto- and chemokine release32. Interestingly, 
increased VEGF concentrations are observed in septic patients, and associated 
with their fluid balance33,34, and anti-VEGF treatment improved outcome 
during models inflammation and sepsis in preclinical studies35. HAM8101 
enhanced renal expression of angiopoietin-1, a vascular specific growth factor, 
also involved in the regulation of vascular permeability during sepsis and septic 
shock36 that appears to counteract the observed VEGF effects. Angiopoietin-1 
levels are also increased in sepsis and septic shock patients, and lower values are 
associated with increased mortality37. Preclinical studies have demonstrated 
beneficial effects of Angiopoietin-1 on microvascular dysfunction and 
endothelial barrier function38,39. Collectively, our immunohistological 
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findings of decreased VEGF expression and enhanced angiopoietin-1 
expression provide mechanistic support for HAM8101's protective effects on 
vascular permeability that we observed in rats. As VEGF is also implicated in 
endothelial dysfunction, it appears plausible that HAM8101 may improve 
endothelial dysfunction as well, although this remains to be determined.
We show that the survival benefit in murine sepsis is comparable for HAM1101 
and HAM8101 for both single and repeated dose administration. This is not 
unexpected, because HAM8101 is derived from HAM1101, and therefore 
both antibodies target the exact same epitope. Furthermore, both antibodies 
were shown to be ideally cross-reactive among all mammalian species tested 
(mice, rats, dogs, pigs, and humans; unpublished data). Also, as mentioned 
previously, both antibodies, despite their high affinity for ADM, only partially 
and to a similar extent inhibit the ADM-induced cAMP response in CHO 
cells overexpressing the ADM (CRLR/RAMP3) receptor26.
Of particular interest is the fact that HAM8101 administration led to a dose-
dependent increase in total ADM levels in our study. This is in line with the 
results from our recently performed phase I study in healthy volunteers40, 
and we have formulated a hypothesis on this aspect of HAM8101 therapy41. 
Briefly, we believe that it involves elongation of ADMs half-life by binding 
with the non-neutralizing antibody HAM8101, providing protection from 
N-terminal proteolytic degradation. Second, we hypothesize that ADM 
distribution is shifted from another compartment (likely the interstitium) 
toward the circulation, based upon the fact that ADM can normally diffuse 
freely over the endothelial barrier (6 kD peptide), whereas it likely cannot 
after binding to HAM8101. This is supported by data from our phase I study, 
showing a low volume of distribution (100 mL/kg)40. Nevertheless, more 
research is required before definite conclusions can be drawn on the purported 
mechanism of action of HAM8101.
It could be argued that the HAM8101-induced increase in circulating ADM 
levels negatively influences blood pressure, as high dosages of ADM have been 
reported to exert vasodilatory effects21–25. We cannot draw direct conclusions 
on this possible untoward effect, because we did not measure blood pressure 
in our experiments. It has to be kept in mind, though, that the increase of 
circulating ADM does not represent free ADM, but ADM complexed with 
Adrecizumab. As alluded to in the section above, this complex is too large to 
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cross the endothelial barrier, and therefore cannot exert vasodilation through 
direct effects on vascular smooth muscle cells. Furthermore, data from 
previous studies do not support detrimental effects on blood pressure either. 
For instance, pretreatment with the murine form of the antibody (HAM1101) 
resulted in reduced vasopressor infusion requirements, which argues against 
hypotensive effects of the antibody, at least under inflammatory conditions27. 
Finally, no effects on blood pressure or heart rate were observed in our phase 
I study40.
A strength of the current work is the use of different animal species, sepsis(-
like) models, and end-points. Several limitations also need to be addressed. 
Although our results are encouraging, it needs to be acknowledged that 
HAM8101 and HAM1101 were administered 5 min prior to LPS-
administration/CLP-surgery in our experiments, to demonstrate proof of 
principle. As time dependency of the effects was not investigated, it remains 
to be determined whether HAM8101 also exerts beneficial effects when 
treatment is delayed, which is more representative of the clinical setting in 
sepsis patients. Moreover, measurements of vascular permeability were only 
performed at one time-point in each study and were restricted to the kidney 
and liver. It would also be of interest to evaluate whether HAM8101 exerts 
similar effects in the lung, as vascular leak in this organ is the major cause of 
acute respiratory distress syndrome in sepsis patients. Another limitation is 
the fact that the CLP-induced kidney barrier dysfunction experiment did not 
include a sham control group.
Conclusion
Pretreatment with the humanized anti-ADM antibody HAM8101 improves 
vascular barrier function and survival in rodent models of systemic 
inflammation and sepsis. The promising findings from the current animal 
experiments warrant further research in humans. Currently, a phase I study 
(ClinicalTrials.gov identifier NCT02991508) is in its final stages and a phase 
II study in septic patients is planned.
Ethics approval and consent to participate
Study protocol approval was obtained from the appropriate governing 
institutes (approval numbers: Preclinics: 2347-35-2015 issued by Landesamt 
für Umwelt, Gesundheit und Verbraucherschutz Brandenburg; Phenos: 33.9-
42502-04-12/0846 issued by Niedersächsisches Landesamt für
Verbraucherschutz und Lebensmittelsicherheit).
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Abstract
Background
Sepsis represents a major health issue, with persisting high morbidity and 
mortality rates. Cardiovascular dysfunction occurs frequently during sepsis. 
Adrenomedullin (ADM) has been identified as a key mediator in vascular 
tone regulation. A non-neutralizing anti-ADM antibody, Adrecizumab, 
may improve hemodynamic dysfunction during murine, cecal ligation and 
puncture (CLP)-induced septic shock. Our objective was to determine the 
role of Adrecizumab on hemodynamics in a rat model of sepsis.
Methods
CLP-surgery was performed in Wistar male rats to induce sepsis. Single 
blinded dose of Adrecizumab (2 mg/kg) or placebo was injected IV 24 hours 
after the surgery and norepinephrine (NE) was infused as standard of care. 
There were > 7 animals per group. Invasive blood pressure (BP) and cardiac 
function (by echocardiography) were assessed until 3 hours after Adrecizumab 
injection.
Results
A single therapeutic injection of Adrecizumab in septic rats induced rapid 
beneficial hemodynamic effects with an increase in systolic BP in CLP-
Adrecizumab rats versus untreated-CLP rats (p=0.049). The shortening 
fraction did not differ in both untreated-CLP and CLP-Adrecizumab 
groups. On the other hand, cardiac output increased during the 3 hours after 
a single dose of Adrecizumab compared to untreated-CLP rats (p=0.006). 
Adrecizumab administration resulted in hemodynamic effects similar to 
continuous administration of norepinephrine. Three hours after Adrecizumab 
administration, there was no change in the inflammatory phenotype (TNFĮ, 
IL-10) in the myocardium of the septic rats. In contrast, myocardial free 
radical production (DHE) was decreased in CLP-Adrecizumab vs. untreated 
CLP rats (p<0.05).
Conclusions
In a rat model of sepsis, a single therapeutic injection of Adrecizumab rapidly 
restored hemodynamic parameters and attenuated myocardial oxidative stress. 
Currently, a proof-of-concept and dose-finding phase II trial (Adrenoss-2) 
is ongoing in patients with septic shock and elevated concentrations of 
circulating bio-ADM.
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Introduction
Despite advances in resuscitation and infectious diseases management, 
sepsis remains one of the leading causes of death worldwide1,2. Sepsis is 
characterized by disturbed vascular integrity, the presence of life-threatening 
organ dysfunction due to a dysregulated response of the body to infection2. 
Today, vasopressor therapy is one of the cornerstone of sepsis treatment, 
however, vasopressor use do not restore vascular integrity and could even lead 
to harmful effects and impair prognosis3.
Adrenomedullin (ADM), a 52 amino acids peptide hormone4,5, has been 
proposed as a pivotal mediator of vascular dysfunction in sepsis6,7. On the one 
hand, ADM can act as a vasodilator, decrease peripheral vascular resistance, 
and increase cardiac output8. On the other hand, ADM has beneficial effects, 
as it reduces capillary hyperpermeability in preclinical studies with models of 
septic shock9,10. Recently, a model has been proposed, which explains these 
different activities of ADM as a function of its compartmental localization11: 
in the interstitium, ADM acts on vascular smooth muscle cells to induce 
vascular relaxation, whereas in the blood circulation ADM promotes the 
stabilization of the endothelial barrier. The ADM pathway acts through ADM 
receptors made of one CRLR subunit and one RAMP 2 or 3 subunit.
In patients with sepsis and septic shock, elevated plasma concentration of 
biologically active ADM (bio-ADM) is associated with disease severity, 
organ dysfunction, and it is a strong prognosticator for 28-day mortality12–15. 
Of interest and related to its vascular effects, high plasma concentrations 
of bio-ADM is correlated to vasopressor use12–15. Therefore, modulation 
of ADM activity could be of therapeutic potential during sepsis to restore 
hemodynamics and improve clinical outcome16. Adrecizumab (HAM8101) 
is a humanized non-neutralizing monoclonal antibody directed against the 
N-terminus of ADM that only partially inhibits ADM activity. Intravenous 
Adrecizumab administration leads to an immediate and substantial increase 
of plasma ADM concentration, thereby enhancing the endothelium-
stabilizing effect of ADM17. In a mouse model of sepsis (cecal ligation and 
puncture, CLP), pretreatment with Adrecizumab increased survival while 
other antibodies directed against different epitopes of ADM (causing 
greater or complete inhibition of ADM signaling) did not17,18. In addition, 
pretreatment with Adrecizumab led to numerous improvements including 
reduced catecholamine and fluid requirements, as well as improvement 
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of renal function19. Given the role of ADM in vasodilation and capillary 
leakage, the objective of this work was to explore the hemodynamic response 
to Adrecizumab therapeutic treatment, by partial ADM inhibition, in a rat 
model of sepsis. We hypothesized that by this treatment a rapid and sustained 
beneficial response could be achieved in septic shock.
Material and methods
Animals and sepsis model
Two months old male Wistar rats weighing 350 to 450 g were obtained from 
Janvier (St Berthevin, France). All experiments were conducted in accordance 
with the National and European Institutes of Health guidelines for the use 
of laboratory animals and were approved by the local animal research ethics 
committee (Lariboisière-Villemin, Paris, France; 77-2014 -ceea9). 
All animals were anesthetized using ketamine hydrochloride (90 mg/kg) and 
xylazine (9 mg/kg) intraperitoneally. For induction of polymicrobial sepsis, 
CLP was performed as previously described20. A ventral midline incision (1 
cm) was made to allow exteriorization of the cecum. The cecum was then 
ligated just below the ileocecal valve and punctured once with an 18-gauge 
needle. The abdominal cavity was closed in two layers and rats were given fluid 
resuscitation (3 ml/100g of body weight of saline injected subcutaneously). 
A sham operation was performed by isolating the cecum without ligation or 
puncture. Twenty-four hours later, rats were split into several groups. CLP 
animals were randomized in 5 subgroups to a single blinded i.v. dose of 
Adrecizumab (2 mg/kg in 1.5 mL) or placebo (1.5 mL of PBS) through the 
jugular vein and norepinephrine (NE), for either 30 minutes or continuously 
as the standard of care for hemodynamic management, or not: CLP, CLP-
Adrecizumab, CLP-cNE (with continuous NE), CLP-cNE-Adrecizumab 
(Adrecizumab + continuous NE) and CLP-NE (with NE infusion during 
30 min). Norepinephrine was administrated at the dose of 1 ȝg/kg/
min. There were at least 7 rats per group (except for the CLP group with 
norepinephrine infusion during only 30 min, n=4). Among CLP rats, 20 
died before administration treatment of either Adrecizumab or placebo and 
hemodynamic exploration. Sham animals received neither Adrecizumab nor 
NE. The experimentation protocol is summarized in Figure 1.
Briefly, 24 hours after CLP procedure, rats were anesthetized with ketamine 
hydrochloride (90 mg/kg) and xylazine (9 mg/kg)20, and placed in supine 
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position. Animals were intubated with a catheter (16G) and ventilated using a 
rodent ventilator with respiratory rate = 53.5 * 0.26 weight, tidal volume = 6.2 
* 1.01 weight. Rectal temperature was maintained throughout the protocol at 
37–37.5 °C by a heating mat. Catheters were inserted into left jugular vein to 
administer antibody or placebo and into the right carotid artery to monitor 
blood pressure.
Figure 1. Experimental protocol
Hemodynamics and cardiac function monitoring
Cardiac function was assessed by transthoracic echocardiographic examination 
at baseline and every hour during the next 3 hours of the experiment using 
GE Healthcare Vivid 7 Ultra-sound System equipped with a high frequency 
(14-MHz) linear probe. All examinations were recorded digitally and stored 
for subsequent off-line analysis as described by Milliez et al.21. Invasive blood 
pressure (BP) measurements were performed after catheter insertion and 
every hour during the next 3 hours. 
Assessment of organ inflammatory response and oxidative stress
EDTA blood was collected from the left carotid artery at the end of the 
experiment, centrifuged at 3500 rpm for 15 min at 4°C, and plasma was stored 
at -80°C until measurement of several analytes. Bio-ADM was measured as 
described previously17. At the end of the protocol, rats were sacrificed and 
organs (heart, lung, liver and left kidney) weighed. The heart was transversely 
divided into 2 parts. The base was embedded into Tissue-Tek optimal cutting 
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temperature (OCT) compound (Sakura Finetek, France) and frozen in liquid 
nitrogen, and stored at -80°C until use for DHE staining; the other part of 
the heart was snap-frozen in liquid nitrogen for RT-PCR and Western Blot 
analysis. Other organs specimens (lung, liver, kidney, brain, aorta and muscle) 
were collected and snap frozen in liquid nitrogen. All samples were stored at 
-80°C until further analysis.
Gene expression analysis
Total RNA was isolated from tissues using the RNeasy Mini Kit® (Qiagen, 
Courtaboeuf, France) according to the manufacturer’s instructions and reverse 
transcribed using QuantiTect® Reverse Transcription (Qiagen, Courtaboeuf, 
France). Then, real-time polymerase chain reaction was performed with 
LightCycler96 (Roche Diagnostics, Meylan, France) using the FastStart 
Essential DNA Green Master® (Roche Diagnostics, Meylan, France). mRNA 
levels for genes of interest were normalized to that of Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) expressed as the relative change 
compared with the control samples. The sequences of the primers used are 
reported in Suppl. Table 1.
Protein analysis
For western blot analysis, tissues were homogenized in cell lysis buffer 
(50 mM Tris HCl at pH 7.4, 1 mM EDTA, and 150 mM NaCl). After 
centrifugation, soluble proteins were quantified using the Pierce BCA Protein 
Assay Kit (Thermo Fischer Scientific, Courtaboeuf, France). Proteins (30 
ȝg) were separated on 10-12% SDS-PAGE gels and were transferred onto 
nitrocellulose membranes (Protan Paris, France). Blots were probed overnight 
at 4°C with the following primary antibodies directed against the following: 
phosphorylated and total Akt (Ser473) (1:1000; #9271 and #9272; 
Cell Signaling, Ozyme, France), p62 (1:1000; ab56416; Abcam, United 
Kingdom), HIF1Į (1:1000; PAI 16601; Thermo Scientific, Massachusetts, 
USA), and GAPDH (1:5000; Millipore, Molsheim, France). Blots were 
incubated with goat anti-rabbit (1:5000; Sigma-Aldrich) or sheep anti-mouse 
peroxidaseconjugated antibodies (1:10,000; GE Healthcare) for 1 h at room 
temperature. Chemiluminescent signals (ECL Plus; GE Healthcare) were 
recorded using an LAS 3000 system (Fuji, Courbevoie, France) and were 
quantified using MultiGauge V2.02 software (Fuji).  The results are expressed 
as arbitrary units (AU) obtained from the ratio between the densitometric 
units of the protein under study and the GAPDH densitometric value.
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Histological and histochemical analyses
Seven ȝm cross sections were stained with hemalun and eosin and examined by 
bright-field microscopy at 20X magnification. Cardiac cryostat cross-sections 
(7 ȝm) of the ventricles were incubated with Dihydroethidium (DHE; Sigma-
Aldrich) (37 ȝM) for 30 min in a dark humidified chamber22. Acquisition of 
fluorescent images of ethidium bromide with Leica fluorescence microscope 
was performed under identical setting whatever the block tissue. The stained 
area was measured with IPLab software and expressed as a percentage of area 
of interest (% of ROI).
Statistical analysis
Data are presented as mean ± SEM. Statistical analysis was performed using 
GraphPad Prism version 5.0 (GraphPad Software Inc., San Diego, California). 
Comparison between groups was performed by 2-way ANOVA or Kruskal 
Wallis followed by Dunn’s Multiple Comparison Test as appropriate. Mann-
Whitney U test was used to compare baseline hemodynamics parameters. A 
p-value < 0.05 was considered statistically significant. 
Results
At the time of hemodynamic resuscitation, clinical signs of sepsis (reduced 
motor activity, lethargy, shivering, piloerection and hunched posture) were 
only present in CLP rats as expected. Furthermore, post-mortem exam-
ination of the abdominal cavity of all CLP rats showed varying degrees of 
peritonitis with a gray-black dilated cecum and purulent and malodorous 
peritoneal fluid. There was no difference in heart, lung, liver and left kidney 
weights between sham and CLP rats (Suppl. Table 2).
Effects of Adrecizumab on hemodynamics
Before initiation of hemodynamic resuscitation, all CLP rats presented with 
altered hemodynamics including a markedly lower mean BP (95 ± 3 versus 
112 ± 3 mmHg, p = 0.0006) and a slight increase in cardiac output (160 ± 
5 versus 133 ± 8ȝL/min, p = 0.018) compared to sham rats (Suppl. Figure 
1). In untreated CLP rats, hemodynamics remained altered during the 3 
hours of experimentation (Figure 2). A single dose of Adrecizumab (CLP-
Adrecizumab rats) without norepinephrine rapidly increased systolic blood 
pressure (p = 0.049 vs. untreated CLP). Adrecizumab injection also tended 
to improve diastolic and mean blood pressures and LV shortening fraction, 
although these did not reach statistical significance (Figure 2).
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In addition, cardiac output and heart rate significantly increased during 
the 3 hours after single dose administration of Adrecizumab compared to 
untreated CLP rats (p=0.006 and p=0.024 respectively; Figure 2). During the 
protocol, restoration of systolic blood pressure and improvement in cardiac 
output were similar in CLP rats receiving continuous NE infusion and those 
receiving a single dose of Adrecizumab (Suppl. Figure 2). Furthermore, the 
addition of a single injection of Adrecizumab to continuous NE infusion 
had a similar effect as NE on hemodynamic parameters and did not lead to 
unwanted further vasoconstriction (Suppl. Figure 2). Of note, short-term 
(30 min) administration of NE only transiently improved hemodynamics and 
parameters either returned to baseline values (e.g. cardiac output and heart 
rate) or worsened (e.g. blood pressure) compared to baseline, after stopping 
NE infusion (Figure 2).
Adrecizumab and metabolic changes in sepsis
Concerning circulating bio-ADM, levels were low in sham animals (14.6 ± 2.1 
pg/mL), while a strong elevation was observed in untreated CLP rats (289.7 
± 42.2 pg/mL, p<0.05 vs. sham; Figure 3). Administration of Adrecizumab 
further increased plasma bio-ADM concentration (1193 ± 349.8 pg/mL, 
p<0.05 vs. sham; Figure 3).
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Figure 2. Hemodynamic parameters measured 24 hours after sepsis induction by CLP and 
then 60, 120 and 180 min after the injection of Adrecizumab or placebo. CLP rats are 
represented by the black line, CLP-Adrecizumab rats by the red line and CLP-NE rats by 
the grey line. Two-way ANOVA was used to compare between-group differences. * p<0.05.
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Myocardial and lung expression of ADM were increased in untreated CLP 
versus sham (heart: 2.17 ± 0.4 vs. 0.9 ± 0.1, p<0.05; lung: 29.1 ± 3.1 vs. 13.4 
± 2.2, p<0.05; Figure 3) and remained high 3 hours after single Adrecizumab 
injection (heart: 2.64 ± 0.6, p<0.05 vs. sham; lung: 28.1 ± 3.6, p<0.05 vs. 
sham). In contrast, adrenal expression of ADM decreased in both untreated 
CLP and in CLP-Adrecizumab rats versus sham (respectively: 2.57 ± 0.6, 1.58 
± 0.3 vs. 7.67 ± 1.9, p<0.05). No change of ADM expression was observed 
in lung.
Expression of the ADM receptor components CRLR and RAMP2 was by far 
highest in the lung, 50-100 fold higher than in heart, kidneys and adrenals. 
Myocardial and kidney expression of CRLR were increased in untreated CLP 
versus sham (heart: 1.11 ± 0.1 vs. 0.54 ± 0.1, p<0.05; kidney: 2.08 ± 0.5 
vs. 0.51 ± 0.1, p<0.05; Figure 3) and remained high 3 hours after single 
Adrecizumab injection (heart: 1.14 ± 0.2, p <0.05 vs. sham; kidney: 1.42 ± 
0.2, p <0.05 vs. sham). In contrast, adrenal expression of CRLR decreased 
significantly in CLP-Adrecizumab versus sham (0.36 ± 0.06 vs. 0.74 ± 0.11, 
p <0.05) and non-significantly in untreated CLP (0.42 ± 04). No change of 
CRLR expression was observed in lung.
Figure 3. Adrenomedullin plasma level (pg/ml) (A). Expression of adrenomedullin (ADM) 
mRNA (B) and its receptor (CRLR, RAMP2) (B, C) in the heart, lung, kidney and adrenals. 
These measurements were performed 3 hours after the Adrecizumab injection and 24 hours 
after the induction of sepsis. Groups were compared using the Kruskal-Wallis test followed 
by Dunn’s multiple comparison test.
Figure 3
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Myocardial and kidney expression of RAMP 2 were increased in untreated 
CLP versus sham (heart: 2.12 ± 0.5 vs. 0.89 ± 0.2, p<0.05; kidney: 5.42 ± 
0.8 vs. 0.71 ± 0.1, p<0.05; Figure 3) and remained high 3 hours after single 
Adrecizumab injection (heart: 1.77 ± 0.3, ns vs. sham; kidney: 6.14 ± 1.1, p 
<0.05 vs. sham). No change of RAMP 2 expression was observed in lung and 
adrenals.
Regarding myocardial inflammatory markers, the expression of the pro-
inflammatory marker TNFƠ, the anti-inflammatory marker IL-10 and CD68, 
a marker of macrophage activation, were all increased in CLP rats. Myocardial 
levels of those markers were not altered in CLP-Adrecizumab rats. Moreover, 
myocardial BNP mRNA was upregulated in untreated CLP rats and remained 
high in CLP-Adrecizumab. In addition, p62, an inflammatory marker, was 
increased in the heart of untreated CLP and CLP-Adrecizumab compared 
with sham rats (Figure 4). Suppl. Figure 3 also shows that myocardial BNP 
mRNA was up regulated in CLP and remained high in CLP-Adrecizumab.
Figure 4 also shows that the Akt phosphorylation level, a myocardial survival 
pathway, was markedly increased in the myocardium of CLP-Adrecizumab 
rats 24 hours after the onset of sepsis (p<0.05). Concerning myocardial 
oxidative stress, the CLP-induced 10-fold elevation of DHE that was blunted 
in CLP-Adrecizumab rats (p<0.05) (Figure 5). 
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Figure 5. Decreased ROS production in the septic myocardium 3 hours after Adrecizumab 
administration. Dihydroethidium (DHE; Sigma-Aldrich) staining was used to evaluate the 
in situ levels of superoxide anion in the myocardium. Data are expressed as a percentage of 
region of interest (% of ROI). Groups were compared using the Kruskal-Wallis test followed 
by Dunn’s multiple comparison test.
Sham CLP CLP-ADZ
0.0
0.5
1.0
1.5 p=0.016
*
*
P-
Ak
t/A
kt
Sham CLP CLP-ADZ
0.0
0.1
0.2
0.3
0.4 p=0.006
*
p6
2/
GA
PD
H 
(A
U)
p62
Sham CLP CLP-ADZ
GAPDH
Sham CLP CLP-ADZ
P-Akt
Akt
Figure 4.Figure 4. W stern Blot of cardiac P-Akt/Akt and p62. Groups were compared using the 
Kruskal-Wallis test followed by Dunn’s multiple comparison test.
Sham CLP CLP ADZ
0
2
4
6
8
10   **
*** ***
% 
of
 R
OI
Sham CLP
CLP - ADZ
50μm50μm
50μm
The non-neutralizing anti-adrenomedullin antibody Adrecizumab improves hemodynamics and 
attenuates myocardial oxidative stress in septic rats
10
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 214
214
Discussion
The present study shows that a single therapeutic injection of Adrecizumab 
in septic rats induced rapid hemodynamic benefits and a marked reduction 
in tissue oxidative stress. Indeed antibodies directed against ADM, an 
endogenous vasodilator peptide had similar hemodynamic effects as 
continuous administration of norepinephrine. 
Our study demonstrates that in a model of sepsis, a single injection of 
Adrecizumab rapidly restored blood pressure and cardiac output. ADM has 
been proposed to be one of the pivotal mediators of vascular dysfunction in 
sepsis. In patients with sepsis or septic shock, high plasma bio-ADM levels 
are related to a worse prognosis and higher need for vasoconstrictors12. As 
recently described, circulating bio-ADM easily diffuses from the lumen of the 
vessels to the interstitium to act on vascular smooth muscle cells and reduce 
vascular tone11. Adrecizumab was described to improve blood pressure when 
given as preventive therapy before induction of sepsis19. Herein we showed 
that, a single injection of Adrecizumab restored blood pressure, 24 hours after 
induction of peritonitis and septic shock in rats. The early benefit of a single 
injection of Adrecizumab on blood pressure (Figure 2) was likely related to 
the rapid binding of Adrecizumab to plasma bio-ADM, hence preventing its 
diffusion to the interstitium. 
Our study further shows that a single injection of Adrecizumab was associated 
with a sustained improvement in cardiac output in septic rats. This is the first 
demonstration that Adrecizumab, likely acting as a scavenger of circulating 
bio-ADM, not only improves blood pressure but also improves systemic 
perfusion. Improvement in cardiac output might be related, at least partially, 
to the higher heart rate after single administration of Adrecizumab. The 
data also indicated that Adrecizumab improved left ventricular shortening 
fraction, though not statistically significant, in septic rats. In septic shock 
patients, hemodynamics, and especially blood pressure is usually restored by 
continuous administration of vasopressors such as catecholamine, vasopressin 
or angiotensin23. The restoration of blood pressure and improved cardiac 
output was similar to continuous administration of norepinephrine. This 
novel approach might be safer as it avoids the long-lasting administration 
of vasopressors, possibly associated with deleterious effects on outcome3. 
Therefore, norepinephrine substitution by Adrecizumab might be of interest. 
Our data show that beneficial effects of Adrecizumab on blood pressure at the 
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dose of 2 mg/kg might decrease after 2 hours though benefits on cardiac output 
appeared to be maintained. Further studies should test greater doses. Hence, 
the present preclinical work confirms and extends the short-term safety and 
efficacy profile of the non-neutralizing ADM-binding antibody Adrecizumab 
in line with improved renal function and survival previously described17,18. 
This led to pursue the program in human septic patients. Adrecizumab is still 
investigational. A phase 2 trial, AdrenOSS-2, has started in December 2017 
to assess safety and efficacy of single injection of Adrecizumab (2 or 4 mg/kg) 
in patients with septic shock (NCT03085758). AdrenOSS-2 trial is one of 
the first personalized medicine trials in septic shock patients.
Regarding CRLR, RAMP 2 and ADM expression in various tissues. Our data 
confirmed that ADM pathway is highly present in lungs compared to other 
organs including heart, kidney and adrenal glands24,25. Twenty-four hours of 
peritonitis and septic shock induced changes in ADM pathway with a greater 
expression in ADM in the heart and lung, in CRLR and RAMP 2 in the heart 
and kidney. Whereas, in adrenals, where ADM was first described4, sepsis 
decreased ADM and CRLR expressions. The single injection Adrecizumab 
had no effect on ADM pathway. Peritonitis and septic shock upregulated 
inflammation and survival pathways in the heart and in other organs. Those 
changes were unaffected as early as 3 hours after a single Adrecizumab 
injection. The observation-time was likely too short to see any significant 
changes on ADM pathway and tissue inflammation and longer observation 
period being needed. By contrast, single Adrecizumab injection succeeded 
to rapidly and markedly reduce myocardial oxidative stress. The mechanisms 
through which Adrecizumab reduced myocardial oxidative stress are not fully 
understood, although anti-apoptotic, anti-inflammatory and anti-oxidative 
properties previously described might be involved11,17. The improvement 
of myocardial function may also be related to the Adrecizumab-induced 
reduction in myocardial oxidative stress26,27.
Conclusion
Therapeutic treatment with the ADM-binding antibody Adrecizumab 
improves short-term hemodynamic parameters and attenuates myocardial 
oxidative stress in rat polymicrobial sepsis. Currently, a proof-of-concept 
and dose-finding phase II trial is ongoing in patients with septic shock and 
elevated concentration of circulating bio-ADM.
The non-neutralizing anti-adrenomedullin antibody Adrecizumab improves hemodynamics and 
attenuates myocardial oxidative stress in septic rats
10
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 216
216
References
1. Angus DC, van der Poll T. Severe sepsis and 
septic shock. N Engl J Med 2013; 369(21): 
840–851.
2. Singer M, Deutschman CS, Seymour 
CW, Shankar-Hari M, Annane D, Bauer 
M, Bellomo R, Bernard GR, Chiche J-D, 
Coopersmith CM, Hotchkiss RS, Levy 
MM, Marshall JC, Martin GS, Opal SM, 
et al. The Third International Consensus 
Definitions for Sepsis and Septic Shock 
(Sepsis-3). JAMA 2016; 315(8): 801–810
3. Mebazaa A, Motiejunaite J, Gayat E, 
Crespo-Leiro MG, Lund LH, Maggioni 
AP, et al. Long-term safety of intravenous 
cardiovascular agents in acute heart 
failure: results from the European Society 
of Cardiology Heart Failure Long-Term 
Registry. Eur J Heart Fail 2018; 20(2): 332–
341.
4. Kitamura K, Kangawa K, Kawamoto M, 
Ichiki Y, Nakamura S, Matsuo H, et al. 
Adrenomedullin: a novel hypotensive peptide 
isolated from human pheochromocytoma. 
Biochem Biophys Res Commun 1993; 192(2): 
553–560.
5. Samson WK, Resch ZT, Murphy TC, Vargas 
TT, Schell DA. Adrenomedullin: Is There 
Physiological Relevance in the Pathology 
and Pharmacology? News Physiol Sci 1999; 
14: 255–259.
6. Hinson JP, Kapas S, Smith DM. 
Adrenomedullin, a multifunctional 
regulatory peptide. Endocr Rev 2000; 21(2): 
138–167.
7. Wang P, Ba ZF, Cioffi WG, Bland 
KI, Chaudry IH. The pivotal role of 
adrenomedullin in producing hyperdynamic 
circulation during the early stage of sepsis. 
Arch Surg 1998; 133(12): 1298–1304.
8. Nicholls MG, Lainchbury JG, Lewis 
LK, McGregor DO, Richards AM, et 
al. Bioactivity of adrenomedullin and 
proadrenomedullin N-terminal 20 peptide 
in man. Peptides 2001; 22(11): 1745–1752.
9. Hippenstiel S, Witzenrath M, Schmeck 
B, Hocke A, Krisp M, Krüll M, et al. 
Adrenomedullin reduces endothelial 
hyperpermeability. Circ Res 2002; 91(7): 
618–625
10. Temmesfeld-Wollbrück B, Hocke AC, 
Suttorp N, Hippenstiel S. Adrenomedullin 
and endothelial barrier function. Thromb 
Haemost 2007; 98(5): 944–51.
11. Geven C, Bergmann A, Kox M, Pickkers 
P. Vascular Effects of Adrenomedullin 
and the Anti- Adrenomedullin Antibody 
Adrecizumab in Sepsis. Shock 2018; 50(2): 
132-140.
12. Marino R, Struck J, Maisel AS, Magrini 
L, Bergmann A, Somma S. Plasma 
adrenomedullin is associated with short-
term mortality and vasopressor requirement 
in patients admitted with sepsis. Crit Care 
2014; 18(1): R34.
13. Rey C, García-Hernández I, Concha A, 
Martínez-Camblor P, Botrán M, Medina A, 
et al. Pro-adrenomedullin, pro-endothelin-1, 
procalcitonin, C-reactive protein and 
mortality risk in critically ill children: a 
prospective study. Crit Care 2013; 17(5): 
R240.
14. Caironi P, Latini R, Struck J, Hartmann O, 
Bergmann A, Maggio G, et al. Circulating 
Biologically Active Adrenomedullin (bio-
ADM) Predicts Hemodynamic Support 
Requirement and Mortality During Sepsis. 
Chest 2017; 152(2): 312–320.
15. Simon T-P, Martin L, Doemming S, 
Humbs A, Bruells C, Kopp R, et al. Plasma 
adrenomedullin in critically ill patients with 
sepsis after major surgery: A pilot study. J 
Crit Care 2016; 38: 68–72.
16. Geven C, Kox M, Pickkers P: 
Adrenomedullin and Adrenomedullin-
Targeted Therapy As Treatment Strategies 
Relevant for Sepsis. Front Immunol 2018; 9: 
292.
17. Geven C, Peters E, Schroedter M, Struck 
J, Bergmann A, McCook O, et al. Effects 
of the Humanized Anti-Adrenomedullin 
Antibody Adrecizumab (HAM8101) on 
Vascular Barrier Function and Survival in 
Rodent Models of Systemic Inflammation 
and Sepsis. Shock 2018; epub ahead of print.
18. Struck J, Hein F, Karasch S, Bergmann A. 
Epitope specificity of anti-Adrenomedullin 
antibodies determines efficacy of mortality 
reduction in a cecal ligation and puncture 
mouse model. Intensive Care Med Exp 2013; 
1(1): 22.
19. Wagner K, Wachter U, Vogt JA, Scheuerle A, 
McCook O, Weber S, et al. Adrenomedullin 
binding improves catecholamine 
responsiveness and kidney function in 
resuscitated murine septic shock. Intensive 
Care Med Exp 2013; 1(1): 21.
20. Lemarie J, Blet A, Bouazza Y, Boisrame-
Helms J, Meziani F, Levy B. Dexamethasone 
The non-neutralizing anti-adrenomedullin antibody Adrecizumab improves hemodynamics and 
attenuates myocardial oxidative stress in septic rats
10
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 217
217
and recombinant human activated protein C 
improve myocardial function and efficiency 
during experimental septic shock. Shock 
2014; 41(6): 522–527.
21. Milliez P, Messaoudi S, Nehme J, Rodriguez 
C, Samuel J-L, Delcayre C. Beneficial effects 
of delayed ivabradine treatment on cardiac 
anatomical and electrical remodeling in rat 
severe chronic heart failure. Am J Physiol 
Heart Circ Physiol 2009; 296(2): H435-441.
22. Fazal L, Azibani F, Bihry N, Coutance G, 
Polidano E, Merval R, et al. Akt-mediated 
cardioprotective effects of aldosterone in 
type 2 diabetic mice. FASEB J 2014; 28(6): 
2430–2440.
23. Levy B, Fritz C, Tahon E, Jacquot A, Auchet 
T, Kimmoun A. Vasoplegia treatments: the 
past, the present, and the future. Crit Care 
2018; 22(1): 52.
24. Ono Y, Okano I, Kojima M, Okada K, 
Kangawa K. Decreased gene expression of 
adrenomedullin receptor in mouse lungs 
during sepsis. Biochem Biophys Res Commun 
2000; 271(1): 197–202.
25. Shoji H, Minamino N, Kangawa K, Matsuo 
H. Endotoxin markedly elevates plasma 
concentration and gene transcription of 
adrenomedullin in rat. Biochem Biophys Res 
Commun 1995; 215(2): 531–5367.
26. Galley HF: Oxidative stress and 
mitochondrial dysfunction in sepsis. Br J 
Anaesth 2011; 107: 57–64.
27. Andrades MÉ, Morina A, Spasić S, 
Spasojević I. Bench-to-bedside review: sepsis 
- from the redox point of view. Crit Care 
2011; 15(5): 230.
The non-neutralizing anti-adrenomedullin antibody Adrecizumab improves hemodynamics and 
attenuates myocardial oxidative stress in septic rats
10
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 218
218
Sham CLP
60
70
80
90
100
p<0.0001
M
ea
n 
B
lo
od
 P
re
ss
ur
e
(m
m
H
g)
Sham CLP
0
100
200
300
400
p=0.0002
H
ea
rt
 R
at
e
(b
pm
)
Sham CLP
45
50
55
60
p=0.0006
Sh
or
te
ni
ng
 F
ra
ct
io
n
(%
)
Sham CLP
0
50
100
150
200
250
p=0.0176
C
ar
di
ac
 O
ut
pu
t
(m
l/m
in
)
A B
C D
Suppl. Figure 1. Hemodynamics 24 hours after CLP and prior to antibody injection.  Average 
arterial pressure (mmHg) (A). Heart rate (bpm) (B). Fraction of shortening (C). Cardiac flow 
(ml / min) (D). Groups were compared using the Mann-Whitney U test were used.
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Suppl. Figure 2. Hemodynamic parameters measured 24 hours after sepsis induction by 
CLP and 120 min after single injection of Adrecizumab or placebo. cNE means continuous 
administration of norepinephrine. Groups were compared using the Kruskal-Wallis test 
followed by Dunn’s multiple comparison test.
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Suppl. Figure 3. Expression of cytokine mRNA in various organs (A, B). Myocardial expression 
of BNP (C). Expression of CD68 mRNA in various organs (C). These measurements were 
performed 3 hours after the Adrecizumab injection and 24 hours after the induction of 
sepsis. Groups were compared using the Kruskal-Wallis test followed by Dunn’s multiple 
comparison test.
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Gene Access GenBank Forward sequence Reverse sequence
ADM Adm NM_012715.1 TTCTCATCGCAGTCAGTCTTGG CGCTTGTAGTTCCCTCTTCCC
BNP Nppb NM_031545.1 TAGCCAGTCTCCAGAACAATCCA AAACAACCTCAGCCCGTCAC
CD68 Cd68 NM_001031638.1 GCCCTCACCAAGTCCTAGTC GATGTCGGTCCTGTTTGAATCCA
CRLR Calcrl NM_012717.1 TCAGCTCAGACACTCATCTCCTC CACCTCCTCAGCAACCTTTCC
GAPDH Gapdh NM_017008.4 GTTCAACGGCACAGTCAAGG ACTCCACGACATACTCAGCAC
IL10 IL10 NM_012854.2 CCTGCTCTTACTGGCTGGAG TGTCCAGCTGGTCCTTCTTT
RAMP2 Ramp2 NM_031646.1 TTGTGGTGTGGAGGAGTAAAGAC GTGGGAAGGATGGGAGTAAGTG
TNF Tnf NM_012675.3 ACTCCCAGAAAAGCAAGCAA CGAGCAGGAATGAGAAGAGG
Suppl. Table 1. Primer sequences
 Sham CLP
CLP
-ADZ
CLP
-cNE
CLP
-cNE
-ADZ
CLP
-NE p-value
Heart/body 
weight * 1000
3.33 ± 0.09 3.17 ± 0.08 3.13 ± 0.05 3.28 ± 0.06 3.26 ± 0.06 3.07 ± 0.05 ns
Lung/body 
weight * 1000
4.02 ± 0.15 3.92 ± 0.08 4.13 ± 0.11 3.86 ± 0.11 3.79 ± 0.20 4.83 ± 0.79 ns
Kidney/body 
weight * 1000
3.51 ± 0.14 3.97 ± 0.13 3.87 ± 0.18 3.74 ± 0.18 3.80 ± 0.19 3.51 ± 0.25 ns
Liver/body 
weight * 1000
37.53 ± 1.33 36.80 ± 1.30 35.10 ± 0.95 35.16 ± 1.36 32.93 ± 1.01 33.16 ± 0.64 ns
Suppl. Table 2. Organ weight/body weight
Data are presented as mean ± Standard Error of Mean (SEM). Comparison between groups 
was performed by Kruskal Wallis analysis followed by Dunns test. A p-value of < 0.05 was 
considered statistically significant. Groups: CLP, cecal legiation and puncture; CLP-ADZ, 
CLP-Adrecizumab; CLP-cNE, CLP-continuous norepinephrine infusion; CLP-cNE-ADZ, 
CLP-continuous norepinephrine infusion-Adrecizumab; CLP-NE, CLP-norepinephrine during 
30 min.
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Abstract
Adrenomedullin (ADM) is a vasoactive peptide in sepsis. The non-neutralizing 
ADM-binding antibody Adrecizumab improved outcome in animal models 
of systemic inflammation and sepsis. Herein, we evaluated the preclinical 
safety of Adrecizumab in various animal species. First, Wistar rats received 
vehicle, 100, 200 or 400 mg/kg/day of Adrecizumab intravenously (n=20 
each) on days 1, 4, 8 and 14. An additional set of rats received vehicle or 
400 mg/kg/day (n=10 each) on the same days and were followed for 42 
days. For toxicokinetics, satellite animals received vehicle (n=6), 100, 200, 
or 400 mg/kg/day Adrecizumab intravenously (n=18 each). A hemodynamic 
study was performed in Beagle dogs (n=3) receiving vehicle (day 1), 2 mg/
kg (day 3), 10 mg/kg (day 5), 50 mg/kg (day 8) and 10 mg/kg Adrecizumab 
intravenously (day 29). In final experiments, cynomolgus monkeys received 
vehicle, 25, 50 or 100 mg/kg/day Adrecizumab intravenously (n=6 each) on 
days 1, 4, 8 and 14. Additional groups of monkeys received vehicle or 100 
mg/kg/day Adrecizumab intravenously (n=4 each) on the same days and were 
followed for 42 days. No mortality or moribund conditions occurred and no 
toxicologically relevant effects were attributed to Adrecizumab. Adrecizumab 
significantly increased circulating concentrations of its target peptide ADM, 
consistent with previous studies and mechanistically relevant. Toxicokinetic 
analyses showed immediate and dose-dependent peak concentrations, slow 
elimination and no gender differences. In conclusion, intravenous, repeated 
administration of high doses of Adrecizumab appeared well-tolerated across 
species. These results pave the way for further investigation of Adrecizumab 
in humans (intended dose of 2 mg/kg).
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Introduction
Sepsis is a major worldwide health issue, with global estimates of approx. 
30 million episodes and over 5 million deaths annually1. It is defined as 
life-threatening organ dysfunction caused by a dysregulated host response 
to infection2. Endothelial dysfunction is a major pathogenic hallmark of 
sepsis, and tissue edema resulting from breakdown of vascular endothelial 
barriers is generally regarded as a key mechanism in widespread lethal organ 
dysfunction3-5. 
Adrenomedullin (ADM) is a vasoactive peptide relevant in the context of 
sepsis6. ADM levels are increased in sepsis patients and associated with organ 
dysfunction, vasopressor requirements and mortality7,8. These observations 
may imply that ADM plays a detrimental role in sepsis. However, no causal 
relationships can be assumed from these observational studies, and increased 
levels of ADM could also indicate a failing protective response. Mechanistic 
in vitro and in vivo studies have shown that ADM exerts strong stabilizing 
effects on the vascular endothelium through binding with ADM-receptors 
present on endothelial cells that line the inside of blood vessels9-12, thereby 
preventing capillary leakage. In addition, anti-inflammatory and antibacterial 
effects have also been attributed to ADM 6. Other studies have shown that 
ADM is a potent vasodilator and can cause hypotension (in vivo, also in 
humans)13-15 through ligation with ADM-receptors present on vascular 
smooth muscle cells6. Interestingly, complete blockade of ADM signaling in 
models of murine sepsis or inflammation does not appear to improve survival, 
although blood pressure was briefly enhanced16-18. Currently, it remains unclear 
whether the increased levels of ADM observed during sepsis are detrimental 
for the patient due to excessive vasodilation (and hypotension), or whether 
they represent a failing protective response.
Attempts have been made to pharmacologically modulate ADM’s effects 
in order to improve outcome in sepsis. To this extent, different antibodies 
(targeting different epitopes of ADM) were administered during murine septic 
shock and effects on survival were observed for an administered dose of 2 mg/
kg18. Interestingly, a C-terminal binding antibody that completely blocked 
ADM signaling did not improve survival, whereas a non-neutralizing antibody 
that binds to ADM’s N-terminal epitope did improve survival (administered 
as a single i.v. dose of 2 mg/kg). Other work with this non-neutralizing 
N-terminal antibody (of which the humanized version was eventually named 
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Adrecizumab) in preclinical models of systemic inflammation and septic shock 
showed attenuated tissue edema formation and vasopressor requirements, 
while renal function and survival were improved19,20. This consistently 
occurred for doses of around 2 mg/kg. The proposed mechanism of action 
relies on an immediate and significant increase of ADM concentrations in the 
blood upon administration of the antibody, increasing ADM’s endothelial 
stabilizing effects on endothelial cells while reducing interstitial ADM that 
causes vasodilation18. This is further elaborated on in the discussion section. 
In previously published preclinical work, no safety issues were observed 
(highest dose tested was 30 mg/kg, in healthy animals)18. In human phase 
I studies (recently published but performed after preclinical safety studies, 
including those described in the present manuscript), doses of 0.5, 2 and 8 
mg/kg were tested and found to be safe21. In the present work, we evaluated 
the toxicological profile, effects on blood pressure, as well as toxicokinetics of 
Adrecizumab in rodents, dogs and non-human primates.
Methods
Animals
Animal experiments were performed according to local applicable guidelines 
and regulations (see supplementary materials for a detailed overview). All 
animals were kept under routine laboratory conditions, with temperature and 
humidity control, as well as 12h/12h light-dark cycle conditions. Animals 
were weighed individually and treatment was prepared for individual animals. 
The repeated-dose toxicology and toxicokinetics study in rats was performed 
by ATRC Aurigon Toxicological Research Center Ltd. (Dunakeszi, Hungary). 
Healthy, naïve, Wistar rats (7-8 weeks old) were obtained from Charles River 
Laboratories (Sulzfeld, Germany). Rats were fed ad libitum with standard 
chow (Ssniff R-Z [Ssniff Spezialdiäten GmbH, Soest, Germany]) and water. 
Rats were kept in polycarbonate cages equipped with metal-wire covers and 
self-feeding baskets (5 rats/cage during acclimatization, 2-3 rats/cage during 
the study period and 5 rats/cage during the recovery period in recovery 
animals).
The repeated-dose cardiovascular and toxicological study in telemetered, 
conscious, beagle dogs was also performed by ATRC Aurigon Toxicological 
Research Center Ltd. (Dunakeszi, Hungary). Three healthy female Beagle 
dogs (24-26 months) were obtained from Marshall BioResources (North 
Rose, NY, U.S.A). Dogs were quarantined and habituated to laboratory 
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conditions for at least 5 days. The dogs were housed individually (one dog/
pen: 1.2 m2 floor area). Sniff Hd-H diet (ssniff, Spezialdiäten GmbH, Soest, 
Germany) was offered daily (300 gram/dog) and dogs had unlimited access to 
water. The dogs were fasted for at least 12 hours before the treatments. On the 
treatment days, food was distributed approximately 4 hours after treatment 
administration.
The repeated-dose toxicology and toxicokinetics study in cynomolgus 
monkeys was performed by SNBL USA, Ltd. (Everett, WA, USA). Purpose-
bred, healthy, naïve, cynomolgus monkeys (2-6 years old) were supplied by 
Tian Hu Cambodia Animal Breeding Research Center or SNBL USA SRC 
(Alice, Texas, USA) and originated from Cambodia. Animals were housed 
in cages that comply with the Animal Welfare Act and recommendations set 
forth in the Guide for the Care and Use of Laboratory Animals (National 
Research  Council 2011). Monkeys were offered PMI’s LabDiet® Laboratory 
Fiber-Plus® biscuits twice a day and drinking water was provided ad libitum. 
In addition, animals were given fruits and vegetables. An overview of the 
experiments is provided in Table 1. These studies are reported according to 
ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines.
Ethical approval
Study protocol approval was obtained from the appropriate governing 
institutes: PEI/001/4557-4/2014 for the rat study (ATRC Animal Ethics 
Committee), XIV-I-001/288-4/2012 for the beagle dog study (ATRC 
Animal Ethics Committee), and 78615-02 for the cynomolgus monkey study 
(IACUC at SNBL USA).
Study medication
Generation of the murine monoclonal antibody HAM1101 directed against 
the N-terminus of Adrenomedullin has been described previously18,19. A 
humanized recombinant monoclonal antibody (HAM8101;IgG1) was 
generated from this murine monoclonal antibody by CDR grafting and 
produced in Chinese hamster ovary cells. HAM8101 was produced by 
Glycotope Biotechnology GmbH (Heidelberg, Germany) under Good 
Manufacturing Practice (GMP) conditions, and this antibody is known under 
the name Adrecizumab. The antibody was kindly provided by Adrenomed 
AG (Hennigsdorf, Germany) in stock solutions in PBS and were stored at 
2-8 °C under temperature-controlled and restricted access conditions. Vehicle 
solution consisted of 20 mM L-histidine monohydrochloride monohydrate 
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(Sigma, Munich, Germany for rats; JT Baker #K21603 for non-human 
primates) in water for injection (Teva Pharmaceuticals Works PLtd. Co., 
Petach Tikva, Israel), pH 6.0. For all groups of rats that were administered 
Adrecizumab, the drug was diluted with vehicle solution (in a vehicle to 
Adrecizumab ratio of 3:1 and 1:1 for the 100 mg/kg and 200 mg/kg doses, 
respectively), except for the 400 mg/kg/day dose (which was ready to use). 
The study drugs were applied in a volume of 20 mL/kg.
Repeated-dose toxicology and toxicokinetics in rats
Previous, less extensive studies (summarized in the Supplementary Methods) 
were performed to assess acute toxicity (rat pilot study 1 and 2), as well as 
repeated dose toxicity (rat pilot study 3). Briefly, acute toxicity of Adrecizumab 
was tested up to 800 mg/kg, a dose which was found to be safe. In the 
repeated dose study with administration of up to 400 mg/kg Adrecizumab 
Study Purpose
Animal species 
and total 
number
Dosage(s) tested Route of administration
Repeated-dose  
toxicology and 
toxicokinetics 
in rats
14-day toxicology Wistar rats (n=80)
Vehicle (n=20)
100 mg/kg/day (n=20)
200 mg/kg/day (n=20)
400 mg/kg/day (n=20)
I.v. repeated-
dose via tail 
vein on day 1, 
4, 8 and 14
14-day toxicology 
with
28-day recovery 
period
Wistar rats 
(n=20)
Vehicle (n=10)
400 mg/kg/day  (n=10)
Toxicokinetic satellite 
animals
Wistar rats 
(n=60)
Vehicle (n=6)
100 mg/kg/day (n=18)
200 mg/kg/day (n=18)
400 mg/kg/day (n=18)
Repeated-dose  
toxicology in 
beagle dogs
14-day toxicology 
with
21-day recovery 
period
Beagle dogs 
(n=3)
Vehicle (day 1)
2 mg/kg (day 3)
10 mg/kg (day 5 and 29)
50 mg/kg (day 8)
I.v. via vena 
cephalica 
antebrachii
Repeated-dose  
toxicology and 
toxicokinetics 
in cynomolgus 
monkeys
14-day toxicology Cynomolgus monkeys (n=24)
Vehicle (n=6)
25 mg/kg/day (n=6)
50 mg/kg/day (n=6)
100 mg/kg/day (n=6)
I.v. via 
cephalic vein,  
repeated-dose 
on day 1, 4, 8 
and 14
14-day toxicology 
with
28-day recovery 
period
Cynomolgus 
monkeys (n=8)
Vehicle (n=4)
100 mg/kg/day (n=4)
Table 1. Overview of animal studies.
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(via the jugular vein) on 4 consecutive days, 4 of 79 animals showed serious 
deterioration of physical condition, 2 of which were sacrificed. Due to the 
fact that there was no dose-dependent relationship and that deterioration 
also occurred in one of the control group animals, these effects were deemed 
unlikely related to Adrecizumab administration. Because permanent 
cannulation of the jugular vein may have attributed to the observed effects, 
the decision was taken to use tail vein catherization for future studies. In the 
present work, to assess early (14-day) toxicology, 80 healthy Wistar rats were 
randomly allocated to 4 groups (n=20 each, divided equally by sex) to receive 
either vehicle or 100, 200 or 400 mg/kg Adrecizumab by i.v. administration 
over a 1-hour period via the tail vein on days 1, 4, 8 and 14. To assess late 
toxicology, 20 additional ‘recovery animals’ received either vehicle or 400 mg/
kg Adrecizumab on the same days (n=10 each, divided equally by sex) and 
were followed-up for an additional period of 28 days after the last infusion 
for a total of 42 days. Finally, for determination of toxicokinetics, 60 satellite 
animals were randomly assigned to 4 groups (divided equally by sex) to receive 
either vehicle (n=6) or 100, 200 or 400 mg/kg Adrecizumab (n=18 each).
Please refer to Figure 1 for a detailed overview of the study procedures and 
endpoints. All animals were observed for general signs of illness, appearance, 
behavior, mental status, body weight, food consumption, appearance of urine 
and stools, genitals, and death. Additional observations in early toxicology 
groups (5 animals of the vehicle control group and 5 animals of the 400 
mg/kg group) included the modified Irwin test. Ophthalmological evaluation 
using split microscopy (PanOptic Ophthalmoscope, Welch Allyn, Skaneateles 
Falls, NY, USA) was performed in both early toxicology and recovery animals. 
Urine analysis included visual inspection, microscopic examination of urine 
sediment and automated analysis with test strips (Medi-Test URYXXON Stick 
10) and the URYXXON® 300 analyzer (Machery-Nagel GmbH & Co. KG, 
Düren, Germany). Blood analyses included parameters of hematology, blood 
coagulation and biochemistry using a Sysmex XT-200-iV analyzer (Sysmex 
Corporation, Kobe, Japan), AMAX Destiny Plus coagulator (Trinity Biotech 
Plc, Bray, Ireland) and Konelab 60i analyzer (Thermo Fischer Scientific, 
Waltham, Ma, USA), respectively. Differential white blood cell evaluation 
was done with light microscopy if automated determination was not feasible. 
Plasma lymphocyte (sub)populations were phenotyped in the short-term (14-
day) toxicology animals using flow cytometry (BD FACSCalibur, Beckton 
Dickinson, Franklin Lakes, NJ, USA). Plasma cytokine analysis was performed 
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in the vehicle and 400mg/kg/day 14-day toxicology animals only, using a 
Rat Cytokine 10-Plex Panel Assay Kit (Invitrogen, Carsbad, CA, USA) on a 
xMAP® system (Luminex, Austin, TX, USA). Animals were sacrificed by rapid 
exsanguination under deep isoflurane anesthesia on day 15 or 43, followed by 
macroscopic and histopathological examinations by a pathologist.
Blood collection in toxicokinetic satellite animals was performed at various 
time points on days 1 and 14 following first and last infusions, respectively, 
via the retro-orbital plexus (blood from 3 animals per time point, max. 3 
samples per animal). Toxicokinetic satellite animals were sacrificed on the 
day after the last infusion using cervical dislocation under deep isoflurane 
anesthesia and were not further examined.
Repeated-dose toxicology in telemetered conscious beagle dogs
To assess toxicological and cardiovascular effects of Adrecizumab, 3 female 
beagle dogs received a single i.v. dose of vehicle on day 1, 2 mg/kg Adrecizumab 
on day 3, 10 mg/kg Adrecizumab on day 5, 50 mg/kg on day 8, and 10 mg/
kg on day 29 (after a 14-day recovery period), which was followed by an 
additional follow-up period of 22 hours after the last infusion. Treatment was 
administered via the vena cephalica antebrachii.  In order to monitor blood 
pressure and heart rhythm, a telemetric device was implanted (DSI’s telemetry 
system, with PhysioTel® MultiplusTM implants), which was operated via 
validated Dataquest A.R.T. software 4.0 (for the recording of all data and 
analysis of blood pressure).
Please refer to Figure 2 for a detailed overview of the study procedures and 
endpoints. Clinical observations were recorded at least twice daily on treatment 
days and at least once daily on treatment-free days with special regard to 
behavior, coat, urine and fecal excretion, condition of body orifices and any 
signs of illness. Measurement of body weight was performed at least once 
during acclimatization and on each treatment day. Blood pressure (systolic, 
diastolic and mean) was measured before and at several timepoints after study 
drug administration on day 1 (vehicle), day 3 (2 mg/kg Adrecizumab), day 5 
(10 mg/kg Adrecizumab) and day 8 (50 mg/kg Adrecizumab). In addition, 
recordings were checked for arrhythmias.
Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and 
non-human primates
11
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 231
231
Figure 1. Study procedures of the repeated-dose toxicology and toxicokinetics study in 
rats. A. Only done in the first 5 male and female rats of the vehicle and 400 mg/kg/day 
group of the early toxicology group, prior to administration and at 3 time points after the 
first and last infusions (0.5h, 1.5h and 4h). B. Examination included cornea, conjunctiva, 
episcleral vessels, anterior chamber, pupil, lens, retina and optic disc. C. Leukocytes, nitrite, 
pH, glucose, urobilinogen, bilirubin, ketones, erythrocytes, protein, specific gravity, visual 
inspection, sediment (microscopic) and volume. D. Leukocytes and differential leukocyte 
count, erythrocytes, hemoglobin, hematocrit, mean corpsular volume, mean corpsular 
hemoglobin, mean corpsular hemoglobin concentration, platelets and reticulocytes. E. 
Prothrombin time and activated partial thromboplastin time. F. Alanine aminotransferase 
activity, aspartate aminotransferase activity, alkaline phosphatase, bilirubin, creatinine, 
urea, glucose, cholesterol, triglycerides, inorganic phosphates, calcium, sodium, potassium, 
chloride, albumin, total protein and albumin/globulin ratio. G. Total T lymphocytes 
(CD3+), T-helper (CD3+, CD4+), T-cytotoxic (CD3+, CD8a+), NK-T cells (CD3+, NKR-
P1A+), T-activated (CD3+, CD25+), NK cells (CD3-, NKR-P1A+) and B lymphocytes 
(CD45RA+). H. IL-1 beta, IL-2, IL-4, IL-6, IL-10, IL-12, TNF-alpha, IFN-gamma, GM-
CSF. Only done in vehicle treated control and 400 mg/kg/day animals, 8 hours after the first 
study drug administration. Blood was drawn from the retro-orbital plexus. I. A complete 
necropsy was performed with macro- and microscopic evaluation. J. Satellite groups of 
animals were included for toxicokinetics. Blood was drawn from a total of 9 time-points 
(pre-value, 5m, 15m, 30m, 1h, 2h, 4h, 8h and 24h) after the first and last administrations. At 
each time point, blood was collected from 3 animals per group with a maximum of 3 samples 
per animal. Blood was collected from the retro-orbital plexus.
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Figure 2. Study procedures of the repeated-dose toxicology in telemetered conscious dogs.
Repeated-dose toxicology and toxicokinetics in cynomolgus monkeys
A previous, less extensive study in 4 animals (summarized in Supplementary 
Methods) was performed to assess acute toxicity after a single dose of 50 mg/
kg (n=1) and 100 mg/kg (n=1), as well as repeated-dose toxicity of 100 mg/kg 
on 2 days (in n=2 animals). No mortality or other adverse effects were observed 
for all tested doses. In the present work, the toxicity and toxicokinetics of 
repeated Adrecizumab administration on separate days over a 14 day period 
were investigated in cynomolgus monkeys (see Table 1 for the study design 
and Figure 3 for an overview of study procedures and outcomes). To assess 
early toxicology, 12 male (2 to 4 years old) and 12 female (2 to 6 years old) 
naïve cynomolgus monkeys were randomly (in a weight-stratified manner) 
assigned to receive repeated-dose infusion of vehicle or Adrecizumab (25, 50 
or 100 mg/kg/day, n=6 each, divided equally by sex) via a peripheral vein on 
days 1, 4, 8 and 14. To assess late toxicology, 8 additional ‘recovery animals’ 
received either vehicle or 100 mg/kg Adrecizumab on the same days (n=4 
each, divided equally by sex) and were followed-up for an additional period of 
28 days after the last infusion for a total of 42 days. Animals were acclimated 
to the study room for 14 days prior to dosing on day 1.
The following parameters were assessed: Mortality and clinical observation, 
body weight, food consumption (per social group of animals), neurological 
observations, blood pressure (collected under ketamine sedation by BAS 
Vetronics – Vital Scan Monitor), respiratory rate (under ketamine sedation), 
electrocardiography (under ketamine sedation, using Ponemah Physiology 
Platform Software, Version 5.2, Data Services International), ophthalmology 
(under ketamine sedation, using indirect ophthalmoscope and slit lamp 
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Figure 3. Study procedures of the repeated-dose toxicology and toxicokinetics study in 
cynomolgus monkeys. A. Neurological examination included stimulus response, behavior, 
gait, brachiation, posture, grasp, activity level, balance, conjugate movement, position and 
pupil reactivity. B. Electrocardiography (ECG) included RR and PR interval, QRS duration, 
QT interval and Bazett’s corrected QT interval (QTc), heart rate (HR), measured over a time 
period of at least 5 consecutive cardiac beats at each time point. C. Urine chemistry included 
bilirubin, clarity, color, glucose, ketones, leukocytes, nitrites, occult blood, pH, protein, 
specific gravity, urobilinogen, volume, sodium, potassium, chloride and creatinine. D. 
Hematological parameters included hematocrit, hemoglobin, mean corpuscular hemoglobin, 
mean corpuscular hemoglobin concentration, mean corpuscular volume, mean platelet 
volume, platelets, red blood cells, red cell distribution width, reticulocytes absolute & percent, 
white blood cells and differential leukocyte count (absolute). E. Serum chemistry included 
alanine aminotransferase, albumin, albumin/globulin ratio, alkaline phosphatase, aspartate 
aminotransferase, blood urea nitrogen, calcium, chloride, creatine kinase, creatinine, gamma 
glutamyltransferase, globulin, glucose, inorganic phosphorus, potassium, sodium, total 
bilirubin, total cholesterol, total protein, triglyceride, IgG. F. Coagulation included activated 
partial thromboplastin time, fibrinogen and prothrombin time (PT). G. Flow cytometric 
lymphocyte phenotyping was conducted on isolated leukocytes using antibodies to CD3, 
CD4, CD8, CD16, CD20, CD25, and CD69. Populations included total T cells, T helper 
cells, T cytotoxic cells, regulatory T helper cells, natural killer (NK) cells, B cells, activated 
T cells, activated NK cells and activated B cells. H. Blood gas analyses included lactate, 
pH, PCO2, PO2, TCO2, HCO3, Base Excess, sO2 (oxygen saturation). I. Cytokines were 
determined in the 100 mg/kg/day group only and included IL (interleukin)-1ȕ, IL-2, IL-4, 
IL-6, IL-8, IL-10, IL-12, IFNȖ (interferon gamma) and TNFƠ (tumor necrosis factor alpha).
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microscopy, with topical administration of mydriatics). Clinical pathology 
included urinalysis (collected using urine pans placed beneath animal cages 
on the evening before collection, analyzed using Clinitek Advantus, AU680 
automated analyzer, Sper Refractometer and manual/visual inspection), 
hematology (1.3 mL blood collected in K2EDTA-containing tubes, analyzed 
using Advia 120 automated analyzer or manually using an Olympus 
microscope), coagulation (1.8 mL blood in 3.2% sodium citrate-containing 
tubes, analyzed with a STACompact automated analyzer), serum chemistry (1 
mL blood in serum separator tubes, analyzed using an AU 680 analyzer) and 
blood gas (0.3 mL blood analyzed using a Marquest™ Gaslyte® syringe system 
from the femoral artery or tail artery), immunoglobulin E (IgE, 0.5 mL blood 
in serum separator tubes, analyzed by ANTECH GLP using an ELISA method 
developed and validated by ANTECH GLP), lymphocyte phenotyping (1-2 
mL blood collected in K3EDTA-containing tubes, analyzed in a FACSCanto™ 
II flow cytometer running FACSDiva™ acquisition software [version 6.1.3]), 
and cytokines (1 mL blood collected in serum separator tubes). Serial blood 
samples for toxicokinetics were collected at specified timepoints on days 1 
and 14. Animals were sacrificed on day 15 (early toxicity) or 42 (recovery 
animals) by intravenous injection of Euthanasol, a commercially available 
euthanasia solution while sedated, followed by exsanguination, macroscopic 
and histopathological examinations by a pathologist. 
Toxicokinetic evaluation in rats and monkeys
Approximately 0.5 mL was collected in K2EDTA-containing tubes and 
stored below -60 to -86 oC until batchwise analyses. The toxicokinetic 
analysis was performed by ATRC Aurigon Toxicological Research Center 
Ltd. (Dunakeszi, Hungary) using validated Phoenix WinNonlin Version 6.3 
(Pharsight Corporation, USA). Unbound Adrecizumab was quantified in the 
samples using a validated luminescence immunoassay with a quantification 
limit of 0.797 ȝg/mL. Plasma concentration-time curves were evaluated 
using non compartmental method. The following parameters were calculated 
from the measured data: Maximum observed plasma concentration (Cmax), 
last quantifiable concentration (Clast), time of maximum observed plasma 
concentration (Tmax), time at last quantifiable concentration (Tlast), terminal 
elimination half-life (t1/2), dose normalized Cmax (Cmax/dose), area under 
the plasma concentration-time curve from time zero up to 24 hours (AUC0-
24h) and dose normalized AUC0-24h (AUC0-24h/dose). AUC values were 
calculated by linear trapezoidal integration. The accumulation ratio Racc was 
calculated from the mean AUC0-24h values as follows: Racc = AUC0-24h on 
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day 14 / AUC0-24h on day 1. In rats, there were not enough data to calculate 
terminal elimination half-life. 
Adrenomedullin measurements
The ADM assay was performed as described previously7. As ADM is highly 
conserved across mammalian species, the same assay was used for both species. 
Briefly, plasma ADM concentrations (including both free and Adrecizumab-
bound ADM) were measured by a sandwich coated luminescence immunoassay, 
based on acridinium NHS-ester labeling and anti-ADM antibodies (solid 
phase antibody targeting the mid region of ADM and a labeled antibody 
against the amidated C-terminal region of ADM). Dilutions of ADM and 
labeled tracer were subsequently added to antibody-coated wells. After 
washing of unbound tracer, chemiluminescence was measured and evaluated 
against a standard curve. 
Statistical analysis
Data are presented as mean and standard deviation or as median and 
interquartile rate depending on its distribution. Statistics were performed 
using the SAS package for Windows (SAS Institute Inc., Cary, NC, USA), 
version 6.12. In addition, analyses were performed separately for each sex. 
Data from early toxicology and recovery animals were combined at each 
shared scheduled time-point up to the terminal necropsy. A two-tailed 
p-values <0.05 were considered statistically significant. 
For the rat study, the Shapiro-Wilk test was performed to test the normality and 
homogeneity of the variance of two groups. In case the Shapiro-Wilk test was 
negative, the F-test was used in order to determine which of the three types of 
t-tests had to be employed. If the F-test indicated homogenous variances, the 
Student’s t-test was used. If the F-test was significant and the two groups had 
an equal numbers of data, the Satterthwaite t-test was performed. If the F-test 
was significant and the number of data within the groups was not equal, the 
Cochran t-test was used. For non-parametric data, the Wilcoxon rank-sum 
test was applied. When analyzing more than two groups, the homogeneity of 
the group variance was analysed using Bartlett’s test. In case of homogeneous 
variances, one-way ANOVA was used, with a Dunnett post-hoc test if the 
ANOVA was significant. In case of inhomogeneous variances, the Kruskall-
Wallis test was used, with non-parametric multiple comparisons (by Gad and 
Weil) in case the Kruskall-Wallis test was significant. For the beagle dog and 
cynomolgus monkey studies, no statistical analyses were performed due to 
small group sizes. 
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Results
Repeated-dose toxicology and toxicokinetics in rats
Mortality and clinical findings 
Repeated intravenous infusion of Adrecizumab on 4 separate days at doses of 
100, 200, and 400 mg/kg body weight per day did not result in mortality. The 
most notable observed clinical sign was a red discoloration of urine (Table 
S1), which could be observed in all vehicle-treated animals on all 4 infusion 
days, and in a total of 6 animals of the 100 mg/kg/day dose group on the 
first infusion day only. This finding was not observed in the 200 and 400 
mg/kg/day groups, and was attributed to the vehicle (further elaborated on 
in the discussion). The only other clinical finding was observed in 1 male rat 
from the 200 mg/kg/day dose toxicokinetics group (Table S1C), and was 
considered to be unrelated to Adrecizumab. The rat showed decreased activity 
and body weight, porphyrin around nose and eyes, piloerection, pale mucosa 
and skin from day 8 to day 14.
Body weight and food intake
Body weight of all rats increased normally throughout the study period and 
was statistically (but not relevantly) different only for male rats treated with 
100 mg/kg Adrecizumab compared to vehicle treated rats (Figure 4A). Food 
consumption was also not significantly affected by Adrecizumab (Figure 4B).
Modified Irwin test
Sensory reactivity to different stimuli (auditory, visual and proprioceptive), as 
well as qualitative assessment of grip strength and motor activity in the high 
dose animals (400 mg/kg/day) did not show any deviation from the vehicle 
group (data not shown). No significant differences were observed in body 
temperature (data not shown).
Ophthalmology
Ophthalmological examination using a slit light ophthalmoscope revealed no 
abnormalities at baseline, 14 and 42 days after the first study drug infusion 
(Table S2).
Hematology
In male rats, RBC and MCV were statistically significantly increased in 
the 200 and 400 mg/kg/day dose groups (Table 2). Hb, Ht and absolute 
lymphocyte numbers were significantly increased in the 400 mg/kg/day dose 
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Figure 4. Bodyweight and food consumption in rats. Data are expressed as mean ± SD. Grey 
dots indicate days on which study drug was administered (day 1, 4, 8 and 14).
group. Absolute and relative numbers of reticulocytes were significantly lower 
in all Adrecizumab groups. In female rats, RBC, Hb and Ht were significantly 
increased in all Adrecizumab groups, and MCV, MCH, as well as MCHC 
were significantly increased in 100 and 200 mg/kg/day dose groups (Table 
2). The absolute numbers of reticulocytes were significantly increased in 200 
and 400 mg/kg/day dose groups, and the relative number of reticulocytes 
were significantly increased in all Adrecizumab groups. In the 400 mg/kg/
day female recovery animals, RBC and HT were significantly increased on 
day 43. All values were within the normal range and therefore considered 
toxicologically irrelevant.
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Clinical chemistry and coagulation
In both male and female rats treated with Adrecizumab, significantly higher 
total protein concentrations in plasma were observed (Table 3). In addition, 
a (dose-dependent) decrease of the albumin/globulin ratio (A/G) indicated 
that the increase of total protein concentrations was due increased levels of 
(immuno)globulins, since albumin remained unchanged. In a few cases, 
statistical analysis showed significant changes in other parameters (e.g. 
ALT and AST in males and ALT in females on day 15), although these 
differences between the vehicle and Adrecizumab groups were caused by the 
relatively lower values of the vehicle animals and not by increased values in 
Adrecizumab-treated animals. All values were within the normal range and 
therefore considered toxicologically irrelevant.
Coagulation parameters were not relevantly influenced by Adrecizumab 
(Table 3). All parameters were within the normal range of variation, and only 
one significant difference was observed (PT: 22 ± 0.6 seconds in the vehicle 
group versus 21 ± 0.7 and 21 ± 0.7 seconds in the 200 and 400 mg/kg/day 
dose groups, respectively; both p<0.05).
Urinalysis
Urine parameters were not relevantly influenced by Adrecizumab (Table S3). 
A slightly lower volume of urine and higher specific gravity was observed in 
Adrecizumab-treated male rats on day 15, and a slightly higher specific gravity 
was also observed in 400 mg/kg/day treated female rats. However, all findings 
were within the normal range of variance for the species and therefore not 
considered toxicologically relevant. 
Plasma lymphocyte phenotyping and plasma cytokines
Neither lymphocyte subpopulations (Table S4), nor plasma cytokine 
concentrations (Table S5) were relevantly influenced by Adrecizumab. Note 
that most cytokines remained below the quantification limit, and therefore 
did not relevantly increase. Concentrations within the quantification limits 
were only observed for IL-2 and IL-12 and did not differ between groups. 
Necropsy and histopathology
Necropsies with macroscopic observation, weighing of organs and 
histopathological examination by a pathologist were performed in toxicological 
animals (animals were sacrificed on day 15 or day 43). All macroscopic 
findings were considered unrelated to Adrecizumab (Table S6). Red areas 
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were observed in the lungs of both all groups, including control animals, 
but considered to be the consequences of deep anesthesia (since animals 
were sacrificed by induction of deep isoflurane anesthesia, followed by rapid 
exsanguination). Organ weight (absolute and relative) did only differ in a 
few cases which were considered incidental and without biological relevance 
(Table S7). 
Histopathological examination did not reveal any effects that were considered 
related to Adrecizumab treatment (Table S8). The microscopic abnormalities 
that were observed at the site of administration were generally considered 
to be procedural in origin. However, a local irritative effect caused by the 
treatment could not be fully excluded because blood clot or fibrin precipitate 
was seen in the vein lumen of animals treated with 200 and 400 mg/kg/day, 
and because recanalisation of organized vein lumen was observed in one 400 
mg/kg/day recovery animal. 
Toxicokinetics
Plasma Adrecizumab concentration time-profiles of male and female rats 
are depicted in Figure 5, and toxicokinetic parameters are listed in Table 
S9. None of the samples collected from vehicle-treated animals contained 
detectable Adrecizumab concentrations, indicating that there was no cross-
contamination between the vehicle and Adrecizumab-treated groups (vehicle 
group data not shown). In all three dose groups, the Cmax was attained almost 
immediately after termination of infusion.  The dose-normalized maximum 
concentrations (Cmax/dose) and dose-normalized AUC0-24h (AUC0-24h/
dose) showed dose-proportionality on day 1, but not after the 4th infusion on 
day 14. The disappearance of Adrecizumab from the circulation was very slow 
for all doses (Figure 5) The accumulation ratio (Racc) was dose-proportional 
in the 100 (1.73 and 1.85 for males and females, respectively) and 200 mg/
kg/day group (1.97 and 1.60 for males and females, respectively), but slightly 
sub-proportional in the 400 mg/kg/day group (1.33 and 1.38 for males and 
females, respectively).
Circulating adrenomedullin concentrations
Administration of Adrecizumab resulted in a rapid and dose-dependent 
increase of circulating levels of total ADM (the assay detects both free and 
Adrecizumab-bound ADM; Supplementary Figure 1).
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Figure 5. Toxicokinetics in rats. Grey dots indicate days on which study drug was administered 
(day 1, 4, 8 and 14). Data are expressed as mean ± SD.
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Repeated-dose toxicology in telemetered conscious dogs
Mortality and clinical findings
No mortality was observed during this study. Also, no clinical findings were 
observed after the first four treatment administrations on days 1 (vehicle), 
3 (2 mg/kg), 5 (10 mg/kg) and 8 (50 mg/kg). However, after the fifth and 
final treatment (10 mg/kg on day 29), several transient clinical findings were 
observed, including weakness (3 animals), moderately decreased activity (2 
animals), preference for lying position (2 animals), vomiting (2 animals), 
spontaneous defecation (2 animals) and spontaneous urination (1 animal). 
Specifics are detailed in Table S10. All animals recovered within 24 hours.
Body weight 
Body weight did not appear changed during the course of the study 
(Supplementary Figure 2).
Blood pressure and heart rhythm
There appeared to be no changes in blood pressure parameters (systolic, 
diastolic and mean blood pressure [MAP]) after any of the treatments (MAP 
shown in Figure 6). No arrhythmias were observed.
Figure 6. Blood pressure in Beagle dogs. Data are expressed as mean ± SD. The first 22 hours 
after treatment administration of the 4 respective doses are shown, on day 1, 3, 5 and 8.
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Repeated-dose toxicology and toxicokinetics in cynomolgus monkeys
Mortality and clinical findings
Repeated intravenous infusion of Adrecizumab on 4 separate days at doses 
of 25, 50, and 100 mg/kg/day body weight did not result in mortality, nor 
were there any study drug-related effects on clinical observations (Table 
S11). Incidences of hair loss, scabs/crust, abnormal skin color, abrasions and 
bruising were observed in various groups, including vehicle control animals. 
Additional observations of soft/liquid feces and red discharge (nostril, anus, 
urogenital area) were limited in duration, sporadic in nature and presented 
in various groups, including vehicle groups or in acclimation. A relationship 
to Adrecizumab was thought to be unlikely due to the sporadic nature of 
the observations, presence in the vehicle group and/or prior to treatment 
initiation, the limited number of animals involved and the lack of a dose-
response relationship.
Body weight and food intake
There appeared to be no Adrecizumab-related effects on body weight (Figure 
7) or food intake (data not shown; food intake was normal in all animals on 
every study day).
 
Neurological observations
There were no Adrecizumab-related effects on the neurological tests performed 
(Table S12). Neurological observations were normal, except for one female 
in the 25 mg/kg/day group who presented with head tilt before treatment 
administration and on day 15. 
Electrocardiography
There were no Adrecizumab-related effects on ECG parameters. All ECGs 
were quantitatively within normal limits (Table S13) and not affected by 
Adrecizumab. One female animal from the 50 mg/kg/day group showed a 
right bundle branch block pattern before treatment administration and on 
day 14 (which is a normal variant in primates). One animal from the 100 
mg/kg/day had 10 ventricular premature complexes on day 14 (a sporadic 
finding that is likely not related to Adrecizumab; this is observed in low 
incidence in cynomolgus monkeys). No other arrhythmias were observed. 
No Adrecizumab-related effects on the RR, PR, QRS, QT intervals, or QTc 
were found at any dose levels based on comparison of predose and postdose 
group values (Table S13). 
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Figure 7. Bodyweight in cynomolgus monkeys. Data are expressed as mean ± SD. Grey dots 
indicate days on which study drug was administered (day 1, 4, 8 and 14).
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Blood pressure and respiratory rate
There were no Adrecizumab-related effects on systolic and diastolic blood 
pressure or on respiratory rate (Table S14). 
Ophthalmology
There were no Adrecizumab-related effects noted in ophthalmology 
examinations. Three animals had lesions that were already present before 
treatment administration, which were unchanged on day 14 and therefore 
not considered Adrecizumab-related (1 male animal from the 25 mg/kg/day 
group: anterior and posterior punctuate cataract in both eyes, 1 female animal 
from the 25 mg/kg/day group: moderate retinal vessel tortuosity in both 
eyes, and 1 female animal from the 100 mg/kg/day group: mild temporal 
optic nerve atrophy in both eyes). Punctate posterior and/or anterior cortical 
cataracts are seen frequently in mature cynomolgus monkeys as is the 
spontaneous findings, of varying severity, of temporal optic nerve atrophy. 
The retinal blood vessel tortuosity observed in one animal appeared to be an 
anomalous development.
Clinical pathology
There appeared to be no Adrecizumab-related effects on urinalysis (Table 
S15), hematology (Table 4), serum chemistry and coagulation (Table 5), 
as well as blood gas parameters (Table S16). One female animal from the 
50 mg/kg/day dose group exhibited low platelets (55 * 103/ȝL) and a low 
neutrophil count (0.18 * 103/ ȝL) on day 15, however, similar findings 
were not observed in any of the remaining animals, and therefore this was 
considered a coincidental finding, likely due to preanalytical factors.
Serum chemistry findings (Table 5) prior to study drug administration and 
on day 15 included increases of AST, ALT and CK, in animals from all 
groups, including the vehicle group. These increases were not observed on 
day 41 in recovery animals. The coordinated nature of these findings and 
predominant increase in CK and AST are suggestive of skeletal muscle injury 
common to restraint and sampling. Additional variations were inconsistently 
observed during acclimation and on day 14 in blood gas parameters, which 
were considered procedural and not Adrecizumab-related.
Lymphocyte phenotyping and cytokines
There appeared to be no Adrecizumab-related effects on flow cytometry 
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parameters (Table S17A and B). Intra-group variability was observed in all 
groups for T cells (including T helper, T cytotoxic, T regulatory), B cells, and 
NK cells (including the activated subset) over the course of the study and 
therefore no consistent change in relationship to Adrecizumab administration 
was observed for the parameters analyzed.
Cytokines
Treatment with 100 mg/kg/day Adrecizumab did appear to not affect plasma 
cytokine levels (Table S18). No relevant changes were observed in the levels 
of IL-2, IL-6, IL-8, IL-12 and IFNȖ.
Antibody-formation (IgE)
There were no apparent Adrecizumab-related effects on serum levels of IgE 
(Table S19). Total IgE exhibited intra- and inter- group variability, and the 
highest total IgE levels were observed in individual vehicle group animals. 
There were no dose-related effects.
Pathology
There were no Adrecizumab-related effects on gross pathology (Table S20), 
organ weights (Table S21) and histopathological evaluation (Table S22). 
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Toxicokinetics
Plasma Adrecizumab concentration time-profiles of male and female monkeys 
are presented in Figure 8, and toxicokinetic parameters are depicted in Table 
S23. None of the samples collected from vehicle treated animals contained 
detectable Adrecizumab, indicating that there was no cross-contamination 
between the vehicle and Adrecizumab-treated groups (data not shown). 
Plasma kinetics of Adrecizumab was not influenced by gender.  In all three 
dose groups, the Cmax was attained virtually immediately after termination 
of infusion. The dose-normalized maximum concentrations (Cmax/dose) and 
dose-normalized AUC0-24h (AUC0-24h/dose) showed dose-proportionality 
on days 1 and 14. The resulting rate of accumulation (Racc) was approximately 
2. Adrecizumab was slowly eliminated from the circulation. The apparent 
elimination half-lives (T1/2) were calculated in a follow-up period of 72 hours 
after the first dose administration, and in the period of 24 hours of follow-up 
after the final dose administration. This resulted in T1/2 of approximately 
80 and 40 hours, respectively. However, because there appeared to be a more 
rapid elimination phase in the first 6 hours post dose administration, and 
the follow-up period for the final dose administration was only 24 hours, 
the latter half-life may be less reliable. Due to uncertainty of the half-life 
determination, the weak fitting for a part of the curves and extremely high 
extrapolations to infinity, the AUC0-inf should not be viewed as a reliable 
parameter.
Circulating adrenomedullin concentrations
Administration of Adrecizumab resulted in a rapid and dose-dependent 
increase of circulating levels of total ADM (the assay detects both free and 
Adrecizumab-bound ADM; Supplementary Figure 3).
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Figure 8. Toxicokinetics in cynomolgus monkeys. Grey dots indicate days on which study 
drug was administered (day 1, 4, 8 and 14). Data are expressed as mean ± SD.
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Discussion
In the present study, we report the toxicological profile and toxicokinetics 
of Adrecizumab in rodents, dogs and non-human primates during and after 
repeated-dose administration over a period of 14 days. Adrecizumab was 
well tolerated in doses of up to 400 mg/kg/day in Wistar rats, 50 mg/kg in 
beagle dogs and 100 mg/kg/day in cynomolgus monkeys (note that these 
no-observed-adverse-effect-levels [NOAEL] are 200, 25 and 50 times greater 
than the intended therapeutic dose of 2 mg/kg in humans). No toxicologically 
significant alterations could be attributed to Adrecizumab. Toxicokinetic 
analysis revealed that peak concentrations were attained almost immediately 
upon cessation of Adrecizumab administration, that peak concentrations 
and area-under-curve increased in a dose-proportional manner, and that 
accumulation ratios of Adrecizumab were fairly consistent. 
Toxicology
Previously published efficacy experiments with a murine variant of the 
Adrecizumab antibody in mice did not show any safety concerns, although in 
this study only single doses were applied18. In the present work, no mortality 
or moribund conditions were observed in any of the animals. Furthermore, 
no Adrecizumab-related changes in any of the safety parameters (including 
vital signs, electrocardiography, ophthalmology, urinalysis, extensive blood 
analysis and [histo]pathological evaluation) were thought to be toxicologically 
significant due to lack of any clear indications of clinical adversity and 
the absence of dose-response relationships. Adrecizumab neither induced 
blood pressure alterations, nor arrhythmias. In the rat study, transient red 
discoloration of urine was observed in all vehicle-treated rats as well as in 6 
animals treated with 100 mg/kg Adrecizumab, but not in 200 and 400 mg/
kg groups. It appears most likely that transient hemolysis was responsible 
for the red discoloration of the urine, based on hypo-osmotic effects of the 
water for injection used to dissolve L-histidine (vehicle) powder, because 
this practically constitutes distilled water (i.e. with no electrolytes). Vehicle-
treated animals only received this L-histidine/water for injection solution, 
while the 100 and 200 mg/kg groups received a mixture of the L-histidine/
water for injection solution and Adrecizumab solution (in a 3:1 and 1:1 ratio, 
respectively). The 400 mg/kg group only received Adrecizumab solution. 
Since Adrecizumab was dissolved in PBS, and therefore less hypo-osmotic, 
this may have counterbalanced the hypo-osmotic effects of the water for 
injection. This may explain why the red discoloration of urine was observed 
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in all vehicle-treated groups (often classified as ‘mild’), while only in a few 
animals of the 100 mg/kg groups (classified as ‘slightly’) and in none of the 
animals of the 200 or 400 mg/kg groups.
Toxicokinetics
Adrecizumab was administered intravenously on 4 separate occasions over a 
14 day period. Toxicokinetics were analyzed after the first and last infusions. 
Importantly, no gender differences were observed. Peak concentrations were 
observed almost immediately after completion of infusion and increased 
in a dose-proportional manner. Adrecizumab was eliminated slowly from 
the circulation, which is typical for monoclonal antibodies22,23. Repeated 
administration of Adrecizumab resulted in quantifiable plasma levels before 
administration on day 14, and also increased total exposure on day 14. It 
was not possible to investigate half-life in rats because the duration of sample 
collection was limited (samples were only taken during the first 24 hours after 
the first and last Adrecizumab infusion). However, in cynomolgus monkeys, 
samples were taken at a few additional time-points. There appeared to be 
multi-phase elimination, with more rapid elimination over the first 6 hours. 
The elimination half-life in cynomolgus monkeys was 40 hours at 24 hours 
and 80 hours in the second phase at 24-72 hours, respectively. 
Effects on the target peptide adrenomedullin
Interestingly, administration of Adrecizumab resulted in a swift, profound, 
and sustained increase of circulating ADM levels, which is in line with 
previous work and already shown not be the result of increased synthesis 
of the ADM peptide20,21. A mechanistic explanation for this effect was 
recently put forward24. In short, it is hypothesized that excess antibody in 
the circulation drains extravascular ADM from the interstitium into the 
circulation. This relies on the fact that ADM is small enough to easily cross 
the endothelial barrier, whereas the antibody is not, effectively “trapping” 
ADM in the circulation. Because Adrecizumab only marginally inhibits 
ADM signaling, the profoundly increased levels of ADM in the circulation 
(bound to Adrecizumab) are thought to result in an overall, “net”, increase 
of ADM signaling in endothelial cells, thereby enhancing endothelial barrier 
function and reducing tissue edema. Furthermore, it is well known that 
high concentrations of ADM can cause hypotension through effects on 
vascular smooth muscle cells located on the interstitial site of arteries13-15. 
Hence, decreased concentrations of ADM in the interstitium may negate its 
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vasodilatory effects. In this context it is important to emphasize that, despite 
the fact that Adrecizumab administration resulted in very high circulating 
ADM levels in the present study, no effects on blood pressure parameters 
were observed in beagle dogs or cynomolgus monkeys. In human studies21, 
administration of the intended therapeutic dose of Adrecizumab (a single 
dose of 2 mg/kg, a dose for which beneficial effects were observed in both 
published18-20 and unpublished preclinical studies) resulted in immediate 
increases of circulating ADM concentrations of approximately 10- to 30-
fold (during non-inflammatory circumstances and during human endotoxin-
induced inflammation, respectively). This is similar to what was observed for 
animals that were administered 2 mg/kg20, suggesting that this dose may also 
confer beneficial effects in humans.
A strength of the present work is the use of two different animal species and 
repeated administration of high doses of Adrecizumab (significantly higher 
than the intended single dose administration of approximately 0.5 to 8 mg/kg 
in humans). In addition, because the ADM peptide and receptors are highly 
conserved across species, the animals used in the present work are well-suited 
for toxicological evaluation of Adrecizumab. However, several limitations also 
need to be addressed. Although repeated administration of very high doses of 
Adrecizumab represent an excellent method to investigate safety, it may limit 
the translatability of toxicokinetic results to pharmacokinetics of single dose 
administration in humans.
Conclusion
Intravenous, repeated administration of high doses of Adrecizumab was safe 
and well-tolerated in rodents, dogs and non-human primates. In addition, 
Adrecizumab administration resulted in a swift and profound increase of 
circulating concentrations of its target peptide ADM, which is consistent 
with previous preclinical studies and may underpin its purported beneficial 
effects on endothelial barrier, as well as smooth muscle cell dysfunction during 
sepsis. These results pave the way for further investigation of Adrecizumab in 
humans. 
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Supplementary Figure 1. Circulating total adrenomedullin concentrations in rats after the 
first (A) and fourth infusion (B). Data are expressed as mean ± SD.
Supplementary Figure 2. Body weight in Beagle dogs (n=3). Data are expressed as mean ± 
SD. Grey dots indicate days on which study drug was administered (day 1, 3, 5, 8 and 29).
Supplementary Figure 3. Circulating total adrenomedullin concentrations in Cynomolgus 
monkeys after the first (A) and fourth infusion (B). Data are expressed as mean ± SD. 
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Sex Dose group(mg/kg/day)
No. of
animals
Clinical sign in 
no. of animals
Study day
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Male
0 15A
NOA 0 15 15 0 15 15 15 0 15 15 15 15 15 0
Slight red 
discoloration of 
urine
14 0 0 15 0 0 0 15 0 0 0 0 0 15
Moderate red 
discoloration of 
urine
1 0 0 0 0 0 0 0 0 0 0 0 0 0
100 10
NOA 8 10 10 10 10 10 10 10 10 10 10 10 10 10
Slight red 
discoloration of 
urine
2 0 0 0 0 0 0 0 0 0 0 0 0 0
200 10 NOA 10 10 10 10 10 10 10 10 10 10 10 10 10 10
400 15A NOA 15 15 15 15 15 15 15 15 15 15 15 15 15 15
Female
0 15A
NOA 0 15 15 0 15 15 15 0 15 15 15 15 15 0
Slight red 
discoloration of 
urine
0 0 0 0 0 0 0 15 0 0 0 0 0 15
Moderate red 
discoloration of 
urine
15 0 0 15 0 0 0 0 0 0 0 0 0 0
100 10 NOA 10 10 10 10 10 10 10 10 10 10 10 10 10 10
200 10 NOA 10 10 10 10 10 10 10 10 10 10 10 10 10 10
400 15A NOA 15 15 15 15 15 15 15 15 15 15 15 15 15 15
A Includes the first 14 study days of the 5 recovery animals in the vehicle and 400 mg/kg 
group. Abbreviations: NOA (no observable abnormality); no (number).
Sex Dose group(mg/kg/day)
No. of
animals
Clinical sign in 
no. of animals
Recovery day
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Male
0 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
400 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Female
0 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
400 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Sex Dose group(mg/kg/day)
No. of
animals
Clinical sign in 
no. of animals
Recovery day
15 16 17 18 19 20 21 22 23 24 25 26 27 28
Male
0 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
400 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Female
0 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
400 5 NOA 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Abbreviations: NOA (no observable abnormality); no (number).
Table S1. Clinical signs in early toxicology animals (rats).
Table S1B. Clinical signs in recovery animals (rats).
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Sex Dose group(mg/kg/day)
No. of
animals
Clinical sign in no. of 
animals
Study day
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Male 0 3 NOA 0 3 3 0 3 3 3 0 3 3 3 3 3 0
Slight red 
discoloration of urine 3 0 0 3 0 0 0 0 0 0 0 0 0 0
Moderate red 
discoloration of urine 0 0 0 0 0 0 0 3 0 0 0 0 0 3
100 9 NOA 9 9 9 9 9 9 9 9 9 9 9 9 9 9
200 9 NOA 9 9 9 9 9 9 9 8 8 8 8 8 8 8
Multiple signsB 0 0 0 0 0 0 0 1 1 1 1 1 1 1
400 9 NOA 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Female 0 3 NOA 0 3 3 0 3 3 3 0 3 3 3 3 3 0
Moderate red 
discoloration of urine 3 0 0 3 0 0 0 3 0 0 0 0 0 3
100 9 NOA 5 9 9 9 9 9 9 9 9 9 9 9 9 9
Slight red 
discoloration of urine 4 0 0 0 0 0 0 0 0 0 0 0 0 0
200 9 NOA 9 9 9 9 9 9 9 9 9 9 9 9 9 9
400 9 NOA 9 9 9 9 9 9 9 9 9 9 9 9 9 9
B Decreased activity and body weight, porphyrin around nose and eyes, piloerection, pale 
mucosa and skin. Abbreviations: NOA (no observable abnormality); no (number).
Sex Dose group(mg/kg/day)
No. of
animals Examination
Before 
treatment
Treatment period Additional recovery period
Day 14 Day 42
Male
0
10 Normal n=10 n=10 -
5 Normal n=5 n=5 n=5
100 10 Normal n=10 n=10 -
200 10 Normal n=10 n=10 -
400
10
Normal n=10 n=8 -
Not possibleA n=0 n=1 -
Not possibleB n=0 n=1 -
5 Normal n=5 n=5 n=5
Female
0
10
Normal n=10 n=9 -
Not possibleC n=0 n=1 -
5 Normal n=5 n=5 n=5
100 10 Normal n=10 n=10 -
200 10 Normal n=10 n=10 -
400
10 Normal n=10 n=10 -
5 Normal n=5 n=5 n=5
A Examination of right eye not possible in 1 animal, damage to left eye due to sampling.
B Examination of left eye not possible in 1 animal, damage to right eye due to sampling.
C Examination not possible in 1 animal, damage to both eyes due to sampling. 
Abbreviations: no (number).
Table S1C. Clinical signs in toxicokinetics sattelite animals (rats).
Table S2. Summary of ophthalmological examinations in rats.
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Data are presented as mean ± SD. * p ≤ 0.05 compared to vehicle.
Abbreviations: Bilirubin (BIL): + 17 ȝmol/L; ++ 35 ȝmol/L; +++ 70 ȝmol/L; blood (BLD): + 
5-10 ery/ȝL; ++ 50 ery/ȝL; +++ 250 ery/ȝL; glucose (GLU): + 2.8 mmol/L; ++ 8.3 mmol/L; 
+++ >27.8 mmol/L; ketones (KIT): + 2.5 mmol/L; ++ 10 mmol/L; +++ 30 mmol/L; leucocytes 
(leu): + 25 leu/ȝL; ++ 75 leu/ȝL; +++ 500 leu/ȝL; nitrite (NIT): + positive (presence of nitrite-
reducing microorganisms); n (number of animals); RBC (red blood cell); urobilinogen (UBG): + 
35 ȝmol/L; ++  70 ȝmol/L; +++ 140ȝmol/L; ++++ 200 ȝmol/L; WBC (white blood cell). 
Parameter
Day 15
(n=10 per group)
42-day follow-up
(n=5 per group)
Vehicle 100 mg/kg/day Adrecizumab
200 mg/kg/day 
Adrecizumab
400 mg/kg/day 
Adrecizumab Vehicle
400 mg/kg/day 
Adrecizumab
Urine volume 42.2 ± 15.44 25.3 ± 12.89* 20.8 ± 9.07* 25.4 ± 14.05* 34.6 ± 10.09 21.2 ± 8.79
Specific gravity 1007 ± 4.73 1016 ± 10.41* 1019 ± 8.44* 1016 ± 5.68* 1018 ± 3.74 1021 ± 6.10
pH 7.1 ± 0.32 6.9 ± 0.74 7.0 ± 0.47 7.1 ± 0.26 7.0 ± 0.45 7.0 ± 0.00
RBC 
(microscopically) 0.7 ± 1.20 1.5 ± 2.55 4.2 ± 8.08 1.1 ± 1.85 0.4 ± 0.89 1.0 ± 1.41
WBC 
(microscopically) 0.2 ± 0.63 0.9 ± 1.52 2.5 ± 2.46 1.1 ± 1.71 1.4 ± 1.95 2.2 ± 1.48
Renal epithelial 
cells 0.1 ± 0.13 0.2 ± 0.63 0.6 ± 0.97 0.1 ± 0.52 0.4 ± 0.89 1.0 ± 1.41
Squamous 
epithelial cells 0.0 ± 0.00 0.9 ± 1.20 0.6 ± 0.97 0.5 ± 0.92 0 ± 0.00 0.8 ± 1.10
Casts 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Colour Normal (n=10) Normal (n=10) Normal (n=10) Normal (n=10) Normal (n=5) Normal (n=5)
Protein - (n=10) + (n=1)- (n=9)
± (n=4)
+ (n=2)
- (n=4)
± (n=6)
+ (n=3)
- (n=1)
± (n=2)
+ (n=2)
- (n=1)
+ (n=1)
- (n=4)
BLD (Ery/ȝL) + (n=1)- (n=9) + (n=3)
+ (n=1)
++ (n=2)
- (n=7)
+ (n=2)
++ (n=1)
- (n=7)
+ (n=1)
++ (n=1)
- (n=3)
- (n=5)
UBG (ȝmol/L) Normal (n=10) Normal (n=10) Normal (n=10) Normal (n=10) Normal (n=5) Normal (n=5)
BIL (ȝmol/L) - (n=10) - (n=10) - (n=10) - (n=10) - (n=5) - (n=5)
NIT (ȝmol/L) + (n=4)- (n=6)
+ (n=4)
- (n=6)
+ (n=5)
- (n=5)
+ (n=4)
- (n=6)
+ (n=3)
- (n=2)
+ (n=1)
- (n=4)
KET (mmol/L) - (n=10) - (n=10) - (n=10) - (n=10) - (n=5) - (n=5)
GLU (mmol/L) - (n=10) - (n=10) - (n=10) - (n=10) - (n=5) - (n=5)
Leu (Leu/ȝL) - (n=10) + (n=7)- (n=3)
+ (n=6)
- (n=4)
+ (n=5)
- (n=5)
+ (n=2)
- (n=3)
+ (n=4)
- (n=1)
Table S3A. Urinalysis in male rats.
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3DUDPHWHU
GD\IROORZXS
Q SHUJURXS
GD\IROORZXS
Q SHUJURXS
9HKLFOH PJNJGD\$GUHFL]XPDE
PJNJGD\
$GUHFL]XPDE
PJNJGD\
$GUHFL]XPDE 9HKLFOH
PJNJGD\
$GUHFL]XPDE
8ULQHYROXPH  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 1RUPDOQ  1RUPDOQ  1RUPDOQ  1RUPDOQ  1RUPDOQ 
3URWHLQ Q  Q  Q  Q Q  Q 
Q 
Q 
%/'(U\ȝ/ Q Q 
Q 
Q 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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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8%*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Q 
%,/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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.(7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 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 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 Q  - 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*/8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 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 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Q 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Data are presented as mean ± SD. * p ≤ 0.05 compared to vehicle.
Abbreviations: Bilirubin (BIL): + 17 ȝmol/L; ++ 35 ȝmol/L; +++ 70 ȝmol/L; blood (BLD): + 
5-10 ery/ȝL; ++ 50 ery/ȝL; +++ 250 ery/ȝL; glucose (GLU): + 2.8 mmol/L; ++ 8.3 mmol/L; 
+++ >27.8 mmol/L; ketones (KIT): + 2.5 mmol/L; ++ 10 mmol/L; +++ 30 mmol/L; leucocytes 
(leu): + 25 leu/ȝL; ++ 75 leu/ȝL; +++ 500 leu/ȝL; nitrite (NIT): + positive (presence of nitrite-
reducing microorganisms); n (number of animals); RBC (red blood cell); urobilinogen (UBG): + 
35 ȝmol/L; ++  70 ȝmol/L; +++ 140ȝmol/L; ++++ 200 ȝmol/L; WBC (white blood cell). 
Table S3B. Urinalysis in female rats.
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Gender Cell type
14 day follow-up
(n=10 per group)
Vehicle (n=10)
100 mg/
kg/day 
Adrecizumab 
(n=10)
200 mg/
kg/day 
Adrecizumab 
(n=10)
400 mg/
kg/day 
Adrecizumab 
(n=10)
Pre Post Pre Post Pre Post Pre Post
Male
Total 
T-lymphocytes CD3
+ (%) 40.77 43.25 41.82 41.13 43.99 39.66 45.01 40.78
T-helper CD3
+ CD4+ 
(%) 28.67 29.23 29.00 27.75 29.26 25.53 30.42 26.76
T-cytotoxic CD3
+ 
CD8a+ (%) 12.10 14.02 12.82 13.39 14.73 14.13 14.59 14.02
NK T-cells CD3
+ NKR-
P1A+ (%) 3.37 3.50 4.80* 3.75 4.06 2.66 4.29 3.63
Activated 
T-cells
CD3- NKR-
P1A+ (%) 2.81 2.41 2.99 2.35 3.18 2.39 3.26 2.28
NK cells CD3
- NKR-
P1A+ (%) 14.61 15.20 14.63 14.69 13.53 15.05 13.54 16.43
B cells CD45RA
+ 
cells (%) 37.41 29.73 35.75 30.99 35.85 33.08 38.16 36.91
Female
Total 
T-lymphocytes CD3
+ (%) 45.65 47.45 47.54 44.77 51.01 47.56 46.08 43.48
T-helper CD3
+ CD4+ 
(%) 32.72 35.35 35.18 32.99 37.01 34.33 34.65 32.05
T-cytotoxic CD3
+ 
CD8a+ (%) 12.94 12.10 12.36 11.78 14.00 13.24 11.43 11.43
NK T-cells CD3
+ NKR-
P1A+ (%) 3.98 3.86 3.35 3.28 3.76 3.62 3.48 3.63
Activated 
T-cells
CD3- NKR-
P1A+ (%) 1.87 2.27 1.77 2.29 1.87 2.59 1.93 2.34
NK cells CD3
- NKR-
P1A+ (%) 11.02 14.48 10.02 14.10 9.41 12.10 9.71 13.65
B cells CD45RA
+ 
cells (%) 29.86 23.11 30.46 27.82 26.88 25.28 28.70 27.69
Data are presented as mean ± SD. * p ≤ 0.05 compared to vehicle.
Lymphocyte phenotyping was only done in the 14-day follow-up toxicology animals, before 
the first and after the last treatment administration. 
Table S4. Lymphocyte phenotyping in rats.
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Data are presented as mean ± SD. * p ≤ 0.05 compared to vehicle.
Abbreviations: BQL (below quantification limit); GM-CSF (granulocyte-macrophage colony-
stimulating factor); IFN-Ȗ (interferon gamma);  IL (interleukin); n (number of animals); 
TNFĮ(tumor necrosis factor alpha). 
Gender Cytokines
14 day follow-up
(n=10 per group)
Vehicle (n=10)
400 mg/kg/day 
Adrecizumab 
(n=10)
Male
GM-CSF BQL BQL
IFN-Ȗ BQL BQL
IL-10 BQL BQL
IL-12 724.02 ± 181.20 693.54 ± 195.57
IL-1ȕ BQL BQL
IL-2 93.38 ± 20.24 77.59 ± 31.94
IL-4 BQL BQL
IL-6 BQL BQL
TNF-Į BQL BQL
Female
GM-CSF BQL BQL
IFN-Ȗ BQL BQL
IL-10 BQL BQL
IL-12 491.26 ± 169.78 486.49 ± 166.74
IL-1ȕ BQL BQL
IL-2 52.09 ± 33.44 71.38 ± 39.20
IL-4 BQL BQL
IL-6 BQL BQL
TNF-Į BQL BQL
Table S5. Plasma cytokine levels in rats.
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Histopathological findings
14 day follow-up
(n=10 per group)
Recovery animals 
(n=5 per group)
Vehicle 100 mg/kg/day 
200 mg/
kg/day 
400 mg/kg/
day Vehicle
400 mg/
kg/day
Liver
Inflammatory cell infiltration, 
focal/perivascular/portal 1 (n=4) 1 (n=4)
1 (n=7)
2 (n=2) 1 (n=5) 1 (n=1) 1 (n=2)
Hepato-diaphragmatic nodule 1 (n=1) - - - - -
Adrenals Vacuolisation, cortex - - M (n=1) - 1 (n=1) -
Spleen Extramedullaris hemopoesis 1 (n=2) 1 (n=2) 1 (n=3) 1 (n=1) 1 (n=4)2 (n=1) 1 (n=5)
Kidney
Cortical tubular degeneration, 
focal - - -
1 (n=2)
2 (n=1) - -
Tubular basophilia, focal 1 (n=1) - - 1 (n=2) - 1 (n=1)
Tubular casts - 1 (n=1) - 1 (n=1)
Pelvis dilatation, bilateral 2 (n=2) 2 (n=1)3 (n=1) - - - -
Pelvis dilatation, unilateral - - 2 (n=1) - 2 (n=2) -
Pancreas
Atrophy, focal - - 2 (n=1) 1 (n=1) - -
Lymphoid cell infiltration, focal - - - 1 (n=2) - -
Lung
Aggregats of alveolar 
macrophages, focal - - 1 (n=2) 1 (n=2) - -
Hematoidin crystals, alveolar 
spaces, focal - 1 (n=1) 1 (n=1) 1 (n=1) - -
Haemorrhages, focal/multifocal 1f (n=1)
1f (n=3)
1m (n=1)
2m (n=1)
1m (n=2)
1f (n=3) 1f (n=5) 1f (n=1)
1m 
(n=2)
Inflammatory cell infiltration, 
perivascular/peribroncial - 1 (n=1) 3 (n=1) - - -
Lymphoid cell infiltration, focal 1 (n=1) - - - - -
Osseous metaplasia - 1 (n=1) - - - 1 (n=1)
Eye
Fully desorganised eyeball, with 
reparative tissue - - - 4 (n=3) 1 (n=1) 1 (n=1)
Inflammatory cell infiltration, 
periocular, unilateral 2 (n=1) - - - - -
Retinal folding, focal 1 (n=1) - -
Harderian 
gland
Lymphocytic infiltration 1 (n=1) 1 (n=1) - - - -
Basophilia/dilated acini/atro-
phy/haemorrhage/inflamma-
tion, unilateral
1 (n=2)
2 (n=1)
-
1 (n=2)
2 (n=1)
1 (n=2)
2 (n=1)
3 (n=2)
- 2 (n=1)
Basophili/dilated acini/atrophy/
haemorrhage/inflammation, 
bilateral
3 (n=1) - - - - -
Thymus
Tingible body macrophages, 
cortex 1 (n=1) - 1 (n=2) 1 (n=1) 1 (n=1) 1 (n=1)
Haemorrhage, focal - - - - - -
Thyroid
Cyst - - - 1 (n=1) - -
Increased lymphoid follicles - - - - 2 (n=1) -
Table S8A. Histopathological findings in male rats.
Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and 
non-human primates
11
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 274
274
Histopathological findings
14 day follow-up
(n=10 per group)
Recovery animals 
(n=5 per group)
Vehicle 100 mg/kg/day 
200 mg/
kg/day 
400 mg/kg/
day Vehicle
400 mg/
kg/day
Prostate
Atrophy, focal 1 (n=2) 1 (n=2) 1 (n=2)2 (n=1)
1 (n=2)
2 (n=1) - -
Acinar dilatation - - 3 (n=1) - - -
Lymphocytic infiltration, 
diffuse 1 (n=1) - 1 (n=1) - - -
Testes
Tubular atrophy, unilateral, 
multifocal - 2 (n=1) - - - -
Tubular atrophy, unilateral, 
focal - - 1 (n=2)
Desorganisation/degeneration 
of tubular semiferous epitheli-
um, focal
- - 1 (n=1) - - -
Cystic dilatation, rete testis - - 1 (n=1) - - -
Mammary N (n=3) N (n=2) N (n=2) N (n=3) N (n=5) N (n=4)
Heart
Lympho-histiocytic infiltration, 
focal/multifocal
1f (n=4)
2f (n=1)
1m (n=1)
1f (n=1) 1f (n=2) - - -
Thickened endocardium, right 
ventricle 2 (n=1) - - - - -
Haemorrhage, subpericardial - - - - - 2 (n=1)
Skeletal 
muscle Necrosis, focal fibrillar 1 (n=1) - 1 (n=1) - - -
Tail/site of 
admin.
Haemorrhage, perivascular 1 (n=1)2 (n=1)
1 (n=3)
2 (n=1)
1 (n=2)
2 (n=3)
1 (n=4)
2 (n=2) - -
Inflammatory cell infiltration, 
perivascular
1 (n=1)
2 (n=1)
1 (n=1)
2 (n=1) 1 (n=2) 1 (n=5) 1 (n=1) -
Blood clot/fibrin precipitate, 
vein lumen - - 1 (n=1) 1 (n=1) - -
Fibrin precipitate, perivascular 1 (n=1) - 1 (n=3) 1 (n=3) - -
Thickened endothelium 1 (n=1) 1 (n=1) 1 (n=1) - - -
Dilated vein, unilateral 2 (n=1) 2 (n=1) 2 (n=1) 2 (n=4) 2 (n=1) -
Dilated vein, bilateral 2 (n=1) 2 (n=3) 2 (n=1) - 2 (n=2) -
Mesenter-
ic lymph 
node
- - - M (n=1) - -
Cervical 
lymph 
node
Erythrocytosis/erythrocytopha-
gia 1 (n=1)
1 (n=2)
2 (n=1) 1 (n=1) 2 (n=1) - -
Pituitary Cyst 2 (n=2) - - - - -
Table S8A. continued.
Abbreviations: 1 (minimal); 2 (mild); 3 (moderate); 4 (severe alteration); f (focal); m 
(multifocal); M (missing); n (number of affected animals); N = not present.
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Histopathological findings
14 day follow-up
(n=10 per group)
Recovery animals 
(n=5 per group)
Vehicle 100 mg/kg/day 
200 mg/
kg/day 
400 mg/
kg/day Vehicle
400 mg/
kg/day
Liver
Inflammatory cell 
infiltration, focal/
perivascular/portal
1 (n=3) 1 (n=7) 1 (n=4) 1 (n=2) - 1 (n=1)
Hepato-diaphragmatic 
nodule - - - - - -
Adrenals
Lymphocytic infiltration, 
focal, cortex - - - 1 (n=1) 2 (n=1)
1 (n=1)
2 (n=2)
Vacuolisation, cortex - - - - - -
Spleen Extramedullaris hemopoesis
1 (n=4)
2 (n=3)
1 (n=6)
2 (n=2) 1 (n=6)
1 (n=3)
2 (n=1) 1 (n=2) 1 (n=2)
Kidney
Cortical tubular 
degeneration, focal 1 (n=1) - - - - -
Tubular basophilia, focal - - - - - -
Tubular casts - - - - - -
Tubular dilatation - - - - 1 (n=1) -
Pelvis dilatation, bilateral - - - - - -
Pelvis dilatation, unilateral - - - - - -
Mineralisation, cortical - 1 (n=1) - 1 (n=1) - 1 (n=1)
Mineralisation, papillary - - - - - 1 (n=1)
Cyst, cortical 2 (n=1) 2 (n=1) - 2 (n=1) - -
Hyperplasia, transitional 
epithelium, focal - 2 (n=1) - - - -
Inflammatory cell 
infiltration, suburothelial - 1 (n=1) - - 2 (n=1) -
Pancreas
Atrophy, focal - - - - - -
Lymphoid cell infiltration, 
focal - - - - - -
Lung
Aggregats of alveolar 
macrophages, focal - - - 1 (n=1) - -
Hematoidin crystals, 
alveolar spaces, focal 1 (n=1) - - - - -
Haemorrhages, focal/
multifocal 1f (n=2) 1f (n=1) - 1f (n=5) - 1m (n=1)
Inflammatory cell 
infiltration, perivascular/
peribroncial
- - - - - -
Inflammatory cell 
infiltration, perivascular, 
eosinophils
1 (n=1)
2 (n=1) 1 (n=1) - 2 (n=1) - -
Lymphoid cell infiltration, 
focal - - - - - -
Osseous metaplasia - - - - 1 (n=1) -
Table S8B. Histopathological findings in female rats.
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Table S8B. Continued.
Histopathological findings
14 day follow-up
(n=10 per group)
Recovery animals 
(n=5 per group)
Vehicle 100 mg/kg/day 
200 mg/
kg/day 
400 mg/
kg/day Vehicle
400 mg/
kg/day
Eye
Granulomatous 
inflammation/fibrosis, 
unilateral
- - - - - -
Fully desorganised eyeball, 
with reparative tissue - - - - - -
Inflammatory cell 
infiltration, periocular, 
unilateral
- - - - - -
Harderian 
gland
Lymphocytic infiltration - - 1 (n=1) - - -
Basophilia/dilated acini/
atrophy/haemorrhage/
inflammation, unilateral
1 (n=1)
2 (n=1) 1 (n=1)
1 (n=1)
2 (n=1) - - 2 (n=1)
Basophili/dilated acini/
atrophy/haemorrhage/
inflammation, bilateral
- - - - - -
Thymus
Perithymic Lnn - - - - - -
Erythrocytosis/
erythrocytophagia - - - 2 (n=1) - -
Tingible body 
macrophages, cortex 1 (n=4) 1 (n=3)
1 (n=3)
2 (n=1) 1 (n=2) - -
Haemorrhage, focal - - - - - -
Thyroid
Cyst - - - - - -
Increased lymphoid 
follicles 1 (n=1) - - - - -
Vagina Inflammatory cell infiltration - - 2 (n=1) - - -
Ovaries Cyst, unilateral - - 1 (n=1) - - -
Mammary - M (n=1) - - - -
Heart
Lympho-histiocytic 
infiltration, focal/
multifocal
1f (n=1) - - - - -
Thickened endocardium, 
right ventricle 1 (n=1) - - - - -
Haemorrhages 1 (n=1) 1 (n=1) 1 (n=4) - - -
Skeletal 
muscle
Necrosis, focal fibrillar 1 (n=1) - 1 (n=1) 1 (n=1) - -
Inflammatory cell 
infiltration, focal 1 (n=1) - - 1 (n=1) - -
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Histopathological findings
14 day follow-up
(n=10 per group)
Recovery animals 
(n=5 per group)
Vehicle 100 mg/kg/day 
200 mg/
kg/day 
400 mg/
kg/day Vehicle
400 mg/
kg/day
Tail/site of 
admin.
Haemorrhage, perivascular 1 (n=3)2 (n=1) 1 (n=2)
1 (n=2)
2 (n=1)
1 (n=4)
2 (n=1) - -
Inflammatory cell 
infiltration, perivascular 1 (n=2) -
1 (n=2)
2 (n=4)
1 (n=5)
2 (n=1) - -
Blood clot/fibrin 
precipitate, vein lumen - - 2 (n=1) 1 (n=1) - -
Fibrin precipitate, 
perivascular 1 (n=2) 1 (n=1) 1 (n=1) 1 (n=1) - -
Hair embolus - - - - - -
Recanalisation - - - - - 1 (n=1)
Thickened endothelium 1 (n=1) - - 1 (n=1) - -
Dilated vein, unilateral 2 (n=1) 2 (n=1) - - - -
Dilated vein, bilateral - - - - 2 (n=3) 2 (n=2)
Cervical 
lymph node
Erythrocytosis/
erythrocytophagia 1 (n=3) - 1 (n=1)
1 (n=1)
2 (n=1) - -
Pituitary Cyst - - - - - -
Femur M (n=1) - - - - -
Oesophagus/
trachea M (n=1) - - M (n=1) - -
Table S8B. Continued.
Abbreviations: 1 (minimal); 2 (mild); 3 (moderate); 4 (severe alteration); f (focal); m 
(multifocal); M (missing); n (number of affected animals); N = not present.
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Gender Parameter 100 mg/kg/day Adrecizumab
200 mg/kg/day 
Adrecizumab
400 mg/kg/day 
Adrecizumab
Day 1 Day 14 Day 1 Day 14 Day 1 Day 14
Male
Tmax (h) 0.083 0.083 0.25 0.083 0.25 0.083
Cmax (ȝg/mL) 2250 3490 4540 5870 7440 9240
Cmax/dose
(kg* ȝg/mL/mg) 25.5 34.9 22.7 29.4 18.6 23.1
Tlast (h) 24 24 24 24 24 24
Clast (ȝg/mL) 771 1640 1300 3290 2590 4730
AUC0-24h 
(h*ȝg/mL) 27000 46600 47800 94100 107000 142000
AUC0-24h/dose
(h*kg* ȝg/mL/mg) 270 466 239 471 268 355
Racc - 1.73 - 1.97 - 1.33
Female
Tmax (h) 0.25 0.083 0.25 0.5 0.25 0.083
Cmax (ȝg/mL) 2280 3660 4550 5190 8440 10100
Cmax/dose
(kg* ȝg/mL/mg) 22.8 36.6 22.8 26.0 21.1 25.3
Tlast (h) 24 24 24 24 24 24
Clast (ȝg/mL) 804 1680 1500 3070 2790 5440
AUC0-24h
(h* ȝg/mL) 26400 48900 54300 86800 10900 150000
AUC0-24h/dose
(h*kg* ȝg/mL/mg) 264 489 272 434 273 375
Racc - 1.85 - 1.60 - 1.38
Table S9. Toxicokinetic parameters in rats.
Data are presented as mean
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Sex
Dose 
group
(mg/kg/
day)
No. of
animals
Clinical 
sign in
no. of 
animals
Study day
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Male
0 n=5A
NOA 0 0 0 1 1 1 3 3 3 5 5 5 5 0 0
Bruising 5 5 5 4 4 4 2 2 2 0 0 0 0 5 5
Feces 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
25 n=3
NOA 1 0 0 0 0 0 3 3 3 3 3 3 3 0 0
Abnormal 
colour 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
Abrasion 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Bruising 2 3 3 3 3 3 0 0 0 0 0 0 0 3 3
Hair loss 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
50 n=3
NOA 0 0 0 0 0 0 1 3 2 2 2 2 3 0 0
Bruising 3 3 3 3 3 3 0 0 1 1 1 1 0 3 3
Hair loss 1 1 2 2 2 2 2 0 0 0 0 0 0 0 0
Scab/crust 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100 n=5A
NOA 1 1 0 0 0 0 1 2 2 3 3 3 1 0 0
Bruising 4 4 5 5 5 5 3 1 1 0 0 0 2 5 5
Discharge 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Hair loss 3 3 3 3 3 2 2 2 2 2 2 2 2 2 2
Scab/crust 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1
Female
0 n=5A
NOA 0 0 0 0 0 0 1 2 1 2 2 2 2 0 0
Abnormal 
colour 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1
Bruising 5 5 5 5 5 5 4 3 3 2 2 2 2 4 4
Discharge 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0
Hair loss 1 1 1 1 1 1 1 1 1 0 0 0 0 0 0
Scab/crust 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1
25 n=3
NOA 0 0 0 0 0 0 1 2 2 2 2 2 2 0 0
Abnormal 
colour 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Bruising 3 3 3 3 3 3 1 0 0 0 0 0 0 3 3
Hair loss 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1
Scab/crust 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0
50 n=3
NOA 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0
Abnormal 
colour 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
Bruising 3 3 3 3 3 3 1 1 1 1 1 1 1 0 3
Discharge 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0
Feces 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0
Hair loss 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2
100 n=5A
NOA 0 0 0 0 0 0 3 2 1 3 2 4 4 0 0
Abnormal 
colour 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
Abrasion 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Bruising 5 5 5 5 5 5 2 1 2 0 0 0 0 4 5
Discharge 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0
Feces 1 0 0 0 0 0 0 3 1 1 1 0 0 0 0
Hair loss 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1
Table S11A. Clinical signs in cynomolgus monkeys.
A Includes the first 14 study days of the 5 recovery animals in the vehicle and 400 mg/kg 
group. 
Abbreviations: NOA (no observable abnormality).
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Table S11B. Clinical signs in cynomolgus monkeys  (recovery animals).
Sex
Dose 
group
(mg/kg/
day)
No. of
animals
Clinical 
sign in
no. of 
animals
Study day
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Male
0 n=2
NOA 0 0 0 0 0 0 1 2 2 2 2 2 2 2 2
Bruising 2 2 2 2 2 2 1 0 0 0 0 0 0 0 0
Discharge 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100 n=2
NOA 0 0 0 0 0 0 1 1 2 2 2 2 2 2 2
Bruising 2 2 2 2 2 2 1 0 0 0 0 0 0 0 0
Discharge 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Hair loss 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0
Scab/crust 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
Female
0 n=2
NOA 0 0 0 0 0 0 1 1 2 2 2 2 2 2 2
Abnormal 
colour 1 1 1 1 1 1 1 1 0 0 0 0 0 0 0
Bruising 2 2 2 2 2 2 0 0 0 0 0 0 0 0 0
Discharge 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Scab/crust 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0
100 n=2
NOA 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1
Bruising 2 2 2 2 0 0 0 0 0 0 0 0 0 0 0
Hair loss 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Abbreviations: NOA (no observable abnormality; n (number of animals).
Sex
Dose 
group
(mg/kg/
day)
No. of
ani-
mals
Clinical 
sign in
no. of 
animals
Study day
31 32 33 34 35 36 37 38 39 40 41 42
Male
0 n=2
NOA 2 2 2 2 2 2 1 1 1 1 0 1
Bruising 0 0 0 0 0 0 1 1 1 1 2 1
Discharge 0 0 0 0 0 0 0 0 0 0 1 0
100 n=2
NOA 2 2 1 1 1 1 1 1 1 1 0 1
Bruising 0 0 0 0 0 0 0 0 0 0 1 0
Discharge 0 0 0 0 0 0 0 0 0 0 1 0
Hair loss 0 0 1 1 1 1 1 1 1 1 1 1
Scab/crust 0 0 0 0 0 0 0 0 0 0 0 0
Female
0 n=2
NOA 2 2 2 2 2 2 2 2 2 2 1 2
Abnormal 
colour 0 0 0 0 0 0 0 0 0 0 0 0
Bruising 0 0 0 0 0 0 0 0 0 0 0 0
Discharge 0 0 0 0 0 0 0 0 0 0 1 0
Scab/crust 0 0 0 0 0 0 0 0 0 0 0 0
100 n=2
NOA 1 1 1 1 1 1 1 1 1 1 1 1
Bruising 0 0 0 0 0 0 0 0 0 0 1 1
Hair loss 1 1 1 1 1 1 1 1 1 1 1 1
Abbreviations: NOA (no observable abnormality; n (number of animals).
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Table S12. Neurological observations in cynomolgus monkeys.
Dose group
(mg/kg/
day)
No. of
animals
Neurological 
observation
Male Female
Day -10 Day 15 Day -10 Day 15
0 n=5
Stimulus response Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Behaviour Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Gait Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Brachiation Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Posture Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Grasp Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Activity level Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Balance Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Conjugate move-
ment Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Position Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Pupil reactivity Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
25 n=3
Stimulus response Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Behaviour Normal (n=3) Normal (n=3) Head tilt (n=1)Normal (n=2)
Head tilt (n=1)
Normal (n=2)
Gait Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Brachiation Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Posture Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Grasp Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Activity level Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Balance Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Conjugate move-
ment Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Position Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Pupil reactivity Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
50 n=3
Stimulus response Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Behaviour Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Gait Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Brachiation Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Posture Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Grasp Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Activity level Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Balance Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Conjugate move-
ment Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Position Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
Pupil reactivity Normal (n=3) Normal (n=3) Normal (n=3) Normal (n=3)
100 n=5
Stimulus response Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Behaviour Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Gait Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Brachiation Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Posture Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Grasp Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Activity level Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Balance Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Conjugate move-
ment Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Position Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Pupil reactivity Normal (n=5) Normal (n=5) Normal (n=5) Normal (n=5)
Abbreviations: n (number of animals).
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Table S13. Electrocardiographic parameters in cynomolgus monkeys.
Dose group
(mg/kg/day)
No. of
animals ECG parameter
Male Female
Day -9 Day 14 Day -9 Day 14
0 n=5
RR (msec) 325 ± 15 372 ± 40 335 ± 46 353 ± 42
HR (bpm) 185 ± 8 163 ± 18 182 ± 26 172 ± 20
PR (msec) 73 ± 5 76 ± 6 77 ± 6 79 ± 8
QRS (msec) 34 ± 3 33 ± 3 33 ± 2 33 ± 4
QT (msec) 197 ± 6 214 ± 11 200 ± 20 207 ± 19
QTc (msec) 347 ± 12 351 ± 9 346 ± 17 348 ± 17
25 n=3
RR (msec) 314 ± 28 354 ± 20 319 ± 31 351 ± 65
HR (bpm) 192 ± 17 169 ± 10 189 ± 19 175 ± 32
PR (msec) 68 ±5 68 ± 6 72 ± 2 73 ± 1
QRS (msec) 32 ± 1 32 ± 4 34 ± 2 35 ± 2
QT (msec) 193 ± 11 204 ± 10 200 ± 15 209 ± 21
QTc (msec) 343 ± 7 343 ± 11 354 ± 12 353 ± 9
50 n=3
RR (msec) 357 ± 18 331 ± 31 302 ± 24 322 ± 33
HR (bpm) 168 ± 9 183 ± 18 200 ± 17 188 ± 20
PR (msec) 74 ± 9 68 ± 10 166 ± 13 67 ± 11
QRS (msec) 35 ± 5 32 ± 2 34 ± 4 33 ± 4
QT (msec) 217 ± 13 202 ± 12 192 ± 11 202 ± 9
QTc (msec) 362 ± 13 352 ± 10 349 ± 9 356 ± 5
100 n=5
RR (msec) 343 ± 55 383 ± 62 363 ± 27 359 ± 38
HR (bpm) 178 ± 28 160 ± 27 166 ± 13 169 ± 18
PR (msec) 75 ± 8 76 ± 4 84 ± 7 79 ± 12
QRS (msec) 34 ± 2 34 ± 2 34 ± 4 36 ± 5
QT (msec) 206 ± 23 217 ± 24 211 ± 6 213 ± 17
QTc (msec) 35 ± 15 351 ± 18 351 ± 8 355 ± 15
Data are presented as mean ± SD .
Abbreviations: bpm (beats per minute); HR (heart rate); msec (millisecond); QTc (corrected QT-
time, using Bazett’s formula).
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Table S14. Blood pressure and respiratory rate in cynomolgus monkeys.
Data are presented as mean ± SD.
Abbreviations: DBP (diastolic blood pressure); mmHg (millimetres mercury); SBP (systolic blood 
pressure). 
Dose group
(mg/kg/
day)
No. of
animals Parameter
Male Female
Day -9 Day 14 Day -9 Day 14
0 5
SBP (mmHg) 126 ± 26 140 ± 40 137 ± 13 145 ± 31
DBP (mmHg) 64 ± 8 62 ± 11 77 ± 4 82 ± 21
25 3
SBP (mmHg) 114 ± 2 109 ± 6 135 ± 18 131 ± 3
DBP (mmHg) 58 ± 5 62 ± 13 84 ± 10 62 ± 5
50 3
SBP (mmHg) 109 ± 11 116 ± 17 136 ± 37 137 ± 39
DBP (mmHg) 68 ± 14 61 ± 6 81 ± 29 77 ± 14
100 5
SBP (mmHg) 128 ± 12 134 ± 21 133 ± 26 149 ± 30
DBP (mmHg) 74 ± 18 78 ± 11 79 ± 14 94 ± 14
0 5 Respiratory rate (rate/min) 61 ± 21 54 ± 22 55 ± 16 52 ± 16
25 3 Respiratory rate (rate/min) 72 ± 32 65 ± 26 48 ± 7 59 ± 10
50 3 Respiratory rate (rate/min) 67 ± 6 61 ± 8 60 ± 17 52 ± 12
100 5 Respiratory rate (rate/min) 41 ± 3 46 ± 7 43 ± 10 43 ± 12
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Table S15. Urinalysis in cynomolgus monkeys.
Dose 
group
(mg/kg/
day)
ECG parameter
Male Female
Day -6 Day 15
Day 41
(recovery 
animals)
Day -6 Day 15
Day 41
(recovery 
animals)
0 (n=5)
Specific gravity 1.017 ± 0.005 1.022 ± 0.012 1.019 ± 0.006 1.021 ± 0.008 1.021 ± 0.015 1.020 ± 0.011
Volume (mL) 58.0 ± 17.9 34.8 ± 27.4 28.0 ± 9.9 60.0 ± 33.9 118.2 ± 128.4 74.5 ± 62.9
Creatinine (mg/dL) 69.6 ± 20.1 105.3 ± 45.0 68.3 ± 29.3 81.81 ± 16.0 95.0 ± 82.0 96.7 ± 61.7
Sodium (mEq/L) 33.6 ± 17.7 40.1 ± 9.6 20.4 ± 2.3 55.8 ± 30.5 39.5 ± 14.7 49.7 ± 18.8
Potassium (mEq/L) 83.9 ± 12.1 66.7 ± 47.3 75.3 ± 18.5 94.5 ± 33.4 61.8 ± 49.6 85.3 ± 61.7
Chloride (mEq/L) 40.7 ± 14.9 66.1 ± 43.8 56.8 ± 12.0 50.7 ± 13.3 57.8 ± 41.98 62.0 ± 33.2
Colour Yellow (n=5) Yellow (n=5) Yellow (n=2) Red (n=1)Yellow (n=4) Yellow (n=5) Yellow (n=2)
Clarity Clear (n=5)
Sl cloudy (n=1)
Cloudy (n=2)
Clear (n=2)
Sl cloudy (n=2) Sl cloudy (n=1)Clear (n=4)
Sl cloudy (n=2)
Cloudy (n=3) Cloudy (n=2)
NitratesA Positive (n=1)Negative (n=4) Positive (n=5) Negative (n=2) Negative (n=5) Negative (n=5) Negative (n=2)
GlucoseA Negative (n=5) Negative (n=5) Negative (n=2) Negative (n=5) Negative (n=5) Negative (n=2)
KetonesA 1+ (n=1)Negative (n=4)
1+ (n=1)
2+ (n=1)
Negative (n=3)
Negative (n=2) Negative (n=5)
1+ (n=3)
2+ (n=1)
Negative (n=1)
Trace (n=1)
Negative (n=1)
BloodA Negative (n=5)
Trace (n=2)
2+ (n=2)
Negative (n=1)
Negative (n=2)
Trace (n=1)
1+ (n=1)
3+ (n=1)
Negative (n=2)
Trace (n=2)
1+ (n=1)
2+ (n=2)
2+ (n=1)
Negative (n=1)
ProteinA Negative (n=5) 1+ (n=1)Negative (n=4) Negative (n=2)
Trace (n=2)
Negative (n=3)
Trace (n=1)
1+ (n=1)
Negative (n=3)
Trace (n=1)
Negative (n=1)
BilirubinA Negative (n=5) Negative (n=5) Negative (n=2) Negative (n=5) Negative (n=5) Negative (n=2)
pHA 8.5 (n=5)
7.0 (n=1)
8.0 (n=2)
8.5 (n=2)
8.5 (n=1)
>=9.0 (n=1)
8.0 (n=1)
8.5 (n=4)
7.0 (n=2)
7.5 (n=1)
8.5 (n=2)
8.5 (n=1)
>=9.0 (n=1)
LeukocytesA Negative (n=5) 2+ (n=1)Negative (n=4) Negative (n=2)
Trace (n=1)
1+ (n=2)
Negative (n=3)
1+ (n=3)
Negative (n=3)
Trace (n=1)
Negative (n=1)
Urobilirubin 
(EU/dL) 0.2 (n=5)
0.2 (n=4)
1.0 (n=1) 0.2 (n=2) 0.2 (n=5)
0.2 (n=4)
1.0 (n=1) 0.2 (n=2)
25 (n=3)
Specific gravity 1.020 ± 0.010 1.021 ± 0.015 1.026 ± 0.007 1.021 ± 0.017
Volume (mL) 76.7 ± 47.3 148.0 ± 162.2 46.7 ± 11.5 61.7 ± 39.0
Creatinine (mg/dL) 70.7 ± 25.9 80.2 ± 74.7 117.5 ± 45.0 98.6 ± 55.6
Sodium (mEq/L) 26.0 ± 5.1 13.5 ± 3.2 28.6 ± 9.9 27.1 ± 10.8
Potassium (mEq/L) 89.5 ± 43.1 72.9 ± 55.3 104.3 ± 41.8 31.5 ± 25.3
Chloride (mEq/L) 38.9 ± 14.5 42.4 ± 14.1 48.2 ± 19.3 44.3 ± 24.4
Colour Yellow (n=3) Orange (n=1)Yellow (n=2) Yellow (n=3) Yellow (n=3)
Clarity Clear (n=3) Cloudy (n=3) Sl cloudy (n=1)Clear (n=2)
Sl cloudy (n=2)
Cloudy (n=1)
NitratesA Negative (n=3) Negative (n=3) Negative (n=3) Negative (n=3)
GlucoseA Negative (n=3) Negative (n=3) Negative (n=3) Negative (n=3)
KetonesA Negative (n=3) 1+ (n=1)Negative (n=2) Negative (n=3)
Trace (n=1)
1+ (n=1)
2+ (n=1)
BloodA Negative (n=3) Trace (n=2)Negative (n=1)
Trace (n=1)
Negative (n=2)
Trace (n=1)
1+ (n=1)
3+ (n=1)
ProteinA Negative (n=3) Trace (n=1)Negative (n=2) Negative (n=3)
1+ (n=1)
Negative (n=2)
BilirubinA Negative (n=3) Negative (n=3) Negative (n=3) Negative (n=3)
pHA 8.0 (n=1)8.5 (n=2)
8.0 (n=1)
8.5 (n=1)
>=9.0 (n=1)
8.0 (n=1)
8.5 (n=2)
7.5 (n=2)
8.5 (n=1)
LeukocytesA Negative (n=3) Negative (n=3)
Trace (n=1)
1+ (n=1)
Negative (n=1)
Trace (n=1)
2+ (n=1)
Negative (n=1)
Urobilirubin 
(EU/dL) 0.2 (n=3) 0.2 (n=3) 0.2 (n=3) 0.2 (n=3)
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Dose 
group
(mg/kg/
day)
ECG parameter
Male Female
Day -6 Day 15
Day 41
(recovery 
animals)
Day -6 Day 15
Day 41
(recovery 
animals)
50 (n=3)
Specific gravity 1.024 ± 0.005 1.027 ± 0.012 1.013 ± 0.009 1.015 ± 0.006
Volume (mL) 50.0 ± 26.5 65.0 ± 86.6 90.0 ± 26.5 18.0 ± 5.3
Creatinine (mg/dL) 93.0 ± 21.1 115.2 ± 45.7 40.4 ± 26.8 73.7 ± 12.6
Sodium (mEq/L) 49.2 ± 26.3 17.0 ± 6.8 19.5 ± 10.4 23.3 ± 4.9
Potassium (mEq/L) 92.3 ± 25.5 45.7 ± 28.6 72.6 ± 46.8 39.0 ± 16.7
Chloride (mEq/L) 47.1 ± 10.5 50.2 ± 3.5 32.5 ± 15.0 43.2 ± 19.6
Colour Yellow (n=3) Yellow (n=3) Yellow (n=3) Brown (n=1)Yellow (n=2)
Clarity Clear (n=3) Sl cloudy (n=1)Clear (n=2)
Cloudy (n=1)
Clear (n=2)
Cloudy (n=1)
Sl cloudy (n=2)
NitratesA Negative (n=3) Negative (n=3) Negative (n=3) Negative (n=3)
GlucoseA Negative (n=3) Negative (n=3) Negative (n=3) Trace (n=1)Negative (n=2)
KetonesA Negative (n=3) 2+ (n=2)Negative (n=1) Negative (n=3)
Trace (n=1)
1+ (n=1)
2+ (n=1)
BloodA Negative (n=3) Trace (n=1)Negative (n=2)
Trace (n=1)
Negative (n=2)
Trace (n=2)
3+ (n=1)
ProteinA Negative (n=3) Trace (n=1)Negative (n=2) Negative (n=3)
2+ (n=1)
Negative (n=2)
BilirubinA Negative (n=3) Negative (n=3) Negative (n=3) Negative (n=3)
pHA 8.0 (n=1)8.5 (n=2)
6.0 (n=1)
7.0 (n=2)
7.5 (n=1)
8.0 (n=1)
8.5 (n=1)
7.0 (n=2)
8.0 (n=1)
LeukocytesA Negative (n=3) Negative (n=3) Trace (n=2)Negative (n=1)
2+ (n=2)
Negative (n=1)
Urobilirubin 
(EU/dL) 0.2 (n=3) 0.2 (n=3) 0.2 (n=3)
0.2 (n=2)
4.0 (n=1)
100 (n=5)
Specific gravity 1.021 ± 0.006 1.027 ± 0.012 1.016 ± 0.004 1.024 ± 0.006 1.020 ± 0.009 1.019 ± 0.008
Volume (mL) 64.0 ± 25.1 56.0 ± 54.9 45.0 ± 24.0 78.0 ± 29.5 42.0 ± 25.8 100.5 ± 17.7
Creatinine (mg/dL) 81.1 ± 17.6 115.2 ± 45.7 63.9 ± 8.4 75.8 ± 21.4 89.7 ± 47.1 52.1 ± 20.8
Sodium (mEq/L) 37.4 ± 18.5 39.4 ± 36.0 29.7 ± 1.4 34.9 ± 13.5 20.0 ± 7.2 40.5 ± 24.4
Potassium (mEq/L) 92.6 ± 30.9 52.4 ± 20.7 64.9 ± 4.9 112.6 ± 27.5 49.2 ± 9.3 99.0 ± 51.8
Chloride (mEq/L) 44.4 ± 11.7 53.4 ± 13.9 55.5 ± 8.9 66.1 ± 20.0 55.1 ± 21.1 64.5 ± 27.6
Colour Yellow (n=5) Yellow (n=5) Yellow (n=2) Brown (n=1)Yellow (n=4) Yellow (n=5) Yellow (n=2)
Clarity Clear (n=5) Cloudy (n=2)Sl cloudy n=2)
Cloudy (n=1)
Sl cloudy (n=1)
Sl cloudy (n=2)
Clear (n=3)
Sl cloudy (n=4)
Clear (n=1)
Sl cloudy (n=1)
Cloudy (n=1)
NitratesA Negative (n=5) Negative (n=5) Negative (n=2) Positive (n=1)Negative (n=4) Negative (n=5)
Positive (n=1)
Negative (n=1)
GlucoseA Negative (n=5) Negative (n=5) Negative (n=2) Negative (n=5) Negative (n=5) Negative (n=2)
KetonesA 2+ (n=1)Negative (n=4)
Trace (n=1)
2+ (n=1)
3+ (n=1)
Negative (n=2)
Negative (n=2) Negative (n=5)
Trace (n=1)
2+ (n=1)
3+ (n=1)
Negative (n=2)
Negative (n=2)
BloodA Negative (n=5) 3+ (n=1)Negative (n=4)
Trace (n=1)
Negative (n=1)
1+ (n=1)
2+ (n=1)
3+ (n=1)
Negative (n=2)
1+ (n=3)
2+ (n=1)
3+ (n=1)
Negative (n=2)
ProteinA Negative (n=5) Trace (n=3)Negative (n=2) Negative (n=2) Negative (n=5)
Trace (n=2)
Negative (n=3) Negative (n=2)
BilirubinA Negative (n=5) Negative (n=5) Negative (n=2) Negative (n=3) Negative (n=3) Negative (n=2)
pHA 8.5 (n=5)
6.0 (n=1)
7.5 (n=2)
8.0 (n=1)
8.5 (n=1)
7.0 (n=1)
8.5 (n=1)
8.0 (n=1)
8.5 (n=4)
6.0 (n=1)
7.0 (n=1)
7.5 (n=1)
8.5 (n=2)
8.5 (n=2)
LeukocytesA Negative (n=5) Negative (n=5) Negative (n=2)
Trace (n=3)
1+ (n=1)
Negative (n=1)
Trace (n=2)
2+ (n=1)
Negative (n=2)
Negative (n=2)
Urobilirubin 
(EU/dL) 0.2 (n=5)
0.2 (n=4)
1.0 (n=1) 0.2 (n=2) 0.2 (n=5) 0.2 (n=5) 0.2 (n=2)
Data are presented as mean ± SD.  
A Urine strips are read with a qualitative result (negative to 4+) to reflect the nature of the 
test.
Abbreviations: n (number of animals); Sl (slightly).
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Table S17A. Immunophenotyping (relative counts) in cynomolgus monkeys.
Day Cell type
Male Female
Vehicle 25 mg/kg/day
50 mg/kg/
day
100 mg/
kg/day Vehicle
25 mg/kg/
day
50 mg/kg/
day
100 mg/kg/
day
Acclima-
tion
No. of animals n=5 n=3 n=3 n=5 n=5 n=3 n=3 n=5
Total T-lympho-
cytes
CD3+ (%)
58.4 ± 
5.0
61.8 ± 
13.8 51.7 ± 2.3
62.8 ± 
13.1
61.1 ± 
6.6
53.8 ± 
12.8
64.6 ± 
11.7 58.6 ± 3.6
T-helper
CD3+ CD4+ (%)
36.3 ± 
4.3
46.4 ± 
11.3 30.5 ± 6.3
33.5 ± 
10.2
36.4 ± 
8.5
33.6 ± 
10.8 39.7 ± 8.7 40.1 ± 2.8
T-cytotoxic
CD3+ CD8a+ (%)
17.0 ± 
3.1 11.9 ± 2.0 12.2 ± 2.7
25.8 ± 
5.0
17.5 ± 
2.1 14.6 ± 2.3 18.2 ± 5.5 15.9 ± 3.3
Reg T Cells
CD25+ (%) 4.6 ± 1.1 6.2 ± 1.7 7.4 ± 5.2 6.7 ± 2.3 4.5 ± 1.4 5.1 ± 2.4 6.1 ± 5.3 5.0 ± 2.1
NK cells
CD3+ CD16+ (%)
11.5 ± 
5.1 10.1 ± 1.4 16.8 ± 1.9
11.9 ± 
7.1
11.2 ± 
6.3 9.8 ± 3.1 9.5 ± 4.9 12.1 ± 8.0
B cells
CD20+ cells (%)
22.5 ± 
5.3
21.0 ± 
11.2 24.5 ± 2.0
22.2 ± 
14.4
24.0 ± 
6.0 32.6 ± 8.4 21.7 ± 6.4 24.7 ± 8.5
Activated T cells
CD69+ (%) 1.7 ± 0.9 3.3 ± 1.8 3.6 ± 1.2 1.7 ± 1.3 3.5 ± 3.2 3.1 ± 2.4 6.1 ± 7.7 2.5 ± 1.4
Activated NK cells
CD69+ (%)
39.0 ± 
23.4 42.6 ± 8.7
38.2 ± 
25.4
26.5 ± 
20.1
28.5 ± 
14.5
43.0 ± 
24.4 39.6 ± 7.9 34.7 ± 6.0
Activated B cells
CD69+ (%) 0.4 ± 0.1 0.4 ± 0.2 0.4 ± 0.1 0.3 ± 0.1 0.2 ± 0.1 0.3 ± 0.1 0.6 ± 0.3 0.3 ± 0.1
Day 15
No. of animals n=5 n=3 n=3 n=5 n=5 n=3 n=3 n=5
Total T-lympho-
cytes
CD3+ (%)
59.8 ± 
3.7
60.3 ± 
13.9 55.8 ± 4.0
63.6 ± 
12.5
57.6 ± 
7.5
52.9 ± 
12.4 66.7 ± 7.7 61.7 ± 2.3
T-helper
CD3+ CD4+ (%)
37.4 ± 
3.1
42.7 ± 
12.4 32.5 ± 2.9
34.6 ± 
8.3
36.4 ± 
8.7
34.8 ± 
10.1 44.7 ± 3.9 43.1 ± 2.4
T-cytotoxic
CD3+ CD8a+ (%)
18.7 ± 
3.9 12.7 ± 0.8 17.1 ± 2.7
25.4 ± 
4.7
16.6 ± 
2.2 16.9 ± 3.5 19.9 ± 2.5 17.2 ± 4.0
Reg T Cells
CD25+ (%) 5.2 ± 1.1 6.8 ± 1.9 8.4 ± 6.4 7.2 ± 2.6 5.2 ± 0.7 7.0 ± 3.2 6.3 ± 4.8 5.8 ± 3.4
NK cells
CD3+ CD16+ (%) 8.5 ± 3.9 12.0 ± 3.0 14.3 ± 4.0 8.9 ± 3.2 7.5 ± 2.3 11.1 ± 3.0 5.6 ± 4.4 10.5 ± 5.4
B cells
CD20+ cells (%)
26.3 ± 
2.3 23.0 ± 9.2 23.9 ± 1.3
23.0 ± 
10.6
28.5 ± 
10.0
30.1 ± 
10.2 22.8 ± 2.2 23.6 ± 6.7
Activated T cells
CD69+ (%) 1.3 ± 0.4 4.2 ± 3.0 3.2 ± 1.6 1.4 ± 0.8 2.2 ± 2.2 2.6 ± 1.1 2.1 ± 1.8 1.9 ± 0.8
Activated NK cells
CD69+ (%)
37.7 ± 
22.6 44.7 ± 6.1
38.4 ± 
16.0
27.4 ± 
17.8
24.8 ± 
11.5
38.0 ± 
18.5
37.9 ± 
22.0 31.3 ± 9.6
Activated B cells
CD69+ (%) 0.5 ± 0.2 0.7 ± 0.5 0.5 ± 0.2 0.5 ± 0.2 0.4 ± 0.1 0.7 ± 0.4 0.6 ± 0.1 0.5 ± 0.2
Day 41
(recov-
ery
animals)
No. of animals n=2 n=0 n=0 n=2 n=2 n=0 n=0 n=2
Total T-lympho-
cytes
CD3+ (%)
68.8 n.d. n.d. 26.1 64.6 ;n.d. n.d. 65.2
T-helper
CD3+ CD4+ (%) 32.5 n.d. n.d. 31.1 36.7 n.d. n.d. 44.2
T-cytotoxic
CD3+ CD8a+ (%) 24.0 n.d. n.d. 9.0 21.5 n.d. n.d. 15.2
Reg T Cells
CD25+ (%) 4.8 n.d. n.d. 7.2 4.5 n.d. n.d. 4.6
NK cells
CD3+ CD16+ (%) 8.9 n.d. n.d. 7.8 7.1 n.d. n.d. 11.6
B cells
CD20+ cells (%) 18.4 n.d. n.d. 27.5 24.8 n.d. n.d. 19.9
Activated T cells
CD69+ (%) 3.9 n.d. n.d. 3.7 3.1 n.d. n.d. 3.8
Activated NK cells
CD69+ (%) 46.6 n.d. n.d. 20.3 31.5 n.d. n.d. 47.6
Activated B cells
CD69+ (%) 0.4 n.d. n.d. 0.3 0.4 n.d. n.d. 0.6
Data are presented as mean ± SD. 
Abbreviations: n.d. (not determined); n (number of animals).
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Table S17B. Immunophenotyping (absolute counts) in cynomolgus monkeys.
Day Cell type
Male Female
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
25 mg/kg/
day
50 mg/
kg/day
100 mg/
kg/day
Accli-
mation
No. of animals n=5 n=3 n=3 n=5 n=5 n=3 n=3 n=5
Total T-lymphocytes 
CD3+ (103/ȝL)
3.48 ± 
0.81
2.09 ± 
0.58
2.09 ± 
0.95
3.18 ± 
1.50
2.85 ± 
1.18
2.03 ± 
0.77
2.84 ± 
1.67
2.50 ± 
0.93
T-helper
CD3+ CD4+ (103/ȝL)
2.22 ± 
0.72
1.57 ± 
0.46
1.17 ± 
0.45
1.62 ± 
0.68
1.64 ± 
0.62
1.26 ± 
0.47
1.84 ± 
1.35
1.70 ± 
0.64
T-cytotoxic
CD3+ CD8+ (103/ȝL)
0.99 ± 
0.19
0.44 ± 
0.24
0.46 ± 
0.13
1.30 ± 
0.62
0.83 ± 
0.38
0.58 ± 
0.27
0.78 ± 
0.44
0.66 ± 
0.23
Reg T Cells
CD25+ (103/ȝL)
0.10 ± 
0.04
0.10 ± 
0.04
0.07 ± 
0.02
0.11 ± 
0.06
0.07 ± 
0.02
0.06 ± 
0.01
0.10 ± 
0.07
0.09 ± 
0.05
NK cells
CD3+ CD16+ (103/ȝL)
0.69 ± 
0.35
0.37 ± 
0.18
0.69 ± 
0.34
0.49 ± 
0.11
0.48 ± 
0.20
0.37 ± 
0.16
0.38 ± 
0.17
0.43 ± 
0.17
B cells
CD20+ cells (103/ȝL)
1.37 ± 
0.46
0.80 ± 
0.56
0.97 ± 
0.42
1.46 ± 
1.87
1.22 ± 
0.77
1.32 ± 
0.66
0.92 ± 
0.41
1.15 ± 
0.73
Activated T cells
CD69+ (103/ȝL)
0.06 ± 
0.04
0.06 ± 
0.02
0.08 ± 
0.05
0.05 ± 
0.04
0.11 ± 
0.13
0.06 ± 
0.04
0.13 ± 
0.15
0.06 ± 
0.04
Activated NK cells
CD69+ (103/ȝL)
0.33 ± 
0.34
0.15 ± 
0.07
0.28 ± 
0.26
0.12 ± 
0.09
0.14 ± 
0.08
0.13 ± 
0.02
0.16 ± 
0.09
0.15 ± 
0.07
Activated B cells
CD69+ (103/ȝL)
0.00 ± 
0.00
0.00 ± 
0.00
0.00 ± 
0.00
0.00 ± 
0.00
0.00 ± 
0.00
0.00 ± 
0.00
0.01 ± 
0.00
0.00 ± 
0.00
Day 15
No. of animals n=5 n=3 n=3 n=5 n=5 n=3 n=3 n=5
Total T-lymphocytes
CD3+ (103/ȝL)
3.37 ± 
0.90
2.62 ± 
0.41
2.24 ± 
0.87
3.00 ± 
0.45
2.35 ± 
0.54
2.05 ± 
0.89
2.38 ± 
1.22
2.36 ± 
0.95
T-helper
CD3+ CD4+ (103/ȝL)
2.13 ± 
0.69
1.85 ± 
0.38
1.30 ± 
0.51
1.62 ± 
0.26
1.46 ± 
0.33
1.34 ± 
0.55
1.59 ± 
0.82
1.64 ± 
0.66
T-cytotoxic
CD3+ CD8+ (103/ȝL)
1.05 ± 
0.30
0.56 ± 
0.07
0.66 ± 
0.18
1.23 ± 
0.32
0.70 ± 
0.25
0.67 ± 
0.33
0.69 ± 
0.30
0.65 ± 
0.25
Reg T Cells
CD25+ (103/ȝL)
0.11 ± 
0.03
0.12 ± 
0.02
0.09 ± 
0.04
0.11 ± 
0.04
0.08 ± 
0.03
0.08 ± 
0.00
0.09 ± 
0.06
0.10 ± 
0.08
NK cells
CD3+ CD16+ (103/ȝL)
0.45 ± 
0.18
0.54 ± 
0.17
0.53 ± 
0.03
0.42 ± 
0.12
0.30 ± 
0.07
0.40 ± 
0.06
0.15 ± 
0.09
0.34 ± 
0.06
B cells
CD20+ cells (103/ȝL)
1.47 ± 
0.36
1.03 ± 
0.46
0.95 ± 
0.35
1.20 ± 
0.86
1.30 ± 
0.87
1.17 ± 
0.52
0.80 ± 
0.39
0.98 ± 
0.58
Activated T cells
CD69+ (103/ȝL)
0.04 ± 
0.02
0.12 ± 
0.10
0.07 ± 
0.03
0.04 ± 
0.02
0.06 ± 
0.06
0.05 ± 
0.03
0.05 ± 
0.04
0.04 ± 
0.03
Activated NK cells
CD69+ (103/ȝL)
0.19 ± 
0.15
0.24 ± 
0.09
0.20 ± 
0.09
0.12 ± 
0.09
0.08 ± 
0.04
0.15 ± 
0.05
0.05 ± 
0.03
0.11 ± 
0.03
Activated B cells
CD69+ (103/ȝL)
0.01 ± 
0.00
0.01 ± 
0.00
0.00 ± 
0.00
0.00 ± 
0.00
0.01 ± 
0.00
0.01 ± 
0.00
0.00 ± 
0.00
0.00 ± 
0.00
Day 41
(recov-
ery
ani-
mals)
No. of animals n=2 n=0 n=0 n=2 n=2 n=0 n=0 n=2
Total T-lymphocytes
CD3+ (103/ȝL) 6.55 n.d. n.d. 5.41 5.56 ;n.d. n.d. 4.48
T-helper
CD3+ CD4+ (103/ȝL) 3.06 n.d. n.d. 2.19 3.16 n.d. n.d. 3.10
T-cytotoxic
CD3+ CD8+ (103/ȝL) 2.29 n.d. n.d. 2.89 1.86 n.d. n.d. 1.03
Reg T Cells
CD25+ (103/ȝL) 0.15 n.d. n.d. 0.20 0.14 n.d. n.d. 0.15
NK cells
CD3+ CD16+ (103/ȝL) 0.81 n.d. n.d. 0.60 0.60 n.d. n.d. 0.62
B cells
CD20+ cells (103/ȝL) 1.72 n.d. n.d. 3.38 2.53 n.d. n.d. 1.51
Activated T cells
CD69+ (103/ȝL) 0.26 n.d. n.d. 0.21 0.18 n.d. n.d. 0.14
Activated NK cells
CD69+ (103/ȝL) 0.40 n.d. n.d. 0.13 0.20 n.d. n.d. 0.30
Activated B cells
CD69+ (103/ȝL) 0.01 n.d. n.d. 0.00 0.01 n.d. n.d. 0.01
Data are presented as mean ± SD. 
Abbreviations: n.d. (not determined); n (number of animals).
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Table S18. Cytokines in cynomolgus monkeys.
Data are presented as mean ± SD. All results below the quantification limit or value could 
not be determined.
Abbreviations: IFN-Ȗ (interferon gamma); IL (Interleukin); ND (no data); TNF-Į (Tumor 
Necrosis Factor alpha).
Day Cytokines
Male & female
100 mg/kg/day
Pre treatment
No. of animals n=10
IL-1ȕ (pg/mL) 16.92 ± 2.74
IFN-Ȗ(pg/mL) 151.41 ± 271.20
TNF-Į(pg/mL) ND
IL-6 (pg/mL) 66.55 ± ND
IL-8 (pg/mL) 263.46 ± 225.12
IL-4 (pg/mL) ND
IL-12 (pg/mL) 624.88 ± 174.44
IL-2 (pg/mL) 219.95 ± 56.50
IL-10 (pg/mL) ND
8 hours
No. of animals n=10
IL-1ȕ (pg/mL) 18.60 ± 3.21
IFN-Ȗ(pg/mL) 113.37 ± 186.99
TNF-Į(pg/mL) ND
IL-6 (pg/mL) 28.93 ± 6.85
IL-8 (pg/mL) 450.00 ± 370.62
IL-4 (pg/mL) ND
IL-12 (pg/mL) 478.52 ± 71.65
IL-2 (pg/mL) 539.45 ± 507.52
IL-10 (pg/mL) ND
Table S19. Plasma IgE levels in cynomolgus monkeys.
Male
Vehicle (n=5) 25 mg/kg/day (n=3) 50 mg/kg/day (n=3) 100 mg/kg/day (n=5)
Day -6 IgE 1028 [566.6-64657] 1180 [456.5-12229] 3090 [1253-6037] 868.3 [425.3-1550]
Day 15 IgE 1668 [575.9-80837] 2144 [1598-61648] 3929 [1230-5382] 1117 [845.5-2748]
Female
Day -6 IgE 2533 [517.9-5488]
782.7 [596.7-987.8] 1587 [227.4-10925] 1639 [424.3-5087]
Day 15 IgE 5087 [1316-80685] 885.8 [703.9-944.1] 1448 [137.5-7526] 2697 [460.4-5122]
Data are presented as median [interquartile range]. 
Abbreviations: IgE (immuneglobulin E); n (number of animals).
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Table S22A. Histopathology in male cynomolgus monkeys
Histopathological findings
14 day follow-up
(n=3 per group)
Recovery animals
(n=2 per group)
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
400 mg/
kg/day
Adrenal glands
No visible lesions n=2 n=3 n=2 n=3 n=2 n=1
Eosinophelia with decreased vacuola-
tion; diffuse n=0 n=0 n=0 n=0 n=0 n=1
... moderate n=0 n=0 n=0 n=0 n=0 n=1
Eosinophilia with decreased vacuola-
tion; focal n=0 n=0 n=1 n=0 n=0 n=0
... minimal n=0 n=0 n=1 n=0 n=0 n=0
Mineralization n=1 n=0 n=0 n=0 n=0 n=0
... minimal n=1 n=0 n=0 n=0 n=0 n=0
Aorta No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Bone marrow, sternum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Bone, femur No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Bone, sternum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Brain
No visible lesions n=3 n=2 n=3 n=2 n=2 n=2
Infiltration, mononuclear cells n=0 n=1 n=0 n=1 n=0 n=0
... minimal n=0 n=1 n=0 n=1 n=0 n=0
Epididymides No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Esophagus
No visible lesions n=3 n=3 n=1 n=1 n=2 n=2
Infiltration, mixed inflammatory cells n=0 n=0 n=0 n=1 n=0 n=0
... minimal n=0 n=0 n=0 n=1 n=0 n=0
Infiltration, mononuclear cells n=0 n=0 n=2 n=1 n=0 n=0
... minimal n=0 n=0 n=2 n=1 n=0 n=0
Eyes No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Gallbladder
No visible lesions n=1 n=1 n=3 n=2 n=1 n=1
Infiltration, mixed inflammatory cells n=2 n=1 n=0 n=0 n=0 n=0
... minimal n=2 n=1 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=0 n=1 n=0 n=1 n=1 n=1
... minimal n=0 n=1 n=0 n=1 n=1 n=1
Heart
No visible lesions n=1 n=2 n=2 n=2 n=1 n=1
Infiltration, mixed inflammatory cells n=2 n=1 n=0 n=0 n=0 n=0
... minimal n=2 n=1 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=0 n=0 n=1 n=1 n=1 n=1
... minimal n=0 n=0 n=1 n=1 n=1 n=1
Injection sites
No visible lesions n=0 n=0 n=1 n=1 n=2 n=0
Hemorrhage n=2 n=3 n=2 n=2 n=0 n=0
... mild n=0 n=1 n=0 n=0 n=0 n=0
... moderate n=2 n=2 n=2 n=1 n=0 n=0
... marked n=0 n=0 n=0 n=1 n=0 n=0
Infiltration, mixed inflammatory cells n=1 n=3 n=1 n=1 n=0 n=0
... mild n=1 n=3 n=1 n=1 n=0 n=0
Infiltration, mononuclear cells n=2 n=1 n=0 n=0 n=0 n=2
... minimal n=2 n=1 n=0 n=0 n=0 n=2
Intestine, cecum
No visible lesions n=3 n=2 n=3 n=3 n=1 n=0
Parasite; protozoa n=0 n=1 n=0 n=0 n=0 n=2
Hyperplasia, germinal centers n=0 n=0 n=0 n=0 n=1 n=0
... mild n=0 n=0 n=0 n=0 n=1 n=0
Intestine, colon
No visible lesions n=3 n=3 n=3 n=3 n=2 n=1
Parasite; protozoa n=0 n=0 n=0 n=0 n=0 n=1
Intestine, duodenum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and 
non-human primates
11
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 296
296
Histopathological findings
14 day follow-up
(n=3 per group)
Recovery animals
(n=2 per group)
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
400 mg/
kg/day
Intestine, ileum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Intestine, jejunum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Intestine, rectum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Kidneys
No visible lesions n=1 n=1 n=0 n=1 n=1 n=0
Infiltration, mononuclear cells n=2 n=2 n=3 n=2 n=1 n=2
... minimal n=2 n=2 n=3 n=2 n=1 n=2
Mineralization n=0 n=0 n=1 n=0 n=1 n=0
... minimal n=0 n=0 n=1 n=0 n=1 n=0
Degeneration/regeneration n=1 n=0 n=0 n=0 n=0 n=0
... minimal n=1 n=0 n=0 n=0 n=0 n=0
Liver
No visible lesions n=2 n=3 n=1 n=1 n=0 n=1
Infiltration, mononuclear cells n=1 n=0 n=2 n=2 n=2 n=1
... minimal n=1 n=0 n=2 n=2 n=2 n=1
Lungs
No visible lesions n=3 n=3 n=2 n=2 n=1 n=2
Infiltration, mononuclear cells n=0 n=0 n=1 n=0 n=1 n=0
... minimal n=0 n=0 n=1 n=0 n=1 n=0
Foreign material n=0 n=0 n=0 n=1 n=0 n=0
Lymph node, mes-
enteric No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Lymph node, man-
dibular No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Nerves, optic No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Nerve, sciatic
No visible lesions n=3 n=2 n=3 n=3 n=2 n=2
Perivascular; infiltration, mononu-
clear cells n=0 n=1 n=0 n=0 n=0 n=0
... minimal n=0 n=1 n=0 n=0 n=0 n=0
Pancreas
No visible lesions n=2 n=3 n=3 n=2 n=1 n=2
Infiltration, mononuclear cells n=1 n=0 n=0 n=1 n=1 n=0
... minimal n=1 n=0 n=0 n=1 n=1 n=0
Parathyroid gland
No visible lesions n=3 n=3 n=3 n=3 n=2 n=1
Ectopic thymus n=1 n=0 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=0 n=0 n=0 n=0 n=0 n=1
... minimal n=0 n=0 n=0 n=0 n=0 n=1
Pituitary gland
No visible lesions n=3 n=2 n=3 n=3 n=2 n=2
Cyst n=0 n=1 n=0 n=0 n=0 n=0
... mild n=0 n=1 n=0 n=0 n=0 n=0
Prostate gland
No visible lesions n=2 n=2 n=1 n=2 n=0 n=1
Infiltration, mononuclear cells n=1 n=1 n=2 n=1 n=2 n=1
... minimal n=1 n=1 n=2 n=1 n=2 n=1
Salivary gland, sub-
mandibular
No visible lesions n=1 n=0 n=1 n=2 n=0 n=1
Infiltration, mononuclear cells n=2 n=3 n=2 n=1 n=2 n=1
... minimal n=2 n=3 n=2 n=1 n=2 n=1
Seminal vesicles
No visible lesions n=3 n=3 n=3 n=3 n=2 n=1
Infiltration, mononuclear cells n=0 n=0 n=0 n=0 n=0 n=1
... minimal n=0 n=0 n=0 n=0 n=0 n=1
Skeletal muscle No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Skin No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
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Table S22A. continued.
Histopathological findings
14 day follow-up
(n=3 per group)
Recovery animals
(n=2 per group)
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
400 mg/
kg/day
Spinal cord, thoracic No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Spleen
No visible lesions n=2 n=3 n=3 n=3 n=2 n=2
Hyperplasia, germinal centers n=1 n=0 n=0 n=0 n=0 n=0
... mild n=1 n=0 n=0 n=0 n=0 n=0
Stomach
No visible lesions n=0 n=1 n=0 n=0 n=1 n=0
Infiltration, mixed inflammatory cells n=3 n=0 n=0 n=3 n=0 n=0
... minimal n=0 n=0 n=0 n=1 n=0 n=0
... mild n=3 n=0 n=0 n=2 n=0 n=0
Hyperplasia, germinal centers n=0 n=2 n=3 n=0 n=1 n=2
... minimal n=0 n=1 n=2 n=0 n=1 n=0
... mild n=1 n=1 n=1 n=0 n=0 n=2
Testes
No visible lesions n=0 n=1 n=0 n=3 n=0 n=0
Fibroplasia n=1 n=1 n=1 n=0 n=0 n=0
... mild n=1 n=1 n=1 n=0 n=0 n=0
Immature but normal n=3 n=2 n=3 n=0 n=2 n=2
Thymus
No visible lesions n=3 n=3 n=3 n=2 n=2 n=2
Involution n=0 n=0 n=0 n=1 n=0 n=0
... mild n=0 n=0 n=0 n=1 n=0 n=0
Thyroid gland
No visible lesions n=3 n=0 n=1 n=2 n=1 n=2
Ectopic thymus n=0 n=1 n=2 n=0 n=1 n=0
Infiltration, macrophages n=0 n=1 n=0 n=0 n=1 n=0
... minimal n=0 n=1 n=0 n=0 n=1 n=0
Infiltration, mononuclear cells n=0 n=2 n=1 n=1 n=1 n=0
... minimal n=0 n=2 n=1 n=1 n=1 n=0
Tongue
No visible lesions n=3 n=1 n=2 n=3 n=1 n=1
Not examined, no section n=0 n=0 n=0 n=0 n=0 n=1
Infiltration, mixed inflammatory cells n=0 n=0 n=1 n=0 n=0 n=0
... mild n=0 n=0 n=1 n=0 n=0 n=0
Infiltration, mononuclear cells n=0 n=2 n=0 n=0 n=1 n=0
... minimal n=0 n=2 n=0 n=0 n=1 n=0
Trachea
No visible lesions n=2 n=2 n=1 n=1 n=1 n=1
Infiltration, mononuclear cells n=1 n=1 n=2 n=2 n=1 n=1
... minimal n=1 n=1 n=2 n=2 n=0 n=1
... mild n=0 n=0 n=0 n=0 n=1 n=0
Urinary bladder
No visible lesions n=2 n=2 n=3 n=1 n=1 n=0
Infiltration, mononuclear cells n=2 n=2 n=3 n=1 n=1 n=2
... minimal n=2 n=2 n=3 n=1 n=1 n=2
Abbreviations: n (number of animals).
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Table S22B. Histopathology in female cynomolgus monkeys.
Histopathological findings
14 day follow-up
(n=3 per group)
Recovery animals
(n=2 per group)
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
400 mg/
kg/day
Adrenal glands
No visible lesions n=3 n=3 n=3 n=2 n=1 n=2
Mineralization n=0 n=0 n=0 n=1 n=1 n=0
... minimal n=0 n=0 n=0 n=1 n=1 n=0
Aorta No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Bone marrow, sternum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Bone, femur No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Bone, sternum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Brain
No visible lesions n=2 n=2 n=2 n=3 n=2 n=2
Infiltration, mononuclear cells n=1 n=1 n=1 n=0 n=0 n=0
... minimal n=1 n=1 n=1 n=0 n=0 n=0
Cervix
No visible lesions n=3 n=3 n=2 n=33 n=2 n=2
Infiltration, mononuclear cells n=0 n=0 n=1 n=0 n=0 n=0
... minimal n=0 n=0 n=1 n=0 n=0 n=0
Esophagus
No visible lesions n=2 n=2 n=2 n=3 n=1 n=2
Infiltration, mononuclear cells n=1 n=1 n=1 n=0 n=1 n=0
... minimal n=0 n=1 n=1 n=0 n=1 n=0
... mild n=1 n=0 n=0 n=0 n=0 n=0
Eyes
No visible lesions n=3 n=3 n=3 n=3 n=1 n=2
Iris; infiltration, mononuclear cells n=0 n=0 n=0 n=0 n=1 n=0
... minimal n=0 n=0 n=0 n=0 n=1 n=0
Gallbladder
No visible lesions n=1 n=2 n=1 n=2 n=2 n=1
Infiltration, mixed inflammatory cells n=0 n=1 n=0 n=1 n=0 n=0
... minimal n=0 n=1 n=0 n=1 n=0 n=0
Infiltration, mononuclear cells n=2 n=0 n=2 n=0 n=0 n=1
... minimal n=2 n=0 n=2 n=0 n=0 n=1
Heart
No visible lesions n=2 n=2 n=1 n=1 n=1 n=1
Infiltration, mixed inflammatory cells n=1 n=0 n=0 n=2 n=0 n=0
... minimal n=1 n=0 n=0 n=2 n=0 n=0
Infiltration, mononuclear cells n=0 n=1 n=2 n=0 n=1 n=1
... minimal n=0 n=1 n=2 n=0 n=1 n=1
Injection sites
No visible lesions n=1 n=1 n=0 n=1 n=1 n=1
Hemorrhage n=1 n=2 n=2 n=1 n=0 n=0
... mild n=0 n=1 n=1 n=0 n=0 n=0
... moderate n=1 n=1 n=1 n=1 n=0 n=0
Infiltration, mixed inflammatory cells n=0 n=2 n=2 n=1 n=0 n=0
... mild n=0 n=0 n=1 n=0 n=0 n=0
... mild n=0 n=2 n=1 n=1 n=0 n=0
Infiltration, mononuclear cells n=1 n=0 n=0 n=1 n=1 n=1
... minimal n=1 n=0 n=0 n=1 n=1 n=1
Intestine, cecum
No visible lesions n=3 n=2 n=3 n=3 n=1 n=2
Parasite; protozoa n=0 n=1 n=0 n=0 n=1 n=0
Glands; infiltration, mixed inflam-
matory cells n=0 n=1 n=0 n=0 n=0 n=0
... minimal n=0 n=1 n=0 n=0 n=0 n=0
Intestine, colon
No visible lesions n=3 n=2 n=3 n=3 n=2 n=2
Glands; infiltration, mixed inflam-
matory cells n=0 n=1 n=0 n=0 n=0 n=0
... minimal n=0 n=1 n=0 n=0 n=0 n=0
Intestine, duodenum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
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Table S22B. continued.
Histopathological findings
14 day follow-up
(n=3 per group)
Recovery animals
(n=2 per group)
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
400 mg/
kg/day
Intestine, ileum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Intestine, jejunum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Intestine, rectum No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Kidneys
No visible lesions n=1 n=0 n=0 n=0 n=0 n=0
Pelvis; infiltration, mixed inflamma-
tory cells n=0 n=0 n=0 n=1 n=0 n=0
... mild n=0 n=0 n=0 n=1 n=0 n=0
Infiltration, mononuclear cells n=2 n=3 n=3 n=2 n=2 n=2
... minimal n=2 n=3 n=3 n=2 n=2 n=2
Liver
No visible lesions n=1 n=0 n=0 n=2 n=1 n=0
Infiltration, mononuclear cells n=2 n=3 n=3 n=1 n=1 n=2
... minimal n=2 n=3 n=3 n=1 n=1 n=2
Lungs
No visible lesions n=2 n=3 n=2 n=3 n=1 n=2
Infiltration, macrophages n=1 n=0 n=0 n=0 n=0 n=0
... minimal n=1 n=0 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=0 n=0 n=1 n=0 n=1 n=0
... minimal n=0 n=0 n=1 n=0 n=1 n=0
Lymph node, mes-
enteric No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Lymph node, man-
dibular
No visible lesions n=2 n=3 n=2 n=3 n=2 n=2
Hematopoiesis; increased n=1 n=0 n=0 n=0 n=0 n=0
... mild n=1 n=0 n=0 n=0 n=0 n=0
Sinus plasmacytosis n=0 n=0 n=1 n=0 n=0 n=0
... mild n=0 n=0 n=1 n=0 n=0 n=0
Mammary gland No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Nerves, optic No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Nerve, sciatic
No visible lesions n=3 n=3 n=3 n=3 n=1 n=2
Perivascular; infiltration, mononu-
clear cells n=0 n=0 n=0 n=0 n=1 n=0
... minimal n=0 n=0 n=0 n=0 n=1 n=0
Ovaries
No visible lesions n=1 n=2 n=2 n=1 n=1 n=2
Mineralization n=2 n=1 n=1 n=2 n=1 n=0
... minimal n=2 n=1 n=1 n=2 n=1 n=0
Pancreas No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Parathyroid gland
No visible lesions n=3 n=3 n=2 n=3 n=1 n=1
Ectopic thymus n=0 n=0 n=1 n=0 n=1 n=0
Cyst n=0 n=0 n=0 n=0 n=0 n=1
... minimal n=0 n=0 n=0 n=0 n=0 n=1
Pituitary gland
No visible lesions n=2 n=3 n=3 n=3 n=2 n=2
Cyst n=1 n=0 n=0 n=0 n=0 n=0
... minimal n=1 n=0 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=1 n=0 n=0 n=0 n=0 n=0
... minimal n=1 n=0 n=0 n=0 n=0 n=0
Salivary gland, sub-
mandibular
No visible lesions n=2 n=1 n=1 n=1 n=1 n=0
Infiltration, mononuclear cells n=1 n=2 n=2 n=2 n=1 n=2
... minimal n=1 n=2 n=2 n=2 n=1 n=2
Skeletal muscle
No visible lesions n=3 n=2 n=2 n=3 n=1 n=1
Infiltration, mononuclear cells n=0 n=1 n=1 n=0 n=1 n=1
... minimal n=0 n=1 n=1 n=0 n=1 n=1
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Table S22B. continued
Histopathological findings
14 day follow-up
(n=3 per group)
Recovery animals
(n=2 per group)
Vehicle 25 mg/kg/day
50 mg/
kg/day
100 mg/
kg/day Vehicle
400 mg/
kg/day
Skin
No visible lesions n=3 n=2 n=2 n=3 n=2 n=2
Infiltration, mixed inflammatory cells n=0 n=1 n=0 n=0 n=0 n=0
... minimal n=0 n=1 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=0 n=0 n=1 n=0 n=0 n=0
... minimal n=0 n=0 n=1 n=0 n=0 n=0
Spinal cord, thoracic No visible lesions n=3 n=3 n=3 n=3 n=2 n=2
Spleen
No visible lesions n=3 n=3 n=3 n=3 n=1 n=2
Hyperplasia, germinal centers n=0 n=0 n=0 n=0 n=1 n=0
... mild n=0 n=0 n=0 n=0 n=1 n=0
Stomach
No visible lesions n=0 n=2 n=1 n=0 n=0 n=0
Infiltration, mixed inflammatory cells n=2 n=0 n=0 n=3 n=0 n=0
... minimal n=0 n=0 n=0 n=1 n=0 n=0
... mild n=2 n=0 n=0 n=2 n=0 n=0
Infiltration, mononuclear cells n=1 n=0 n=0 n=0 n=0 n=0
... mild n=1 n=0 n=0 n=0 n=0 n=0
Hyperplasia, germinal centers n=0 n=1 n=2 n=0 n=2 n=2
... minimal n=0 n=1 n=0 n=0 n=1 n=1
... mild n=0 n=0 n=2 n=0 n=1 n=1
Thymus
No visible lesions n=2 n=3 n=2 n=3 n=2 n=2
Cyst n=1 n=0 n=0 n=0 n=0 n=0
... minimal n=1 n=0 n=0 n=0 n=0 n=0
Involution n=1 n=0 n=1 n=0 n=0 n=0
... mild n=1 n=0 n=1 n=0 n=0 n=0
Thyroid gland
No visible lesions n=3 n=2 n=1 n=1 n=1 n=0
Cyst n=0 n=0 n=0 n=1 n=0 n=1
... mild n=0 n=0 n=0 n=1 n=0 n=1
Infiltration, macrophages n=0 n=1 n=1 n=0 n=0 n=1
... minimal n=0 n=1 n=1 n=0 n=0 n=1
Infiltration, mononuclear cells n=0 n=0 n=1 n=2 n=1 n=1
... minimal n=0 n=0 n=1 n=2 n=1 n=1
Tongue
No visible lesions n=2 n=2 n=3 n=2 n=0 n=2
Infiltration, mononuclear cells n=1 n=1 n=0 n=1 n=2 n=0
... minimal n=1 n=1 n=0 n=1 n=1 n=0
Trachea
No visible lesions n=1 n=0 n=3 n=2 n=1 n=1
Infiltration, mononuclear cells n=2 n=3 n=0 n=1 n=1 n=1
... minimal n=2 n=3 n=0 n=1 n=0 n=1
... mild n=0 n=0 n=0 n=0 n=1 n=0
Urinary bladder
No visible lesions n=1 n=0 n=3 n=2 n=2 n=2
Infiltration, mononuclear cells n=2 n=3 n=0 n=1 n=0 n=0
... minimal n=2 n=3 n=0 n=1 n=0 n=0
Uterus
No visible lesions n=3 n=3 n=2 n=3 n=2 n=2
Infiltration, mononuclear cells n=0 n=0 n=1 n=0 n=0 n=0
... minimal n=0 n=0 n=1 n=0 n=0 n=0
Vagina
No visible lesions n=0 n=0 n=0 n=0 n=0 n=0
Infiltration, mononuclear cells n=3 n=3 n=3 n=3 n=2 n=2
... minimal n=1 n=1 n=3 n=2 n=0 n=1
... mild n=2 n=2 n=0 n=1 n=2 n=1
Abbreviations: n (number of animals).
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Table S23. Toxicokinetics of Adrecizumab in cynomolgus monkeys
Gender Parameter
25 mg/kg/day 50 mg/kg/day 100 mg/kg/day
Day 1A Day 14 Day 1 Day 14B Day 1C Day 14D
Male
No. of animals n=3 n=3 n=3 n=3 n=5 n=5
Tmax (h) 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00
Cmax (ȝg/mL) 478 ± 19.8 732 ± 61.8 948 ± 161 1560 ± 398 2150 ± 440 3620 ± 635
AUC0-24h 
(h* ȝg/mL) 6110 ± 88.9 11270 ± 493 11700 ± 702 23200 ± 3390 28800 ± 3410 52300 ± 5850
AUC0-inf 
(h* ȝg/mL)E
23700 ± 
1400 28700 ± 500
42200 ± 
3500 68900 ± 14400
103200 ± 
18500
184000 ± 
67600
Tn=1 (h) 66.8 ± 0.862 41.2 ± 4.31 66.8 ± 0.862 41.2 ± 4.31 49.5 ± 9.12 -
Female
No. of animals n=3 n=3 n=3 n=3 n=5 n=5
Tmax (h) 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00
Cmax (ȝg/mL) 493 ± 63.3 797 ± 177 944 ± 90.9 1650 ± 488 2120 ± 647 3530 ± 183
AUC0-24h
(h* ȝg/mL) 6880 ± 1770 12610 ± 3500 12470 ± 153 26400 ± 4530 23900 ± 7630 48000 ± 7470
AUC0-inf 
(h*ȝg/mL)
28800 ± 
8590
40300 ± 
27200
50400 ± 
2890 78000 ± 33900 84200 ± 22600
185400 ± 
103500
Tn=1 (h) 68.9 ± 12.0 437 ± 31.5 68.9 ± 12.0 42.2 ± 16.12 51.3 ± 10.4 -
Male 
&
Female
No. of animals n=6 n=6 n=6 n=6 n=10 n=10
Tmax (h) 0.517 ± 0.00 0.517 ± 0.00 0.517 ± 0.00 0.571 ± 0.00 0.517 ± 0.00 0.517 ± 0.00
Cmax (ȝg/mL) 487 ± 46.5 764 ± 124 946 ± 117 1590 ± 376 2140 ± 504 3570 ± 413
AUC0-24h
(h* ȝg/mL) 6500 ± 1200 11940 ± 2360 12100 ± 631 24480 ± 3730 26400 ± 6150 50100 ± 6720
AUC0-inf 
(h* ȝg/mL)
26300 ± 
6160
34500 ± 
18340
46300 ± 
5350 72500 ± 20420 93700 ± 21900
184700 ± 
82400
Tn=1 (h) 78.2 ± 6.28 38.2 ± 14.1 67.8 ± 7.68 42.2 ± 16.12 51.3 ± 10.4 -
AUC0-24h/dose
(h*kg* ȝg/mL/
mg)
260 ± 48.0 478 ± 94.3 241 ± 12.6 490 ± 74.6 264 ± 5.04 501 ± 67.2
Cmax/dose
(kg* ȝg/mL/
mg)
19.5 ± 1.88 30.6 ± 4.95 18.9 ± 2.33 31.9 ± 7.51 21.4 ± 5.04 35.7 ± 4.13
Racc - 1.84 ± 0.101 - 2.04 ± 0.227 - 2.00 ± 2.04
Data are presented as mean ± SD 
A 1 male animal was excluded as an outlier for Tmax and Cmax
B 1 female animal was excluded from the evaluation (dosing problem)
C 1 female animal was excluded as an outlier for Tmax and Cmax
D 1 male animal was excluded as an outlier for Tmax and Cmax
E AUC0-inf, high uncertainty because extrapolation to infinity > 20% or weak regression
- not calculated
Racc(0-24h) = AUC(0-24h) on Day 14 / AUC(0-24h) on Day 1
Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and 
non-human primates
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Abstract
Aims
Adrenomedullin (ADM) is an important regulator of endothelial barrier 
function and vascular tone, and may represent a novel treatment target in sepsis. 
The non-neutralizing ADM antibody Adrecizumab has shown promising 
results in preclinical sepsis models. In the present study, we investigated 
the safety, tolerability and pharmacokinetics (PK)/pharmacodynamics of 
Adrecizumab in a first-in-man study and in a second study during experimental 
human endotoxemia.
Methods
Forty-eight healthy male volunteers were enrolled in two randomized, double-
blind, placebo-controlled phase I studies. In both studies, subjects received 
placebo or one of three doses of Adrecizumab (n = 6 per group). In the second 
study, a bolus of 1 ng/kg endotoxin was followed by infusion of 1 ng/kg/h 
endotoxin for 3 h to induce systemic inflammation, and the study medication 
infusion started 1 h after endotoxin bolus administration.
Results
Adrecizumab showed an excellent safety profile in both studies. PK analyses 
showed proportional increases in the maximum plasma concentration of 
Adrecizumab with increasing doses, a small volume of distribution, a low 
clearance rate and a terminal half-life of ~14 days. Adrecizumab elicited a 
pronounced increase in plasma ADM levels, whereas levels of mid-regional 
proadrenomedullin remained unchanged, indicating that de novo synthesis 
of ADM was not influenced. In the second study, no effects of Adrecizumab 
on cytokine clearance were observed, whereas endotoxin-induced flu-like 
symptoms resolved more rapidly.
Conclusions
Administration of adrecizumab is safe and well tolerated in humans, both in 
the absence and presence of systemic inflammation. These findings pave the 
way for further investigation of Adrecizumab in sepsis patients.
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Introduction
Sepsis is a major health problem for patients with infectious diseases 
worldwide, with increasing incidence and a high mortality rate1-3. It is defined 
as life-threatening organ dysfunction caused by a dysregulated host response 
to infection4. Sepsis-induced vascular effects include vasodilation and loss 
of vascular barrier function5. This results in hypotension, tissue oedema and 
ultimately, lethal organ dysfunction. Besides (supportive) therapies such as 
antibiotics, mechanical ventilation and vasopressors, there are currently no 
adjuvant therapies available. 
Adrenomedullin (ADM) is a free circulating peptide hormone, which is 
involved in the regulation of vascular tone and stabilization of the endothelial 
barrier6-8. During sepsis and most pronounced during septic shock, elevated 
concentrations of circulating ADM are observed, which correlate with disease 
severity and mortality9,10. However, correlation does not imply causation, 
and increased levels of ADM could also represent a (failing) compensatory 
response. Mechanistic studies actually indicate that ADM can exert both 
beneficial and detrimental effects in sepsis. Therefore, ADM is referred to 
as a 'double-edged' sword in sepsis. On one hand, preclinical studies in 
animal models of systemic inflammation and sepsis have shown that ADM 
administration restores vascular barrier function through effects on endothelial 
cells, thereby reducing detrimental tissue oedema11-14. On the other hand, 
ADM has also been reported to induce vasodilation and hypotension15-17, 
which could in theory further aggravate hypotension in patients with septic 
shock. It was thus hypothesized that modulation of ADM with antibodies 
could be beneficial, if it would retain or even potentiate the beneficial effects 
of ADM while negating its potentially detrimental vasodilatory effects. 
Interestingly, a highly specific non-neutralizing mouse monoclonal antibody 
(HAM1101) was previously shown to improve survival in cecal ligation and 
puncture (CLP)-induced sepsis in mice18. In addition, in a fully resuscitated 
murine CLP-induced septic shock model, treatment with this antibody 
resulted in reduced vasopressor demand and improved organ function19. 
These promising results led to the development of a humanized antibody 
for further clinical investigation (HAM8101, later named Adrecizumab). In 
lipopolysaccharide (LPS)-induced systemic inflammation in rats and CLP-
induced sepsis in mice, Adrecizumab attenuated vascular leakage and vascular 
dysfunction, as well as improved survival20. Extensive preclinical safety and 
toxicological studies did not reveal any safety concerns (unpublished data). 
The present work describes two phase I studies in which the first-in-human 
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safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) 
of single, escalating intravenous doses of Adrecizumab were investigated. 
The first study was conducted in healthy male volunteers during normal 
non-inflammatory conditions. The second study was conducted during 
systemic inflammation evoked by experimental human endotoxemia. The 
experimental endotoxemia model is a safe and reproducible method for 
inducing a controlled transient systemic inflammatory response in humans 
by intravenous administration of E. coli endotoxin (LPS)21.
Methods
General
Firstly, a first-in-human phase I, randomized, double-blind, placebo-
controlled study was conducted to evaluate single escalating intravenous 
(i.v.) doses of Adrecizumab in healthy male subjects. Next, a second phase 
I, randomized, double-blind, placebo-controlled study was conducted to 
evaluate single escalating i.v. doses of Adrecizumab in healthy male subjects 
during experimental human endotoxemia (details provided below). Both 
studies were conducted at a single site (the Department of Intensive Care 
Medicine at the Radboud University Medical Center in Nijmegen, the 
Netherlands), and were carried out in accordance with the Declaration of 
Helsinki and Good Clinical Practice standards. The study protocols were 
approved by the local ethics committee of the Radboud University Medical 
Center (approval numbers 2016–2283 and 2016–2740) prior to recruitment 
and inclusion of subjects, and registered at clinicaltrials.gov (NTC02991508 
and NTC03083171).
Study medication
Adrecizumab is a non-neutralizing humanized high-affinity immunoglobulin 
(Ig) G1ț full-length antibody directed against the N-terminus of ADM. 
Adrecizumab was produced using Chinese hamster ovary cells under good 
manufacturing practice conditions. Adrecizumab and placebo were supplied 
by the study sponsor (Adrenomed AG, Hennigsdorf, Germany) as a solution 
for injection in identical sterile single-use vials, containing 10.4 ml solution, 
allowing for an extractable volume of 10 ml. Adrecizumab (20 mg/ml) was 
dissolved in a vehicle consisting of histidine-hydrochloride monochloride, 
glycine and water. The placebo solution consisted of the identical vehicle. 
Vials were manufactured by Glycotope Biotechnology GmbH (Heidelberg, 
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Germany). Manufacturing, packaging, quality control and preparation were 
described in an Investigational Medicinal Product Dossier. Randomization 
of subjects (using a predetermined randomization list) and preparation of 
study medication was performed by an independent and unblinded research 
team, who were not involved in any other aspect of the studies. Dose selection 
for the present human studies (0.5, 2.0 and 8.0 mg/kg Adrecizumab) was 
based on preclinical data, showing a no adverse events level (NOAEL) of 400 
mg/kg and 100 mg/kg for rats and cynomolgus monkeys, respectively. Using 
a conversion factor of 6.2 for the rat and 3.1 for the monkey, the human 
equivalent doses are 65 mg/kg and 32 mg/kg, providing a safety margin 
factor of 130 or 64 to the proposed starting dose of 0.5 mg/kg. In addition, 
a therapeutic dose of 2.0 mg/kg was regarded as sufficient, based on various 
preclinical efficacy studies18-20 (and other, as yet unpublished, data). Including 
an additional higher dose of 8.0 mg/kg in humans provides the opportunity 
to demonstrate potential dose dependency of this higher dosage.
Subjects
After giving written consent, male subjects, aged 18–35 years, with a body 
mass index (BMI) between 18 kg/m2 and 30 kg/m2 were included. Before 
participation, health status was determined by past medical history, physical 
examination, 12-lead electrocardiography (ECG) and safety laboratory tests 
at a screening visit. Exclusion criteria included atopic constitution, use of any 
medication, flu-like symptoms 14 days prior to the studies, significant blood 
loss and/or participation in any other clinical trial within 90 days prior to 
the studies. For the experimental endotoxemia study, previous participation 
in endotoxemia trials was an additional exclusion criterion. The use of 
recreational drugs was prohibited 7 days prior to and during the study and 
in the subsequent 90-day follow-up period. Alcohol and tobacco use was 
prohibited 24 h before and after the experimental day.
Study procedures
The general study procedures are depicted in Figure 1 and were virtually 
identical for both studies, except for the administration of LPS in the 
endotoxemia study. Fasted subjects were admitted to the research unit in the 
morning (07:30 h). An i.v. cannula was placed for infusion of fluids, as well 
as administration of endotoxin and study drug. An intra-arterial cannula 
was placed for continuous blood pressure monitoring and frequent blood 
withdrawal. Vital signs were continuously monitored until discharge. In each 
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study, 24 eligible subjects were assigned to one of three dose groups: 0.5, 2 and 
8 mg/kg body weight. Each dose group consisted of eight subjects randomly 
assigned to receive either Adrecizumab or placebo (n = 6 active study drug, 
n = 2 placebo). Frequent blood samples were collected during the first 8 h 
after study drug administration, for analyses of safety laboratory parameters 
as well as PK and PD parameters. Subjects were discharged 8 h after study 
drug administration, after assessment and confirmation of their fitness by 
the investigator. Owing to the expected long half-life (T½) of Adrecizumab, 
subjects returned for further follow-up visits after 1, 7, 14, 28, 60 and 90 
days.
Figure 1. Schematic overview of study procedures for the first-in-human study (A) 
and the human endotoxemia study (B). Abbreviations: ECG, electrocardiography; LPS, 
lipopolysaccharide.
Safety, tolerability and pharmacokinetics/dynamics of the adrenomedullin antibody Adrecizumab in a 
first-in-human study and during experimental human endotoxemia in healthy subjects
12
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 311
311
Induction of systemic inflammation in the human endotoxemia model
In the present study, an endotoxemia model, applying continuous infusion 
of LPS for 3 h, was used because this is thought to be a better representation 
of the inflammatory response as observed in patients with sepsis than a bolus 
administration of LPS22. Systemic inflammation was induced by a bolus 
administration of 1 ng/kg Escherichia coli type O113 LPS (List Biological 
Laboratories Inc., Campbell, CA, USA) 1 h prior to study drug administration. 
This bolus was followed by a continuous intravenous infusion of LPS 1 ng/
kg/h for 3 h to induce systemic inflammation. To prevent vasovagal responses, 
subjects received prehydration with 1.5 L glucose 2.5%/NaCl 0.45% over the 
course of 45 min23.
Safety parameters
Safety and tolerability were the primary endpoints of both studies. Frequent 
safety and tolerability assessments were performed on the study drug 
administration day for both studies until discharge and during the 90-day 
follow-up period. Safety parameters included blood pressure, heart rate and 
peripheral oxygen saturation (recorded from a Philips MP50 patient monitor 
[Philips, Eindhoven, the Netherlands]; on the study drug administration day, 
data were sampled every 30 s by a custom inhouse-developed data recording 
system), temperature (FirstTemp Genius 2; Sherwood Medical, St Louis, 
MO, USA), 12-lead ECG (Philips PageWriter Trim III, Philips, Amsterdam, 
the Netherlands) and routine haematology and biochemistry laboratory tests. 
An adverse event (AE) was defined as any untoward medical occurrence in a 
clinical trial subject administered a study product, which did not necessarily 
have a causal relationship with this treatment. AEs were recorded throughout 
the study and follow-up period. All AEs were judged by the investigator with 
regard to severity (mild, moderate or severe) and their relation to the study 
drug (unrelated, possible, probably or definite). In the human endotoxemia 
study, common symptoms of endotoxemia (headache, abdominal pain, back 
pain, fever and muscle aches) were not regarded as AEs unless they were of 
abnormal severity or duration. In order to minimize the risks for subjects 
in both studies, dosage groups were tested sequentially if the previous dose 
was tolerated without relevant side effects. In each dose group, the first four 
subjects were tested consecutively, with 48 h between experimental days. In 
both studies, an independent data safety monitoring board reviewed safety 
data, including vital signs, laboratory parameters and AEs, and approved to 
continue the study with the next dose groups.
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Sample collection
Blood was drawn in ethylenediaminetetraacetic acid anticoagulated 
vacutainers and centrifuged (10 min, 2000 g, 4°C), after which plasma was 
stored at -80°C until analysis.
Pharmacokinetic analysis
For both studies, PK analysis was performed on samples collected at the 
following time points relative to study drug administration: immediately 
prior to administration and then 15, 30, 60 and 90 min; 2, 3, 4 and 8 h; and 
1, 7, 14, 28, 60 and 90 days after administration. PK analysis was performed 
by Aurigon Toxicological Research Center (Dunakeszi, Hungary) under good 
laboratory practice conditions. Free (unbound) Adrecizumab was quantified 
in the human plasma samples using a validated luminescence immunoassay, 
with a quantification limit of 0.85 ƫg/ml. The highest observed plasma 
concentration was defined as Cmax. The area under the plasma concentration–
time curve from t0 to the last measurement (AUC0–t) was calculated using the 
linear trapezoidal rule. The elimination rate constant (Ȝz) was calculated by 
log linear regression of concentrations observed during the terminal phase of 
elimination. The AUC from t0 to infinity (AUC0–∞) was calculated as the sum 
of AUC0–t and the extrapolated area using the last measured concentration 
(C(last)) and the elimination rate constant by taking the formula C(last)/Ȝz. The 
terminal half-life (T½Ȝ) was calculated by dividing the natural logarithm of 2 
by Ȝz. Clearance (Cl) was calculated as dose/AUC0–∞. The apparent volume 
of distribution during the terminal phase (Vz) was calculated as Cl/Ȝz. The 
individual and mean plasma concentration–time curves were evaluated using 
the non-compartmental method for infusion administration. PK analysis 
was performed using validated Phoenix WinNonlin Version 6.3 software 
(Pharsight Corporation, St Louis, MO, USA).
Pharmacodynamic analysis
Concentrations of total ADM (Adrecizumab bound and unbound) were 
measured using the Spingotest® bio-ADM assay24. Mid-regional pro-
Adrenomedullin (MR-proADM) was measured using the B·R·A·H·M·S MR-
proADM KRYPTOR assay (BRAHMS GmbH, Hennigsdorf, Germany). 
Endothelin-1 was analysed using an enzyme-linked immunosorbent assay 
(QuantiGlo®, R&D systems, Minneapolis, MN, USA). Noradrenaline, 
adrenaline and dopamine levels were measured using routine analysis methods 
(high-pressure liquid chromatography with fluorometric detection, as 
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described previously25). Plasma renin was analysed using a radioimmunoassay 
(RENIN III, Cisbio, Codolet, France). In the endotoxemia study, circulating 
concentrations of the inflammatory cytokines tumour necrosis factor alpha 
(TNF-Į), interleukin (IL) 6, IL-8, IL-10, granulocyte-colony stimulating 
factor, monocyte chemoattractant protein 1 and interferon gamma-induced 
protein 10 were determined batchwise using a simultaneous Luminex assay 
(Milliplex, Millipore, Billerica, MA, USA) according to the manufacturers’ 
instructions.
Endotoxemia-induced symptoms
Subjects scored endotoxemia-induced flu-like symptoms (the ‘sickness score’) 
every 30 min throughout the study drug administration day on a numerical 
response scale ranging from 0 to 10 (0 meaning no complaint at all, 10 
extremely severe complaints). LPS-induced flu-like symptoms were not 
considered to be AEs unless they were of abnormal severity or duration, as 
judged by the blinded investigators.
Statistical analysis
Data were tested for normality using the Kolmogorov–Smirnov test, and all 
data were normally distributed. Demographic data were expressed as mean ± 
standard deviation, and other data were expressed as mean ± standard error 
of the mean. Differences between placebo and Adrecizumab groups were 
tested pair-wise using the interaction term from two-way analysis of variance 
(ANOVA) with repeated measures in the factor time. The dose proportionality 
of Cmax and AUC0–∞ of Adrecizumab was assessed using one-way ANOVA 
followed by a Bonferroni post-hoc test in case a P-value <0.05 indicated non-
proportionality. Calculations and statistical analyses were performed using 
GraphPad Prism version 5 for Windows (Graphpad Software Inc., La Jolla, 
CA, USA). In case of missing data, values were imputed by the mean of 
the two adjacent data points. A two-tailed P-value of <0.05 was considered 
statistically significant.
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Results
Study population and subject disposition
A total of 48 subjects were included and randomized in the two studies. The 
baseline characteristics are listed in Table 1. All participating subjects received 
study medication as intended, completed the study and 90-day follow-up 
period, and were deemed compliant with the study protocol. No subjects 
were replaced.
A. First-in-human
Placebo 0.5 mg/kg 2 mg/kg 8 mg/kg
n=6 n=6 n=6 n=6
Age (years) 23 ± 2 23 ± 2 21 ± 1 23 ± 3
BMI (kg/m2) 25 ± 4 23 ± 2 22 ± 2 23 ± 2
Weight (kg) 80 ± 13 75 ± 7 76 ± 9 76 ± 9
Height (cm) 181 ± 10 182 ± 3 185 ± 3 184 ± 5
B. Endotoxemia
Placebo 0.5 mg/kg 2 mg/kg 8 mg/kg
n=6 n=6 n=6 n=6
Age (years) 22 ± 1 22 ± 3 23 ± 3 23 ± 3
BMI (kg/m2) 24 ± 1 23 ± 2 25 ± 2 26 ± 3
Weight (kg) 80 ± 6 76 ± 4 86 ± 8 87 ± 11
Height (cm) 184 ± 5 181 ± 3 187 ± 7 185 ± 9
All presented parameters were determined during the screening visit and are presented as 
mean ± standard deviation. Abbreviations: BMI, body mass index.
Table 1. Subject characteristics of the first-in-human study (A) and the human 
endotoxemia study (B). 
Safety and tolerability
Safety and tolerability were the primary endpoints of both studies. 
Administration of a single dose of Adrecizumab was well tolerated by all 
subjects in all dose groups, for both studies, and did not result in any safety 
concerns. All reported AEs were transient, except for one (new-onset type 1 
diabetes mellitus, requiring ongoing insulin treatment, detailed below). One 
serious AE (SAE) was reported in the human endotoxemia study (the afore-
mentioned type 1 diabetes). All variations in laboratory parameters, vital signs 
and 12- lead ECG were deemed not clinically significant.
First-in-human study
A total of 37 AEs were reported over the 90-day study period (Table 2A). Thirty-
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four AEs were judged to be mild, whereas three AEs were moderate (these 
three were deemed ‘unrelated’ to the study drug) and required treatment: one 
case of a sexually transmitted disease (Chlamydia infection), one dislocated 
shoulder and one subject with repeated nose bleeds (details of all AEs are listed 
in Table S1A). Fifteen AEs (41%) were judged by the blinded investigators 
to be ‘unrelated’ to the study drug, whereas the rest was deemed ‘possibly’ 
related (59%). Twelve AEs were observed in the placebo group, whereas six, 
11 and eight AEs were found in the 0.5, 2 and 8 mg/kg Adrecizumab groups, 
respectively. Commonly reported AEs were nasopharyngitis and headaches, 
the latter occurring predominantly in the placebo group (see Table S1A). 
Human endotoxemia study 
A total of 27 AEs were observed over the 90-day study period (Table 2B). 
Twenty-five AEs were mild, one was moderate and required treatment (a 
traumatic carpal bone fracture during the follow-up period; details of all AEs 
are listed in Table S1B) and one was severe and also required treatment (new-
onset type 1 diabetes). Eighteen (67%) AEs were judged to be ‘unrelated’ to 
the study drug by blinded investigators, and the nine others were deemed to 
be ‘possibly related’ (33%). Four AEs were observed in the placebo group, 
compared with eight, eight and six in the 0.5, 2 and 8 mg/kg Adrecizumab 
groups, respectively. Commonly reported AEs were nasopharingitis and 
headaches. One SAE (new-onset type 1 diabetes mellitus) was reported in 
a subject in the 2.0 mg/kg group. Briefly, this subject experienced weight 
loss, starting approximately 2 months after study drug administration, and 
increased thirst and diuresis starting approximately 5 months after study 
drug administration. Eventually, approximately 8 months after study drug 
administration, the subject was admitted to the hospital for acute dehydration 
and a total of 18 kg weight loss. Laboratory results showed hyperglycaemia, 
ketonuria and elevated glycated haemoglobin, and the subject was diagnosed 
with type 1 diabetes mellitus. After treatment with insulin and intravenous 
fluids, he recovered rapidly (<24 h). Currently, no long-term complications 
have been reported, although the subject remains dependent on exogenous 
insulin administration. The severity was graded as 'severe'. To investigate 
the possible relationship with the administration of the study drug, specific 
type 1 diabetes antibodies were determined on 4 April 2018 in spare 
baseline samples (taken on 3 January and 6 February 2017, prior to study 
participation). Causality with Adrecizumab was deemed 'unrelated' because a 
strong presence of specific type 1 diabetes antibodies was demonstrated in the 
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baseline blood samples obtained prior to Adrecizumab administration (anti-
islet cell antigen, anti-zinc transporter 8, anti-glutamic acid decarboxylase 
and anti-islet antigen 2 antibodies were all positive at baseline, indicating that 
the disease was already developing prior to participation in the study, several 
months before the first clinical signs became apparent).
Pharmacokinetics
Plasma Adrecizumab concentration-time profiles for both studies are presented 
in Figure 2, and PK parameters are summarized in Table 3.
First-in-human study
In all three dose groups, the Cmax was attained immediately after termination 
of infusion. Dose-proportional increases in Cmax and AUC0–∞ were observed 
A. First-in-human Placebo(n=6)
0.5 mg/kg
(n=6)
2 mg/kg
(n=6)
8 mg/kg
(n=6)
Overall 
(n=24)
Adverse Events (AE) 12 (32%) 6 (16%) 11 (30%) 8 (22%) 37 (100%)
Severe AE (SAE) 0 0 0 0 0
Discontinued study drug due 
to (S)AE 0 0 0 0 0
AE of mild intensity 12 (35%) 6 (18%) 8 (23.5%) 8 (24%) 34 (100%)
AE of moderate intensity 0 0 3 (100%) 0 3 (100%)
AE of severe intensity 0 0 0 0 0
Unrelated AE 6 (40%) 3 (20%) 4 (27%) 2 (13%) 15 (100%)
Possibly related AE 6 (27%) 3 (14%) 7 (32%) 6 (27%) 22 (100%)
Probably related AE 0 0 0 0 0
Definitely related AE 0 0 0 0 0
B. Endotoxemia Placebo(n=6)
0.5 mg/kg
(n=6)
2 mg/kg
(n=6)
8 mg/kg
(n=6)
Overall 
(n=24)
Adverse Events (AE) 4 (14.8%) 8 (29.6%) 8 (29.6%) 7 (25.9%) 27 (100%)
Severe AE (SAE) 0 0 1 (100%) 0 1 (100%)
Discontinued study drug due 
to (S)AE 0 0 0 0 0
AE of mild intensity 4 (16%) 8 (32%) 7 (28%) 6 (24%) 25 (100%)
AE of moderate intensity 0 0 0 1 (100%) 1 (100%)
AE of severe intensity 0 0 1 (100%) 0 1 (100%)
Unrelated AE 1 (5.6%) 5 (27.8%) 7 (38.9%) 5 (27.8%) 18 (100%)
Possibly related AE 3 (33%) 3 (33%) 1 (11%) 2 (22%) 9 (100%)
Probably related AE 0 0 0 0 0
Definitely related AE 0 0 0 0 0
Table 2. Overview of adverse events in the first-in-human study (A) and the human 
endotoxemia study (B). 
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(Figure S1A). The T½ and the T½-dependent parameters of two subjects were 
excluded from analysis because their elimination phase was not characterized 
well. The small Cl value (~0.2 ml/h/kg) indicates a slow overall elimination 
of Adrecizumab from the circulation. A small Vz (~100 ml/kg) indicates that 
Adrecizumab predominantly remains within the circulation. The terminal 
elimination T½Ȝ of Adrecizumab was ~15 days.
Human endotoxemia study
Similarly to the first‐in‐human study, values of Cmax were attained shortly after 
cessation of study drug infusion. Again, dose‐proportional increases in Cmax 
were observed (Figure S1B). However, dose proportionality was not observed 
for AUC0–∞ when comparing 0.5 mg/kg with 2.0 mg/kg, and 0.5 mg/kg with 
8.0 mg/kg Adrecizumab (Figure S1B). PK parameters were virtually identical 
to those found in the first‐in‐human study, with the exception of a reduced 
TòȜ (a mean of 10 days compared with 14 days; P = 0.02) and Vz (94 ml/kg 
compared with 78 ml/kg; P = 0.03) in the 0.5 mg/kg dose group.
Figure 2. Plasma concentration–time profiles of adrecizumab in the first-in-human study (A) 
and the human endotoxemia study (B). Data are expressed as mean ± standard error of the 
mean. The dark grey area indicates the study drug administration period, and the light grey 
period the lipopolysaccharide (LPS) infusion period.
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A. First-in-human 0.5 mg/kg(n=6)
2 mg/kg
(n=6)
8 mg/kg
(n=6)
Cmax (ȝg/mL) 9.71 ± 0.86 44.1 ± 4.50 179 ± 21.10
AUC0-∞ (ȝg*h/mL)# 2610 ± 222 10700 ± 1870 39000 ± 3340
Vz (mL/kg)
# 94.4 ± 8.98 95.9 ± 9.70 107 ± 11.50
T1/2 (h)
# 340 ± 6.3 352 ± 51.3 361 ± 49.9
Cl (mL/h/kg)# 0.193 ± 0.02 0.193 ± 0.04 0.206 ± 0.02
B. Endotoxemia 0.5 mg/kg(n=6)* 
2 mg/kg
(n=6)*
8 mg/kg
(n=6)
Cmax (ȝg/mL) 10.6 ± 2.07 51.0 ± 6.28 203 ± 17.00
AUC0-∞ (ȝg*h/mL) 2120 ± 660 12500 ± 1010 46100 ± 5390
Vz (mL/kg) 78.4 ± 11.5 86.9 ± 10.3 93.6 ± 9.9
T1/2 (h) 233 ± 85.3 377 ± 67.3 372 ± 46.4
Cl (mL/h/kg) 0.260 ± 0.10 0.162 ± 0.01 0.176 ± 0.02
Data are expressed as mean ± standard deviation. 
aOne subject from the 0.5 mg/kg group was excluded from these variables because the 
elimination phase was not well characterized.
bThe T½ and the T½‐dependent parameters for two subjects (one from the 0.5 mg/kg group 
and one from the 2.0 mg/kg group) were excluded from the mean calculation because their 
elimination phase was not well characterized.
Abbreviations: AUC0−∞, area under the plasma concentration–time curve from time zero to infinity; 
Cmax, highest observed plasma concentration; CL, total clearance calculated; T½Ȝ, elimination half‐
life; Vz, volume of distribution characterized by the terminal phase.
Table 3. Pharmacokinetic parameters of Adrecizumab in the first-in-human study (A) and 
the human endotoxemia study (B). 
Pharmacodynamics
First-in-human study
Administration of adrecizumab did not influence heart rate, mean arterial 
pressure, peripheral oxygen saturation or temperature (Figure S2, all P > 
0.05), and there were no significant differences between groups in routine 
haematological and biochemical safety laboratory measurements (data not 
shown). Of interest, adrecizumab administration resulted in a rapid and 
statistically significant dose‐dependent increase in total plasma ADM levels 
(note that the assay detects both bound and unbound ADM), whereas 
plasma levels of MR‐proADM (an inactive peptide originating from the 
same precursor as ADM) were not increased (Figure 3A), implying that the 
adrecizumab‐induced increase in total plasma ADM was not due to increased 
synthesis. We also measured plasma concentrations of renin, dopamine, 
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noradrenaline, adrenaline and endothelin‐1 in the first‐in‐human study 
because these could theoretically counteract possible vasodilatory effects 
resulting from increased ADM levels. The plasma concentrations of none 
of these endogenous hormones were influenced relevantly by adrecizumab, 
as between‐group differences were only subtle and not dose dependent (see 
Figure S3).
Figure 3. Plasma concentration–time profiles of adrenomedullin (AMD) and mid‐regional 
pro‐adrenomedullin (MR‐proADM) in the first‐in‐human study (A) and the human 
endotoxemia study (B). Data are expressed as mean ± standard error of the mean. Differences 
between adrecizumab groups and placebo were evaluated using repeated measures two‐way 
analysis of variance, and interaction term P‐values are displayed. * P < 0.05.
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Human endotoxemia study
LPS administration caused a transient increase in body temperature 
and heart rate, whereas mean arterial pressure decreased (Figure 4A‐C). 
Adrecizumab did not influence the LPS‐induced effects on blood pressure 
or heart rate, although a statistically significant effect was observed for the 
0.5 mg/kg dose group for the change in body temperature over time (P = 
0.02) (Figure 4). However, this difference was very slight, and because no 
effects for the higher doses were observed, this was likely to be a chance 
finding. LPS administration caused a transient increase in self‐reported 
flu‐like symptoms over time (Figure 4D). The highest sickness scores were 
observed in the placebo group, and resolution of symptoms was significantly 
more swift in the 8 mg/kg Adrecizumab group compared with placebo 
(P = 0.01), whereas a trend was observed for the 0.5 mg/kg and 2 mg/kg 
dose groups (P = 0.08 and P = 0.07, respectively). Similarly to the first‐in‐
human study, Adrecizumab caused a dose‐dependent increase in total ADM 
levels (Figure 3B). Compared with the Adrecizumab administration in the 
absence of LPS, much higher concentrations were reached during systemic 
inflammatory conditions, which could, at least in part, be explained by the 
LPS‐induced increased synthesis reflected by elevated MR‐proADM levels 
(Figure 3B). Expectedly, increased plasma concentrations of various cytokines 
and chemokines were observed after induction of endotoxemia (Figure 5). 
Typically, cytokine responses showed very high inter‐individual variation. 
For instance, profound between‐subject and between‐group differences were 
observed in plasma levels of the archetypal proinflammatory cytokine, and 
main driver of the inflammatory response, TNF‐Į, as early as during the first 
hour after endotoxin administration, when the study drug had not yet been 
administered. As these differences were already present prior to Adrecizumab 
or placebo administration, it was not possible to interpret the Adrecizumab‐
induced effects on absolute cytokine levels. In order to evaluate the effects on 
cytokine kinetics (e.g. Cl) instead, we normalized cytokine levels to their peak 
concentrations on a per‐subject basis. As depicted in Figure 5, Adrecizumab 
did not influence cytokine kinetics.
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Figure 4. Clinical parameters from the human endotoxemia study: mean arterial pressure 
(MAP) (A), heart rate (B), temperature (C) and sickness score (D). Data are expressed as 
mean ± standard error of the mean. Differences between Adrecizumab groups and placebo 
were evaluated using repeated measures two‐way analysis of variance, and interaction term 
P‐values are displayed. * P < 0.05
Abbreviations: LPS, lipopolysaccharide.
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Figure 5. Cytokine clearance from the human endotoxemia study. Data were normalized for 
the peak cytokine value and are expressed as mean ± standard error of the mean. Differences 
between Adrecizumab groups and placebo were evaluated using repeated measures two‐way 
analysis of variance, and interaction term P‐values are displayed. * P < 0.05
Abbreviations: GCSF, granulocyte‐colony stimulating factor; IL, interleukin; IP‐10, interferon 
gamma‐induced protein 10; LPS, lipopolysaccharide; MCP‐1, monocyte chemoattractant protein 
1; TNF‐Į, tumour necrosis factor alpha.
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Discussion
In the present study, we evaluated the safety, tolerability, PK and PD of 
the novel ADM‐binding antibody Adrecizumab in a first‐in‐human study 
during non‐inflammatory conditions, and in a subsequent study during 
systemic inflammation using the experimental human endotoxemia model. 
Adrecizumab was well tolerated and demonstrated an excellent safety profile 
throughout the investigated dose range. Our data revealed dose‐proportional 
maximum concentrations of Adrecizumab which were reached almost 
immediately after cessation of study drug infusion, a low Vz, low Cl and a 
long T½Ȝ. Moreover, Adrecizumab infusion induced a rapid and profound 
dose‐dependent increase in its target peptide ADM, which is thought to 
explain its mechanism of action26. Adrecizumab did not affect vital signs or 
cytokine clearance, although it did result in a swifter resolution of flu‐like 
symptoms in the human endotoxaemia study.
Safety
One SAE occurred during the 90 day follow‐up period, and was demonstrated 
to be unrelated to the study drug. The majority of AEs were transient, of mild 
severity and evenly distributed among study groups. The few AEs of moderate 
severity that occurred (three in the first‐in‐human study, one in the human 
endotoxaemia study) were all deemed to be unrelated to the study drug by the 
blinded investigators. Moreover, we observed no ECG abnormalities, a normal 
local tolerability at the site of infusion and no clinically relevant changes in 
vital signs or safety laboratory values. Administration of Adrecizumab during 
systemic inflammation also did not result in any safety concerns.
Pharmacokinetics
Peak concentrations of adrecizumab were typically observed at the end of 
infusion and were dose proportional. A low Cl and long T½Ȝ of approximately 
14 days were observed, which are typical for monoclonal antibodies27,28. A low 
volume of distribution, typical for IgG monoclonal antibodies with a large 
molecular weight27,28, indicates that Adrecizumab predominantly remains 
confined to the blood compartment. Some PK parameters were influenced 
by systemic inflammation. A slightly lower volume of distribution and T½Ȝ 
were observed for the lowest dose group of 0.5 mg/kg Adrecizumab in the 
second study, performed under inflammatory conditions. In accordance with 
these observations, systemic exposure based on AUC0–∞ was slightly lower 
for the 0.5 mg/kg dose group in the present study. This observation can be 
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explained neither by nonlinear protein binding of Adrecizumab to its target 
peptide ADM, nor by increased binding of ADM–Adrecizumab complexes 
due to inflammation‐induced upregulation of the ADM receptors13,29 because 
adrecizumab is present in great excess over ADM in the blood. Therefore, these 
mechanisms cannot relevantly affect Adrecizumab levels. A more plausible 
explanation is increased clearance of Adrecizumab through inflammation‐
induced Fc receptor upregulation27.
Pharamcodynamics
Interestingly, Adrecizumab induced a rapid and profound dose‐dependent 
increase in its target peptide ADM, which is in line with results from 
animal studies and may be of importance for the underlying mechanism 
of action. It is well known from various in vitro11,12,30,31 and in vivo13,14,32 
studies that ADM is a strong endothelial barrier‐stabilizing peptide and that 
administration of ADM to animals with septic shock improves outcome. 
In fact, the Adrecizumab‐induced increase in circulating ADM may well be 
responsible for the beneficial effects observed in preclinical studies, as a result 
of the non‐neutralizing nature of the antibody allowing ADM to bind with 
its receptors and activate second messengers18. The proposed mechanism of 
action of Adrecizumab and the role of the observed increase in ADM levels 
and resulting beneficial effects have recently been put forward26. In short, 
because concentrations of the inactive peptide MR‐proADM (derived from 
the same precursor peptide) were not increased, the Adrecizumab‐induced 
rise in ADM is probably not due to increased production. Hence, it appears 
plausible that two other mechanisms are responsible for the increase in ADM. 
First, the binding of ADM to the non‐neutralizing antibody Adrecizumab 
prolongs its T½Ȝ because ADM is normally subject to proteolytic degradation 
by proteases targeting its N‐terminus, which is now bound to Adrecizumab26. 
Second, ADM's distribution is shifted towards the blood. This is based 
upon the fact that ADM can normally diffuse freely across the blood barrier, 
whereas ADM–Adrecizumab complexes cannot, as Adrecizumab is a large 
IgG antibody with a low volume of distribution, indicating that it remains 
confined to the blood compartment. As a consequence, the binding of ADM 
to the antibody that remains in the circulation will drain ADM from the 
interstitium.
ADM has been described as a double‐edged sword in sepsis33 because, on the 
one hand, it improves endothelial barrier stability and outcome in preclinical 
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animal sepsis models but, on the other hand, it possesses vasodilatory effects 
which can cause hypotension at high concentrations16,34,35. Therefore, it could 
be hypothesized that the adrecizumab‐induced increase in ADM would cause 
hypotension. However, our data clearly showed that blood pressure was not 
influenced by Adrecizumab, and that Adrecizumab did not influence the LPS‐
induced decrease in blood pressure. Moreover, we also measured dopamine and 
catecholamines in our first‐in‐human study, to evaluate whether Adrecizumab 
influenced circulating levels of these vasoactive hormones and therefore might 
have counteracted, and thereby masked, vasodilation. The finding that the 
circulating concentrations of these endogenous were not relevantly influenced 
indicates that the higher levels of (Adrecizumab‐bound) ADM do not reach 
vascular smooth muscle cells and cause vasodilation.
No relevant effects of Adrecizumab on mean arterial pressure, heart rate or 
inflammatory parameters were observed. In relation to the inflammatory 
response, it should be stressed that the endotoxemia study was not designed 
primarily to evaluate this endpoint. Adrecizumab administration was initiated 
1 h following the start of the LPS infusion. Therefore, it is not surprising that 
cytokine kinetics were not influenced by Adrecizumab, as the inflammatory 
response had already been activated, to a large extent, prior to adrecizumab 
administration. Unfortunately, it was not possible to evaluate endpoints 
which were favourably influenced by Adrecizumab in preclinical studies, such 
as reduced catecholamine demand, organ dysfunction and endothelial barrier 
leakage18-20, as the transient and relatively mild human endotoxemia model 
does not induce such effects. Nevertheless, Adrecizumab did attenuate the 
sickness score in the highest dose group and tended to decrease it for the two 
lower doses. This is remarkable, considering the small number of subjects per 
group and the stringent method of analysis used, yielding limited statistical 
power to detect significant differences. As no immunomodulatory effects were 
detected in the present study, it is tempting to speculate that Adrecizumab's 
effects on the sickness score are mediated through beneficial effects on 
vascular integrity. As alluded to earlier, our group has previously shown that 
human endotoxemia does not induce overt microvascular leakage36 but the 
analytical methods used may not have been sensitive enough to detect subtler 
differences in vascular integrity.
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Conclusion
Intravenous administration of Adrecizumab was safe and well tolerated in 
healthy human volunteers, both in non‐inflammatory conditions and during 
systemic inflammation induced by the administration of endotoxin. Moreover, 
Adrecizumab induced a rapid and profound increase in its target peptide 
ADM in the blood circulation. This is consistent with previously reported 
beneficial effects in preclinical sepsis models. Our results pave the way for 
further investigation of Adrecizumab in septic patients. A phase II proof‐
of‐concept, precision medicine study in septic shock patients has recently 
started recruitment and is anticipated to enrol 300 patients (clinicaltrials.gov, 
NCT‐number: NCT03085758). Furthermore, as endothelial dysfunction 
is not restricted to sepsis/septic shock but also occurs in other diseases37-39, 
Adrecizumab might have broader applicability.
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Figure S1. The dose proportionality of Cmax and AUC0–∞ of adrecizumab was assessed using 
one‐way analysis of variance followed by a Bonferroni post‐hoc test in case a P‐value < 0.05 
indicated nonproportionality. Data from both the first‐in‐human study (A) and the human 
endotoxaemia study (B) were analysed. Data are expressed as mean ± standard deviation. 
Abbreviations: AUC0‐∞, area under the plasma concentration–time curve from time zero to 
infinity; Cmax, highest observed plasma concentration.
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Figure S2. Vital signs in the first‐in‐human study: mean arterial pressure (A), heart rate 
(B), temperature (C) and peripheral oxygen saturation (D). Data are expressed as mean 
± standard error of the mean. The dark grey area indicates the study drug administration 
period. Differences between Adrecizumab groups and placebo were evaluated using repeated 
measures two‐way analysis of variance, and interaction term P‐values are displayed. *P < 0.05.
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Figure S3. Plasma concentrations of dopamine (A), renin (B), noradrenaline (C), adrenaline 
(D) and endothelin-1 (E), measured in the first‐in‐human study. Data are presented as mean 
± standard error of the mean. Differences between adrecizumab groups and placebo were 
evaluated using repeated measures two‐way analysis of variance, and interaction term P‐
values are displayed. *P < 0.05.
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A. First-in-human Placebo(n=6)
0.5 mg/kg
(n=6)
2 mg/kg
(n=6)
8 mg/kg
(n=6) Overall
General disorders
Nasopharingitis 3 4 3 3 13
Nervous system
Headache 6 1 0 2 9
Cardiovascular
Lightheadedness during exercise 0 0 1 0 1
Gastrointestinal
Abdominal pain 0 0 1 0 1
Travelers diarrhea 0 0 1 0 1
Infectious
STD (Chlamydia) 0 0 1 0 1
Skin infection (wound ankle) 1 0 0 0 1
Musculoskeletal
Dislocated shoulder 0 0 1 0 1
Back pain 0 1 0 0 1
Chest pain 1 0 0 0 1
Sensation of light pressure on shoulder 0 0 1 0 1
Muscle soreness 0 0 0 1 1
Thumb pain 0 0 0 1 1
Dermatological
Erythemateus rash at site of infusion 1 0 0 0 1
Eczema 1 1
Peri-anal fungal skin infection with ecze-
ma-like symptoms 0 0 1 0 1
Other
Repeated nose bleeds 0 0 1 0 1
Table S1. Summary of adverse events by system organ class for the first-in-human study (A) 
and the human endotoxemia study (B).
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B. Human endotoxemia† Placebo(n=6)
0.5 mg/kg
(n=6)
2 mg/kg
(n=6)
8 mg/kg
(n=6) Overall
General disorders
Nasopharingitis 2 5 4 1 12
Nervous system
Headache 1 1 1 0 3
Twitches in left arm 0 1 0 0 1
Paresthesia 0 0 1 0 1
Respiratory
Apnea and oxygen saturation while sleeping 0 0 0 1 1
Gastrointestinal
Rectal blood loss 0 1 0 0 1
Infectious
Cold sore (upper lip) 0 0 0 1 1
Musculoskeletal
Bone fracture 0 0 0 1 1
Back pain 0 0 1 0 1
Dermatological
Erythemateus rash at site of infusion 0 0 0 1 1
Metabolic
New onset type I diabetes 0 0 1 0 1
Other
Nose bleed 1 0 0 1 2
Swelling upper eye lid 0 0 0 1 1
Table S1. continued.
† LPS-induced symptoms were not included as AEs unless they were of abnormal intensity 
or duration, as decided by the blind investigator.
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Abstract
Introduction
Sepsis remains a major health problem with an increasing incidence, high 
morbidity and high mortality. Apart from treatment with antibiotics 
and organ support, no approved specific adjunct therapies currently exist. 
Adrenomedullin (ADM) is a vasoactive peptide. High plasma concentrations 
of ADM correlate with worse outcome in sepsis patients. Preclinical work with 
the non-neutralizing ADM-binding antibody Adrecizumab showed promising 
effects in animal models of septic shock, including improved vascular barrier 
function, reduced vasopressor demand and organ dysfunction and increased 
survival. Therapeutic use of Adrecizumab may therefore improve outcome in 
critically ill patients with septic shock and high ADM plasma concentrations. 
Phase I studies in healthy volunteers did not reveal any safety concerns. In 
this biomarker-guided trial, the safety and efficacy of Adrecizumab will be 
investigated in patients with septic shock.
Methods and analysis
We describe a phase II, randomised, double-blind, placebo-controlled, 
biomarker-guided, proof of concept and dose-finding clinical trial in patients 
with early septic shock and high concentration of circulating ADM. A total 
of 300 patients will be enrolled at approx. 30 sites within the European 
Union. Patients are randomized to receive active treatment (2 and 4 mg/
kg Adrecizumab) or placebo, in a 1:1:2 ratio. Patient selection is not only 
guided by clinical parameters, but also biomarker-guided by measurement 
of circulating biologically active ADM concentration at admission. Primary 
endpoint is safety and tolerability of Adrecizumab over a 90 day period. A key 
secondary endpoint is the Sepsis Severity Index (SSI) over a 14-day period.
Ethics and dissemination
This study is approved by relevant institutional review boards/independent 
ethics committees and is conducted in accordance with the ethical principles 
of the Declaration of Helsinki, the European Medicines Agency guidelines of 
Good Clinical Practice, and all other applicable regulations. Results of this 
study will be published in a peer-reviewed scientific journal.
ClinicalTrial.gov registration number 
NCT03085758
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Introduction
Worldwide, sepsis is a major health problem, with an increasing incidence and 
high mortality1-3. It is defined as life-threatening organ dysfunction caused by 
a dysregulated host response to infection4. Septic shock is defined as a subset 
of sepsis in which profound circulatory, cellular, and metabolic abnormalities 
occur, which are associated with an increased risk of mortality4. The most 
prominent abnormalities are vasodilation and loss of vascular integrity, 
resulting in hypotension, and ultimately, in organ dysfunction and death5. 
Besides antibiotics and organ supportive therapies such as vasopressors, 
mechanical ventilation and renal replacement therapy (RRT), there are 
currently no sepsis-specific adjunctive therapies registered.
Adrenomedullin (ADM) is a vasoactive peptide hormone that plays an 
important role in sepsis. Circulating ADM exerts endothelial barrier-
stabilizing effects and maintains vascular integrity6-10. ADM has vasodilatory 
properties in the vascular interstitium, and at high concentrations, as observed 
during sepsis, may contribute to hypotension11-13. Elevated concentrations 
of plasma ADM at admission have been reported in septic patients, and 
these were correlated with vasopressor requirement, organ dysfunction and 
mortality14-16. The cut-off value of biologically active ADM (bio-ADM) of 70 
pg/mL at admission was found to predict mortality for sepsis patients14. This 
cut-off has been validated in independent, large multicentre studies15,17,18.
Based on these data, ADM may be an interesting therapeutic target for 
sepsis. A potential new adjunctive therapy for the treatment of septic shock 
is Adrecizumab (previously known as HAM8101). It is a non-neutralizing 
ADM-binding antibody that has shown beneficial effects in preclinical 
studies. Adrecizumab reduced vascular leakage, organ dysfunction and need 
for vasopressor treatment during cecal ligation and puncture (CLP) induced 
sepsis in several animal studies, and improved urine output and survival19-21. 
Importantly, Adrecizumab administration was not associated with any safety 
concerns in the first-in-human phase I study in healthy volunteers (n=24)22,24 
and in a follow-up study in healthy volunteers, which were intravenously 
challenged with lipopolysaccharide (LPS) to induce systemic inflammation 
(also n=24)23,24. Of note, in the latter study, LPS-induced flu-like symptoms 
resolved more swiftly in Adrecizumab-treated subjects compared to the 
placebo-treated subjects. Pharmacokinetic (PK) analysis of Adrecizumab 
showed a half-life of approximately 14 days, indicating that administration 
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of a single dose is sufficient to achieve excess of plasma concentrations of the 
antibody over adrenomedullin for the entire sepsis period. 
Based on these preclinical and human phase I data, it is hypothesised that 
therapeutic use of Adrecizumab may improve endothelial dysfunction, restore 
and maintain vascular integrity and augment hemodynamics in critically ill 
patients with sepsis and septic shock. In the trial described in the present 
work, the safety, tolerability and efficacy of Adrecizumab is investigated in 
patients with early septic shock and elevated concentrations of circulating 
bio-ADM. This will be one of the first precision medicine, biomarker-guided 
studies in septic patients.
Methods and analysis
Design and setting
AdrenOSS-2 is a phase II, randomised, double-blind, placebo-controlled, 
biomarker-guided, proof-of-concept and dose-finding clinical trial that is 
currently being conducted in patients with early septic shock and elevated 
concentration of circulating bio-ADM (> 70 pg/mL). A total of 300 patients 
will be recruited in medical, surgical and mixed Intensive Care Units (ICU) 
at approximately 30 sites across Belgium, France, Germany, the Netherlands 
and Italy (see clinicaltrials.gov for a list of current centres). Patient selection 
is guided by clinical parameters as well as by biomarker concentrations, by 
measuring circulating bio-ADM (sphingotest® bio-ADM, sphingotec GmbH, 
Hennigsdorf, Germany)25. Based upon preclinical studies, two dosages of 
Adrecizumab will be investigated (2 and 4 mg/kg bodyweight), in addition 
to a placebo control arm. After informed consent has been signed by the 
patient or his/her legal representative, circulating bio-ADM concentrations 
will be assessed. If bio-ADM concentrations are > 70 pg/mL, the clinical 
coordination center (CCC) will be contacted for final confirmation of patient 
eligibility and the patient will be randomized. An interim analysis for futility 
is planned after 150 patients have completed day 28 of the study. An overview 
of the study design is depicted in Figure 1 and study procedures in Figure 2. 
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Figure 1. Study design. Abbreviations: ADM, adrenomedullin; AUC, area under the curve; CL, 
systemic clearance; QoL, quality of life.
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Figure 2. Study timeline. Abbreviations: ADM, adrenomedullin; CCC, clinical coordination 
centre; SAE, severe adverse event.
Primary objective
The primary objective is safety and tolerability, consisting of: mortality 
possibly related to Adrecizumab, interruption of infusion due to suspected 
intolerability of Adrecizumab, new treatment-emergent adverse events  (AEs) 
possibly related to Adrecizumab and changes in severity and frequency of 
treatment-emergent AEs. During the study, an independent Data and Safety 
Monitoring Board (DSMB) will review safety data on at least a monthly base.
Secondary objectives
The secondary objectives are related to the efficacy and PK of Adrecizumab. 
The primary efficacy endpoint, the 'Sepsis Support Index' (SSI), is a composite 
endpoint reflecting organ dysfunction or death within the first 14 days of 
follow-up. More precisely: within the first 14 days of follow-up, every day on 
which a vasopressor or mechanical ventilation is used, or renal dysfunction 
(defined as renal Sequential Organ Failure Assessment [SOFA] score=4) is 
apparent, or the patient is not alive anymore, is counted as l. The sum over 
the 14 day follow-up period is defined as the SSI score, which can have a 
maximum of 14 and a minimum of 1 (as vasopressor usage on day 1 is an 
inclusion criteria). The calculation of the SSI is further illustrated in Figure 3.
Additional secondary objectives include: SSI at day 28 of follow-up, penalised 
SSI (patients who die get penalised with the maximum score), individual 
SSI components, persistent organ dysfunction or death at day 14 and 28 
of follow-up26, day 28 and day 90 mortality rate and quality of life (Euro-
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QOL-5), change over time in SOFA and other parameters such as functional 
parameters (including, but not limited to heart rate, blood pressure, PaO2/
FiO2, fluid balance, blood lactate, creatinine, pro-enkephalin, mid-regional-
proADM, inflammatory markers, including procalcitonin and interleukin-6), 
total duration of vasopressor/catecholamine use as well as length of stay at 
ICU/hospital.
For the PK substudy (n=80 patients), endpoints are key PK parameters, 
including peak plasma concentrations (Cmax), systemic exposure (area 
under the curve), volume of distribution (V), systemic clearance (CL) and 
elimination half-life (t1/2) of Adrecizumab.
Figure 3. Primary efficacy endpoints: 14-day Sepsis Support Index (SSI) example calculation.
Patient selection
A total of 300 adult patients with early septic shock and elevated bio-ADM 
concentration will be randomised. Early septic shock is defined as sepsis 
with hypotension (mean arterial pressure <65 mmHg) refractory to fluid 
rescucitation and requiring vasopressor therapy4. Patients with a measurement 
of circulating bio-ADM >70 pg/mL will be eligible to be randomised. The 
cut-off point for bio-ADM of 70 pg/mL was selected based on the specific 
needs and purpose of this study. Per patient data available for this evaluation 
included data from ALBIOS, Frog-ICU and AdrenOSS-1 studies, to name 
the largest and most relevant, as well as data from healthy normal individuals. 
Specific needs to be met for the study were that patients with normal bio-
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ADM, as well as low severity and low expected mortality were to be excluded, 
to maximise the observable treatment effect, while keeping the eligible 
population as large as possible. The window for inclusion and infusion of 
study medication is 12 h following initiation of vasopressor therapy. A lactate 
concentration <2 mmol/L is not an inclusion criteria, as concentrations may 
change quickly in response to initial therapy. Patients will be screened for 
clinical inclusion and exclusion criteria (Table 1). Screening and enrolment 
logs will be maintained for all patients. For patients not enrolled in the study, 
the reason for non-enrolment is documented. Patients will undergo various 
screening assessments, including recording of information on hospital and 
ICU admission (date, time, location before admission, diagnosis, origin of 
sepsis), documenting of relevant ongoing conditions, relevant medical history 
and comorbidities present or treated within the last year (cardiovascular and 
non-cardiovascular), concomitant medication use, age, gender, ethnic origin, 
physical examination including weight and height, blood sampling for 
laboratory examinations and bio-ADM measurement, pregnancy test (urine 
or serum), recording of 12-lead electrocardiography (ECG), and calculation 
of APACHE (Applied Physiology And Chronic Health Evaluation) II and 
SOFA score. Eligibility will be confirmed by the clinical coordination centre 
(CCC) in Brussels, Belgium. Patients that fulfill all inclusion criteria and 
none of the exclusion criteria will be eligible to be randomised.
Measuring bio-ADM
For measurement of bio-ADM, 5 mL ethylenediaminetetraacetic acid (EDTA) 
blood will be collected after written informed consent is obtained. After 
centrifugation (2500 G, 15 min, 20 °C), bio-ADM levels are determined using 
a fully validated, CE-marked, commercially available immunoluminometric 
assay (sphingotest bio-ADM assay). This assay is performed locally by trained 
personnel. The assay is highly specific for C-terminally amidated ADM (bio-
ADM). Each patient sample will be measured in duplicate, and in parallel 
2 calibrators (1 with a concentration around the decision-making point 
[70 pg/mL]) will be run in triplicate along with each patient sample. The 
functionality of the measuring system will be checked on a monthly basis at 
each site. Finally, bio-ADM will be remeasured from banked aliquots in batch 
at a central laboratory to verify locally gained results. Further details about the 
assay are described elsewhere25.
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Inclusion criteria
1. Written informed consent by patient or legal representative (according to country-
specific regulations)
2. Male and female patients, age ≥18 years.
3. Body weight 50–120 kg.
4. Bio-ADM concentration >70 pg/mL.
5. Patient with early septic shock (start of vasopressor therapy <12 hours).
6. Women of childbearing potential must have a negative serum or urine pregnancy test 
before randomization and have to use a highly effective method of contraception.
Exclusion criteria
1. Moribund.
2. Pre-existing unstable condition (e.g., a recent cerebral hemorrhage or infarct, a recent 
acute unstable myocardial infarction (all <3 months), congestive heart failure NYHA 
class IV.
3. Patients who required cardiopulmonary resuscitation in the last 4 weeks prior to 
evaluation of enrolment.
4. Severe chronic obstructive pulmonary disease (COPD) with chronic oxygen need at 
home (GOLD IV).
5. Any organ or bone marrow transplant in the last 4 weeks prior to evaluation of 
enrolment.
6. Uncontrolled serious hemorrhage (≥2 units of blood / platelets in the previous 24 
hrs). Patients may be considered for enrollment if bleeding has stopped and patient is 
otherwise qualified.
7. Uncontrolled hematological / oncological malignancies.
8. Absolute neutropenia <500 per µL.
9. Severe chronic liver disease (Child-Pugh C).
10. Systemic fungal infection or active tuberculosis.
11. Neuromuscular disorders that impact breathing/spontaneous ventilation.
12. Burns  >30% of body surface.
13. Plasmapheresis.
14. Women who are pregnant or nursing.
15. Participation in a clinical trial involving another investigational drug within 4 weeks 
prior to inclusion.
16. Unwilling or unable to be fully evaluated for all follow-up visits.
Table 1. Inclusion and exclusion criteria
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Randomisation
Patients are randomly assigned to receive active treatment (2 and 4 mg/
kg Adrecizumab) or placebo, using a block randomisation scheme (1:1:2 
treatment allocation ratio). A randomisation code list will be generated by 
an independent statistician not involved in the study. For each centre, study 
medication is provided in boxes containing 4 pairs of vials according to the 
4-block randomisation list, allowing stratification by centre.
Informed consent
Prior to any study-related procedures, patients must provide informed consent 
in accordance with the EU Clinical Trial Directive, the Declaration of Helsinki 
and ICH-GCP requirements. Informed  consent is obtained according to 
local requirements in participating countries. Written informed consent is 
obtained by trained investigators after providing adequate verbal and written 
information about the study (in order to fully understand the study and 
any risks it entails), and giving the patient opportunity to ask questions as 
well as appropriate time to decide on participation in the study. For patients 
unable to provide consent themselves due to their medical condition, written 
informed consent is to be obtained by the patient's legal representative or 
by other accepted procedures according to applicable national law and local 
regulations, for example, consent by relatives or family members. In addition, 
retrospective patient consent to voluntary continue the study will be obtained 
once the patient has sufficiently recovered. Patient and/or the patient's legal 
representative can withdraw their consent on study participation at any time 
without providing an explanation. 
Blinding
The study will be performed in a double-blinded fashion. All study personnel, 
including the investigator and site staff, monitors, sponsor and Contract 
Research Organisation (CRO) staff will be blinded to treatment assignment 
until study closure. The randomisation list is kept strictly confidential by 
the data management vendor and accessible only to authorised perosns who 
are not involved in the conduct of the study. In case of emergency, blinding 
will only be broken if specific emergency treatment would be indicated by 
knowing the treatment status of the patient. Specific emergency envelopes 
will be available at each site. The investigator is required to notify the sponsor 
within 24 hours following the code break reporting the reason for unblinding. 
The investigational drug and its matching placebo are indistinguishable and all 
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study drug kits will be packed in the same way. Unblinding will be authorised 
by the sponsor after completion of the study, locking of the database and 
performance of a blinded data review.
Study intervention
A single dose of the study drug (2 or 4 mg/kg Adrecizumab, or placebo) 
is administered over a 1-hour period by continuous intravenous infusion, 
as soon as possible, but at the latest, within 12 hours following start 
of vasopressor therapy. Study drug is administered separately from any 
concomitant drugs using a dedicated lumen of a central venous catheter or a 
separate peripheral line. Study medication is provided in boxes according to 
the 4-block randomisation list. Each box contains 4 pairs of vials for a 1:1:2 
treatment allocation ratio. The following pairs of vials are supplied in the box, 
in a blinded fashion: a set of 2 vials of Adrecizumab (for reconstitution of 
the 4 mg/kg dose), a set of 1 vial of Adrecizumab and 1 vial of placebo (for 
reconstitution of the 2 mg/kg dose) and 2 sets of 2 placebo vials. All vials are 
indistinguishable from each other, containing the same volume of solution, 
the same aqueous buffer and identical packaging. The study drug, adjusted 
to the patient's body weight, has to be reconstituted from a pair of vials. 
All study drug are stored in a secure and adequately temperature-monitored 
pharmacy storage facility at 2-8 °C.
Concomitant medication
There are no specific restrictions regarding use of concomitant medication 
or other therapies. All patients will be treated according to 'International 
Guidelines for Management of Severe Sepsis and Septic Shock'27. All 
concomitant medical treatments and medication will be recorded from 
inclusion until day 28 or ICU discharge (whichever comes first). 
Patient and public involvement
Patients and the public were not involved in elaboration of the study protocol. 
There is no plan to disseminate the results directly to the study participants. 
Results will be published in a peer-reviewed journal and presented on 
conferences. 
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Statistical and analytical plan
Sample size calculations
The sample size was calculated for the primary efficacy endpoint (SSI up to day 
14). A sample size of n=150 patients is planned for the combined treatment 
groups receiving 2 and 4 mg/kg Adrecizumab. As both dosages result in an 
excess of antibody over the target peptide ADM, no difference in treatment 
effect is expected between the dosage groups. Therefore, the two dosage groups 
are pooled together for the final analysis, unless either dose is insufficient or 
safety and tolerability analysis indicate that one dose is not safe or tolerable. 
Power calculation was based on simulation analyses. The distribution of the 
SSI was based on real patient data from the ALBIOS study (n=539)15 and 
underlying assumptions were re-evaluated using results from the AdrenOSS-1 
observational study18. Based on the AdrenOSS-1 study performed in septic 
patients, we anticipate a median SSI in the control group of 4 [IQR 2-11], 
while in the ALBIOS study the median was 7 [IQR 4-14] (these medians 
reflect a selection of patients with septic shock and bio-ADM >70 pg/mL). 
However, due to the non-normal distribution of the SSI, the median is still 
highly volatile (the majority of patients have either a low SSI [1-3 days, if 
improving and discharged early], or a high SSI [14 days, as patients that die 
within the first 14 days are usually on organ support while alive and in ICU]). 
For the simulations, a sample size of n=150 per group (treatment or placebo), 
and an effect size resulting in approximately 10% decrease in SSI in the 
Adrecizumab-treatment group (compared with the simulated control group) 
resulted in a power of the study of >80% to demonstrate an improvement of 
SSI of >0 with at least 80% probability. The 80% probability corresponds to 
the lower limit of the 60% confidence interval of the effect estimate, delta 
SSI, which is based on the estimated difference of location from the Wilcoxon 
test. If the simulated lower limit of delta SSI was >0, the simulation run 
reached the endpoint. 
Statistical analyses
Continuous variables will be summarised by the number of patients, mean, 
SD or median, quartile and range, as appropriate. Categorical variables will 
be summarized using number and percentage by category. Demographic and 
medical background data, secondary endpoints and safety variables will be 
analysed by means of descriptive and exploratory methods. Regarding the 
primary endpoint (safety), all AEs will be listed. The number and percentage 
of patients experiencing one or more AEs will be summarised by treatment 
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arm/control group, relationship to study drug and severity/grade. Severe 
Adverse Event (SAE)-specific listings for each patient population will be 
generated on reported SAEs, but not as SUSARs. The same will be made for 
treatment-related SAEs. Mortality analysis is described below.
The primary analysis for efficacy will be performed as an intention-to-treat 
analysis based on the combined dosage groups of Adrecizumab (n=150 
patients total) versus placebo. A secondary analysis will compare the two 
doses for differences in efficacy. In case patients did not receive the treatment 
they were randomised to, an analysis based on the actual treatment will also 
be performed (as-treated analysis). The primary efficacy endpoint, 14-day 
SSI, will be analysed using the non-parametric Wilcoxon test, to estimate the 
treatment effects (based on the Wilcoxon estimate for difference in location) 
as well as its confidence interval. First, it will be determined whether the 
improvement in SSI due to treatment is >0 with at least 80% probability 
(based on the lower limit of the one-sided confidence interval of the effect 
estimate of the Wilcoxon test). If this is achieved, the classical p-value from 
the Wilcoxon test will also be calculated. All-cause mortality will be evaluated 
using Kaplan-Meier plots comparing treatment (separate for each dose, as 
well as a comparison combining both doses into one group) versus placebo 
(log-rank test) and Cox regression modelling including covariates to adjust 
for potential confounders. Potential confounders include age, gender, mean 
arterial pressure, heart rate, source of infection, blood culture, comorbidities 
and initial SOFA score as well as variables showing significant between-
group differences (despite randomisation). In order to identify subgroups 
which may possibly benefit more from Adrecizumab treatment, interactions 
with other drugs, as well as exploratory subgroup analyses are planned in 
patients, defined by disease severity, biomarkers, concomitant medication or 
other clinical data. The subgroup analyses is nevertheless purely exploratory. 
Subgroups will be defined by tertiles for continuous variables. For categorical 
variables, categories will be summarised such that they best represent tertiles 
if more than three categories are available. Statistical analysis of secondary 
endpoints is exploratory, and will be specified ina separate statistical analysis 
plan, which is to be finished before conclusion of the study.
Interim analysis with futility stop
An unblinded interim analysis is planned after 50% of patients completed 
the study on day 28. The study will be terminated if the probability of a 
positive outcome after recruitment of all patients is below 40%, based on the 
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primary efficacy endpoint 14 day SSI. In case the futility stop is reached, but 
if some of the other efficacy endpoints show a promising outcome for the full 
study, the futility stop may be suspended. Statistical consequence of applying 
the futility analysis was included in the power simulation. An independent 
statistician is responsible for analysing the data at interim analysis, and the 
steering committee, as well as the sponsor, will remain blinded until the end 
of the study. Note that the interim analysis focuses on futility only, potential 
termination of the trial based on harm is based on the reviewing and evaluation 
of unblinded data on safety and mortality by the DSMB (described further 
below).
Data quality assurance
All data management activities are done according to ICH-GCP as required 
by regulatory agencies. A commercial CRO, M.A.R.C.O. GmbH & Co. 
KG (M.A.R.C.O®), will be responsible for data management. All sites will 
maintain source documentation and enter patient data into an electronic 
case report form (eCRF). The clinical center is responsible for the secure and 
restrictive archiving of source data for at least 15 years or until the written 
notification from the sponsor that the documents are no longer required. 
During the required period, the clinical center will ensure that archived data 
and documents will be undamaged, legible and accessible to the sponsor and/
or for regulatory purposes, if required. The study master file, the ECRFs, code 
envelopes and other material supplied for the performance of the study will be 
retained by the sponsor according to applicable regulations and laws, including 
the new GDPR (see also the section on 'Confidentiality'). Regarding the eCRF, 
automated and manual checks will be performed to ensure completeness and 
consistency of the data, and investigator site personnel seeking access must go 
through training processes before access to the system is granted. The eCRF 
was designed by M.A.R.C.O.® in the Amedon system. Validation checks are 
implemented in the system or programmed with SAS®, version 9.1 or higher, 
according to the data validation plan set up by M.A.R.C.O.®. 
Safety assessments
Medication error
Adequately trained hospital staff will prepare, double-check and administer 
study medication. The dose levels that are administered in the study have 
not caused any safety concerns in previous studies in healthy volunteers22-24 
or in preclinical safety and toxicological studies in animals and non-human 
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primates. The risk for adverse health effects due to medication errors are 
thought to be minimal. 
Overdose risks
No drug-specific antidote for Adrecizumab is available. An overdose is defined 
as any dose higher than the assigned treatment dose. However, if by accident, 
the maximum volume would be withdrawn from a pair of Adrecizumab vials 
during preparation of study medication, this would not exceed the tested 
maximum dose of 8 mg/kg Adrecizumab in healthy volunteers, which did not 
result in any safety concerns22-24.
AE reporting
All patients are monitored for adverse events (AEs). AEs are defined as 
any untoward medical occurrence in a patient administered a product and 
which does not necessarily have a causal relationship with this treatment. 
Investigators must document all AEs (whether serious or non-serious and 
judged related or unrelated to the study drug) that occur during the study 
period extending from day 1 (inclusion) until 90 days after study drug 
administration in the eCRF. If the AE is serious, a ‘serious adverse event report 
form’ must also be sent to the safety contact of the sponsor (spm2, Safety 
Projects & more GmbH, Hirschberg an der Bergstraße, Germany) within 24 
hours of becoming aware of the SAE. The severity of the AE will be rated as 
'mild', 'moderate', 'severe', 'life-threatening', 'disabling' or 'death related to 
event'. Investigators will use medical judgement to determine whether there is 
evidence for a causal relationship and will describe this causality using terms 
such as 'certain', 'probably/likely', 'possible', 'unlikely' or 'unrelated'. All AEs 
will be followed-up until they have abated, or until a stable situation has been 
reached, and will be reported as such. 
External data monitoring committee
An independent DSMB has been established to monthly review safety data 
including SAEs and, overall safety data, and will judge the relevance of events 
for patient safety. DSMB members will have no direct relationship to the 
study or to the study sponsor. The DSMB, composed by two clinical experts 
in the field of sepsis, a biostatistician and a pharmacovigilance representative, 
will operate independently. The DSMB is empowered to recommend changes 
in the design of the study to ensure the safety of the patients and scientific 
integrity of the study.
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Withdrawal
Participation is strictly voluntary and a patient or their legal representative 
may withdraw the patient from the study at any time without providing an 
explanation. This will not affect his/her right for future medical care. If a 
patient would withdraw from the study, the date, circumstances and any reason 
provided will be documented on the withdrawal page of the eCRF. No data 
obtained after withdrawal of consent will be recorded on eCRFs, unless the 
patients consents to the use thereof. For safety analysis, the patient's outcome 
status (dead or alive) at day 90 will be collected. For the main efficacy analysis, 
these patients will be excluded. In order to rule out that patient withdrawal is 
linked to treatment, a sensitivity analysis will be conducted assigning missing 
endpoint data with the worst possible value (i.e., worst possible value for 
patients in the treatment group, the best possible value for patients in the 
control group). In addition, an analysis will be conducted where missing data 
points will be imputed using interpolation or extrapolation, if applicable.
Study period
The study started enrolling patients in December 2017. The estimated study 
enrolment completion date is anticipated in the first half of 2019. Please note 
that this manuscript was finalized prior to the interim analysis.
Ethics and dissemination
Ethics
The study was started after approval of the study protocol and all other 
relevant study documents by the relevant institutional review boards / 
independent ethics committees. The study is performed in accordance with 
the Declaration of Helsinki, ICH, Code of Federal regulations and all other 
applicable regulations. Collection of personal data is performed according to 
country-specific regulations.
Confidentiality
After written informed consent has been obtained, patients will be assigned 
a unique 6-digit patient identification number. This allows identification 
of patients, while maintaining patient confidentiality. The investigators, 
designated CRO and sponsor and all other involved parties will preserve the 
confidentiality of all patients taking part in the study, in accordance with 
ICH-GCP and local regulations. Confidentiality of all patient identities 
will be maintained, except during source data verification when monitors, 
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auditors and other authorized agents of the sponsor or its designee, the ethics 
committee or any other applicable regulatory authorities are granted direct 
access to the study patient’s original medical records. No material bearing a 
patient’s name will be kept on file by the CRO or sponsor. The code list with 
treatment allocations (randomisation list) is stored separately from the sponsor 
at the data management vendor (CRO) during the course of the study. These 
data management vendors will provide all relevant data (pseudonymised) to 
the sponsor after the end of the study. In addition, sets of sealed envelopes 
with randomisation codes are kept at the site for emergency unblinding, with 
the DSMB and with the party responsible for reporting SUSARs as required 
by regulatory agencies. Data retained from this study will be protected in 
accordance with all applicable legal requirements. Information about study 
patients will be kept confidential and managed according to the requirements 
of EU-directives 2001/20/EC, 2005/28/EC and 2003/63/EC, and relevant 
national and local legislation. All ongoing subjects signed the informed consent 
form (including the data protection part) and additionally the 'Information 
letter for ongoing patients' regarding the new GDPR (DSGVO, Germany). 
All patients have been informed by investigators before they signed these 
documents.
Data access
The following parties have access to the data: sponsor, sites and selected 
vendors (data management, pharmacovigilance). Individual patient data may 
be used by site investigators for publication in agreement with the sponsor. 
Please note that the confidentiality section also specifies some external parties 
that may access data (regulatory authorities, etc.).
Sample storage
A biobank for biomarkers is implemented and samples are stored for potential 
future use.
Study monitoring
The study is monitored by a clinical monitor, who will visit the investigator 
and study sites at periodic intervals in addition to phone, letter and e-mail 
contact. The monitor will follow the study closely through reviewing of study 
records and source documents, and will determine if the reported data are 
accurate and complete. 
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Dissemination policy
The data of the study will be reported at scientific meetings and published 
in a peer-reviewed scientific journal, regardless of the results on outcome, in 
accordance with the good publication practice guideline of the international 
society for medical publication professionals. The sponsor and the investigator 
and other individuals who have expertise in the area and who are willing to 
interpret the data and write or review articles and presentations will form 
a publication steering committee to oversee the preparation of articles and 
presentations from this study. 
Discussion
The development of new therapies for the treatment of sepsis and septic shock 
has proven to be a challenging task over the last decades. Many trials have 
investigated potential adjunctive therapies, predominantly focussing on anti-
inflammatory agents. Unfortunately, this enormous effort put into dozens of 
clinical trials has not yielded compounds with clinically relevant beneficial 
effects. This can be explained by many factors, such as heterogeneous study 
populations and difficulties in selecting patients who may best benefit from 
an intervention. Also, the timing of the intervention, inappropriate outcome 
measures and the complexity of the disease with multiple pathways of injury 
hamper clinical research in sepsis patients5,28.
Importantly, when antibodies were used, most interventions were based on 
complete neutralization of the target. However, physiology probably is more 
balanced as some targets can exert both beneficial and detrimental effects, 
often even simultaneously. This may also represent a major contributing 
factor to the failure of many therapies to improve outcome witnessed in the 
last decades. Along these lines, it might be argued that a partially neutralizing 
therapy is more effective than total neutralization. The AdrenOSS-2 trial is an 
innovative, biomarker driven trial with a novel, supposedly clinically relevant 
efficacy endpoint.
Patient heterogeneity is a substantial contributor to the difficulties in 
identifying effective therapies for sepsis. Patient selection is innovative in 
this study for two reasons. First, a more homogeneous subgroup of sepsis 
patients is selected, based on the combination of presence of early signs of 
shock, that is, requiring vasopressor support, as well as elevated concentration 
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of the biomarker bio-ADM. Selecting patients in the early phase of septic 
shock should select patients with preventable organ dysfunction compared 
to patients for whom septic shock and need of vasopressors lasted more 
than 12 hours. Furthermore, as previously described, measuring bio-ADM 
at baseline correlates strongly with the need for organ supporting therapy 
and mortality14,15,17,18. Therefore, including bio-ADM as an inclusion criteria 
likely allows for better selection of patients who need vasopressors and have 
a poor outcome. Combining need of vasopressor and high bio-ADM may 
contribute to obtaining a more homogeneous population of patients whom 
may benefit most from this adjunctive sepsis therapy. To our knowledge, this 
is one of the first precision medicine study in sepsis patients29.
ADM is a key vasoactive peptide involved in several important pathways 
in sepsis, which makes it an attractive therapeutic target in sepsis10. It has 
previously been described as a double-edged sword in sepsis30. On vascular 
smooth muscle cells, ADM exerts vasodilatory effects and thereby induces 
vasodilation and hypotension11-13. This effect of interstitial ADM may 
exacerbate the severity of shock and may lead to organ hypoperfusion and 
organ dysfunction. In contrast, ADM present in the circulation exerts 
potent endothelial barrier stabilizing effects, reducing vascular leakage that 
may improve survival, as was demonstrated in vitro6,7,31,32 and in vivo in 
animal models of sepsis and systemic inflammation8,9,33,34. However, direct 
administration of ADM during sepsis poses several limitations. Because of a 
short half-life11, continuous infusion of ADM would be required. In addition, 
due to ADM’s potent vasodilative effects, ADM-induced hypotension might 
be an issue, which might further aggravate shock in septic patients. A non-
neutralizing antibody might attenuate ADM’s vasodilatory effects on VSMCs 
and potentiate ADM’s effects on endothelial cells.
Adrecizumab, a non-neutralizing ADM-binding antibody, is one of the first 
therapies specifically aimed at improving vascular endothelial barrier function, 
and represents a new candidate drug for the treatment of septic shock. A detailed 
description of Adrecizumab’s supposed mode of action is described elsewhere35. 
Briefly, during sepsis, increased concentrations of ADM in the interstitial 
compartment are thought to contribute to hypotension. Adrecizumab, which 
is confined to the blood compartment, shifts the distribution of ADM away 
from the interstitium towards the blood, by preventing diffusion of bound 
ADM35. This results in a strong increase of (bound) ADM concentrations 
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in the blood22,23,24, where it, being bound to a non-neutralizing antibody, 
interacts with receptors on endothelial cells and reduces vascular leakage 
and tissue edema. At the same time, concentrations in the interstitium are 
reduced through this mechanism, leading to less vasodilation and subsequent 
hypotension. This increase in plasma ADM concentration was observed in 
a rapid and dose dependent manner upon intravenous administration of 
Adrecizumab, both in animals and in humans21-24. Through reducing vascular 
leakage, tissue edema and hypotension, Adrecizumab could increase tissue 
perfusion and improve the prognosis of sepsis patients, whereas it might also 
reduce the use of vasopressors, thereby limiting potential adverse effects of 
vasopressors36,37.
Adrecizumab, administered as a single intravenous dose (due to its long half-
life of 14 days), showed promising results in preclinical studies of systemic 
inflammation and septic shock, including attenuation of vascular leakage, 
lower vasopressor infusion rates and less organ dysfunction, related to 
improved survival19-21.
Substantial effort has been directed at reducing mortality in sepsis patients. 
Nevertheless, all major sepsis trials have failed to improve survival. Although 
survival is a clear and relevant end-point, it may be too insensitive to 
demonstrate a beneficial effect of a novel intervention. Therefore, novel 
endpoints beyond all-cause mortality should be considered38. The use of 
composite endpoints allows for more nuanced assessment of morbidity and 
mortality. A new composite endpoint, the SSI, is used in the present study as 
the primary efficacy endpoint. The SSI is a composite index reflecting days 
on organ supportive therapy (hemodynamics, pulmonary), days with organ 
dysfunction (renal), as well as all-cause mortality. These organ systems were 
improved by Adrecizumab administration in preclinical models, and support 
of these organ systems defines ICU care, indicating that a therapeutic effect is 
of clinical relevance. The SSI is thought to allow for earlier and more sensitive 
observations of possible clinically relevant beneficial effects of Adrecizumab 
compared to more traditional primary efficacy endpoints.
Potential limitations of the study include strict inclusion and exclusion 
criteria and a short window for patient inclusion (within 12 hours following 
vasopressor therapy). These limitations result in a more homogenous study 
population, but they may make recruitment more difficult and limit the 
generalisability of the results.
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Conclusion
Despite the exponential increase of knowledge gathered in the last decades 
pertaining the pathophysiology of septic shock, this has not translated to 
effective therapeutic interventions and as a consequence, this condition remains 
to have an unacceptable high morbidity and mortality. The AdrenOSS-2 trial 
is one of the first personalised medicine trials in patients with septic shock, 
aimed at characterising the safety and efficacy of the ADM-binding antibody 
Adrecizumab in patients with septic shock with elevated concentrations of 
bio-ADM. The trial incorporates a number of innovative features such as 
biomarker-guided patient selection and a novel efficacy endpoint in its design 
to avoid ptifalls of previous sepsis trials. Adrecizumab represents a promising 
approach to treat this lethal syndrome. The results of this proof-of-concept 
and dose-finding phase II trial are eagerly awaited, and will importantly aid 
the design of future trials with this drug.
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The primary aim of this thesis was to investigate the potential of the non-
neutralizing, adrenomedullin-binding antibody Adrecizumab as a novel 
treatment strategy for septic shock. To do so, we first thoroughly evaluated the 
current knowledge on endogenous adrenomedullin, including intracellular 
pathways, effects of adrenomedullin on organ systems affected by sepsis, and 
the potential use of adrenomedullin-targeted therapies in part I. In this part, 
we also evaluated the existing literature on adrenomedullin in heart failure 
and reviewed the experimental human endotoxemia model which we used 
for translational research later in this thesis. In part II, we studied the kinetics 
of circulating endogenous adrenomedullin and its relation with outcome in 
both a general critically ill patient population and in sepsis patients. Next, we 
performed preclinical studies to assess the safety, efficacy and mode of action 
of Adrecizumab in part III. Finally, we focused on the clinical evaluation of 
Adrecizumab in part IV.
In the general introduction and outline of this thesis (chapter 1), we provided 
a brief historical perspective on sepsis and focussed on the vascular endothelial 
barrier as a potential target for pharmacological interventions. In addition, we 
introduced the vasoactive peptide adrenomedullin and the novel humanized 
adrenomedullin-binding antibody Adrecizumab.
Part I: Background
In chapter 2, we reviewed the existing literature on adrenomedullin and sepsis. 
Briefly, adrenomedullin is a peptide hormone that is predominantly produced 
by endothelial and vascular smooth muscle cells. Several factors present in 
patients suffering from sepsis stimulate adrenomedullin synthesis, including 
hypoxia, catecholamines, lipopolysaccharide and various cytokines. As such, 
increased concentrations of adrenomedullin are indeed observed in septic 
patients, which correlate with disease severity and mortality. Adrenomedullin 
has a relatively short half-life of 22 minutes, and is removed from the circulation 
through proteolytic degradation or through internalisation upon binding 
with its receptors. Although strong vasodilation was the first discovered 
biological effect of adrenomedullin, more recent studies revealed that it exerts 
a multitude of actions, including anti-inflammatory, anti-apoptotic and anti-
microbial effects, as well as strong endothelial barrier-protection properties. 
In this review, we also provided an extensive overview of preclinical in vitro 
and in vivo studies that have investigated the potential therapeutic use of 
adrenomedullin in animal models of systemic inflammation and sepsis. In 
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many of these studies, administration of adrenomedullin exerted beneficial 
effects on outcome. This might be attributed to its barrier-enhancing effects 
upon ligation with endothelial cells, and we describe the involved pathways 
in greater detail. However, there are likely some drawbacks to adrenomedullin 
therapy that make it less attractive as a potential therapeutic agent in patients. 
The most important one is potent vasodilation, which causes hypotension and 
could further aggravate shock in patients with low blood pressure due to sepsis 
already. Several attempts have been made to negate the hypotensive effects of 
adrenomedullin and enhance its beneficial effect, for example through co-
administration of adrenomedullin with adrenomedullin-binding peptide-1 
(AMBP-1), administration of PEGylated adrenomedullin and by complete 
or partially (i.e. non-neutralizing) inhibiting antibodies (Adrecizumab). 
In chapter 3, we focussed on the vascular effects of adrenomedullin in sepsis and 
of preclinical studies with Adrecizumab and its murine predecessor HAM1101. 
In addition, we formulated a completely novel hypothesis on the mechanism 
of action of Adrecizumab. The observation that plasma adrenomedullin levels 
are increased upon administration of the antibody is a fundamental aspect 
of this hypothesis. In short, we theorised that Adrecizumab induces a shift 
of adrenomedullin from the interstitium into the blood compartment, since 
the small peptide adrenomedullin – which normally is able to defuse freely 
over the endothelial barrier – cannot do this anymore upon binding with the 
much larger antibody in the circulation. This leads to increased circulating 
levels of adrenomedullin complexed with Adrecizumab. Since Adrecizumab 
only partially inhibits adrenomedullin signaling, we hypothesize that there 
is ‘net’ enhanced adrenomedullin signaling on endothelial cells, thereby 
exerting endothelial barrier-stabilizing effects. At the same time, the draining 
of the vascular interstitium (as Adrecizumab is retained in the circulation 
and binds ADM) may lead to lower interstitial levels of adrenomedullin 
following treatment with Adrecizumab. As a therapeutic property, this may 
attenuate vascular smooth muscle cell-mediated vasodilation and improve 
hemodynamic stability in patients with septic shock. In addition, we show 
that Adrecizumab prolongs the half-life of circulating adrenomedullin, likely 
by protecting the N-terminal epitope from proteolytic degradation. This 
aspect may also be partially responsible for the observed increased circulating 
levels of adrenomedullin.
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In chapter 4, we commented on a review by others detailing vasopressor 
treatments. Herein, Adrecizumab is mentioned as an adrenomedullin-
blocking compound, which does not accurately describe Adrecizumab’s 
purported mechanism of action. In this letter, we briefly summarized our 
aforementioned hypothesis.
In chapter 5, we reviewed the existing literature on heart failure and 
adrenomedullin, and speculated on the potential of Adrecizumab as a 
treatment option for patients with heart failure. Interestingly, increased 
concentrations of adrenomedullin and related peptides (such as the inactive 
mid-regional pro-adrenomedullin [MR-proADM] peptide) are observed in 
heart failure patients and correlate with adverse outcome and fluid overload. 
Because higher levels of adrenomedullin appear to reflect residual tissue 
congestion, which in turn is related to impaired outcome and a higher 
likelihood for hospital readmission, we propose that adrenomedullin levels 
might guide diuretic treatment and/or discharge decisions. Finally, we discuss 
the potential of Adrecizumab as a treatment strategy for heart failure patients. 
Because adrenomedullin has potent endothelial barrier-stabilizing properties 
and also inhibits aldosterone secretion, the enhancement of circulating levels 
of adrenomedullin by Adrecizumab treatment might be advantageous in this 
group of patients.
A thorough evaluation of the literature on the experimental human 
endotoxemia model utilized in chapter 12 of this thesis is provided in chapter 
6. In this model, healthy volunteers are administered purified endotoxin 
(lipopolysaccharide) intravenously. This induces a safe, transient, and well-
controlled systemic inflammatory response, which bears several similarities to 
the inflammatory response observed in sepsis patients. Because this model can 
be used in a highly standardized and reproducible manner, the model allows 
researchers to investiage the underlying mechanisms of systemic inflammation 
and potential interventions in humans in vivo. We describe several strengths 
and limitations of this translational model, possible study designs and organ-
specific changes elicited by endotoxin infusion.
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Part II: Adrenomedullin as a biomarker in the critically ill
A novel assay has recently been developed to measure circulating levels of 
biologically active adrenomedullin (bio-ADM). This assay enables rapid and 
highly specific measurements of bio-ADM using a sandwich immunoassay and 
has several advantages over previously used radioimmunoassays. Furthermore, 
it yields actual bioactive ADM concentrations and not surrogates such as the 
inactive precursor MR-proADM. The assay has potential as a tool to monitor 
tissue congestion, predict progression of disease, and stratify patients to specific 
treatments (for example new compounds that target the adrenomedullin 
system, such as Adrecizumab). 
In chapter 7, using data from the FROG-ICU study (French and European 
Outcome reGistry in Intensive Care Units), the relation between bio-ADM 
levels at admission and outcome parameters was assessed in a critically ill ICU 
population (including both septic and non-septic ICU patients). Over 2000 
patients were enrolled. The highest concentrations of bio-ADM at admission 
were found in patients with septic shock (median 99.7 [IQR 62-194.4] pg/
mL), whereas the lowest levels were observed in patients with neurological 
disorders (median 28 pg/mL [IQR 18-48]). Bio-ADM concentrations were 
independently associated with the need for organ support, renal replacement 
therapy as well as the use of inotropes and/or vasopressors, even in patients 
who were not on inotropic/vasopressive support at baseline. In addition, 
elevated bio-ADM levels were independently associated with prolonged 
length of stay and 28-day mortality. These observational data illustrate that 
circulating concentrations of endogenous ADM have prognostic value in a 
general ICU population, especially in those patients that suffer from systemic 
inflammation.
A second study was performed in patients with sepsis and septic 
shock (AdrenOSS study; The prospective observational multinational 
Adrenomedullin and Outcome in Sepsis and Septic Shock study), and the 
results are presented in chapter 8. Bio-ADM concentrations at admission were 
significantly higher in septic shock vs. severe sepsis patients (114 vs. 58 pg/
mL). In addition, bio-ADM levels at ICU admission correlated significantly 
with initial organ dysfunction (SOFA), need for organ support, and 28-day 
mortality. Moreover, patients with bio-ADM concentrations >70 pg/mL at 
admission were more likely to require renal replacement therapy and had 
a more positive fluid balance compared to patients with bio-ADM levels 
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<70 pg/mL. Bio-ADM had additional value in concert with APACHE and 
lactate levels. Finally, in patients with bio-ADM concentrations >70 pg/mL at 
admission, a decrease to below 70 pg/mL on ICU day 2 was associated with a 
full recovery of organ dysfunction by day 7 and a 28-day mortality of 10%. In 
contrast, persistently elevated bio-ADM levels on day 2 were associated with 
prolonged organ dysfunction and a 28-day mortality of 38%. Taken together, 
bio-ADM has additional prognostic value compared to currently used clinical 
scores and lactate at ICU-admission in sepsis patients. Moreover, repeated 
measurements improve this prognostic accuracy even further.
Part III: Preclinical evaluation of the adrenomedullin-binding antibody 
Adrecizumab
Previously, the efficacy of the murine adrenomedullin-binding antibody 
HAM1101 (the predecessor of Adrecizumab) was demonstrated in rodent 
models of sepsis. We investigated the safety and efficacy of the humanized 
form of this antibody, known as ‘Adrecizumab’, in healthy animals and in 
preclinical models of systemic inflammation and sepsis.
In chapter 9, we studied the effects of Adrecizumab on vascular barrier 
dysfunction and survival in rodent models of systemic inflammation and 
sepsis. In 48 Wistar rats, pretreatment with Adrecizumab or placebo was 
directly followed by administration of 5 mg/kg lipopolysaccharide to induce 
systemic inflammation. Twenty-four hours later, rats were sacrificed and 
renal albumin concentrations were assessed as a measure of vascular leakage. 
Pretreatment with 0.1 and 2.5 mg/kg Adrecizumab significantly reduced 
renal, but not hepatic, albumin leakage compared to placebo. In addition, 
circulating levels of adrenomedullin were dose-dependently increased 
following Adrecizumab administration. In another experiment in 24 C57BL/6 
mice, pretreatment with Adrecizumab was followed by cecal ligation and 
puncture (CLP) surgery to induce polymicrobial sepsis. It was demonstrated 
that Adrecizumab attenuated renal expression of albumin and the detrimental 
peptide VEGF, while concentrations of the protective protein angiopoietin-1 
were augmented. Finally, survival was assessed in 60 C57BL/6 mice following 
CLP-induced sepsis. Pretreatment with either HAM1101 or Adrecizumab 
significantly increased survival compared to placebo, both when administered 
as single dose, as well as following repeated dosages. Note that Adrecizumab 
was administered before the onset of systemic inflammation and sepsis in this 
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chapter (pretreatment). As, in clinical practise, patients receive treatment after 
they become ill, this limits the generalizability.
 
In chapter 10, the effects of delayed administration of Adrecizumab on 
hemodynamic parameters and cardiac function were further studied in rats. 
Male Wistar rats underwent CLP and 24 hours later, a single dose of 2 mg/
kg Adrecizumab (or placebo) was administered intravenously. Control groups 
included sham-operated animals and rats receiving noradrenaline with or 
without concurrent Adrecizumab administration. For the next 3 hours, blood 
pressure was measured invasively, and cardiac function was assessed hourly 
by echocardiography. Thereafter, animals were sacrificed and several organs 
were analysed for inflammatory peptides and oxidative stress. Adrecizumab 
significantly increased systolic blood pressure, heart rate and cardiac output 
compared to placebo-treated animals, to a similar extent as in rats in which 
CLP-induced septic shock was treated with norepinephrine only. Addition of 
Adrecizumab administration to norepinephrine-treated rats did not further 
improve hemodynamic parameters. CLP resulted in a significant increase of 
circulating bio-ADM levels compared to sham-operated animals (15 vs. 290 
pg/mL). Administration of 2 mg/kg Adrecizumab enhanced CLP-induced 
bio-ADM levels greatly (1193 pg/mL). Adrecizumab treatment did not affect 
cytokine concentrations in various organs or myocardial Akt phosphorylation 
levels. However, Adrecizumab did significantly blunt CLP-induced myocardial 
oxidative stress.
The preclinical safety of Adrecizumab was thoroughly evaluated in rats, beagle 
dogs and cynomolgus monkeys, and these data are presented in chapter 
11. Briefly, Wistar rats and cynomolgus monkeys received four repeated 
administration of Adrecizumab in various dosages over a period of 14 days, 
whereas beagle dogs received a single administration of various dosages of 
Adrecizumab. Safety observations included clinical signs and symptoms, 
mortality, extensive blood and urine analyses, as well as histopathology. The 
beagle study focussed primarily on hemodynamics, measured in the first 
24 hours post-administration by telemetry devices. Adrecizumab was well-
tolerated in tested dosages of up to 400 mg/kg/day in rats, 50 mg/kg/day 
in beagle dogs and 100 mg/kg/day in cynomolgus monkeys. No significant 
toxicologically alterations could be attributed to Adrecizumab. Toxicokinetic 
analysis revealed that peak concentrations were attained almost immediately 
after Adrecizumab administration, that peak and area-under-curve 
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concentrations of Adrecizumab increased in a dose-proportional manner, 
and that accumulation ratios of Adrecizumab were reasonably consistent. 
In addition, plasma levels of bio-ADM were significantly increased upon 
Adrecizumab administration, which did not coincide with lower blood 
pressure (measured non-invasively in cynomolgus monkeys and invasively in 
beagle-dogs). 
Part IV: Clinical evaluation of the adrenomedullin-binding antibody 
Adrecizumab
The results from part III paved the way for clinical safety evaluation of 
Adrecizumab. In chapter 12, the safety, tolerability and pharmacokinetics/-
dynamics of Adrecizumab were evaluated in healthy male volunteers in a 
phase I, first-in-human study and in a second study during experimental 
human endotoxemia. Forty-eight healthy male volunteers were enrolled 
in two randomized, double-blind, placebo-controlled studies. In both 
studies, subjects received one of three dosages of Adrecizumab (0.5, 2 and 
8 mg/kg, n=6 per group) or placebo. In a second study, a bolus of 1 ng/
kg of lipopolysaccharide was followed by continuous infusion of 1 ng/kg/
hour (for 3 hrs) of lipopolysaccharide to induce systemic inflammation, 
and administration of Adrecizumab (or placebo) was started 1 hour after 
endotoxin bolus administration. Because the half-life of Adrecizumab was 
predicted to be quite long from the animal studies, subjects were followed for 
a 90-day period. Excellent safety profiles of Adrecizumab were demonstrated 
both during non-inflammatory, as well as inflammatory conditions. 
Pharmacokinetic analyses revealed results typical for monoclonal antibodies, 
including proportional increases of the maximum plasma concentrations 
with increasing dosages, a small volume of distribution, low clearance rate 
and a terminal elimination half-life of approximately 14 days. Systemic 
inflammation (in the volunteers of the endotoxemia trial) did not relevantly 
alter the pharmacokinetics. In line with the animal data presented in chapters 
9-11, Adrecizumab induced a swift, profound and dose-dependent increase of 
circulating bio-ADM levels (see also chapters 3 and 4 for our hypothesis on 
this observation). Importantly, Adrecizumab did not affect the endotoxemia-
induced decrease in mean arterial pressure or increase in body temperature, 
nor did it influence cytokine kinetics. This was not surprising, as the design 
of the study focussed on pharmacokinetics and safety of Adrecizumab during 
inflammation and therefore Adrecizumab was administered 1 hour after 
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initiation of LPS infusion, during which the immune response was already 
fully mounted. As a consequence, Adrecizumab was not expected to modulate 
the innate immune response. Nevertheless, endotoxemia-induced flu-like 
symptoms were significantly attenuated in the 8 mg/kg dosage group, while 
a trends towards significance were observed in the lower Adrecizumab dosage 
groups. 
 
Based on the results of this preclinical and translational research in humans, 
in chapter 13, the study protocol of the AdrenOSS-2 study is presented. 
In this double blind, placebo-controlled, randomized, multicenter, proof of 
concept and dose-finding phase II first-in-patient clinical trial, the safety and 
efficacy of Adrecizumab will be investigated in patients with septic shock and 
elevated adrenomedullin concentrations. The primary endpoint is the safety 
and tolerability of Adrecizumab over a 90-day period. Some notable features 
of this study are biomarker-guided patient selection (bio-ADM >70 pg/mL at 
ICU admission) and a novel composite efficacy endpoint (the Sepsis Support 
Index). The former is aimed at selecting patients with a high likelihood of 
an impaired outcome who are expected to benefit most from Adrecizumab 
therapy. The latter combines all-cause mortality and organ dysfunction 
over a 14-day period, and is expected to be more sensitive for assessment 
of treatment efficacy than mortality only. A total of 300 patients will be 
enrolled at approximately 30 sites in the European Union, and two dosages 
of Adrecizumab will be investigated (2 and 4 mg/kg). The study started in 
December 2017 and results are eagerly awaited.
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The peptide hormone adrenomedullin has been referred to as a ‘double-
edged sword’ in sepsis1. Elevated levels likely exert endothelial barrier-
stabilising effects, but simultaneously may contribute to more pronounced 
vasodilation and hypotension. In this thesis, we show that circulating levels 
of biologically active adrenomedullin (bio-ADM) reflect disease severity, need 
for organ support, and mortality in a general ICU population and in sepsis 
patients, and therefore has potential use as a prognostic biomarker as well 
as for patient stratification. In addition, we demonstrated promising effects 
of adrenomedullin-binding by the novel antibody Adrecizumab in animals 
and humans, and proposed a mechanism of action. In this final chapter, we 
discuss the findings described in this thesis and present future perspectives.
Potential use of bioactive adrenomedullin as a biomarker in critically ill 
patients
The term biomarker (biological marker) is defined as ‘a characteristic that 
is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes or pharmacological responses to a therapeutic 
intervention’2. In clinical practice, biomarkers are already used in the form 
of (routine) laboratory tests, and can aid in screening (detecting subclinical 
disease), diagnosis (confirming overt disease), prognosis or staging (predicting 
the disease course/assessing severity), patient stratification (selecting patients 
which may benefit most from a given intervention), and titration of therapies 
(with regard to efficacy and/or toxicological side-effects). In the field of 
sepsis, which is characterized by a very heterogeneous patient population 
and a highly complex pathophysiology, it has been proposed that a more 
personalized approach would be required to move the field forward, with 
medical decisions and treatments being tailored to the individual patient3. 
Biomarkers could potentially play an important role in this process, which is 
also known as ‘precision medicine’.
In line with previous work, we showed that bio-ADM has potential prognostic 
value in several critically ill patient categories, as it independently reflected 
disease severity, positive fluid balance (possibly reflecting capillary leakage that 
arises through endothelial barrier disruption), need for organ support and 
mortality. Notably, in patients who did not yet receive vasopressors during ICU 
admission, bio-ADM predicted later vasopressor requirement. Nevertheless, 
it is important to critically assess bio-ADM’s advantages and limitations, and 
to compare bio-ADM to other biomarkers related to the adrenomedullin 
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pathway, as well as to currently used means of prognostication (e.g. clinical 
criteria and blood lactate levels4). In addition, possible implications for clinical 
practice and stratification for clinical trials need to be discussed.
Let us first consider the technical robustness of the bio-ADM assay. This was 
thoroughly evaluated by others recently5, showing a high specificity of the assay 
for biologically active adrenomedullin. No cross-reactivity with the putative 
adrenomedullin-binding complement factor H, inactive glycine-extended 
adrenomedullin or related peptides such as adrenomedullin-2, calcitonin 
gene-related peptide, calcitonin or amylin was observed. In addition, the 
assay showed stable results even when plasma samples were stored for up to 24 
hours at ambient temperature and over multiple freeze-thaw cycles. Finally, 
the lower and upper levels of detection and quantification allows researchers 
to assess bio-ADM levels over a wide range of diseases with varying plasma 
levels.
Midregional pro-adrenomedullin (MR-proADM) represents the most 
prominent alternative biomarker of the adrenomedullin system, and has often 
been used as a surrogate marker for adrenomedullin, partially due to technical 
difficulties related to the measurement of the latter in the past (e.g. need 
for large sample volumes, difficult preanalytical sample extraction and long 
incubation times). At first glance, this makes sense, as both MR-proADM 
and bio-ADM are derived from the same precursor peptide in a similar ratio 
(Figure 1). Also, several studies have demonstrated that MR-proADM levels 
are elevated in critically ill patients and correlate strongly with mortality, 
indicating that it also has potential as a biomarker, for example in triage in 
the emergency department6,7. However, MR-proADM measurements do not 
take into account that a significant amount of adrenomedullin is circulating 
in its ‘inactive’ glycine-extended form8. In addition, clearance kinetics of 
MR-proADM and bio-ADM likely differ (MR-proADM has a longer half-
life). Therefore, bio-ADM measurements may better reflect the activity of the 
ADM system and may correlate better with the clinical status of the patient. 
So far, only one study assessed bio-ADM and MR-proADM concurrently, 
and showed that the correlation of bio-ADM with 28-day mortality in sepsis 
patients was higher compared to MR-proADM9. However, the fact that 
MR-proADM levels were only measured in a subset of patients represents 
an important limitation of this study. Given the lack of other studies that 
measured these peptides simultaneously, no definite conclusions can be 
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Figure 1. Schematic representation of adrenomedullin's biogenesis.
drawn. Future research is warranted to compare bio-ADM and MR-proADM 
head-to-head in order to determine whether the theoretical benefits of bio-
ADM indeed translate into a better reflection of the clinical status of patients 
and exerts superior prognostication.
Another important aspect is to determine in which patient groups bio-ADM 
has prognostic value: are (changes in) bio-ADM levels relevant for all critically 
ill patients, or are there exceptions? In the study presented in chapter 7 of 
this thesis, which was performed in a general ICU population, bio-ADM 
correlated strongly with disease severity, organ support and outcome. 
Although this was already established for sepsis patients9,10, we were able to 
extend this observation to a general ICU population including subgroups of 
acute respiratory failure, cardiac arrest and cardiogenic shock. In our study, 
across all patient categories, bio-ADM levels were highest in septic shock. This 
is most likely related to the severity of the systemic inflammatory response, 
as a previous study demonstrated a correlation between pro-inflammatory 
plasma cytokine levels and adrenomedullin concentrations in patients with 
both infectious and non-infectious systemic inflammation11. In accordance, 
in our study, patients with a higher bio-ADM level showed more systemic 
inflammation (e.g. higher CRP concentration and leukocyte counts), while 
bio-ADM levels were the lowest in patients with neurological disorders and did 
not correlate well with outcome in this specific subgroup. These observations 
support the notion that systemic inflammation and bio-ADM are related to 
endothelial dysfunction. The interplay between bio-ADM release from the 
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endothelium and endothelial dysfunction in the relation to the prognosis of 
patients warrants further exploration, as the endothelium is both an important 
source, as well as target of adrenomedullin12,13. In addition, future studies that 
measure adrenomedullin and interventions that target this pathway should 
focus on patients with profound systemic inflammation and/or heart failure. 
Use of bio-ADM as a biomarker is only useful if it has additional value 
compared to existing clinical scores or for example, lactate levels. In the 
AdrenOSS study presented in chapter 8, the prognostic value of bio-ADM at 
admission for the primary endpoint 28-day mortality was only moderate, with 
a C-index (comparable to the AUROC) of approximately 0.7, similar to that 
of lactate, SOFA and APACHE II. However, for initial mortality prediction, 
many risk scores or individual biomarkers show AUCs of around 0.7, possibly 
due to the fact that many critically ill patients eventually die of causes not 
directly related to the initial disease. Note that bio-ADM’s prognostic value 
for mortality was independent from the aforementioned variables and other 
covariates, and that it showed added prognostic value when combined with 
these variables (which was also observed in chapter 7 of this thesis). This 
illustrates that a combination of biomarkers improves prognostication at 
ICU admission. A combination of several biomarkers and/or clinical scores 
is likely superior, which represents an opportunity for further research with 
bio-ADM. Interestingly, repeated measurement of bio-ADM later in the 
disease course (48 hours after the first measurement) showed interesting 
results (described in chapter 8). Survival of patients with high initial bio-
ADM levels which subsequently recovered towards normal concentrations 
was comparable to that of patients already displaying low bio-ADM levels at 
admission. In contrast, patients with a persistently high bio-ADM level had 
poor survival. Apparently, there is a group of patients that has high initial 
bio-ADM at admission, but nevertheless makes a quick recovery. Therefore, 
early bio-ADM measurements may not always yield reliable prognostic 
information and a repeated measurement may be of more value. The reasons 
behind these observations remain to be explored; perhaps the source of sepsis 
(e.g. pneumonia or abdominal infection), other timely interventions (e.g. 
antibiotic treatment, fluid resuscitation), or other factors are involved. Finally, 
it is of no use to compare bio-ADM with other commonly used biomarkers 
such as procalcitonin, C-reactive peptide and/or leukocytes, because these are 
used as diagnostic biomarkers for infection vs. sterile inflammation, and do 
not have prognostic value. Bio-ADM has not yet been compared head-to-
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head to other experimental biomarkers for sepsis prognostication, of which 
there are many. 
Another aspect that warrants discussion is the 70 pg/mL cut-off value for 
bio-ADM, which was first proposed in a 2014 paper9. The scientific rationale 
for choosing this concentration was described somewhat ambiguous (the 
paper only stated that it was close to the 99th percentile of the normal 
range [43 pg/mL]), but nevertheless, it proved to correlate well with organ 
dysfunction/support and mortality. After the initial study, three subsequently 
performed studies, including ours (chapters 7 and 8 of this thesis)10, used the 
70 pg/mL cut-off value and confirmed that it indeed exerts prognostic value. 
However, it may be the case that a different cut-off value is more optimal for 
risk stratification, depending on the specific population, setting and diseases 
studied. In the AdrenOSS study described in chapter 8, additional ROC 
analyses were performed to assess optimal cut-off values for 28-day mortality. 
The Youden cut-off value of bio-ADM at admission was 102 pg/mL for severe 
sepsis and septic shock patients combined (sensitivity 68%, specificity 67%), 
102 pg/mL for severe sepsis patients (sensitivity 58%, specificity 79%), and 99 
pg/mL in septic shock patients (sensitivity 71%, specificity 52%), compared 
to a sensitivity of 77% and specificity of 49% for the predefined cut-off 
value of 70 pg/mL in severe sepsis and septic shock patients combined. In 
the Frog-ICU study, a cut-off value of 75 pg/mL was found using sensitivity 
analysis. For AdrenOSS-2, a cut-off value of 70 pg/mL was adopted to aid 
in selecting the most severely ill patients with a higher likelihood to develop 
organ dysfunction, vasopressor requirement, vascular leakage and a higher 
mortality: patients who may benefit most from treatment with Adrecizumab. 
Future studies should further evaluate different bio-ADM cut-off values for 
different patient populations and diseases.
Altogether, bio-ADM is a promising biomarker with prognostic value in 
critically ill patients with various diseases, such as sepsis9,10,14, cardiogenic 
shock15, acute myocardial failure16 and acute heart-failure17,18. It is of interest 
to compare groups of patients based on bio-ADM levels, however, it remains 
to be determined to what extent the prognostic value of bio-ADM will 
actually influence bedside management of sepsis patients. Comparable to the 
use of APACHE score and lactate, in these patients that are already in an 
environment with a continuously high level of monitoring where discharge 
decisions primarily depend on whether a patient is weaned off organ support, 
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individual policy decisions should not be dependent on a single biomarker. 
Ultimately, the real value of (serial measurements of ) bio-ADM may lie in 
initiation and/or guidance of specific therapies, such as diuretics for heart 
failure (speculated on in chapter 5 of this thesis), identifying patients with 
endothelial barrier disruption who may benefit from future endothelial 
barrier-stabilising drugs, or selecting patients for studies or stratification of 
patients within a study with novel therapies that target the adrenomedullin 
system (such as the AdrenOSS-2 study presented in chapter 13).
 
Adrenomedullin as a double-edged sword in sepsis
We want to address the fact that several authors have referred to adrenomedullin 
as a ‘double-edged sword’ in sepsis. It is interesting to speculate whether 
endothelial barrier-stabilising and vasodilatory effects of adrenomedullin are 
exerted at bio-ADM concentrations commonly observed in septic patients 
(median of 100-125 pg/mL, see chapters 7 and 8 of this thesis)9,10. In 
order to shed more light on this issue, we reviewed the literature pertaining 
concentration-dependent effects of ADM observed in in vitro and in vivo 
studies. 
Starting with endothelial barrier-stabilising effects, in in vitro studies with 
(human) endothelial cell monolayers, stabilising effects were observed using 
adrenomedullin concentrations of 0.01-0.1 ȝmol/L19,20, which roughly 
translates to 60000-600000 pg/mL, much higher than those observed in 
septic shock patients. Unfortunately, comparing effective concentrations 
between in vitro and in vivo studies is notoriously troublesome, and therefore 
no definite conclusions can be drawn based upon this. In vivo studies showed 
that treatment with 24-500 ȝg/kg/hr adrenomedullin improved survival 
and reduced endothelial hyperpermeability in various animal models21-23. 
However, plasma adrenomedullin concentrations were unfortunately not 
measured, and in our opinion it is too speculative to convert these dosages to 
plasma concentrations. Note that we did observe attenuated vascular leakage 
(as a measure of endothelial barrier stabilisation) at ADM concentrations of 
approximately 100 pg/mL and higher in chapter 9 of this thesis.
Next, let us consider the cardiovascular effects of adrenomedullin. In contrast 
to endothelial effects, in vitro work showed that vasodilation of rat carotid 
arteries was attained by much lower adrenomedullin concentrations, starting 
at approx. 60 pg/mL24. In vivo in humans, cardiovascular effects were 
demonstrated at dosages of approximately 150 pg/min/mL25, and in other 
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studies, at plasma concentrations of roughly 180 pg/mL and 70 pg/mL26,27. 
These data indicate that adrenomedullin likely exerts vasodilatory effects 
leading to hypotension at concentrations that are commonly observed in 
septic shock patients.
Taken together, these (rough) calculations suggest that adrenomedullin – in 
concentrations commonly observed in septic patients – very likely exerts 
cardiovascular effects, including hypotension, but may not accomplish 
endothelial barrier stabilisation. This is in line with the fact that in septic 
patients, higher adrenomedullin concentrations are associated with worse 
outcome, hypotension and vasopressor requirement. The term “double-edged 
sword” may therefore not be appropriate in sepsis patients. Furthermore, this 
emphasizes the need for therapies that enhance adrenomedullin’s beneficial 
effects and negate its detrimental ones. Adrecizumab appears to represent a 
prime example of such a therapy. 
Adrecizumab as a novel therapy for sepsis
After promising studies with the murine predecessor of Adrecizumab 
(HAM1101)28,29, a humanized form of this antibody was developed and 
named Adrecizumab. We evaluated the efficacy and safety of Adrecizumab 
in preclinical animal studies and two clinical studies in healthy volunteers 
(chapters 9-12). Furthermore, we formulated a hypothesis on Adrecizumab’s 
mechanism of action (discussed in chapters 2-4), and we published the 
study protocol for a phase II study with Adrecizumab in patients with septic 
shock (chapter 13). These studies provide the basis for further discussion and 
potential future studies.
Let us first consider the proposed mechanism of action of Adrecizumab. 
Central to this hypothesis is the observation that adrenomedullin-binding 
with Adrecizumab causes a shift from the vascular interstitium to the blood 
compartment resulting in a profound increase of circulating concentrations 
of its target peptide adrenomedullin. We showed that this increase is not 
due to enhanced synthesis (as MR-proADM concentrations remained 
stable), but instead hypothesised that this is 1) due to a redistribution 
from the tissue/interstitium to the blood and 2) enhanced half-life due 
to protection from proteolytic degradation that normally occurs via the 
N-terminal epitope of adrenomedullin (where Adrecizumab also binds). 
Interestingly, Adrecizumab is not the first antibody described in literature 
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to enhance circulating levels of its target peptide. It is well known that 
antibody binding can lead to redistribution of a ligand from the tissue to 
the blood, with significant decreases in tissue ligand concentrations30. Prime 
examples of this are antibody fragments used to treat patients with digoxin-
intoxication. Shortly after administration of anti-digoxin antibody fragments, 
plasma concentrations of digoxin increase strongly due to redistribution of 
digoxin to the blood, and since the majority of digoxin is bound to antibody 
fragments, it can no longer interact with its biological tissue receptor and thus 
reverses cardiac digoxin toxicity31. Likewise, we propose that Adrecizumab 
lowers tissue/vascular interstitial levels of adrenomedullin, which in turn 
attenuates adrenomedullin’s vasodilatory effects on vascular smooth muscle 
cells located at the abluminal side of blood vessels. This observation is 
supported by a study presented in chapter 10 of this thesis, in which blood 
pressure improved after Adrecizumab administration in a model of murine 
sepsis, possibly through the aforementioned mechanism. Importantly, in 
contrast to most antibodies, Adrecizumab does not completely inhibit 
interaction of adrenomedullin with its biological receptor, and thus can still 
induce signalling in endothelial cells located on the luminal side of the blood 
vessel28,32. Therefore, we hypothesise that a strong increase of plasma levels 
results in ‘net’ increased signaling in endothelial cells, resulting in activation 
of intracellular pathways that enhance endothelial barrier structure (reviewed 
in chapter 2), which may explain beneficial effects related to capillary leakage 
that we observed (chapter 9)33. For future research, it would be interesting 
to 1) show that adrenomedullin levels in the interstitium indeed decrease 
upon administration of Adrecizumab, for example by measuring interstitial 
adrenomedullin concentrations in vivo through microdialysis, or via post-
mortem techniques such as absolute quantification in tissue homogenates 
or immunohistochemistry to confirm our hypothesis, and 2) investigate 
relevant intracellular pathways in endothelial cells (we hypothesise that these 
are activated), as well as in vascular smooth muscle cells (we hypothesise that 
these are suppressed) following Adrecizumab administration.
With regard to Adrecizumab/adrenomedullin pharmacokinetics/-dynamics, 
there are some more interesting aspects to discuss. Adrenomedullin has been 
described to be cleared from the circulation via proteolytic degradation by 
proteases34-36 and internalisation and degradation upon binding with its 
receptor, a process that also results in internalisation of the receptor37,38. It 
remains to be fully elucidated how these clearance mechanisms are affected 
General discussion and future perspectives
15
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 378
378
when Adrecizumab complexes with adrenomedullin. For example, it 
appears plausible that the ADM-antibody-complex becomes too large for 
internalisation, and therefore, the antibody-ligand complex could remain 
bound to ADM receptor for a long time, leading to prolonged endothelial 
stimulation. However, such prolonged stimulation could eventually also result 
in suppressed adrenomedullin signaling, either through reduced adenylyl 
cyclase coupling to the adrenomedullin receptor39, or possibly alteration of 
adrenomedullin receptor expression, although no studies have been performed 
on this subject. When discussing receptor pharmacology, it also needs to be 
acknowledged that adrenomedullin is able to bind not to 1, but to 3 different 
receptors (CGRP, ADM1 and ADM2 receptors), all of which are expressed on 
vascular endothelial and smooth muscle cells. So far, effects of Adrecizumab 
were only investigated in a functional assay for the AMD2 receptor, focussing 
on the cAMP response, which showed partial inhibition of signaling28. It 
remains unknown what effects are for the other receptors or other second 
messenger systems, and whether Adrecizumab binding results in antagonistic 
or agonistic effects for these other receptors and pathways. In addition, next 
to adrenomedullin, these receptors may bind to other ligands as well, with 
varying affinities (a phenomenon known as ‘functional selectivity’ or ‘biased 
signaling’)40. If the affinity of these receptors for adrenomedullin is altered by 
Adrecizumab binding, it would be interesting to compare the receptor affinity 
for Adrenomedullin-adrecizumab complexes with that for other ligands, of 
which the effects could therefore either be enhanced or attenuated.
Of note, some of the Adrecizumab-related data presented in this thesis may 
appear to be conflicting with our proposed mechanism of action. In the study 
presented in chapter 9, in which 0.1, 0.5 and 2.5 mg/kg of Adrecizumab 
attenuated renal vascular leakage in a rat model of systemic inflammation, 
there appears to be inconsistency regarding the Adrecizumab-induced increase 
of adrenomedullin33. Animals treated with 0.5 and 2.5 mg/kg Adrecizumab 
showed a strong increase of adrenomedullin levels (to approximately 250 and 
500 pg/mL) compared to LPS-control animals (100 pg/mL), and according 
to our hypothesis, increased ‘net’ adrenomedullin signaling on endothelial 
cells may be responsible for barrier stabilisation. However, the 0.1 mg/kg 
group also attenuated vascular leakage, while adrenomedullin levels were not 
additionally increased compared to LPS-control animals (peak concentrations 
were also approximately 100 pg/mL). Because the first measurement was 
performed 3 hours after Adrecizumab administration, it is possible that the 
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‘peak’ adrenomedullin concentration for this group was attained earlier and 
therefore missed. On the other hand, it may also indicate that the actual 
mechanism of action is more complex than we currently think, and that more 
factors play a role than adrenomedullin levels only, such as the aforementioned 
changes in receptor expression, receptor pharmacology/affinity, or 
possibly involvement of other, yet undetermined pathways. For example, 
adrenomedullin is known to exert immunomodulatory effects (also reviewed 
in chapter 2)41. The Adrecizumab-induced increase of adrenomedullin could 
therefore theoretically also exert immunomodulatory effects. A previous study 
in murine sepsis using the murine predecessor HAM1101 showed attenuated 
levels of cyto- and chemokines TNFĮ, IL-6, IL-10, KC and MCP-1 at the end 
of the experiment29. However, it is unclear whether these effects were attained 
by direct immunomodulatory effects, or secondary to an overall improved 
condition of the animals, for instance due to improved hemodynamic stability 
or vascular barrier function. In addition, we did not find effects on plasma 
cytokine clearance in our experimental human endotoxemia study described 
in chapter 12 of this thesis, although the study was not designed to evaluate 
this endpoint (Adrecizumab infusion was started 1 hour after initiation of LPS 
infusion, when the immune response was already initiated and concentrations 
of various cytokines were increased). To give another example, in chapter 10 
we demonstrated that delayed Adrecizumab administration in a murine sepsis 
model (24 hours after cecal ligation and puncture [CLP] surgery) resulted 
in attenuated free radical production in the myocardium, which coincided 
with increased cardiac output. Notably, no effects on organ cytokine levels 
were observed in this study, although these were only assessed at a single, 
relatively early timepoint (3 hours following Adrecizumab infusion). Further 
research should investigate if, and to what extent, adrenomedullin-binding 
by Adrecizumab, and the subsequent increase of circulating adrenomedullin, 
influences immunological and other pathways. 
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Overall, the pathophysiological role, especially focused on vascular and 
endothelial dysfunction, of the ADM-pathway in sepsis patients is convincing 
and Adrecizumab appears to be a promising novel drug for patients with septic 
shock. We demonstrated a favourable safety profile in preclinical and clinical 
studies. It has a plausible mechanism of action, and its effects likely include 
stabilisation of the endothelial barrier and attenuation of vasodilation and 
hypotension. Future research should focus on further exploring the mechanism 
of action and involvement of other pathways. In addition, it might also be of 
benefit in other diseases that are characterized by cardiovascular abnormalities 
and/or endothelial barrier dysfunction, such as heart failure, Dengue fever 
and other capillary leak syndromes. Most importantly, the safety and efficacy 
of Adrecizumab in patients with septic shock with elevated plasma levels of 
adrenomedullin are currently under investigation in the AdrenOSS-2 study, 
of which the results are eagerly awaited.
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Sepsis (‘bloedvergiftiging’) is een veelvoorkomend probleem bij patiënten 
op de intensive care. Het is een ernstig ziektebeeld dat wordt veroorzaakt 
door een ontregelde afweerreactie van het lichaam op een infectie, zoals 
bijvoorbeeld een longontsteking of een urineweginfectie. In de ergste gevallen 
leidt dit tot een daling van de bloeddruk en orgaanschade, dan spreekt men 
van ‘septische shock’. Ondanks moderne behandelingen met antibiotica en 
orgaanondersteunende therapieën (zoals bloeddrukverhogende medicatie, 
beademing en dialyse) overlijdt ongeveer een op de drie patiënten die lijden 
aan septische shock. De patiënten die het overleven hebben vaak blijvende 
restschade. Gezien de hoge ziektelast en sterfte, is er een dringende behoefte 
aan nieuwe behandelingen voor sepsis. De laatste decennia zijn tientallen 
experimentele behandelingen onderzocht, vaak gericht op het verminderen 
van de ontstekingsreactie door remming van specifieke eiwitten of biologisch 
processen. Helaas bleken geen van deze behandelingen effectief te zijn. Dit 
heeft mede te maken met de hoge complexiteit van sepsis, met activatie 
van meerdere biologische processen en grote onderlinge verschillen tussen 
patiënten.
Een belangrijk probleem bij sepsis is het disfunctioneren van bloedvaten. 
Allereerst treedt er vaatverwijding op, wat leidt tot de reeds benoemde 
lage bloeddruk. Een lage bloeddruk is gevaarlijk omdat door de slechtere 
doorbloeding orgaanschade (o.a. in hart, nieren, darmen, hersenen) kan 
ontstaan. Daarnaast is er disfunctie van de endotheelcellen die de binnenkant 
van de bloedvaten bekleden. Deze endotheelcellen vormen de barrière tussen 
het bloed en de omliggende weefsels. Deze essentiële barrière reguleert de 
uitwisseling van moleculen tussen deze twee compartimenten. In het geval van 
sepsis kan deze cellaag meer doorgankelijk worden voor grotere moleculen. 
Door de toename in permeabiliteit verlaat eiwitrijk vocht het bloed en 
ontstaat oedeem. Dit draagt eveneens bij aan een lagere bloeddruk en een 
verminderde zuurstofuitwisseling in de weefsels, wat verdere orgaanschade in 
de hand werkt.
Adrenomedulline is een eiwit dat met name geproduceerd wordt bij patiënten 
met septische shock. De hoogte van de concentratie is geassocieerd met een 
slechtere prognose voor de patiënt.  Adrecizumab is een nieuw geneesmiddel dat 
ingrijpt op de werking van het lichaamseigen eiwithormoon adrenomedulline. 
Adrecizumab is een antilichaam dat mogelijk de functionaliteit (zowel de 
permeabiliteit als de overmatige vaatverwijding) van de bloedvaten kan 
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herstellen bij patiënten met septische shock. Twee experimentele studies met 
een voorloper van Adrecizumab lieten gunstige effecten zien op de bloeddruk 
en een vermindering van orgaanfalen en sterfte in proefdiermodellen waarin 
septische shock nagebootst werd. Deze veelbelovende resultaten hebben 
geleid tot de ontwikkeling van een geoptimaliseerde variant van het medicijn 
voor gebruik in mensen (Adrecizumab). Dit proefschrift heeft als doel om de 
veiligheid en effectiviteit van Adrecizumab als potentiele nieuwe behandeling 
voor sepsis nader te onderzoeken.
In de algemene introductie en achtergrond van dit proefschrift (hoofdstuk 
1) wordt een historische beschrijving van sepsis gegeven. Verder worden 
het eiwithormoon adrenomedulline en het adrenomedulline-antilichaam 
Adrecizumab geïntroduceerd.
Deel I – Achtergrond 
In hoofdstuk 2 wordt een gedetailleerd overzicht gegeven van de 
wetenschappelijke literatuur omtrent adrenomedulline en meer specifiek, 
relevante effecten in de context van sepsis. Adrenomedulline is een 
eiwithormoon dat onder andere geproduceerd wordt door de endotheel- 
en spiercellen in de vaatwand. De productie van adrenomedulline wordt 
gestimuleerd door verschillende factoren, onder andere door zuurstoftekort 
en diverse ontstekingsmediatoren. Het is dan ook niet verwonderlijk dat er 
verhoogde concentraties adrenomedulline gemeten worden in het bloed van 
zieke patiënten met sepsis of septische shock. Tevens bestaat er een correlatie 
tussen de concentratie adrenomedulline in het bloed en de ziekte-ernst van 
patiënten: hoe hoger het adrenomedulline gehalte, des te zieker is de patiënt 
en des te groter ook de kans op overlijden. Adrenomedulline oefent diverse 
biologische effecten uit, onder andere vaatverwijdende, ontstekingsremmende, 
anti-apoptotische en antimicrobiële effecten. Daarnaast is gebleken dat het 
sterk beschermende effecten heeft op de endotheelbarrière en zo lekkage van 
vocht van de bloedvaten naar de omliggende weefsels kan voorkomen.
Verder geeft hoofdstuk 2 een overzicht weer van studies waarbij 
adrenomedulline toegediend werd in dierexperimentele modellen met 
systemische ontstekingsreacties of septische shock. Uit deze studies bleek 
dat toediening van adrenomedulline gunstige effecten uitoefent op het 
ziekteproces, hetgeen mogelijk verklaard kan worden door de gunstige effecten 
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op endotheelcellen. Er kleven echter ook een aantal mogelijke nadelen aan 
adrenomedulline-toediening, waardoor het mogelijk minder geschikt is voor 
toediening bij de mens. Het belangrijkste nadeel is vaatverwijding, hetgeen 
kan leiden tot een lagere bloeddruk wat mogelijk ongunstig is voor patiënten 
die reeds een lage bloeddruk hebben (zoals patiënten met septische shock). 
Daarom heeft men op verschillende manieren gepoogd om adrenomedulline 
op een dusdanige manier te beïnvloeden, dat de bloeddrukverlagende 
effecten verminderd worden, terwijl gunstige effecten op bijvoorbeeld 
endotheelcellen versterkt worden. Voorbeelden hiervan zijn gelijktijdige 
toediening van adrenomedulline met adrenomedullin-binding protein-1 
(AMBP-1), structurele modificatie van adrenomedulline door toevoeging 
van polyethyleenglycol, of toediening van adrenomedulline-bindende 
antilichamen (zoals Adrecizumab).
In hoofdstuk 3 worden allereerst de vasculaire effecten van adrenomedulline 
tijdens sepsis beschreven en wordt gefocust op dierexperimenteel onderzoek 
met het adrenomedulline-antilichaam Adrecizumab. Daarnaast wordt een 
nieuwe hypothese geformuleerd rondom het werkingsmechanisme van 
Adrecizumab. Centraal in deze hypothese is de observatie dat adrenomedulline 
concentraties in het bloed stijgen na toediening van Adrecizumab. Er wordt 
gehypothetiseerd dat Adrecizumab zorgt voor een herverdeling van het 
beschikbare adrenomedulline, van buiten de bloedvaten (het interstitium), 
naar het bloed. Normaliter kan adrenomedulline, als relatief klein molecuul, 
zich vrijelijk verplaatsten over de vaatwand tussen het interstitium en 
het bloed. Echter, wanneer adrenomedulline in het bloed bindt aan het 
antilichaam Adrecizumab, een veel groter molecuul wat niet in staat is om 
zich te verplaatsen over de vaatwand, is adrenomedulline eveneens niet langer 
in staat om de vaatwand te passeren. Dit zorgt ervoor dat adrenomedullin 
als het ware ‘gevangen’ raakt in het bloed, wat resulteert in een stijging van 
adrenomedullineconcentraties in het bloed. Omdat Adrecizumab een niet-
blokkerend antilichaam is (ondanks binding aan adrenomedulline is het 
adrenomedulline-Adrecizumab complex nog steeds in staat om een interactie 
aan te gaan met receptoren op endotheelcellen), zou dit gunstige effecten 
op endotheelcellen kunnen bewerkstelligen, hetgeen leidt tot minder 
capillaire lekkage en oedeemvorming. Tegelijkertijd zal de concentratie 
adrenomedulline in de weefsels rondom de bloedvaten afnemen, wat leidt 
tot minder vaatverwijdende effecten op de meer naar de buitenzijde gelegen 
spierlaag van de bloedvaten. Daarnaast worden er resultaten getoond waaruit 
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blijkt dat binding van Adrecizumab aan adrenomedulline leidt tot een 
verlengde halfwaardetijd van adrenomedulline, doordat het door binding 
aan het antilichaam beschermd wordt tegen afbraak door zogenaamde 
proteases, wat mogelijk ook kan bijdragen aan de geobserveerde stijging van 
adrenomedullineconcentraties in het bloed.
In de ingezonden brief in hoofdstuk 4 wordt commentaar gegeven op 
een recentelijk gepubliceerd overzichtsartikel over bloeddrukverhogende 
geneesmiddelen. De auteurs van het overzichtsartikel beschrijven Adrecizumab 
als een middel wat de werking van adrenomedulline blokkeert, wat echter 
niet accuraat is. Zoals benoemd in het voorgaande hoofdstuk blokkeert 
Adrecizumab de werking van adrenomedulline niet. In deze brief wordt tevens 
de eerder vermelde hypothese over de werking van Adrecizumab samengevat.
In hoofdstuk 5 wordt een uitstapje gemaakt naar de rol van adrenomedulline 
bij hartfalen. Er wordt een overzicht gegeven van de bestaande literatuur 
omtrent adrenomedulline en hartfalen en wordt gespeculeerd over de potentie 
van Adrecizumab als nieuwe behandeling voor dit ziektebeeld. Interessant is 
dat bij patiënten met hartfalen (net zoals bij patiënten met sepsis) verhoogde 
concentraties van adrenomedulline in het bloed geobserveerd worden, 
hetgeen correleert met een slechtere ziekte-uitkomst. Daarnaast reflecteren 
hogere concentraties van adrenomedulline een teveel aan extravasculair 
vocht (oedeem), wat ongunstig is voor patiënten met hartfalen. Daarom zou 
het meten van adrenomedulline in het bloed mogelijk kunnen helpen om 
behandeling met diuretica te sturen en een bijdrage kunnen leveren aan de 
beslissing om patiënten met hartfalen wel of niet te ontslaan uit het ziekenhuis. 
Tot slot wordt Adrecizumab als potentiele nieuwe behandeling voor patiënten 
met hartfalen beschreven. Omdat Adrecizumab sterke stabiliserende effecten 
heeft op de endotheelbarrière en oedeem kan verminderen, zou behandeling 
met Adrecizumab gunstig kunnen zijn voor deze groep patiënten.
Tot slot wordt in hoofdstuk 6 een uitgebreide beschrijving gegeven van 
het experimentele endotoxinemiemodel bij de mens, een model dat tevens 
gebruikt wordt in hoofdstuk 12. In dit onderzoekmodel wordt endotoxine 
(lipopolysaccharide; LPS) aan gezonde vrijwilligers toegediend. LPS is een 
onderdeel van de celwand van E. Coli bacteriën, en toediening ervan leidt 
tot een kortdurende, goed-gecontroleerde ontstekingsreactie die op meerdere 
vlakken vergelijkbaar is met de ontstekingsreactie die plaatsvindt bij patiënten 
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met sepsis. Omdat dit model consistent en reproduceerbaar is, kan het door 
onderzoekers gebruikt worden om de afweerreactie en eventuele interventies 
die ingrijpen op deze afweerreactie te bestuderen bij de mens. Verder worden 
in dit hoofdstuk de effecten van deze ontstekingsreactie op diverse cellen en 
orgaansystemen beschreven, samen met de voor- en nadelen van het model. 
Tot slot wordt ingegaan op de verschillende manieren waarop dit model 
gebruikt kan worden.
Deel II – Adrenomedulline als biomarker bij kritisch zieke patiënten
Recent heeft men een nieuwe, snelle en specifieke methode ontwikkeld om 
biologisch-actief adrenomedulline (bio-ADM) te meten in het bloed. Deze 
methode heeft diverse voordelen boven het gebruik van andere methoden 
(zoals radioimmunoassays of het meten van het inactieve precursorhormoon 
MR-proADM) en geeft theoretisch een beter beeld van activatie van het 
adrenomedullinesysteem. Dit laatste is echter nog niet goed onderzocht. 
Deze nieuwe testmethode kan potentieel gebruikt worden als biomarker 
voor de hoeveelheid extravasculair vocht (oedeem), het voorspellen van 
klinische achteruitgang bij patiënten en het selecteren van patiënten voor 
nieuwe behandelingen (bijvoorbeeld geneesmiddelen die ingrijpen op het 
adrenomedulline systeem zoals Adrecizumab). In dit deel van het proefschrift 
worden twee studies beschreven waarin de prognostische waarde van de bio-
ADM concentratie in het bloed van patiënten onderzocht is.
In hoofdstuk 7 werd het bio-ADM gehalte in het bloed bepaald bij 
patiënten ten tijde van intensive care opname en is de relatie met de ziekte-
uitkomst onderzocht. Dit vond plaats bij intensive care patiënten met diverse 
ziektebeelden, dus niet enkel in patiënten met sepsis. Hierbij werd gebruik 
gemaakt van data uit de FROG-ICU studie (French and European Outcome 
reGistry in Intensive Care Units). Meer dan 2000 IC-patiënten namen deel 
aan deze studie. Van alle ziektebeelden waarmee de patiënten opgenomen 
werden, werden de hoogste concentraties bio-ADM gevonden in het bloed 
van patiënten met septische shock, cardiogene shock en acuut respiratoir 
falen, terwijl de laagste concentraties gevonden werden in patiënten met 
neurologische ziektebeelden. Dit reflecteert mogelijk een meer uitgesproken 
ontstekingsreactie en een hogere mate van betrokkenheid van endotheelcellen 
bij deze ziektebeelden. Verder waren bio-ADM concentraties onafhankelijk 
geassocieerd met de noodzaak voor orgaan-ondersteunende behandelingen, 
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dialyse en het gebruik van bloeddrukverhogende medicatie. Ten slotte 
waren verhoogde bio-ADM concentraties geassocieerd met een langere 
ziekenhuisopname en een verhoogde kans op overlijden.
Een tweede biomarkerstudie (beschreven in hoofdstuk 8) werd uitgevoerd 
specifiek bij IC-patiënten met sepsis en septische shock, de AdrenOSS studie 
(Adrenomedullin and Outcome in Sepsis and Septic Shock). Deze studie 
toonde aan dat bio-ADM concentraties bij IC opname hoger waren bij 
patiënten met septische shock dan bij patiënten met sepsis. Daarnaast was er 
een relatie tussen bio-ADM concentraties bij intensive care opname enerzijds 
en orgaandisfunctie en kans op overlijden anderzijds. Patiënten met een bio-
ADM concentratie hoger dan 70 pg/mL bij opname hadden een grotere kans 
dat ze dialyse nodig zouden hebben en hadden tevens een groter overschot aan 
extravasculair vocht (oedeem) dan patiënten met een bio-ADM concentratie 
lager dan 70 pg/mL. Dit had een toegevoegde voorspellende waarde bovenop 
andere parameters zoals de APACHE score en lactaat. Tot slot werden er op 
dag 2 van de intensive care opname opnieuw bio-ADM spiegels gemeten. 
Wanneer de bio-ADM concentratie initieel hoger dan 70 pg/mL was maar 
daalde tot onder 70 pg/mL op dag twee, was dit geassocieerd met volledig 
herstel van orgaanfunctie op dag 7 en een verlaagde kans op overlijden (10% 
na 28 dagen). Echter, wanneer de bio-ADM spiegel op dag 2 hoger dan 70 
pg/mL bleef was dit juist geassocieerd met meer orgaandisfunctie en een 
verhoogde kans op overlijden (38% na 28 dagen). Deze studie toont aan 
dat bio-ADM een prognostische waarde heeft die onafhankelijk van en van 
toegevoegde waarde is aan andere prognostische parameters. Verder laat dit 
onderzoek zien dat een tweede meting later in het opnametraject meerwaarde 
heeft voor het voorspellen van de prognose.
Deel III – Effecten van Adrecizumab in proefdieren
Eerder werd de effectiviteit van het adrenomedulline-antilichaam HAM1101 
(de voorloper van Adrecizumab) reeds aangetoond in proefdiermodellen 
van systemische ontsteking en sepsis. Dit leidde tot ontwikkeling van het 
antilichaam Adrecizumab wat geoptimaliseerd was voor gebruik in mensen. In 
dit deel van het proefschrift worden de effecten van dit nieuwe geneesmiddel 
bij proefdieren beschreven.
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In hoofdstuk 9 werd de effectiviteit van Adrecizumab onderzocht in 
knaagdieren waarin een ontstekingsreactie werd opgewekt. In een eerste 
experiment werden 48 ratten behandeld met Adrecizumab of placebo, 
waarna endotoxine toegediend werd om een systemische ontstekingsreactie 
op te wekken. Vierentwintig uur later werden de ratten geofferd en werd 
het albuminegehalte in de nier en lever gemeten als maat voor vasculaire 
lekkage. Behandeling met 0.1 en 2.5 mg/kg Adrecizumab resulteerde in 
significant minder lekkage in de nier, maar niet in de lever, ten opzichte 
van placebo. Daarnaast resulteerde toediening van Adrecizumab in hogere 
adrenomedullineconcentraties in het bloed, hetgeen informatie verschaft over 
het werkingsmechanisme van Adrecizumab. In een ander experiment kregen 
24 muizen Adrecizumab of placebo toegediend, gevolgd door een CLP (cecal 
ligation and puncture) operatie om sepsis te induceren. Tijdens deze ingreep 
wordt een stukje dikke darm afgebonden en doorgeprikt, waarbij feces de 
buikholte in lekt en een bacteriële sepsis ontstaat. In muizen die behandeld 
waren met Adrecizumab werd er verminderde expressie van het eiwit 
albumine (als teken van minder vaatlekkage) in de nier aangetoond. Verder 
kwam in Adrecizumab-behandelde muizen het eiwit VEGF (veroorzaakt 
meer capillair lek) verminderd tot expressie, terwijl het eiwit angiopoietin-1 
(vermindert capillaire lekkage) juist verhoogd tot expressie kwam. Tot slot 
had Adrecizumab een gunstig effect op overleving in model van sepsis bij 
muizen. Een belangrijke kanttekening bij dit werk was dat Adrecizumab reeds 
toegediend werd voordat de proefdieren ziek gemaakt werden, hetgeen in de 
praktijk bij mensen uiteraard niet het geval kan zijn.
In hoofdstuk 10 werden de effecten van Adrecizumab op hemodynamische 
parameters en hartfunctie onderzocht in ratten. Om sepsis te induceren 
ondergingen ratten de eerder genoemde CLP-operatie (of een ‘nepoperatie’ 
in een controlegroep). Dit werd 24 uur later gevolgd door intraveneuze 
toediening van Adrecizumab of placebo. Tevens waren er controlegroepen 
waarin ratten het bloeddrukverhogend geneesmiddel noradrenaline 
toegediend kregen, met of zonder Adrecizumab. Gedurende de eerste 3 uur na 
toediening van Adrecizumab of placebo werd de bloeddruk invasief gemeten 
en werd de hartfunctie ieder uur onderzocht middels echografie. Vervolgens 
werden de ratten geofferd en werden verschillende organen uitgenomen 
en nader geanalyseerd om ontstekingsmediatoren en oxidatieve stress te 
kwantificeren. Toediening van Adrecizumab resulteerde in een significante 
verhoging van de systolische bloeddruk en het hartminuutvolume. Het 
16
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 393
393
Nederlandse samenvatting
tegelijktijdig gebruik van Adrecizumab en noradrenaline resulteerde niet in 
een verdere verbetering van hemodynamische parameters en hartfunctie. 
Vergelijkbaar met het onderzoek in het vorige hoofdstuk zorgde toediening van 
Adrecizumab voor een forse toename van bloedspiegels van adrenomedulline. 
Behandeling met Adrecizumab had geen effect op concentraties van diverse 
ontstekingsmediatoren in verschillende organen. Er werd daarentegen wel 
een significante vermindering gezien van oxidatieve stress in het hart van 
de ratten, hetgeen de gunstige effecten die gezien werden op de hartfunctie 
mogelijk kan verklaren.
In hoofdstuk 11 werd het veiligheidsprofiel van Adrecizumab onderzocht 
bij ratten, honden en apen. Bij ratten en apen werd over een periode van 
twee weken 4 keer Adrecizumab toegediend. In het experiment met honden 
vonden eveneens herhaalde toedieningen plaats, maar dan over een langere 
periode van 28 dagen. De veiligheidsanalyse bestond onder andere uit 
het registreren van eventuele bijwerkingen, analyse van bloed en urine, en 
(histo)pathologisch onderzoek. In de hondenstudie lag de nadruk op de 
evaluatie van hemodynamische parameters. Uit deze experimenten kwamen 
geen veiligheids-issues naar voren die gerelateerd konden worden aan de 
toediening van Adrecizumab. Alle toegepaste doseringen (tot 400 mg/kg/dag 
in ratten, tot 50 mg/kg in honden en tot 100 mg/kg/dag in apen) werden 
goed getolereerd. Farmacokinetische analyse liet onder andere zien dat 
Adrecizumabconcentraties proportioneel stegen in relatie tot de toegediende 
dosering en dat het middel een lange halfwaardetijd heeft, zoals vaker gezien 
wordt bij antilichamen. Net als in de voorgaande hoofdstukken steeg het 
adrenomedullinegehalte in het bloed sterk na de toediening van Adrecizumab, 
hetgeen niet gepaard ging met een lagere bloeddruk in honden en apen.
Deel IV – Effecten van Adrecizumab bij de mens
Op basis van de voorgaande resultaten in dieren werd besloten om nader 
onderzoek te verrichten bij de mens. In hoofdstuk 12 werd Adrecizumab 
voor het eerst aan mensen toegediend. In een zogeheten first-in-human studie 
hebben we de veiligheid, farmacokinetiek en andere effecten van Adrecizumab 
onderzocht bij gezonde vrijwilligers. In een tweede studie werden deze 
parameters onderzocht in het experimentele endotoxinemiemodel, waarbij 
endotoxine toegediend werd aan gezonde vrijwilligers om een systemische 
ontstekingsreactie op te wekken. In totaal hebben 48 gezonde mannelijke 
16
528527-L-bw-Geven
Processed on: 7-2-2019 PDF page: 394
394
Nederlandse samenvatting
vrijwilligers deelgenomen aan deze 2 dubbelblind gerandomiseerde 
placebogecontroleerde studies. In beide studies kregen de proefpersonen 0.5, 
of 2, of 8 mg/kg Adrecizumab, of placebo (n=6 per groep) toegediend. Omdat 
de halfwaardetijd van Adrecizumab in de dierstudies erg lang was, werden alle 
proefpersonen gedurende een periode van 90 dagen opgevolgd. Beide studies 
lieten een uitstekend veiligheidsprofiel zien van Adrecizumab. Analyse van de 
farmacokinetiek toonde aan dat Adrecizumabconcentraties in het bloed op een 
proportionele manier stegen in relatie tot de toegediende dosering, net zoals 
in de dierstudies. Daarnaast werd een klein verdelingsvolume, een langzame 
klaring en een halfwaardetijd van ongeveer 14 dagen waargenomen, hetgeen 
zeer vergelijkbaar is met andere antilichaammedicijnen. De door endotoxine 
opgewekte ontstekingsreactie in de 2e studie had geen relevante invloed op 
deze farmacokinetische parameters. Net zoals in de dierstudies (hoofdstuk 
9 t/m 11), leidde toediening van Adrecizumab tot een sterke stijging van 
adrenomedullinespiegels in het bloed. Adrecizumab had geen effecten op de 
endotoxinemie-geïnduceerde daling van bloeddruk, temperatuurstijging of 
klaring van ontstekingsmediatoren. Dit kwam niet als een verrassing, omdat 
de opzet van de studie was gericht op veiligheid en farmacokinetiek, waarbij 
Adrecizumab pas 1 uur na start van LPS-infusie toegediend werd, op een 
moment dat de ontstekingsreactie al in gang gezet was. Desalniettemin werd 
er een significant lagere symptoomscore gezien in vrijwilligers die behandeld 
werden met 8 mg/kg Adrecizumab, en werd er een vergelijkbare trend gezien 
bij de lagere dosisgroepen.
De resultaten bij proefdieren en vrijwilligers waren dusdanig veelbelovend dat 
besloten werd de veiligheid en effectiviteit van Adrecizumab bij patiënten met 
septische shock te onderzoeken. In hoofdstuk 13 wordt het studieprotocol 
van de AdrenOSS-2 studie beschreven, een internationale dubbelblind 
gerandomiseerde, placebogecontroleerde, multicenter, proof-of-concept en 
dose-finding fase II first-in-patient studie. Het primaire eindpunt van de 
studie is de veiligheid van Adrecizumab. Om dit te onderzoeken worden 
patiënten tot 90 dagen na toediening opgevolgd. De studie heeft een aantal 
interessante kenmerken. Zo wordt het bio-ADM gehalte in het bloed van 
patiënten gebruikt als een inclusiecriterium: alleen patiënten met een 
verhoogd gehalte (> 70 pg/mL) mogen deelnemen aan de studie. Omdat 
dit geassocieerd is met een ongunstiger ziektebeloop, een lagere bloeddruk, 
meer vaatlekkage en een hogere kans op overlijden, kan dit van nut zijn om 
patiënten te identificeren die het meeste baat zouden kunnen ondervinden 
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van behandeling met Adrecizumab. Het is uniek voor een sepsistrial dat 
een biomarker als inclusiecriterium wordt toegepast en een voorbeeld van 
personalized medicine. Daarnaast wordt gebruik gemaakt van een nieuw 
eindpunt: de sepsis support index. Dit eindpunt combineert sterfte en een 
orgaandisfunctiescore over een periode van 14 dagen. Er wordt verwacht dat 
dit eindpunt gevoeliger (en daardoor meer geschikt) is om een mogelijk effect 
van Adrecizumab aan te tonen, vergeleken met enkel sterftecijfers. Er zullen 
in totaal 300 patiënten geïncludeerd worden in 30 deelnemende centra in 
Europa, waarbij 2 doseringen Adrecizumab onderzocht worden (2 en 4 mg/
kg). De studie is in december 2017 van start gegaan en de resultaten worden 
in eind 2019 verwacht.
Conclusie
Adrenomedulline speelt een belangrijke rol in het ziektebeeld sepsis door 
beïnvloeding van de bloeddruk en lekkage van bloedvaten. Bloedspiegels 
van bioactief adrenomedulline hebben een voorspellende waarde voor het 
ziektebeloop van IC patiënten en het is van meerwaarde om deze spiegel later 
in het opnametraject opnieuw te bepalen. Het experimentele geneesmiddel 
Adrecizumab lijkt een veelbelovende behandeling voor patiënten met 
septische shock. In proefdieren en gezonde vrijwilligers laat het een uitstekend 
veiligheidsprofiel zien. Daarnaast is er een plausibele hypothese voor het 
werkingsmechanisme van Adrecizumab, wat nog wel nader onderzoek vereist 
in de toekomst. Adrecizumab zou daarnaast ook gunstige effecten kunnen 
hebben bij ziektebeelden anders dan sepsis, waarbij eveneens disfunctie 
van hart en bloedvaten optreedt, zoals hartfalen, dengue of andere capillair 
leksyndromen. Momenteel wordt onderzocht of Adrecizumab daadwerkelijk 
effectief is bij patiënten met septische shock in de AdrenOSS-2 studie, 
waarvan de resultaten binnenkort volgen.
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